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ABSTRACT	
This	thesis	investigates	the	effects	of	psychological	stress	on	bladder	function	in	mice	and	
the	 potential	 benefit	 of	 current	 clinical	 therapies.	 	 Psychological	 stress	 and	 bladder	
dysfunction	encompass	a	wide	range	of	disorders	known	to	affect	a	large	portion	of	the	
society.		There	is	convincing	clinical	evidence	that	links	psychological	stress	with	bladder	
dysfunction,	 but	 the	 underlying	 physiological	mechanisms	 involved,	 and	 suitability	 of	
drug	 treatments,	 remain	 elusive.	 	 The	 effects	 of	 social	 stress,	 witness	 stress	 and	
environmental	 stress	 on	 bladder	 function	 were	 observed	 using	 a	 social	 defeat	 and	
witness	trauma	model,	as	well	as	a	water	avoidance	stress	model,	with	animals	exposed	
to	stress	for	1	h/day	for	10	consecutive	days.		These	models	were	used	to	investigate	the	
effects	on	voiding	behaviour	and	local	bladder	function.			
Social	defeat	but	not	witness	trauma	stress	decreased	urinary	frequency	in	male	mice,	
indicative	 of	 urinary	 retention,	 which	 could	 be	 due	 to	 the	 increase	 in	 purinergic	
responses	 observed	 in	 the	 isolated	 whole	 bladder	 preparations	 from	 these	mice.	 	 In	
contrast,	 the	water	 avoidance	model	 produced	 increased	urinary	 frequency	 in	 female	
mice	and	an	increase	in	overall	contractility	of	the	bladder.		Due	to	the	clinical	association	
between	 psychological	 stress	 and	 overactive	 bladder	 (OAB),	 rather	 than	 urinary	
retention,	recovery	studies	were	completed	in	the	water	avoidance	stress	model,	as	were	
drug	 treatment	 studies	using	 the	anxiolytic	 sertraline	and	commonly	used	OAB	drugs	
mirabegron	and	solifenacin.	
Ten-days	stress-free	recovery	increased	bladder	compliance	in	water	avoidance	stressed	
animals	and	reduced	urinary	frequency,	although	not	back	to	unstressed	control	levels,	
with	 a	 new	 elevated	 baseline	 evident.	 	 All	 drug	 treatments	 decreased	 the	 hormonal	
response	 to	 stress,	measured	 as	 plasma	 corticosterone	 levels,	 and	 decreased	 voiding	
dysfunction,	 measured	 as	 voiding	 frequency.	 	 Sertraline,	 however,	 reduced	 stress	
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hormone	 levels	 the	 most,	 while	 also	 targeting	 the	 increased	 bladder	 contractility	
observed	 after	 psychological	 stress	 more	 efficiently.	 Despite	 this,	 mirabegron	 and	
solifenacin	were	more	effective	at	reducing	the	 impact	of	stress	on	urinary	 frequency,	
returning	voiding	behaviour	to	that	of	unstressed	control	animals.			
Overall,	bladder	dysfunction	induced	by	stress	exposure	appears	to	be	dependent	upon	
sex	and/or	stressor	type;	with	urinary	retention	evident	 in	male	mice	following	social	
defeat,	 no	 voiding	 changes	 in	 male	 witness	 mice	 and	 development	 of	 an	 overactive	
phenotype	in	female	mice	after	water	avoidance	stress.		The	bladder	overactivity	induced	
by	water	avoidance	stress	was	associated	with	detrusor	hypercontractility.		Mirabegron	
and	solifenacin	were	equally	effective	at	reducing	the	impact	of	water	avoidance	stress	
on	 voiding	 behaviour	 and	 were	 both	 superior	 to	 the	 selective	 serotonin	 reuptake	
inhibitor	sertraline.	
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CHAPTER	1:	INTRODUCTION	 	
2 
 
SIGNIFICANCE	
Psychological	 stress	 and	 bladder	 dysfunction	 encompass	 a	 range	 of	 disorders	 which	
affect	a	 large	proportion	of	society.	 	Stressors	cannot	generally	be	defined	by	any	one	
cause	and	greatly	depend	on	a	person’s	surroundings,	however	the	most	common	forms	
of	psychological	stress	include	anxiety	and	depression	(Schneiderman,	Ironson,	&	Siegel,	
2005).			A	national	survey	by	The	Australian	Institute	of	Health	and	Welfare	has	reported	
that	45%	of	the	population	were	affected	by	a	mental	health	disorder	at	some	point	in	
their	lives.		Of	this,	anxiety	disorder	was	most	prevalent,	affecting	14.4%,	and	depression	
the	next	most	common,	afflicting	6.2%	of	this	group	(Statistics,	2008).		
Several	studies	have	observed	links	between	psychological	stress	and	disease	outcomes.		
It	is	well	understood	that	psychological	stress	often	occurs	as	a	result	of	disease,	however,	
there	have	been	 studies	which	have	 associated	psychological	 stress	with	 the	 cause	of	
disease/disorder.	 	 Many	 studies	 have	 observed	 that	 stress	 can	 greatly	 influence	 the	
development	of	bladder	symptoms,	or	worsen	symptom	severity	(Chang	et	al.,	2009).		In	
spite	 of	 this,	 very	 little	 research	 has	 focused	 on	 the	 precise	 changes	 and	 underlying	
mechanisms	of	psychological	stress-induced	bladder	dysfunction.		
Lower	urinary	tract	symptoms	(LUTS)	are	common	among	Australian	men	over	the	age	
of	45,	with	the	most	common	symptoms	being	nocturia	and	urgency.		Risk	factors	of	LUTS	
include	increased	plasma	glucose	and	abdominal	fat	as	well	as,	low	HDL	cholesterol	and	
obstructive	 sleep	 apnoea	 (Martin	 et	 al.,	 2011).	 	Most	men	with	LUTS	have	 associated	
benign	 prostatic	 hyperplasia,	 which	may	make	 diagnosis	 difficult	 to	 distinguish	 from	
overactive	bladder	(Woo,	Gillman,	Gardiner,	Marshall,	&	Lynch,	2011).			
Overactive	bladder,	incontinence	and	interstitial	cystitis	are	well	documented	forms	of	
bladder	dysfunction	and	have	been	widely	researched	over	a	number	of	years	(Wallace	
&	Drake,	2015).		In	2020	the	Continence	Foundation	of	Australia	reported	that	10%	of	
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Australian	men	and	38%	of	Australian	women	live	with	urinary	incontinence	and	only	
30%	of	the	patients	sought	treatment	from	a	health	professional.		The	total	financial	cost	
of	incontinence	in	2010	was	$271	million	and	was	projected	to	rise	to	$450	million	by	
this	year,	2020	(Deloitte	Access	Economics,	2011).		
The	 symptoms	of	bladder	dysfunction	have	been	 shown	 to	 increase	with	 age	and	are	
more	frequently	observed	in	women	(Coyne	et	al.,	2011).	 	While	not	well	understood,	
approximately	 40%	 of	 patients	 with	 bladder	 dysfunction	 still	 report	 poor	 treatment	
outcomes	from	the	currently	available	treatments	(Teleman	et	al.,	2004).	 	This	 lack	of	
effective	treatment	leads	to	declines	in	quality	of	life	and	mental	health	issues	in	patients,	
which	may	 impact	 severity	 of	 psychological	 stress	 (Rothrock,	 Lutgendorf,	Hoffman,	&	
Kreder,	 2002).	 	 Despite	 strong	 clinical	 associations,	 and	 reports	 of	 increased	 bladder	
symptom	 severity	 with	 stress,	 there	 has	 been	 very	 little	 attention	 given	 to	 the	
mechanisms	underlying	bladder	dysfunction	induced	by	stress	and	anxiety.		
Thus,	this	thesis	will	further	investigate	the	pathophysiological	pathways	and	increase	
knowledge	 of	 the	mechanisms	 causing	 changes	 in	 lower	 urinary	 tract	 (LUT)	 function	
following	stress.		Evidence	will	also	be	provided	as	to	the	most	appropriate	and	beneficial	
pharmacotherapies	 for	 use	 in	 patients	 with	 urological	 dysfunction	 associated	 with	
chronic	psychological	stress.	 	
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THE	BLADDER	
Anatomy	of	the	Bladder	
The	urinary	bladder	is	a	muscular	sac	which	serves	to	collect,	store	and	transport	urine.		
The	bladder	lies	posterior	to	the	pubic	symphysis,	and	anterior	to	the	vagina	and	uterus	
of	females,	and	the	rectum	in	males	(Hickling,	Sun,	&	Wu,	2015).		The	bladder	consists	of	
several	structures	including	the	openings	of	the	ureters	and	urethra,	bladder	trigone	and	
a	layered	bladder	wall.		The	layers	of	the	bladder	wall,	from	inside	out,	are	the	transitional	
epithelium	 (urothelium),	 lamina	propria,	 detrusor	muscle	 and	 adventitia	 (Figure	 1.1)	
(Keane	&	O'Sullivan,	2000).		
	
Figure	1.1:	Diagram	displaying	the	full	bladder	anatomy	with	detailed	description	of	the	
bladder	wall	(Created	with	BioRender.com	by	the	author).	
	
The	bladder	urothelium	is	a	continuous	superficial	lining,	made	up	of	several	different	
cell	 types	 (Figure	 1.2.A)	 (Hill,	 2015).	 	 The	 three	 different	 cell	 types	 making	 up	 the	
urothelium	 include	 basal	 cells,	 intermediate	 cells	 and	 umbrella	 cells	 (Figure	 1.2.B)	
(Lewis,	 2000).	 	 Undifferentiated	 basal	 cells	 line	 the	 basement	 membrane	 and	 were	
originally	 thought	to	replenish	damaged	surface	umbrella	cells,	however,	studies	have	
now	found	that	intermediate	cells	contain	the	progenitor	population	used	to	repopulate	
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lost	 umbrella	 cells	 (Gandhi	 et	 al.,	 2013).	 	 The	 umbrella	 cells	 (top	 cell	 layer	 of	 the	
urothelium)	 are	 connected	 via	 tight	 junction,	 which	 produces	 	 an	 impermeable	
superficial	layer	of	the	bladder	(Hill,	2015).		The	urothelium	also	serves	a	sensory	and	
signalling	role	which	will	be	discussed	in	detail	later.	
	
Figure	1.2:	A.	Histology	of	the	murine	bladder	wall	(Reproduced	with	permission	from	
Hill	(2015))	and	B.	Schematic	drawing	of	cells	of	the	bladder	urothelium	(Reproduced	
with	permission	from	Lewis	(2000)).	
	
The	 lamina	 propria	 sits	 beneath	 the	 urothelium,	 and	 contains	 blood	 vessels,	 nerves,	
connective	tissue	and		 interstitial	cells	(IC)	(Paner	et	al.,	2007).	 	While	there	has	been	
some	speculation	as	to	the	function	of	the	ICs	in	the	lamina	propria,	the	most	common	
theory	is	that	the	IC	pace	the	smooth	muscle	bladder	contractions	during	the	filling	phase	
of	 micturition	 and	 act	 as	 intermediates	 between	 the	 urothelium,	 nerves	 and	 muscle	
(Andersson	&	McCloskey,	2014).	 	This	 theory	 is	 further	 strengthened	by	unpublished	
data	 from	 Monaghan	 &	 McCloskey,	 presented	 in	 Andersson	 and	 McCloskey	 (2014),	
collected	on	 the	mucosa-intact	 tissue	 strips	 from	neurogenic	 rat	 bladder,	which	were	
found	to	develop	better	spontaneous	contractions,	compared	to	the	controls.		
The	muscular	 layer	 called	 the	 detrusor	 is	 the	 thickest	 layer	 of	 the	 bladder	wall.	 	 The	
smooth	muscle	contains	a	high	number	of	receptors	and	signalling	pathways,	all	of	which	
are	 important	 for	 overall	 bladder	 function	 (Andersson	&	 Arner,	 2004).	 	 A	 non-linear	
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relationship	 is	 present	 between	 muscle	 stretch	 and	 tension	 eluding	 to	 the	 “stretch-
relaxation	phenomenon”,	meaning	that	the	smooth	muscle	cells	stretch	and	elongate	to	
accommodate	bladder	filling	(Orabi	et	al.,	2013).		During	voiding,	the	cells	shorten	and	
generate	the	contractions	required	to	empty	the	bladder	through	the	urethra	(Drew	&	
Murphy,	1997).	 	The	urethra	is	lined	by	uroepithelial	cells	which	express	microvilli	on	
the	 apical	 surface.	 	 The	 importance	 of	 this	 microvilli	 has	 not	 yet	 been	 determined,	
however,	 it	 has	 been	 considered	 to	 affect	 bacterial	 adherence	 (Birder	 &	 Andersson,	
2013).	There	is	evidence	that	the	uroepithelial	may	also	serve	as	sensors	for	mechanical	
and	chemical	signals,	which	play	an	integral	role	in	regulation	of	the	lower	urinary	tract	
(LUT)	function	(Snellings,	Yoo,	&	Grill,	2012).			
	
Innervation	and	Neurotransmission	of	the	Bladder		
The	 storage	 and	 periodic	 elimination	 of	 urine,	 from	 the	 bladder,	 is	 controlled	 by	 a	
multitude	of	neural	circuits	(Fowler,	Griffiths,	&	de	Groat,	2008).		Complex	interactions	
between	 the	 somatic	 and	 autonomic	pathways	 are	 required	 to	 relax	 and	 contract	 the	
bladder	during	filling	and	voiding	(Yoshimura	&	Chancellor,	2003).		Micturition	relies	on	
both	 the	 urinary	 bladder	 as	 a	 reservoir	 and	 the	 bladder	 neck,	 urethra	 and	 urethral	
sphincter	as	an	outlet	(Fowler	et	al.,	2008).		The	LUT	is	innervated	by	3	sets	of	peripheral	
nerves,	which	include	the	pelvic	parasympathetic	nerves	arising	from	the	sacral	level,	the	
sympathetic	nerves	and	the	pudenal	nerves	(Figure	1.3)	(Yoshimura	&	Chancellor,	2003).		
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Figure	1.3:	 Innervation	of	the	bladder.	(A)	Sympathetic	 fibres	(blue),	parasympathetic	
fibres	 (green)	 and	 somatic	 nerves	 (yellow);	 Hypogastric	 nerves	 (HGN),	 Inferior	
mesenteric	plexus	(IMP),	Pelvic	plexus	(PP),	Pelvic	nerves	(PEL),	Superior	hypogastric	
plexus	(SHP).	 	(B)	Neurotransmitter	release	onto	receptor	types;	Acetylcholine	(ACh),	
Adrenergic	 receptors	 (o1	 and	 p3),	 Muscarinic	 receptors	 (M3),	 Noradrenaline	 (NA).	
(Reproduced	with	permission	from	Fowler	et	al.	(2008)).		
	
Sympathetic	Innervation	
The	sympathetic	innervation	originates	from	the	T11-L2	segment	of	the	spinal	cord.	This	
runs	 through	 the	mesenteric	ganglia	and	hypogastric	nerve	 to	 the	bladder.	 	The	post-
ganglionic	 nerves	 release	 noradrenaline	 (NA)	 to	 activate	 the	 β3-adrenoceptors	
(Yoshimura	&	Chancellor,	2003).	 	This	 is	 responsible	 for	 the	 inhibition	of	 the	bladder	
smooth	muscle,	thereby	keeping	the	bladder	relaxed	during	filling.			
β-adrenoceptors	 are	 members	 of	 the	 G	 protein-coupled	 receptor	 family	 and	 have	 7	
transmembrane	spanning	regions.	 	They	are	classified	as	β1-,	β2-,	or	β3-adrenoceptors,	
with	the	main	subtype	in	humans	being	β3-adrenoceptor	(Figure	1.4)	(Li,	De	Godoy,	&	
Rattan,	 2004).	 	 b1	 and	 b3-adrenoceptors	 have	 been	 observed	 to	 activate	 Gi/o-protein	
subunit,	 which	 subsequently	 goes	 on	 to	 stimulate	 the	 guanylate	 cyclase	 enzyme,	
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increasing	guanosine	3’5’-cyclic	monophosphate	(cGMP)	production	(Figure	1.4).	The	b2-
adrenoceptors,	however,	activate	both	Gi/o	as	well	as	Gs-protein	subunits	which	stimulate	
cGMP	 and	 adenylate	 cyclase	 (cAMP)	 respectively	 (Li	 et	 al.,	 2004).	 These	 second	
messengers	result	in	relaxation	in	the	smooth	muscle.			
Mirabegron,	 a	 drug	 which	 will	 be	 discussed	 in	 future	 chapters,	 acts	 as	 a	 b3-
adrenoreceptor	agonist.		The	mode	of	action	of	the	agonist	is	similar	to	NA,	stimulating	
the	receptors	to	increase	relaxation	of	the	detrusor	smooth	muscle,	thereby	increasing	
the	volume	of	urine	storage.					
NA	has	also	been	noted	to	act	on	α1-adrenoreceptors	including	subtypes;	α1A,	α1B,	and	α1D,	
where	 α1A-	 is	 the	 main	 subtype	 found	 in	 human	 urethra	 (Burnstock,	 2007).	 	 a1-
adrenoreceptors	are	linked	to	the	Gq-protein	and	when	stimulated	with	activate	enzyme	
PLC	 (not	 shown	 in	 Figure	 1.4)	 and	 cause	 production	 of	 IP3	(Figure	 1.4).	 	 This	 causes	
contraction	and	closure	of	the	bladder	neck	during	filling	(Fowler	et	al.,	2008;	Hegde	et	
al.,	1998).	
9 
 
	
Figure	 1.4:	 Inhibitory	 and	 stimulatory	 effects	 of	 noradrenaline	 on	 the	 detrusor	 and	
urethra.	 	 Sympathetic	 nerves	 (S),	 Noradrenaline	 (NA),	 Guanylate	 cyclase	 (GC),	 Cyclic	
Guanylate	 Monophosphate	 (cGMP),	 Inositol	 triphosphate	 (IP3).	 (Created	 with	
BioRender.com	by	the	author)	
	
Parasympathetic	Innervation	
The	parasympathetic	innervation	arises	from	the	S2-S4	segments	of	the	spinal	cord	and	
travels	in	the	pelvic	nerves	and	along	to	the	pelvic	plexus	of	the	bladder	wall	(Fowler	et	
al.,	2008).		The	parasympathetic	post	ganglionic	nerves	release	both	acetylcholine	(ACh)	
and	 non-adrenergic,	 non-cholinergic	 (NANC)	 neurotransmitters.	 	 The	 cholinergic	
transmission	of	ACh	is	the	main	excitatory	mechanism	of	the	human	bladder,	and	acts	at	
muscarinic	receptors	in	the	detrusor	muscle	(Andersson	&	Arner,	2004).	
ACh	 activates	 predominately	 M3	 muscarinic	 receptors	 to	 initiate	 bladder	 contraction	
(Matsui	et	al.,	2002).		The	role	of	M2	receptors	is	not	clear	although	there	is	evidence	that	
there	 is	 an	 indirect	 ‘re-contraction’	 of	 the	 bladder	 via	M2	Muscarinic	 receptors.	 	 This	
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occurs	 by	 the	 reduction	 in	 adenylate	 cyclase	 activity	 which	 reverses	 the	 relaxation	
induced	by	β3-adrenoreceptor	stimulation	(Chess-Williams,	2002).		Activated	muscarinic	
receptors	primarily	couple	to	the	Gq-protein	which	activate	phospholipase	C	(PLC)	which	
produces	 IP3	 and	 diacylglycerol	 (DAG)	 from	 the	 membrane	 phospholipids	
phosphatidylinositol	4,5-biphosphate	(PIP2).		This	results	in	calcium	(Ca2+)	release	from	
the	sarcoplasmic	reticulum	(SR),	so	that	it	may	become	available	to	calmodulin	(CaM).		
When	 these	 molecules	 bind,	 myosin	 light	 chain	 kinase	 (MLC)	 is	 activated	 and	
phosphorylation	activates	myosin	to	bind	to	actin	and	cause	contraction	(Andersson	&	
Arner,	2004)	(Figure	1.5).		
Solifenacin,	discussed	in	further	detail	later	in	this	thesis,	is	an	antagonistic	drug	that	acts	
by	 binding	 M3	 muscarinic	 receptors	 and	 blocking	 the	 action	 of	 ACh.	 This	 results	 in	
decreased	contractility	of	the	bladder	smooth	muscle,	thereby	increasing	urine	storage.			
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Figure	 1.5:	 Diagram	 illustrating	 the	 contractile	 pathway	 of	 parasympathetic	 ACh	
neurotransmitter	via	muscarinic	receptors	of	the	detrusor	smooth	muscle.		Acetylcholine	
(ACh),	Adenosine	triphosphate	(ATP),	Adenosine	diphosphate	(ADP),	Calmodulin	(CaM),	
Calcium	(Ca2+),	Diacylglycerol	(DAG),	Inositol	trisphosphate	(IP3),	Muscarinic	receptor	3	
(M3),	Myosin	light	chain	(MLC),	Phosphatidylinositol	biphosphate	(PIP2),	Phospholipase	
C	(PLC),	Sarcoplasmic	reticulum	(SR).		(Created	with	BioRender.com	by	the	author).	
	
Adenosine-tri-phosphate	 (ATP)	 is	 stored	 and	 co-released	 in	 conjunction	with	 ACh	 to	
cause	 contraction	 of	 the	 urinary	 bladder	 (Vial,	 2000).	 	 ATP	 is	 released	 from	
parasympathetic	postganglionic	neurons	and	can	bind	to	either	P2X	or	P2Y	receptors,	
where	P2Y	receptors	are	metabotropic	G-protein	coupled	and	P2X	are	ligand-gated	non-
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specific	cation	channels.		ATP	activates	the	channels	which	causes	and	influx	of	sodium	
(Na2+)	 and	 Ca2+,	 depolarising	 the	 cell	 and	 activating	 the	 L-type	 Ca2+channels.	 	 This	
generates	and	action	potential	for	further	influx	of	Ca2+	(Figure	1.6)	(Fry,	Meng,	&	Young,	
2010).	
Non-cholinergic	bladder	contractions	have	been	reported	to	be	mediated	by	ATP	release	
onto	 the	 P2X	 purinergic	 receptors	 (Burnstock,	 2001).	 	 Several	 studies	 of	 the	 rat	 and	
mouse	urinary	bladder	have	found	that	the	P2X	purinergic	receptor	mediated	response	
may	be	responsible	for	up	to	50%	of	the	neurogenic	bladder	contraction	(Hegde	et	al.,	
1998).		In	normal	human	bladder,	P2X	receptors	are	expressed	but	ATP	does	not	appear	
to	contribute	to	neurogenic	contractions	(Vial,	2000).		In	diseased	states,	however,	the	
contribution	of	P2X	receptor	stimulation	in	contraction	is	significantly	increased.			
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Figure	 1.6:	 Diagram	 illustrating	 the	 contractile	 pathway	 of	 parasympathetic	
neurotransmitters	ATP	via	purinergic	receptors	of	detrusor	smooth	muscle.		Adenosine	
triphosphate	(ATP),	Adenosine	diphosphate	(ADP),	Calmodulin	(CaM),	Calcium	(Ca2+),	
Long	lasting	type	Calcium	channel	(L-type	Ca2+	channel),	Myosin	light	chain	(MLC),	P2X	
Purinoceptor	 1	 (P2X1),	 Sodium	 (Na+),	 Sarcoplasmic	 reticulum	 (SR).	 	 (Created	 with	
BioRender.com	by	the	author).	
	
	
Parasympathetic	 nerves	 also	 release	 nitric	 oxide	 (NO)	 which	 is	 responsible	 for	 the	
relaxation	of	the	bladder	smooth	muscle	during	micturition	(Sugaya,	Nishijima,	Miyazato,	
&	Ogawa,	2005).		The	role	of	NO	is	still	unclear,	however,	NO	has	also	been	shown	to	play	
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a	direct	role	 in	the	micturition	reflex,	by	activating	the	cyclic	GMP	(cGMP)	pathway	in	
detrusor	of	rats	(Caremel,	Oger-Roussel,	Behr-Roussel,	Grise,	&	Giuliano,	2010).			
	
The	Urothelium		
The	bladder	urothelium	was	once	 thought	 to	act	 solely	as	a	distensible	barrier	 to	 the	
noxious	effects	of	urine.		It	has	since	been	established	as	a	complex	anatomical	layer	with	
a	number	of	dynamic	abilities,	with	one	of	the	main	abilities	being	its	ability	to	act	as	a	
sensor	to	the	intravesical	environment	(Winder,	Tobin,	Zupancic,	&	Romih,	2014)	and	
the	release	of	a	number	of	chemical	mediators	that	act	on	underlying	cells	as	well	as	back	
on	the	urothelium	itself	(Figure	1.7).	
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Figure	1.7:	Illustration	of	proposed	interactions	between	urothelial	cells,	bladder	nerves,	
interstitial	cells	and	smooth	muscle.		Acetylcholine	(ACh),	Adenosine	triphosphate	(ATP),	
β3	 adrenoceptor	 (β3),	 Calcium	 (Ca2+),	 G	 coupled	 protein	 receptor	 (GC),	 Muscarinic	
receptor	3	(M3),	Noradrenaline	(NA),	Neurokinin	(NK1/NK2),	Nitric	oxide	(NO),	Nitric	
oxide	 synthase	 (NOS),	 Protein	 kinase	 C	 (PKC),	 Protein	 kinase	 G	 (PKG),	 Purinergic	
receptors	 (P2X/P2Y,	 P2),	 Transient	 receptor	 potential	 cation	 channel,	 subfamily	 A,	
member	 1	 (TRPA1),	 Transient	 receptor	 potential	 cation	 channel,	 vanilloid	 (TRPV).	
(Created	with	BioRender.com	by	the	author).	
	
	
Receptors	 and	 ion	 channels	 of	 the	 urothelium	 have	 been	 implicated	 in	 the	
mechanoceptive	 or	 nociceptive	 sensations.	 	 The	 urothelium	 contains	 a	 number	 of	
receptors	including	P2X1-7,	P2Y1,	P2Y2	and	P2Y4	as	well	aa	adrenergic	α	and	β	receptors,	
along	with	muscarinic	receptors.		Besides	these	main	receptors,	a	group	of	receptors	also	
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exist	within	 the	 urothelium	which	 are	 important	 for	mechanoceptive	 and	nociceptive	
responses.		These	receptors	all	belong	to	the	transient	receptor	potential	(TRP)	channel	
family.		TRPA1	is	a	receptor	which	is	activated	by	noxious	cold	and	stretch	or	swelling.		
The	 main	 function	 of	 this	 receptor	 is	 detrusor	 muscle	 contraction,	 urethral	
mechanosensation	 and	 bladder	 hyperreflexia	 (Figure	 1.7).	 	 There	 are	 3	 main	 TRPV	
receptors,	which	all	respond	to	moderate	to	noxious	heat.		TRPV1	is	involved	in	sensing	
bladder	 distention,	 bladder	 hyperreflexia	 and	 pain,	 and	 TRPV2	 is	 responsible	 for	
urothelial	cell	mechanosensation,	chemosensation	and	thermosensation.		The	final	TRPV	
receptor,	 TRPV4,	 	 plays	 a	 role	 in	 	 detrusor	 contractility,	 bladder	 distension,	 voiding	
dysfunction,	 detrusor	 sphincter	 dyssynergia	 and	 pain	 (Merrill,	 Gonzalez,	 Girard,	 &	
Vizzard,	2016).	
The	 urothelium	 also	 releases	 a	 range	 of	 chemical	 mediators	 and	 neurotransmitters.	
Stretch	 has	 been	 found	 to	 induce	 the	 release	 of	 ACh	 from	 the	 urothelium	 (Moro,	
Uchiyama,	&	Chess-Williams,	2011;	Yoshida	et	al.,	2006).		ACh	can	be	released	in	both	a	
neuronal	and	non-neuronal	manner.		Neuronal	release	of	ACh	begins	in	the	mitochondria	
when	acetyl	CoA	is	combined	with	choline	to	produce	ACh.			ACh	is	then	transported	in	
the	synaptic	vesicle	to	the	synaptic	cleft	where,	once	released,	it	will	bind	to	muscarinic	
receptors	or	be	broken	down	by	acetylcholinesterase.		Choline	is	then	transported	back	
into	the	axon	terminal	by	cotransport	with	sodium.		The	choline	is	then	recycled	and	used	
to	make	more	ACh	(Nausch,	Heppner,	&	Nelson,	2010).		The	mechanisms	of	non-neuronal	
ACh	release,	such	as	observed	in	the	urothelium,	continues	to	be	investigated	however,	a	
study	by	Hanna-Mitchell	et	al.	(2007)	used	cultured	rat	urothelial	bladder	cells	and	found	
high	 affinity	 choline	 transporters	 (CHT1),	 which	 are	 involved	 in	 synthesis	 of	
acetylcholine	in	the	bladder.	 	The	study	also	found	that	the	ACh	synthesising	enzymes	
such	 as	 choline	 acetyltransferase	 (ChAT)	 and	 carnitine	 acetyltransferase	 (CarAT)	 are	
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located	 in	 the	 urothelium.	 The	 same	 study	 also	 found	 that	 ACh	 release	 from	 the	
urothelium	does	not	depend	on	vesicular	storage	of	acetylcholine	(Hanna-Mitchell	et	al.,	
2007).	 	There	is	a	suggestion	that	the	synthesis	of	acetylcholine	involves	several	steps	
beginning	with	the	uptake	of	choline	from	the	extracellular	compartment	via	CHT1	and	
then	formation	of	ACh	with	the	cytoplasmic	enzymes	mentioned	above,	ChAT	and	CarAT.		
It	 is	 therefore	unlikely	 that	ACh	 is	 stored	within	vesicles	 in	urothelial	 cells	 as	 several	
studies	 did	 not	 find	 the	 vesicular	 acetylcholine	 transporter	 (VAChT)	 present	 in	 the	
urothelial	 cells	 (Hanna-Mitchell	 et	 al.,	 2007;	 Lips	 et	 al.,	 2005;	 Wessler	 et	 al.,	 2001).		
Urothelial	released	ACh	(non-neuronal)	may	target	several	different	areas	of	the	bladder,	
including	nicotinic	and	muscarinic	receptors	on	nerve	terminals,	detrusor	muscle	cells	
and	 urothelial	 cells	 (Birder	 &	 Andersson,	 2013).	 	 ACh	 may	 have	 indirect	 effects	 by	
inducing	the	release	of	other	substances	such	as	NO,	ATP	and	prostanoids	(Nile,	2012).		
The	 urothelial	 release	 of	 ACh	 has	 been	 reported	 to	 increase	 with	 age	 in	 the	 human	
bladder	(Yoshida	et	al.,	2006)	and	may	vary	in	diseased	states.		It	is	for	this	reason	that	it	
is	believed	that	urothelial	ACh	may	facilitate	or	inhibit	afferent	signalling	depending	on	
the	pathology	of	the	bladder	(Winder	et	al.,	2014).			
Urothelial	 ATP	 is	 the	 most	 well	 studied	 mediator,	 although	 it	 is	 still	 not	 completely	
understood	 (Winder	 et	 al.,	 2014).	 Filling	 of	 the	 urinary	 bladder	 induces	
mechanotransduction	pathways	which	are	thought	to	be	initiated	by	increased	tension	
in	the	umbrella	cells.		These	mechanical	stimuli	are	likely	to	induce	the	stretch-activated	
release	of	ATP	from	the	bladder	urothelium	(Cheng	et	al.,	2011).		Once	outside	the	cell,	
ATP	functions	as	a	signalling	molecule,	modulating	a	range	of	cell	functions	via	purinergic	
receptors	 (Burnstock,	 2007).	 	 In	 the	 urothelium,	ATP	 is	 released	 from	 the	 apical	 and	
basolateral	surfaces	and	acts	via	P2X2	and	P2X3	receptors	on	urothelial	cells,	interstitial	
cells	and	G-coupled	protein	receptors	of	the	afferent	nerve	terminal	(Wang	et	al.,	2005).		
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ATP	release	has	also	been	shown	to	be	induced	by	other	mediators	that	may	be	present	
in	 the	 urine,	 and	 by	 the	 release	 of	 mediators	 through	 nerve	 stimulation	 and	 other	
mediator	release	from	the	urothelial	membrane	(Sui	et	al.,	2014).		
Urinary	ATP	levels	have	been	noted	to	increase	in	patients	with	bladder	pathologies	such	
as	overactive	bladder	and	interstitial	cystitis.		Reflex	bladder	activity	has	been	shown	to	
be	modulated	by	an	alteration	of	basal	ATP	release,	thus	suggesting	that	ATP	may	also	
play	a	role	in	control	of	micturition.		ATP	has	recently	been	shown	to	be	released	from	
both	vesicular	and	non-vesicular	(pannexin	channel)	mechanisms	(Beckel	et	al.,	2015).		
What	 is	 unclear,	 however,	 is	 if	 these	 two	 pathways	 mediate	 the	 same	 downstream	
mechanisms.		Physical	stimuli,	such	as	stretch,	activates	ATP	release	through	pannexin	
channels	while	stimulation	of	Toll-like	receptors	(TLRs)	activate	vesicular	release.		When	
this	 is	 considered,	 ATP	 release	 can	mediate	 separate	 downstream	 effects	 on	 bladder	
function	depending	on	its	mechanism	of	release	(Beckel	et	al.,	2018).	
NO	 is	 formed	 from	 the	 amino	 acid	 L-arginine	 by	 the	 enzyme	 to	 nitric	 oxide	 synthase	
(NOS).		Studies	in	cats,	rats	and	rabbits	have	shown	that	urothelial	cells	release	NO	when	
stimulated	by	various	chemicals	and	neurotransmitters	such	as	ACh,	capsaicin,	nicotine	
and	noradrenaline	(Birder	&	Andersson,	2013).		NO	is	thought	to	inhibit	afferent	nerve	
signalling.	 	This	was	shown	in	a	study	using	oxyhaemoglobin,	a	nitric	oxide	scavenger,	
where	 the	 absence	 of	 NO	 caused	 bladder	 overactivity,	 possibly	 via	 modulation	 of	
threshold	firing	(Yoshimura,	Seki,	&	de	Groat,	2001).		Yoshimura	et	al.	(2001),	concluded	
that	the	cGMP	pathway	modulated	the	high	voltage	Ca2+	channels	thereby	affecting	the	
firing	 threshold.	 	 NO	 has	 also	 been	 found	 to	 play	 different	 roles	 within	 the	 bladder	
depending	on	how	it	is	synthesised.		NO	formed	by	inducible	nitric	oxide	synthase	(iNOS),	
may	 sensitize	 the	 bladder	 afferent	 nerves	 and	 thereby	 increase	 bladder	 contractility,	
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while	 NO	 formed	 by	 endothelial	 nitric	 oxide	 synthase	 (eNOS)	 may	 inhibit	 bladder	
contraction	(Lee,	Chiang,	Tain,	Wu,	&	Chuang,	2012).			
	
Urothelial	Derived	Inhibitory	Factor	(UDIF)	
The	urothelium	has	the	ability	to	modulate	contractile	responses	of	the	detrusor	muscle.		
Hawthorn,	Chapple,	Cock,	and	Chess-Williams	(2000)	found	that	the	urothelium	releases	
a	diffusible	inhibitory	factor	that	inhibits	contraction	of	the	pig	bladder	detrusor	muscle	
when	 the	 urothelium	 was	 stimulated	 with	 carbachol.	 	 Contractions	 of	 urothelium-
denuded	tissue	were	inhibited	when	a	second	bladder	strip	with	intact	urothelium	was	
added	to	the	organ	bath,	confirming	the	diffusible	nature.		The	identity	of	the	urothelial	
derived	inhibitory	factor	was	not	concluded,	but	it	was	neither	NO,	gamma-aminobutyric	
acid	(GABA),	a	catecholamine	nor	adenosine	nucleotide	(Hawthorn	et	al.,	2000).		
There	seems	to	be	controversy	around	the	existence	of	UDIF	in	different	species.		While	
it	has	been	confirmed	 in	 the	pig	urinary	bladder,	 some	studies	 show	 that	UDIF	 is	not	
present	in	the	rat	bladder,	while	others	conclude	that	it	is	present	(Munoz,	2010).		The	
role	of	UDIF	in	the	human	bladder	has	been	under	discussion.		Studies	have	observed	the	
effects	 of	 NO,	 cyclooxygenase	 and	 β-adrenoceptors	 products	 on	 the	 bladder	 and	
concluded	that	there	must	be	some	other	factor	that	is	inhibiting	detrusor	contraction.		It	
has	therefore	been	hypothesised	that	another	factor,	distinct	from	NO,	cyclooxygenase	
products,	 and	 β-adrenoceptors	 is	 contributing	 to	 inhibition	 of	 detrusor	 contractions	
(Chaiyaprasithi,	 Mang,	 Kilbinger,	 &	 Hohenfellner,	 2003).	 	 While	 there	 has	 not	 been	
extensive	investigation	of	the	effect	of	age	on	UDIF,	a	study	of	urethral	tissues	of	young	
pigs	and	older	sows	 found	 that	 the	urothelium	and	 lamina	propria	have	an	 inhibitory	
effect	on	the	contraction	of	the	urethra,	which	was	not	affected	by	age	(Folasire,	Chess-
Williams,	&	Sellers,	2017).			
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Detrusor	Muscle	
The	 detrusor	muscle	makes	 up	 the	majority	 of	 the	 bladder	 wall	 and	 is	 composed	 of	
bundles	of	muscle	cells	surrounded	by	connective	tissue	(Andersson	&	Arner,	2004).		The	
lengthening	 and	 shortening	 of	 the	muscle	 dictates	 the	 strength	 of	 contraction	 during	
bladder	filling	and	voiding	(McLafferty,	Johnstone,	Hendry,	&	Farley,	2014).		Contraction	
of	 the	 bladder	 mainly	 occurs	 by	 ACh	 release	 from	 parasympathetic	 nerves	 onto	
muscarinic	receptors,	thereby	stimulating	emptying	of	the	bladder.		The	location	of	the	
muscarinic	 receptor	 subtypes	 differs	 depending	 on	 the	 mode	 of	 action.	 	 M1	 and	 M4	
receptors	 are	 located	of	 the	pre-junctional	nerve	 terminals	 (Sellers	&	Chess-Williams,	
2012).	 	M2	receptors	and	M3	receptors	are	located	directly	on	the	smooth	muscle	cells	
and	 while	 M2	 receptors	 are	 the	 predominant	 subtype,	 M3	 receptors	 are	 the	 main	
receptors	 mediating	 	 contraction	 (Yamanishi,	 2001).	 	 During	 bladder	 filling,	 NA	 is	
released	from	sympathetic	nerves,	stimulating	detrusor	muscle	relaxation	by	acting	on	
β3	adrenoceptors	(Yoshimura	&	Chancellor,	2003).			
	
Spontaneous	Activity	
Spontaneous	 activity	 occurs	 in	 the	 normal	 bladder,	 however,	 the	 role	 of	 spontaneous	
activity	 in	 micturition	 has	 not	 been	 defined	 (Kushida	 &	 Fry,	 2016).	 	 Spontaneous	
contractions	have	been	observed	in	many	different	models	including,	rat,	pig,	rabbit	and	
mouse,	both	in	in	vivo	and	ex	vivo	preparations	(Ng,	de	Groat,	&	Wu,	2006).		In	mice,	in	
particular,	the	detrusor	smooth	muscle	cells	generate	spontaneous	action	potentials	at	a	
low	frequency	(Meng,	Young,	&	Brading,	2008).		It	has	been	noted	in	some	studies	that	
spontaneous	 contractions	 may	 be	 responsible	 for	 increased	 pressure	 during	 bladder	
filling,	in	some	bladder	disorders	(Szigeti,	Somogyi,	Csernoch,	&	Szell,	2005).	
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It	 is	 known	 that	 detrusor	 overactivity	 may	 contribute	 to	 incontinence	 and	 large	
amplitude	spontaneous	bladder	contractions	evoke	afferent	nerve	firing	which	may	be	
linked	to	detrusor	overactivity	(McCarthy	et	al.,	2009).		Spontaneous	activity	or	phasic	
contractions	 have	 been	 widely	 researched	 for	 their	 ability	 to	 contribute	 to	 bladder	
dysfunction.		Prostaglandins	have	been	found	to	increase	the	frequency	of	spontaneous	
contractions	and	the	same	study	found	that	blocking	P2X	receptors	results	in	decreased	
frequency	of	spontaneous	activity	(Kobayter,	Young,	&	Brain,	2012).		Another	study	has	
found	that	potassium	channels	have	a	fundamental	role	in	stabilising	detrusor	smooth	
muscle	excitability	and	if	these	channels	are	blocked,	there	is	a	reduction	in	spontaneous	
activity.		Calcium	transients	were	also	observed	to	generate	in	detrusor	muscle	cells	and	
propagated	 to	 neighbouring	 cells	 which	 suggests	 that	 spontaneous	 contractions	 pass	
through	the	bladder	wall	(Hayase,	Hashitani,	Kohri,	&	Suzuki,	2009).	
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PSYCHOLOGICAL	STRESS		
Psychological	stress	is	known	to	affect	a	large	portion	of	society.		Stress	cannot	be	defined	
by	any	one	cause	and	depends	greatly	on	a	person’s	surroundings.		Stressors,	no	matter	
what	 severity,	 have	 been	 documented	 to	 promote	 behavioural	 and	 psychological	
disturbances	(Schneiderman	et	al.,	2005).		
	
Types	of	Psychological	Stress	
Stress	can	be	broken	down	into	two	types:	acute	stress	and	chronic	stress.		Acute	stress	
is	often	caused	by	reactive	thinking	to	a	situation	and	is	usually	brief	while	chronic	stress	
occurs	over	a	long	period	of	time	and	is	the	most	harmful	form	of	stress.		The	longevity	
of	 the	 stress	 is	 often	 the	 cause	 of	 chronic	 depression	 and	 anxiety.	 	 Stressors	 such	 as	
anxiety	and	depression	often	develop	after	a	negative	life	event.		A	long-term	follow	up	
study	 has	 observed	 that	 anxiety	 disorders	 often	 occur	 before	 depression	 (Breslau,	
Schultz,	&	Peterson,	1995).		A	number	of	studies	have	observed	the	difference	between	
both	stressors	and	concluded	that	activation	of	the	stress	response	centres	in	the	brain	
depends	on	the	type	of	stress	(Retana-Marquez	et	al.,	2003).		Therefore,	chronic	stress	
leads	to	an	increase	in	activity	of	the	hypothalamus-pituitary-adrenal	(HPA)	axis,	leading	
to	an	increase	in	stress	hormone	release,	discussed	more	below	(Herman,	2013).		There	
have	also	been	studies	which	have	observed	that	chronic	stress	leads	to	atrophy	of	the	
brain	mass	and	a	decrease	in	brain	weight.		These	changes	affect	cognition	and	memory	
and	often	result	in	long-term	effects	on	the	nervous	system	(Reznikov	et	al.,	2007).		
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Psychological	Stress	Pathways	
Stress	 is	 generally	defined	as	 any	 form	of	 stimulus	 that	disrupts	or	 affects	 the	body’s	
internal	balance.		The	best	studied	component	of	the	stress	pathways	of	humans	is	the	
HPA	axis.		The	HPA	system	is	modulated	through	a	negative	feedback	system	to	maintain	
stress	 hormone	 levels	 (Stephens	&	Wand,	 2012).	 	 The	 paraventricular	 nucleus	 of	 the	
hypothalamus	releases	two	hormones,	corticotropin	releasing	factor	(CRF)	and	arginine	
vasopressin	 (AVP).	 	 Both	 hormones	 stimulate	 the	 anterior	 pituitary	 to	 produce	
adrenocorticotropic	 hormone	 (ACTH).	 	 ACTH	 in	 turn,	 stimulates	 the	 adrenal	 glands,	
located	atop	of	the	kidneys,	to	synthesise	glucocorticoids	and	catecholamines	(Ranabir	&	
Reetu,	2011).		
Adrenaline	 is	 the	 primary	 catecholamine	 produced	 by	 the	 adrenal	 medulla.	 	 During	
stress,	 adrenaline	 is	 synthesised	 and	 transported	 into	 the	 blood	 stream	 and	 has	 key	
actions	 in	 a	 number	 of	 body	 systems	 including	 the	 cardiovascular	 system,	 increasing	
heart	rate	as	well	as	the	force	of	contraction.		This	increases	cardiac	output	and	increases	
blood	pressure.		In	the	respiratory	system,	adrenaline	promotes	bronchodilation,	while	
in	 the	 digestive	 system,	 gastrointestinal	 (GI)	 function	 is	 inhibited	 (Goldstein,	 2010)	
(Figure	1.8).		
Glucocorticoids	 are	 synthesised	 in	 the	 zona	 fasciculata	 of	 the	 adrenal	 gland	 from	
cholesterol.	 	 There	 are	 three	 glucocorticoids;	 cortisol,	 cortisone	 and	 corticosterone	
(Rosol,	2001).		The	main	glucocorticoid	varies	between	humans	and	mice,	being	cortisol	
and	corticosterone	respectively	(Stephens	&	Wand,	2012)	(Figure	1.8).		Cholesterol	is	the	
first	 step	 in	 the	 synthesis	 pathway	 to	 the	 dominant	 glucocorticoid	 (Ranabir	&	 Reetu,	
2011).	 	In	humans,	cholesterol	is	converted	to	pregnenolone	by	cholesterol	desmolase	
(Rosol,	 2001).	 17α-hydroxylase	 then	 converts	 pregnenolone	 to	 17-
hydroxypregnenolone,	which	 is	 the	 first	step	of	 the	synthesis	pathway	 to	occur	 in	 the	
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zona	 fasciculata.	 3β-hydroxysteroid	 dehydrogenase	 then	 converts	 17-
hydroxypregnenolone	 to	 17-hydroxyprogesterone.	 21-hydroxylase	 converts	 17-
hydroxyprogesterone	 to	 11-deoxycortisol	 and	 finally,	 11β-hydroxylase	 converts	 11-
deoxycortisol	to	cortisol	(Ranabir	&	Reetu,	2011).		In	the	rodent,	however,	the	pathway	
is	slightly	different.		Cholesterol	is	converted	to	pregnenolone	by	cholesterol	desmolase,	
and	then	is	converted	further	to	progesterone	by	3β	hydroxysteroid	dehydrogenase.		21-
hydroxylase	 converts	 progesterone	 to	 11-deoxycorticosterone	 (Stephens	 &	 Wand,	
2012).	 	 Finally,	 11-deoxycorticosterone	 is	 converted	 to	 corticosterone	 by	 11β-
hydroxylase.		Below	is	a	summary	of	the	cortisol	and	corticosterone	pathway	(Figure	1.8).		
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Figure	 1.8:	 Psychological	 stress	 pathways	 of	 rodents	 and	 humans.	 (Created	 with	
BioRender.com	by	the	author).	
	
There	 are	 two	 types	 of	 receptors	 that	 cortisol	 binds	 to:	 mineralocorticoid	 receptors	
(MRs)	 and	 glucocorticoid	 receptors	 (GRs).	 	 Cortisol/corticosterone	 binds	with	 higher	
affinity	 to	MRs	 than	GRs	where	MRs	maintain	 low	cortisol	 levels	during	normal	daily	
circadian	 rhythm	 (Stephens	 &	 Wand,	 2012).	 	 	 During	 a	 stressful	 situation,	
cortisol/corticosterone	will	activate	GRs	which	results	 in	the	termination	of	the	stress	
response.	 	 When	 stress	 hormones	 bind	 to	 GRs,	 there	 is	 a	 strong	 influence	 on	
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cardiovascular	function,	immunologic	status,	arousal,	learning	and	memory	(Ranabir	&	
Reetu,	2011).	 	Therefore,	all	of	these	responses	are	affected	during	stressful	situations	
and	 too	 much	 or	 too	 little	 exposure	 to	 cortisol	 or	 corticosterone	 can	 have	 adverse	
consequences	to	general	health	and	wellbeing	(Stephens	&	Wand,	2012).	
	
Psychological	Stress	and	Disease	
There	have	been	many	studies,	looking	at	stress	and	disease	outcomes.			In	many	cases,	
psychological	stress	is	a	result	of	disease,	however,	there	are	cases	where	stress	is	known	
to	cause	disease	(Cohen,	Gianaros,	&	Manuck,	2016).		Hormones	have	been	shown	to	elicit	
effects	on	different	parts	of	the	central	nervous	system	(CNS)	and	play	a	role	in	behaviour	
and	cognitive	function	(de	Kloet,	2000).			
The	relationship	between	stress	and	the	immune	system	is	one	that	has	been	discussed	
for	years.		Following	stress,	neuroendocrine	and	neural	responses	result	in	the	release	of	
corticotropin	 releasing	 hormone	 (CRH)	 and	 ACTH	 (Stephens	 &	Wand,	 2012).	 	 Early	
research	has	shown	that	the	lymphatic	system	is	also	able	to	release	these	two	mediators	
or	other	mediators	that	increase	synthesis	of	these	CRH	and	ACTH	(Khansari,	Murgo,	&	
Faith,	1990).		For	example,	thymus	peptides,	such	as	thymopoietin	cause	an	increase	in	
ACTH	production	(Goya,	Castro,	Hannah,	Sosa,	&	Lowry,	1993).		In	severe	cases,	stress	
has	been	documented	to	lead	to	malignancy	by	suppression	of	the	immune	system.		This	
occurs	by	stress	decreasing	the	activity	of	cytotoxic	T	lymphocytes	and	natural	killer	cells	
thereby	leading	to	proliferation	of	malignant	cells	(Reiche,	Nunes,	&	Morimoto,	2004).		
Several	studies	have	observed	the	effects	of	stress	on	the	cardiovascular	system	and	have	
found	these	effects	can	be	stimulatory	or	inhibitory	in	nature.	 	Stress	was	observed	to	
cause	the	autonomic	nervous	system	to	activate	and	indirectly	affect	the	function	of	the	
cardiovascular	 system	 (Vrijkotte,	 van	 Doornen,	 &	 de	 Geus,	 2000).	 	 If	 this	 occurs	 and	
27 
 
subsequently	the	sympathetic	system	is	activated,	there	will	be	an	increase	in	heart	rate,	
strength	of	 contraction,	vasodilation	 in	 the	arteries	of	 skeletal	muscles,	 contraction	of	
arteries	in	the	spleen	and	kidneys	and	decreased	sodium	excretion	(Gordan,	Gwathmey,	
&	Xie,	 2015).	 	On	 the	other	hand,	 stress	may	 cause	 activation	of	 the	parasympathetic	
system	which	leads	to	stimulation	of	the	limbic	system	and	reduced	heart	rate	(Cohen	et	
al.,	2016).		
Stress	may	also	cause	dysfunction	in	the	gastrointestinal	tract.		Stress	can	affect	appetite	
and	is	related	to	involvement	of	the	ventral	tegmental	area	(VTA)	or	the	amygdala	of	the	
brainstem	 (Nasihatkon	 et	 al.,	 2014).	 	 Stress	 has	 been	 shown	 to	 affect	 the	 absorption	
process,	 mucus	 and	 stomach	 acid	 secretion,	 function	 of	 ion	 channels,	 intestinal	
permeability	and	GI	inflammation	(Qin,	Cheng,	Tang,	&	Bian,	2014).		Crohn’s	disease	and	
Inflammatory	 bowel	 disease	 are	 examples	 of	 diseases	 exacerbated	 by	 stress,	 where	
inflammatory	 markers	 are	 increased	 and	 there	 is	 recruitment	 of	 T	 lymphocytes.		
Lymphocyte	aggregation	leads	to	production	of	inflammatory	markers	which	ultimately	
results	in	the	appearance	of	inflammatory	diseases	(Konturek,	Brzozowski,	&	Konturek,	
2011).	 	 Stress	 is	 also	 able	 to	 affect	 the	movement	of	 the	GI	 tract	 by	 slowing	 stomach	
emptying	and	accelerating	colonic	motility	(Konturek	et	al.,	2011).		CRH	has	been	shown,	
especially	 in	 the	 case	of	 irritable	bowel	 syndrome,	 to	 increase	movement	of	 the	 large	
intestine	(O'Mahony	et	al.,	2009).		
The	endocrine	system	and	psychological	 stress	have	a	 complex	 relationship.	 	 In	 some	
cases,	stress	has	many	subtle	effects	on	the	activity	of	the	endocrine	system,	while	the	
endocrine	 system	works	 to	 respond	 to	 stress	 (Ulrich-Lai	 &	 Herman,	 2009).	 	 A	 small	
amount	of	stress	stimuli	has	been	shown	to	activate	the	HPA	axis	which	from	previous	
research	has	been	shown	to	be	intricately	involved	in	the	activation	of	different	hormone	
secreting	pathways	(Stephens	&	Wand,	2012).	
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It	was	first	reported	by	McEwen,	Weiss,	and	Schwartz	(1968)	that	the	brain	of	rodents	is	
capable	of	responding	to	glucocorticoids,	thereby	causing	functional	changes	in	the	CNS.			
It	 was	 later	 determined	 that	 the	 hippocampus	 has	 both	 the	 mineralocorticoids,	 and	
glucocorticosteroid	 receptors,	while	 other	 parts	 of	 the	 brain	 only	 have	 glucocorticoid	
receptors	 (de	Kloet,	 Oitzl,	 &	 Joels,	 1999).	 	 Stress	 has	 been	 shown	 to	 cause	 structural	
changes	in	different	areas	of	the	brain		and	chronic	stress	can	lead	to	atrophy	of	the	brain	
(Lupien,	McEwen,	Gunnar,	&	Heim,	2009).	 	While	it	does	depend	on	the	type	of	stress,	
and	 length	of	 time	of	 the	 stressor,	 it	 is	 clear	 from	many	 studies	 that	 stress	 can	 cause	
structural	changes	in	the	brain	resulting	in	long-term	effects	on	the	entire	nervous	system	
(Reznikov	 et	 al.,	 2007).	 	 The	 structural	 changes	 of	 the	 brain	 include	 atrophy	 and	
neurogenesis	 disorders,	 and	 chronic	 stress	 has	 been	 shown	 to	 lead	 to	 an	 increase	 in	
plasma	 cortisol	 levels	which	has	been	 shown	previously	 to	 lead	 to	 a	 reduction	 in	 the	
number	of	dendritic	branches,	as	well	as	changes	in	the	synaptic	terminal	and	decreased	
neurogenesis	in	the	surrounding	tissue	(Sapolsky,	Uno,	Rebert,	&	Finch,	1990).		Studies	
have	 reported	 that	 stress	 directly	 affects	 the	 functional	 aspects	 of	 the	 CNS,	 such	 as	
sensory,	short-term	and	long-term	memory	(Wood,	Dudchenko,	Robitsek,	&	Eichenbaum,	
2000).	 	 The	 conversion	 of	 short-term	 memory	 to	 long-term	 memory	 relies	 on	 the	
hippocampus	 which	 has	 been	 shown	 to	 have	 the	 highest	 density	 of	 glucocorticoid	
receptors	 (Asagloo,	 2015).	 	 Noradrenaline	 is	 one	 of	 two	 factors	 involved	 in	memory	
process	and	creates	emotional	aspects	of	memory	in	the	basolateral	amygdala	area.		The	
second	 factor	 of	 memory	 process	 is	 facilitated	 by	 corticosteroids.	 	 If	 the	 release	 of	
corticosteroids	is	earlier	i.e.,	in	a	time	of	stress,	it	will	cause	inhibition	of	the	amygdala	
and	 subsequent	 lack	 of	 memory	 processing	 (Joels,	 Fernandez,	 &	 Roozendaal,	 2011).		
Animal	models	of	psychological	stress	have	been	useful	in	determining	the	areas	of	the	
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brain	affected	by	stress	and	the	subsequent	behavioural	changes	which	contribute	to	the	
symptoms	of	depression	and	anxiety.	
	
Brain	Regions	and	Molecular	changes	Involved	in	Psychological	Stress	
There	 are	 several	 regions	 of	 the	 brain	 that	 are	 known	 to	 be	 affected	 by	 anxiety	 and	
depression.		A	number	of	clinical	and	experimental	studies	have	observed	changes	both	
structurally	and	at	the	molecular	level.		The	table	below	gives	a	brief	overview	of	the	type	
of	animal	stress	models	and	the	symptoms	of	depression	observed	as	well	as	the	effects	
on	the	brain	and	endocrine	system.		Figure	1.9	also	displays	the	brain	regions	highlighted	
in	the	table	below.	
Table	1.1:	Animal	models	of	stress	and	the	effects	on	the	brain;	Brain	derived	neurotropic	factor	
(BDNF),	Hypothalamic	pituitary	adrenal	axis	(HPA),	Ventral	tegmental	area	(VTA).	
Model	 Symptoms	 Affected	areas/factors	 References	
Forced	swim	test	 Behavioural	
changes	
HPA	axis,	
corticosterone,	BDNF,	
zinc	transporters	
(Dou	et	al.,	2014;	Wang,	
Gu,	et	al.,	2013)	
Tail	 suspension	
test	
Behavioural	
changes	
HPA	axis,	
corticosterone,	BDNF	
(Wang,	Gu,	et	al.,	2013)	
Social	defeat	stress	 Social	avoidance	 BDNF,	VTA,	astrocyte	
degradation,		
(Krishnan	et	al.,	2007;	
Vialou	et	al.,	2014;	
Wang,	Fanous,	et	al.,	
2013)	
Reward	based	tests	 Social	avoidance,	
decreased	sugar	
preference	
VTA	dopamine	neurons	 (Chaudhury	et	al.,	
2013)	
Early	 maternal	
separation	
Memory	
impairment,	
behavioural	
changes	
Hippocampus,	HPA	axis,	
ATPase	and	Na+,	
serotonin	
(Sung	et	al.,	2010;	von	
Poser	Toigo	et	al.,	
2012)	
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Olfactory	
bulbectomy	
Anosmia,	
behavioural	
changes,	irritability	
HPA	axis,	hippocampus,	
amygdala,	pre-frontal	
cortex,	serotonergic	
system	
(Song	&	Leonard,	2005;	
Yang	et	al.,	2014)	
Chronic	
unpredictable	
stress	
Decreased	sugar	
preference,	
locomotor	activity	
and	escape	
tendency	
BDNF,	hippocampus,	
pre-frontal	cortex	
(Banerjee,	Hazra,	
Ghosh,	&	Mondal,	2014;	
Faria	et	al.,	2014)	
Learned	
helplessness	test	
Behavioural	
desperation	
Serotonergic	neurons,	
serotonin,	CRH	
(Maier	&	Watkins,	
2005)	
	
	
Figure	1.9:	Diagram	of	the	cortical	and	limbic	systems	involved	in	the	stress	response.	
Ventral	Tegmental	Area	(VTA).		(Created	with	BioRender.com	by	the	author).		
	
Changes	 in	 the	 HPA	 axis	 with	 stress	 has	 been	 linked	 to	 depression	 and	 anxiety	 in	 a	
number	of	studies.	As	stated	previously,	when	the	HPA	axis	is	stimulated,	corticosterone	
release	is	upregulated	(Keeney	et	al.,	2006).		As	seen	above	the	forced	swim	test	and	tail	
suspension	test	upregulated	corticosterone	production,	pointing	to	a	link	with	the	HPA	
axis	(Wang,	Gu,	et	al.,	2013).		The	study	also	found	a	decrease	of	BDNF,	which	is	a	nerve	
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growth	factor	found	in	the	brain	and	periphery,	in	both	stressed	groups.		BDNF	binds	with	
its	 receptor,	 tropomyosin-related	 kinase	 B	 and	 activates	 a	 number	 of	 downstream	
signalling	pathway	(Duman	&	Voleti,	2012).		While	reduced	BDNF	in	the	hippocampus	
and	prefrontal	 cortex,	appears	 to	play	an	 important	 role	 in	 the	cause	of	depression,	a	
study	by	Duman	and	Voleti	(2012),	observed	that	genetic	deletion	of	BDNF	in	rodents	
was	insufficient	to	cause	depressive	symptoms	and	therefore	would	not	be	a	target	for	
anti-depressant	treatment.		A	model	of	chronic	unpredictable	stress	also	found	that	BDNF	
protein	and	messenger	RNA	(mRNA)	levels	were	decreased	in	the	hippocampus	and	pre-
frontal	cortex	(Banerjee	et	al.,	2014).		In	contrast,	sub-threshold	social	defeat	stress	has	
been	 observed	 to	 increase	 BDNF	 in	 the	 Ventral	 Tegmental	 Area	 of	 the	 brain	 stem	
(Krishnan	et	al.,	2007).	 	The	study	found	an	association	between	VTA-BDNF	elevation	
after	social	defeat	stress	and	increased	vulnerability	to	psychostimulants	(Wang,	Fanous,	
et	al.,	2013).		The	VTA	is	also	a	brain	region	known	to	be	affected	by	stress.		Within	this	
region	of	the	brain	there	are	dopamine	neurons	which	play	a	crucial	role	in	mediating	the	
stress	 response.	 	 One	 study	 observed	 increased	 phasic	 firing	 of	 the	 VTA	 dopamine	
neurons	 in	 the	 reward-based	 tests	 of	 social	 defeat	mice	which	 induced	 a	 susceptible	
phenotype	 of	 depression	 with	 social	 avoidance	 and	 decreased	 sucrose	 preference	
observed	(Chaudhury	et	al.,	2013).		
Another	model	 of	 stress	which	 has	 been	used	 to	measure	 depression	 is	 the	 early	 life	
stress	model.		This	model	involves	mother	rats	being	separated	from	their	pups,	one	day	
after	birth.	Several	studies	have	used	this	model	to	measure	changes	to	the	brain	and	one	
study	found	that	repeated	stress	decreased	cell	proliferation	and	increased	apoptosis	in	
the	hippocampus	of	the	maternal	rat	brain	(Sung	et	al.,	2010).		Another	study	of	maternal	
separation	observed	a	decrease	in	hippocampal	sodium	and	adenosine	triphosphatase	
(ATPase)	activity	and	concluded	that	the	withdrawal	of	rat	pups	causes	mothers	to	be	
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more	 susceptible	 to	 neurochemical	 alterations	 (von	 Poser	 Toigo	 et	 al.,	 2012).	 	 Other	
studies	 have	 observed	 reduced	hippocampal	 volume	 and	 atrophy	 of	 the	 hippocampal	
neurons	(Balu	&	Lucki,	2009;	Spalding	et	al.,	2013).		There	is	also	evidence,	from	a	rat	
model	 of	 depression,	 that	 zinc	 levels	 and	 zinc	 transporting-associated	 proteins	 are	
decreased	in	the	hippocampus	after	psychological	stress.		As	zinc	is	an	important	cofactor	
involved	with	biochemical	processes	in	the	brain,	this	change	could	greatly	affect	other	
molecular	aspects	(Dou	et	al.,	2014).		
Several	 rodent	 studies	 have	 observed	 synaptic	 loss	 in	 the	 cortical	 and	 limbic	 areas,	
especially	 in	 the	 prefrontal	 cortex	 and	 hippocampus	 regions	 that	 control	 emotion	 in	
response	 to	 psychological	 stress	 (McEwen	 &	 Morrison,	 2013).	 	 Other	 brain	 imaging	
studies	have	shown	that	depression	is	associated	with	atrophy	in	prefrontal	cortex	and	
hippocampus	volume	(MacQueen	&	Frodl,	2011).		One	particular	model	of	social-defeat	
stress	has	 found	 that	neuronal	activity	 is	 reduced	 in	 the	medial	prefrontal	 cortex	and	
astrocyte	degradation	is	increased	(Vialou	et	al.,	2014).	 	Other	experimental	studies	of	
the	prefrontal	cortex	 investigated	the	role	of	astrocyte	degradation	 in	development	of	
depressive	 symptoms	 and	 found	 a	 positive	 correlation	 between	 the	 factors	 (Domin,	
Szewczyk,	Wozniak,	Wawrzak-Wlecial,	&	Smialowska,	2014).	 	The	olfactory	centre	is	a	
part	of	the	limbic	system,	including	the	amygdala	and	hippocampus,	which	are	known	to	
contribute	to	emotional	and	memory	components	of	behaviour	(Song	&	Leonard,	2005).		
Bilateral	olfactory	bulbectomy	is	a	procedure	which	results	in	the	changes	of	behaviour	
often	seen	in	patients	with	major	depression.		Studies	using	this	method	have	found	that	
neuronal	 degradation	 occurs	 throughout	 the	 pre-frontal	 cortex,	 hippocampus	 and	
amygdala	resulting	in	dysfunction	of	the	noradrenergic	systems	of	the	HPA	axis	(Song	&	
Leonard,	2005;	Yang	et	al.,	2014).		
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Several	models	of	stress	have	observed	changes	and	deficiencies	in	serotonin	within	the	
brain.		The	study	of	early	life	stress	found	that	serotonin	depletion	occurs	over	the	course	
of	 the	 stress	 period	 (Sung	 et	 al.,	 2010).	 	 The	 model	 of	 stress	 involving	 olfactory	
bulbectomy	has	 also	demonstrated	dysfunction	of	 the	 serotonergic	 system	within	 the	
HPA	axis	(Yang	et	al.,	2014).		The	learned	helplessness	test	had	similar	findings	where	
the	uncontrollable	nature	of	the	stressor	lead	to	serotonergic	neuron	sensitisation	and	
subsequent	exaggerated	release	of	 serotonin	(Maier	&	Watkins,	2005).	 	These	studies	
implicate	serotonin	as	a	major	cause	of	behavioural	changes	observed	in	the	rodents	and	
indicate	 that	 the	 use	 of	 Selective	 serotonin	 reuptake	 inhibitors	 (SSRI’s)	may	mediate	
these	changes.		SSRI’s	act	by	blocking	reuptake	of	serotonin	into	the	pre-synaptic	neuron	
thereby	 increasing	 the	 amount	 of	 serotonin	 in	 the	 synapse.	 SSRI’s	 will	 be	 further	
discussed	in	the	following	experimental	chapters.	
	
Psychological	Stress	and	Bladder	dysfunction	
Bladder	pathologies	 such	 as	 overactive	bladder	 (OAB),	 interstitial	 cystitis	 and	painful	
bladder	 syndrome	 (IC/PBS)	 are	 common	 in	 the	 general	 population	 and	 even	 more	
common	with	age	(Teleman	et	al.,	2004).	 	OAB	 is	 characterised	by	urinary	 frequency,	
nocturia	and	urgency	with	or	without	incontinence.		The	cause	of	OAB	has	been	a	highly	
debated	 topic	 for	many	years,	with	 two	main	 theories	being	proposed;	myogenic	 and	
neurogenic	 (Haferkamp,	 Dorsam,	 Resnick,	 Yalla,	 &	 Elbadawi,	 2003),	 while	 in	 many	
instances	the	pathophysiology	of	OAB	remains	idiopathic.		IC/PBS	is	a	chronic	condition	
which	occurs	when	the	lining	of	the	bladder	is	constantly	irritated	(Torpy,	2012)	and	is	
characterised	by	pelvic	 pain	 and	 irritative	 voiding	 symptoms	 in	 the	 absence	 of	 lower	
urinary	tract	infection	(Sant,	2002).			The	frequent	urination	and	painful	bladder	that	is	
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caused	 by	 interstitial	 cystitis	 results	 in	 a	 reduced	 quality	 of	 life	 (Siddiqui,	 Lagesen,	
Nederbragt,	Jeansson,	&	Jakobsen,	2012).		
It	has	been	documented	that	psychological	stress	can	impact	several	visceral	functions	
with	pathological	consequences	(Smith	et	al.,	2011)	and	a	body	of	clinical	evidence	exists	
linking	bladder	disorders	with	stress,	anxiety	and	depression,	including	witness	trauma	
(Lai,	2015).		Stress	appears	to	greatly	influence	the	development	of	bladder	symptoms,	
or	worsen	symptom	severity	(Minassian,	Devore,	Hagan,	&	Grodstein,	2013).		Research	
also	suggests	that	lower	urinary	tract	dysfunction	induces	psychological	stress	symptoms	
in	both	children	and	adults	(Sinclair,	2011;	von	Gontard,	Baeyens,	Van	Hoecke,	Warzak,	
&	Bachmann,	2011).		In	spite	of	this,	there	is	little	research	on	the	precise	changes	and	
underlying	mechanisms	of	several	bladder	pathologies.	
The	two	bladder	pathologies	mentioned	above	share	some	overlapping	symptoms.		The	
severity	of	these	symptoms	was	assessed	in	a	recent	clinical	study	which	compared	stress	
levels	of	OAB,	IC/PBS	and	control	patients;	using	a	series	of	questions	all	related	to	the	
patient’s	psychological	stressors,	and	the	number	of	times	the	patient	needed	to	urinate.		
The	study	found	that	OAB	patients	reported	psychological	stress	 levels	 just	as	high	as	
those	 reported	 by	 IC/PBS	 patients,	 with	 both	 groups	 of	 patients	 experiencing	
significantly	higher	stress	levels	compared	to	the	healthy	controls.		This	study	reported	
that	 there	 is	 a	 positive	 correlation	 between	 perceived	 stress	 levels	 and	 urinary	
incontinence	symptoms	(Lai,	2015).	
In	another	study	by	the	same	group,	it	was	observed	that	half	of	OAB	patients	experienced	
anxiety	 like	 symptoms,	 while	 a	 quarter	 of	 the	 OAB	 patients	 experienced	 acute	 to	
moderate	 anxiety.	 	 OAB	 patients	 with	 anxiety	 reported	 having	 more	 severe	 OAB	 or	
incontinence	symptoms	which	impacted	their	quality	of	life.		The	study	concluded	that	
there	was	a	trend	toward	higher	urinary	frequency	in	patients	with	anxiety	(Lai.,	2016).		
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While	 the	 studies	above	have	observed	 the	 correlation	of	 stress	and	OAB	at	one	 time	
point,	 another	 study	has	observed	 incidence	and	remission	rate	of	OAB	over	a	1-year	
period.		Participants	were	all	females	who	had	returned	from	US	Army	deployment	in	the	
previous	 two	 years.	 	 The	 study	 looked	 at	 the	 impact	 of	 depression,	 anxiety,	 post-
traumatic	 stress	 disorder	 (PTSD)	 and	 lifetime	 sexual	 assault	 on	 OAB	 incidence	 and	
remission	rates.		One	thousand	and	seven	women	were	eligible	to	participate	in	the	study	
and	of	those	women,	22%	identified	OAB	symptoms	at	the	beginning	of	the	year.		New	
OAB	occurred	more	often	in	women	with	baseline	anxiety	at	the	beginning	of	the	year.		It	
was	 concluded	 that	 anxiety	predicted	1-year	 incidence	of	OAB.	 It	was	also	 found	 that	
remission	of	OAB	occurred	less	in	those	with	baseline	depression	and	anxiety	(Bradley,	
2017).	 	The	 study	demonstrates	 that	 anxiety	 can	 influence	 the	natural	progression	of	
OAB.		
Bladder	 dysfunction	 has	 been	 observed	 amongst	 various	 groups	 of	 people	 including	
sexual	 abuse	 survivors.	 	 Seventy-two	 percent	 of	 sexual	 abuse	 survivors	 report	
experiencing	 urinary	 incontinence	 symptoms	 compared	 to	 controls	 (22%)	 (Davila,	
Bernier,	Franco,	&	Kopka,	2003).				A	number	of	clinical	studies	have	observed	the	effects	
of	stress	on	development	of	IC/PBS.	 	One	particular	study	investigated	the	correlation	
between	 childhood	 sexual	 trauma	and	 IC/PBS	 incidence	 in	 later	 life.	 	 Female	patients	
were	 questioned	 about	 their	 symptoms	 of	 IC/PBS	 and	 any	 childhood	 trauma.	 	 It	was	
found	 that	before	17	years	of	age,	 IC/PBS	cases	were	 increased	 in	participants	with	a	
history	of	 being	 raped	or	molested.	 	Within	 this	 group,	 participants	 reported	 sensory	
pain,	depression	and	poorer	physical	quality	of	 life	 compared	 to	 the	 controls	without	
IC/PBS	symptoms.	 	 It	was	concluded	 that	women	with	a	history	of	 sexual	 trauma	are	
more	likely	to	develop	IC/PBS	symptoms	later	in	life	(Nickel	et	al.,	2011).	
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The	clinical	evidence	reported	above	shows	that	there	is	a	definite	correlation	between	
psychological	stress	and	bladder	dysfunction.		While	this	gives	a	basic	indication	of	the	
impact	of	 stress	on	 the	bladder,	 the	mechanisms	underlying	 this	dysfunction	 remains	
unknown.		Some	research	groups	have	attempted	to	fill	this	knowledge	gap	using	rodent	
models.		
Experimental	studies	in	rodents,	see	Table	1.2,	typically	focus	on	two	different	forms	of	
psychological	stress:	water	avoidance	stress	and	social	defeat	stress.		These	models	will	
be	discussed	in	greater	detail	within	the	experimental	chapters.		Water	avoidance	stress	
replicates	acute	 stress	and	 is	 repeated	 for	a	 length	of	 time	 to	 simulate	ongoing	stress	
(Smith	et	al.,	2011)	while	social	defeat	stress	replicates	social	stress	and	as	a	model	for	
depression	(Hollis	&	Kabbaj,	2014).		Most	recent	studies	have	focused	on	rats	and	have	
observed	 the	 effects	 of	 psychological	 stress	 on	 voiding	 function.	 	 This	 is	 where	 the	
knowledge	 gap	 becomes	 more	 apparent,	 where	 studies	 such	 as	 Wang	 et	 al.	 (2017)	
observe	 the	 effects	 of	 psychological	 stress	 on	 brain	 function	 related	 to	 regulation	 of	
micturition	 and	 Smith	 et	 al.	 (2011)	 observe	 changes	 in	 voiding	 activity.	 	 Isolated	
functional	bladder	responses	have	received	little	attention.		
	Wang	et	al.	(2017)	used	female	Wistar-Kyoto	rats	and	exposed	them	to	10-days	of	water	
avoidance	 stress.	 	 Brain	 function	 was	 assessed	 using	 autoradiography	 and	 bladder	
function	was	assessed	using	cystometrograms	and	the	study	found	that	stressed	animals	
demonstrated	 a	 decreased	 pressure	 threshold	 and	 visceromotor	 threshold	 triggering	
during	the	voiding	phase,	compared	to	the	control	rats.		Water	avoidance	stressed	rats	
also	displayed	greater	activation	of	the	cortical	region	of	the	central	micturition	circuit.		
Overall,	 the	 study	 found	 that	 water	 avoidance	 stress	 animals	 experienced	 visceral	
hypersensitivity	during	bladder	filling.		The	stressed	rats	also	had	increased	engagement	
of	 portions	 of	 the	micturition	 circuit	 which	 lead	 to	 bladder	 contraction	 (Wang	 et	 al.,	
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2017).		Smith	et	al.	(2011)	observed	voiding	frequency	of	stressed	rats	more	closely	than	
the	previous	study.		In	this	study,	it	was	found	that	rats	exposed	to	water	avoidance	stress	
developed	a	significant	increase	in	micturition	frequency.		The	study	also	discovered	that	
stress	 decreased	 latency	 to	 void,	 volume	 to	 void	 and	 the	 volume	 of	 the	 first	 void	
compared	to	the	baseline	of	the	control	rats.		Histology	also	revealed	that	in	stressed	rats,	
there	was	increased	angiogenesis	and	increased	activated	mast	cells	(Smith	et	al.,	2011).		
This	finding	was	supported	by	Matos	(2017),	who	also	found	that	mast	cell	infiltration	
was	increased	in	the	mucosa	of	stressed	rats.		This	study	was	based	on	the	theory	that	
chronic	adrenergic	stimulation	produces	pain	and	bladder	changes	mediated	by	alpha	1A	
adrenoceptor	mechanisms.	 	 The	 study	 found	 that	water	 avoidance	 stress	 reproduces	
signs	 of	 nociception	 and	 bladder	 changes	 that	 occur	 in	 patients	with	 IC/PBS	 (Matos,	
2017).	 	 The	 finding	 by	Matos	 (2017)	 is	 supported	 by	 another	 study	which	 observed	
chronically	 stressed	Wistar	 Kyoto	 rats.	 	 The	 rats	 exposed	 to	 chronic	 stress	 exhibited	
enhanced	responses	to	urinary	bladder	filling	and	significant	stress	induced	changes	in	
nociceptive	responses	to	mechanical	stimuli	(Robbins,	DeBerry,	&	Ness,	2007).			
Other	stress	models	have	also	been	used	to	study	the	effects	of	stress	models	on	bladder	
function.		While	this	will	be	discussed	in	further	detail	in	the	following	chapters,	there	are	
physiological	bladder	changes	which	occur	with	different	forms	of	psychological	stress.	
For	example,	the	effect	of	social	stress	in	particular	has	been	found	to	decrease	voiding	
frequency	and	 increase	voided	volume	while	also	 increasing	 the	amount	of	 the	 stress	
neuropeptide	CRF	mRNA	in	the	Barrington’s	nucleus	neurons	located	within	the	pontine	
micturition	centre	(PMC)	(Butler	et	al.,	2018).		This	corresponds	to	the	study	by	Mann	
(2015)	which	found	that	chronic	social	defeat	results	 in	an	altered	voiding	phenotype	
indicative	of	urine	retention.		Studies	have	also	found	that	this	altered	voiding	phenotype	
corresponds	to	bladder	wall	remodelling,	increasing	bladder	mass	(Chang	et	al.,	2009).		
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Contradictory	 to	 this,	 another	 study	 has	 found	 that	 social	 stress	 induced	 TRPV1-
dependent	 nerve	 activity	 leading	 to	 increased	 urinary	 frequency	 and	 an	 overactive	
bladder	phenotype	(Mingin	et	al.,	2015).	 	The	neonatal	maternal	stress	model	has	also	
been	 investigated	 and	was	 found	 to	 increase	bladder	hypersensitivity	 in	 female	mice.	
Hypersensitivity	was	further	exacerbated	by	water	avoidance	stress	(Pierce	et	al.,	2016).		
See	Table	1.2	below	for	abbreviated	 list	of	both	clinical	and	experimental	research	on	
psychological	stress	and	bladder	dysfunction.			
Both	human	and	animal	studies	consistently	establish	the	effects	of	psychological	stress	
on	bladder	function,	however,	despite	this	growing	clinical	and	experimental	evidence,	
the	 precise	 changes	 and	 underlying	 bladder	 mechanisms	 have	 received	 very	 little	
attention.	 	In	addition,	very	few	studies	to	date	have	assessed	the	potential	benefits	of	
current	drug	treatments	in	stress	induced	bladder	dysfunction.		One	study	looked	at	the	
effect	of	mirabegron,	β3	adrenoceptor	agonist,	solifenacin,	M3	muscarinic	antagonist	and	
duloxetine,	 serotonin	 and	 norepinephrine	 reuptake	 inhibitor	 (SNRI),	 on	 reducing	
overactive	bladder	correlated	with	psychological	stress	and	found	that	the	only	drug	that	
made	a	significant	difference	was	duloxetine.		In	this	case,	Duloxetine	was	able	to	reverse	
the	symptoms	of	overactive	bladder	co-existing	with	depression	via	an	action	in	central	
nervous	pathways	(Wrobel	et	al.,	2020).		The	effect	of	pharmaceutical	drugs	on	bladder	
dysfunction	caused	by	psychological	stress	will	be	further	discussed	in	Chapter	5.	
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Hypothesis	and	Overall	Aim	
Psychological	 stress	 and	 bladder	 dysfunction	 affect	 a	 large	 proportion	 of	 society	
however,	 it	 is	 still	 unclear	 as	 to	 the	 exact	 effects	 of	 psychological	 stress	 on	 bladder	
function.		It	is	hypothesised	that	due	to	the	known	influence	psychological	stress	has	on	
other	disease	and	pathologies,	it	will	also	contribute	to	bladder	dysfunction.	If	this	is	the	
case,	it	can	then	be	postulated	that	both	psychological	and	bladder	pharmaceuticals	may	
have	an	effect	in	reducing	this	dysfunction.		
This	 thesis	 aims	 to	 further	 investigate	 the	 pathophysiological	 pathways	 and	 increase	
knowledge	 of	 the	mechanisms	 causing	 changes	 in	 lower	 urinary	 tract	 (LUT)	 function	
following	stress.		It	also	aims	to	provide	sufficient	evidence	as	to	the	most	appropriate	
and	 beneficial	 pharmacotherapies	 for	 use	 in	 patients	 with	 urological	 dysfunction	
associated	with	chronic	psychological	stress.
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Table	1.2:	Comparison	of	clinical	and	experimental	studies	looking	at	the	effects	of	psychological	stress	on	bladder	dysfunction.	
Author,	 year,	
journal	
Title	 Experimental	Model	 General	conclusions	
Clinical	Studies	
Bradley,	et	al.	2017	
–	 American	 Journal	
of	Obstetrics	
Longitudinal	 associations	 between	
mental	health	conditions	and	overactive	
bladder	in	women	veterans	
Computer-assigned	
telephone	 interviews	 at	
enrolment	and	1	year	later	of	
female	veterans	
-	 New	 OAB	 occurred	 in	 women	 with	 baseline	
anxiety	
-	Anxiety	and	 lifetime	sexual	 assault	predicted	
1-year	incident	OAB	
-	 Anxiety,	 depression	 and	 prior	 sexual-assault	
influenced	natural	progression	of	OAB	
Nickel,	et	al.	2011	–	
Canadian	Urological	
Association	
Childhood	sexual	trauma	in	women	with	
interstitial	 cystitis/bladder	 pain	
syndrome:	a	case	control	study	
Psychological	 phenotyping,	
psychosocial	 parameters	 and	
quality	 of	 life	 questionnaires	
of	female	IC/PBS	patients	
-	 IC/PBS	 cases	 reported	 higher	 prevalence	 of	
rape	and	molestation	compared	to	controls	
-	 IC/PBS	 cases	 reported	 greater	 sensory	 pain,	
depression	and	poorer	physical	quality	of	life	
-	Childhood	trauma	is	more	common	in	IC/PBS	
patients	
Lai,	 et	 al.	 2016	 –	
Elsevier	Inc.	
The	 Relationship	 Between	 Anxiety	 and	
Overactive	 Bladder	 or	 Urinary	
Incontinence	 Symptoms	 in	 the	 Clinical	
Population	
Anxiety	and	depression	were	
assessed	 using	 Hospital	
Anxiety	and	Depression	Scale	
in	 patients	 diagnosed	 with	
OAB	
-	 Half	 of	 OAB	 patients	 had	 anxiety	 while	 a	
quarter	had	symptoms	of	anxiety	
-	OAB	patients	have	psychosocial	difficulties		
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Lai,	 et	 al.	 2015	 –	
BMC	Urology	
Correlation	between	psychological	stress	
levels	 and	 the	 severity	 of	 overactive	
bladder	symptoms	
Patients	 with	 OAB	 were	
assessed	 using	 perceived	
stress	scale	
-	 OAB	 patients	 reported	 psychological	 stress	
levels	as	high	as	IC/PBS	patients	
-	Positive	correlation	between	perceived	stress	
levels	and	urinary	incontinence	symptoms	
Davila,	et	al.	2003	–	
The	 Journal	 of	
Urology	
Bladder	 Dysfunction	 in	 Sexual	 Abuse	
Survivors	
Sexual	 abuse	 survivors	
completed	 a	 questionnaire	
regarding	OAB	symptoms	and	
sexual	abuse	history	
-	 Sexual	 abuse	 survivors	 had	 a	 significantly	
higher	rate	of	OAB	symptoms		
	
Gontard,	 2012	 –	
Neurourology	 and	
Urodynamics	
Does	 psychological	 stress	 affect	 LUT	
function	in	children?	
Psychological	 evaluation	
using	 parental	 behavioural	
questionnaires		
-	 Psychological	 symptoms	 may	 be	 a	 result	 of	
lower	urinary	tract	dysfunction	in	children	
Sinclair,	 et	 al.	 2011	
–	 The	 Obstetrician	
and	Gynaecologist		
The	 psychosocial	 impact	 of	 urinary	
incontinence	in	women	
Review	 of	 results	 from	
psychosocial	questionnaires	
-	 Incontinent	 women	 often	 have	 anxiety	 and	
embarrassment	with	their	condition	
-	Women’s	sexual	function	and	relationships	are	
often	affected	
	
Experimental	Studies	
Wang,	et	 al.	2017	–	
Public	 Library	 of	
Science	
Effects	 of	 water	 avoidance	 stress	 on	
peripheral	and	central	responses	during	
bladder	filling	in	the	rat.	
Water	avoidance	stress	-		
Female	Wistar-Kyoto	rats	
-	 Decreased	 pressure	 threshold	 for	 triggering	
the	voiding	phase	
-	 Greater	 activation	 of	 the	 cortical	 regions	 of	
micturition	circuit	
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Matos,	et	al.	2017	–	
Naunyn	
Schmiedebergs	
Archives	 of	
Pharmacology	
The	 water	 avoidance	 stress	 induces	
bladder	pain	due	to	a	prolonged	alpha1A	
adrenoceptor	stimulation.	
Water	avoidance	stress	-		
Female	Wistar	rats	
-	Increased	urinary	noradrenaline		
-	Decreased	mechanical	pain	threshold	
-Induced	lymphocytic	and	mast	cell	infiltration	
in	mucosa	
-	 Alpha	 1A	 adrenoceptor	 stimulation	 plays	 an	
important	role	in	bladder	pain	in	rats	
Yamamoto,	 et	 al.	
2012	 –	
International	
Journal	of	Urology	
Water	 avoidance	 stress	 induces	
frequency	 through	 cyclooxygenase-2	
expression:	a	bladder	rat	model.	
Water	avoidance	stress	-		
Rat	
-	 Shorter	 voiding	 intervals	 and	 less	 volume	 in	
Water	Avoidance	Stress	(WAS)	mice	
-	 Higher	 levels	 of	 cyclo-oxygenase	 2	 (COX-2)	
protein	in	WAS	bladders	
Smith,	et	al.	2011	–	
Journal	of	Urology	
The	 effects	 of	 acute	 and	 chronic	
psychological	stress	on	bladder	function	
in	a	rodent	model	
Water	avoidance	stress	-		
Wistar	rats	
-	Micturition	frequency,	interval	and	volume	
Lee,	 et	 al.	 2015	 –	
Physiology	
Behaviour	
Chronic	 psychological	 stress	 in	 high-
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This	 chapter	will	 specify	 the	materials	 and	general	methodology	used	 throughout	 the	
studies.		Specific	information	regarding	the	experimental	stress	protocols	will	be	detailed	
in	the	subsequent	experimental	chapters.	
	
ANIMALS	
Approval	 for	 this	 project	 was	 obtained	 from	 the	 University	 of	 Queensland	 Animal	
Research	Ethics	Committee	 (BOND/536/17).	 	Adult	 female	or	male	C57BL/6JArc	 and	
ARC(S)	 mice	 were	 obtained	 from	 the	 Animal	 Resource	 Centre	 (Canning	 Vale,	 WA,	
Australia).	 	Mice	were	housed	 for	one	week	prior	 to	experimental	use	 in	a	 controlled	
environment	with	12-hour	light/dark	cycles,	temperature	23oC	with	free	access	to	food	
and	water.	
	
VOIDING	PATTERN	ANALYSIS	
Voiding	 pattern	 analysis	 (VPA)	 is	 a	 semi-quantitative	 method	 that	 has	 been	 used	
previously	to	assess	changes	in	voiding	behaviour	in	rodents	and	the	method	used	here	
has	been	previously	used	by	our	research	group	(West,	Lang,	Sellers,	Chess-Williams,	&	
McDermott,	2018).	 	Voiding	pattern	analysis	was	generally	carried	out	as	stated	here,	
apart	 from	 the	 recovery	 protocol	which	was	 undertaken	 for	 20	 days.	 	 This	 change	 is	
discussed	in	more	detail	in	Chapter	4	part	2.		
	Voiding	pattern	analysis	was	performed	prior	to	(baseline)	and	at	intervals	(1,	3,	5,	7	and	
10-days)	during	and	following	the	stress	protocols.	 	Standard	mouse	cages	were	lined	
with	‘Filtech’	hardened	ashless	filter	paper,	Quantitative	2	µm	grade	225.		The	mice	were	
placed	individually	into	the	lined	cage	for	4	hours	at	the	beginning	of	the	light	cycle,	7am.		
During	this	time,	the	mice	were	supplied	with	food	and	drinking	water.	 	Water	bottles	
were	weighed	before	and	after	voiding	pattern	analysis	to	monitor	water	consumption.		
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After	 the	 4-hour	 period,	 VPA	 filter	 papers	 were	 collected.	 	 Faecal	 pellets	 were	 also	
collected	after	the	analysis	period	and	were	dried,	counted	and	weighed.		Voiding	events	
were	quantified	by	assessing	urine	spots,	detected	using	a	Molecular	Imager	ChemiDoc	
XRS	ultraviolet	transilluminator	(#720BR1293	BioRad,	California	USA).		The	papers	were	
photographed,	digitized,	and	then	analysed	using	Image	J	software,	considering	both	the	
size	(surface	area)	and	number	of	voids.	 	Figure	2.1	shows	two	representative	voiding	
pattern	analysis	photographs	of	A,	control	female	mice	and	B,	stressed	female	mice.	
	
Figure	2.1:	Representative	voiding	pattern	analysis	images	from	A)	control	and	B)	water	
avoidance	stress	(stressed)	animals	at	day	5	(Photographs	taken	by	the	author).	
	
BLOOD	COLLECTION	AND	PLASMA	CORTICOSTERONE	MEASUREMENTS	
At	the	end	of	the	experimental	protocol,	mice	were	euthanized	by	cervical	dislocation	and	
blood	was	collected	for	quantification	of	plasma	corticosterone.		Five	hundred	µL	of	blood	
was	taken	from	the	thoracic	cavity	and	placed	into	a	heparin	blood	collection	tube	for	
centrifugation.	 	The	blood	was	centrifuged	 for	15	minutes	at	900	rpm	to	separate	 the	
blood	cells	from	the	plasma.		The	plasma	was	then	collected,	placed	into	an	Eppendorf	
and	frozen	at	-80oC.		
A	Corticosterone	Competitive	ELISA	kit	(Invitrogen)	was	used	to	quantify	the	amount	of	
corticosterone	in	the	plasma	of	stressed	and	control	mice	and	was	performed	according	
to	the	manufacturer’s	instructions.		To	perform	the	assay,	corticosterone	stock	solution	
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was	used	to	make	up	8	standards	and	50µL	of	standards	or	samples	were	added	to	each	
well	in	duplicate.		Seventy-five	µL	of	ELISA	assay	buffer	was	added	to	one	well	to	detect	
non-specific	binding	(NSB).		Twenty-five	µL	of	the	ELISA	corticosterone	conjugate	was	
then	added	to	each	well,	followed	by	another	25	µL	of	ELISA	corticosterone	antibody	to	
all	wells,	except	the	wells	to	detect	NSB.		The	plate	was	then	incubated	for	1	hour	at	room	
temperature	on	a	plate	shaker.		After	incubation,	the	solution	was	aspirated	and	washed	
from	the	wells	4	times	with	300	µL	of	wash	buffer.		Once	washed	thoroughly,	100	µL	of	
tetramethylbenzidine	 (TMB)	 substrate	 was	 added	 to	 each	 well	 and	 incubated	 for	 a	
further	30	minutes	without	shaking.	 	After	the	second	incubation,	50	µL	of	ELISA	Stop	
Solution	was	added	to	each	well.		The	plate	was	gently	mixed	until	the	solution	turned	
from	blue	to	yellow	(Chemical,	2018).	
The	absorbance	was	then	read	on	the	Modulus	Microplate	Multimode	Reader	(Turner	
Biosystem	inc.)	at	450	nm,	within	10	minutes	of	applying	the	Stop	Solution.		Once	read,	
NSB	readings	were	subtracted	from	all	samples	and	standards.			A	four-parameter	curve	
fit	was	produced	using	Prism	8	software	and	concentrations	of	unknown	samples	were	
generated	from	the	standard	curve.		An	example	of	the	standard	curve	is	given	below	in	
Figure	2.2.	
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Figure	2.2:	Representative	Corticosterone	standard	curve	prepared	using	Corticosterone	
Competitive	ELISA	kit,	absorbance	analysed	using	a	Modulus	Microplate	Reader.	
	
	
GENERAL	WHOLE	BLADDER	PREPARATION		
A	whole	bladder	preparation	was	used	for	functional	bladder	studies.		The	protocol	was	
previously	used	by	our	research	group	(West	et	al.,	2018).	 	Mice	were	sacrificed	using	
cervical	dislocation	and	placed	onto	a	dissection	board.		Surgical	grade	scissors	were	used	
to	 cut	 through	 layers	 of	 fur	 and	 skin	 of	 the	mouse	 below	 the	 rib	 cage.	 	 This	 process	
exposes	the	gastrointestinal	tract	which	was	then	lifted	out	of	the	body	and	removed	by	
cutting	 through	colon	and	connective	 tissue.	 	The	abdominal	region	of	 the	mouse	was	
then	separated	from	the	upper	body	of	the	mouse	by	cutting	through	the	spine,	above	the	
kidneys.		The	lower	half	was	then	turned	to	remove	the	skin	and	fur.		The	tail	and	lower	
limbs	were	then	removed,	and	the	abdominal	section	of	the	animal	was	placed	into	Krebs-
bicarbonate	solutions	(8mL)	and	gassed	with	95%	O2	and	5%	CO2.		
Using	a	dissection	microscope,	surrounding	connective	tissue	was	removed	to	expose	the	
ureters.		Note	that	sex	differences	will	be	described	in	following	chapters.		The	ureters	
were	then	ligated	using	sewing	thread.		The	connective	tissue	above	the	pubic	symphysis	
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was	then	cut	away	until	the	cartilage	of	the	pubic	symphysis	was	visible.		Once	located,	
the	pubic	symphysis	was	cut	down	the	middle	and	removed.		The	external	urethral	orifice	
was	removed	and,	using	2x	magnification	of	the	microscope,	the	three-way	catheter	was	
inserted	through	the	urethra	and	up	into	the	bladder.		The	urethra	was	then	ligated	by	
cutting	 up	 the	 vagina	 on	 either	 side	 of	 the	 urethra,	 being	 careful	 not	 to	 release	 the	
catheter.		At	this	time,	the	ureters	were	then	ligated	a	second	time	closer	to	the	bladder.		
This	was	 to	 ensure	 that	 the	 ureters	were	 completely	 secured	before	 the	 bladder	was	
removed	from	the	abdominal	cavity.		Once	the	bladder	was	removed	as	pictured	in	Figure	
2.3.B,	it	was	placed	into	an	8	mL	bath	of	Krebs-bicarbonate	solution	at	37⁰C.		
The	three-way	catheter	was	attached	to	an	infusion	pump	filled	with	Krebs-Bicarbonate	
solution	and	was	set	to	deliver	30	µL	per	minute	of	Krebs	to	the	bladder.	Also	attached	
was	 a	 pressure	 transducer	 which	 measured	 the	 pressure	 inside	 the	 bladder	 and	
transmitted	 this	 to	 the	 Lab	 Chart	 program	 for	 analysis.	 	 An	 outflow	 syringe	was	 also	
attached	to	allow	intraluminal	fluid	to	be	collected	(Figure	2.3A).		The	bladder	was	filled	
to	40	mmHg	to	assess	viability	and	catheterisation.		
	
Figure	2.3:	(A)	Schematic	displaying	the	three-way	catheter	set	up.	(B)	Whole	bladder	
preparation	 attached	 to	 three-way	 catheter.	 (Reproduced	with	 permission	 from	 Farr	
(2015)).		
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FUNCTIONAL	PHYSIOLOGICAL	STUDIES	
Collection	of	Intravesical	and	Serosal	Fluid	to	Quantify	Mediator	Release	
Once	assessed	as	viable,	the	bladder	was	emptied	for	10	minutes.		The	bladder	was	then	
filled	to	20	mmHg	twice,	and	at	this	time	samples	of	intraluminal	and	serosal	fluid	were	
collected.	 	 The	 outflow	 tap	 allowed	 for	 intraluminal	 fluid	 to	 be	 collected	 during	 the	
emptying	period	after	filling	to	20	mmHg.		800	µL	of	serosal	fluid	was	also	collected	from	
the	8	mL	bath	at	a	constant	sample	site,	beside	the	bladder.		Samples	were	stored	at	-80⁰C	
for	later	assay	of	ATP	and	ACh.		The	bladder	was	filled	once	more	to	20	mmHg	and	left	to	
equilibrate	for	30-minutes.		The	final	fill	to	20	mmHg	was	quantified	and	assessed	as	a	
pressure-volume	 relationship	 to	 measure	 bladder	 compliance.	 	 The	 30-minute	
equilibration	 period	 was	 used	 to	 assess	 the	 stretch-relaxation	 of	 the	 bladders	 by	
measuring	 the	 time	 versus	 pressure	 relationship.	 	 The	 amplitude	 and	 frequency	 of	
spontaneous	activity	was	also	 assessed	during	 this	 time.	 	An	example	of	 spontaneous	
activity	is	given	below	in	Figure	2.4.	
	
Figure	 2.4:	 Representative	 trace	 showing	 amplitude	 and	 frequency	 of	 spontaneous	
activity	in	a	control	animal.	
	
	
Electrical	Field	Stimulation	
To	investigate	the	effects	of	stress	on	nerve-mediated	responses	of	the	bladder,	electrical	
field	 stimulation	 (EFS)	 was	 performed	 after	 the	 30-minute	 equilibration	 period.			
Platinum	electrodes	attached	to	an	electrical	stimulator,	were	placed	into	the	bath	to	sit	
 
 
51 
on	either	 side	of	 the	bladder,	allowing	 for	an	electrical	 field	 to	be	passed	 through	 the	
bladder.	 	 After	washing	with	Krebs-bicarbonate	 solution,	 the	 bladder	was	 electrically	
stimulated	 (50	 V),	 every	 100	 seconds	 for	 5	 seconds,	 at	 1,	 5,	 10,	 and	 20	Hz.	 	 At	 each	
frequency,	the	bladder	was	stimulated	at	least	4	times,	until	3	consistent	responses	were	
achieved.	 	 The	 contractions	were	measured	 as	pressure	 change	 from	baseline	 and	 an	
example	of	frequency-response	is	given	below	in	Figure	2.5.	
	
Figure	2.5:	Representative	frequency	response	trace	in	an	isolated	bladder	from	a	control	
animal	during	electrical	field	stimulation	for	5	seconds,	every	100	seconds.		Responses	to	
1,	5,	10	and	20	Hz	are	shown,	each	stimulus	being	0.1	ms	duration	at	50	V:	Hertz	(Hz).	
	
EFS	was	also	completed	at	20	Hz	in	the	absence	and	presence	of	pharmacological	agents	
towards	the	end	of	the	experiment.		The	first	agent	that	was	added	to	the	bath	was	the	
competitive	 inhibitor	 of	 nitric	 oxide	 synthase,	 Nω-nitro-L-arginine	 (L-NNA)	 (100	 µM).		
After	4	contractions	at	20	Hz,	the	muscarinic	receptor	antagonist	atropine	(1	µM)	was	
added	to	the	bath	and	the	bladder	was	again	stimulated	at	20	Hz.		The	EFS	stimulator	was	
switched	off	and	the	purinergic	agonist	alpha,	beta-methylene	adenosine	triphosphate	
(αβ-mATP)	(1	mM)	was	added	to	the	bath	twice	and	left	for	5	minutes	to	desensitize	the	
purinergic	 receptors.	 	 EFS	was	 then	 repeated	 in	 the	presence	of	 αβmATP	and	 after	 4	
contractions,	tetrodotoxin	(TTX;	1	µM)	was	added	to	the	bath	while	EFS	continued.		It	is	
important	 to	 note	 that	 throughout	 the	 EFS	 process	with	 pharmacological	 agents,	 the	
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bladder	was	not	washed.		The	bladder	was	only	washed	after	EFS	stimulation	with	TTX.		
After	this,	a	60	mM	potassium	chloride	(KCl)	solution	was	used	to	fill	the	entire	bath,	to	
measure	a	final	contraction.	
	
Response	to	Pharmacological	Agents	
To	 investigate	 the	 effects	 of	 stress	 on	 receptor-mediated	 bladder	 responses,	
pharmacological	 agents	 were	 added	 to	 the	 bath	 in	 order	 to	 act	 on	 the	 muscle	 and	
subsequent	 pressure	 changes	 were	 measured.	 	 Contractile	 responses	 to	 purinergic	
stimulation	were	assessed	using	ATP	(10	mM)	and	αβ-mATP	(1	mM).		After	stimulation	
with	ATP	the	bladder	was	washed	and	the	muscarinic	agonist	carbachol	was	added	to	the	
bath	 in	 3-fold	 incremental	 concentrations	 to	 produce	 a	 cumulative	 concentration-
response	curve	(Figure	2.6).		The	maximum	carbachol	dose	concentration	examined	was	
6.84	 µM	 because	 concentrations	 above	 this	 were	 found	 in	 preliminary	 studies	 to	
desensitize	tissues.		Once	responses	were	recorded,	the	bladder	was	washed	with	fresh	
Krebs-bicarbonate	solution	and	until	pressure	returned	to	initial	baseline.		
	
Figure	2.6:	Representative	 trace	 showing	 intravesical	 pressure	 responses	of	 a	 control	
isolated	whole	bladder	preparation	to	the	muscarinic	agonist	carbachol.	
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Once	stable,	684.1	nM	of	carbachol	was	added	to	increase	initial	pressure.		The	bladder	
was	 left	 for	 15	 minutes	 to	 stabilize	 before	 obtaining	 an	 isoprenaline	 concentration-
response	curve.		During	this	15-minute	period,	the	frequency	and	amplitude	of	carbachol	
induced	phasic	contractions	were	measured.		Once	stable	isoprenaline,	a	non-selective	β-
adrenoreceptor	agonist	which	causes	bladder	relaxation,	was	added	to	the	bath	in	3-fold	
incremental	concentrations.		Once	the	isoprenaline	curve	was	recorded,	the	bladder	was	
washed	again	with	fresh	Krebs-bicarbonate	solution	and	allowed	to	return	to	baseline	
pressure.	 	 All	 contractions	 and	 relaxation	 responses	 were	 measured	 as	 a	 change	 in	
pressure	from	baseline.		
	
UROTHELIAL	MEDIATOR	ASSAYS	
Quantification	of	Acetylcholine	
To	 measure	 ACh	 present	 in	 the	 intraluminal	 and	 serosal	 samples,	 the	 Amplex	 Red	
Acetylcholine	 (Molecular	Probes)	Assay	kit	was	used	according	 to	 the	manufacturer’s	
instructions.		The	assay	works	by	acetylcholinesterase	converting	the	ACh	present	in	the	
sample	or	standard	to	choline	which	is	then	oxidised	to	betaine	and	hydrogen	peroxide	
(H2O2).	 	 When	 combined	 with	 horseradish	 peroxidase	 (HRP),	 H2O2	 reacts	 with	 the	
Amplex	Red	reagent	which	produces	a	fluorescent	product,	resorufin.		
Briefly,	 the	 samples	were	diluted	with	1	X	Reaction	buffer	and	a	positive	 control	was	
made	by	diluting	20	mM	H2O2	working	solution	with	10	µL	of	1	X	Reaction	buffer.		One	
hundred	µL	of	both	the	samples	and	controls	were	added	to	each	well	on	a	96	well	plate.		
A	working	solution	was	made	by	mixing	of	200	µL	Amplex	Red	reagent,	100	µL	HRP	stock,	
100	µL	choline	oxidase,	100	µL	acetylcholinesterase	and	9.5	mL	of	1	X	Reaction	buffer.		
One	hundred	µL	of	the	Amplex	Red	reagent/HRP/choline	oxidase/acetylcholinesterase	
was	added	to	each	well	containing	samples	and	controls.		The	plate	was	then	incubated,	
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while	protected	from	light,	for	30	minutes	at	room	temperature.		The	fluorescence	of	the	
samples	and	standards	were	then	measured	by	using	a	Modulus	Microplate	Multimode	
Reader	using	an	excitation	range	of	530-660	nm	and	emission	detection	at	approximately	
590	nm.		A	standard	curve	of	known	ACh	concentrations	was	generated	using	Prism	8	
software	(Figure	2.7).		Unknowns	were	interpolated	using	linear	regression	analysis.	
	
Figure	2.7:	Representative	ACh	standard	curve	prepared	using	Amplex	Red	Ach	assay	kit,	
fluorescence	analysed	using	a	Modulus	Microplate	Reader,	r2	=	0.9998.	
	
Quantification	of	ATP		
ATP	 present	 in	 intraluminal	 and	 serosal	 samples	 was	 quantified	 using	 the	 ATP	
Luciferin/Luciferase	ATP	Determination	Kit	(Molecular	Probes).		This	bioluminescence	
assay	uses	recombinant	firefly	luciferase	and	the	substrate	D-luciferin	to	determine	ATP	
concentrations	of	the	standards	and	samples.		In	the	presence	of	ATP,	luciferin	converts	
to	oxyluciferin,	which	produces	light	as	a	by-product.		
Briefly,	low-concentration	ATP	standard	solutions	were	made	by	diluting	5	mM	ATP	in	
dH2O.		The	standard	reaction	solution	was	made	by	mixing	8.9	mL	dH2O	with	0.5	mL	20	
X	Reaction	buffer,	0.1	mL	0.1	M	DTT,	0.5	mL	of	10	mM	D-luciferin	and	2.5	µL	of	firefly	
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luciferase.		Ten	µL	of	the	standards	and	samples	and	90	µL	of	standard	reaction	solution	
were	added	to	each	well	on	a	96	well	plate.		Luminescence	was	measured	using	a	Modulus	
Microplate	 Reader	 with	 emission	 maximum	 of	 approximately	 560	 nm.	 	 ATP	
concentrations	were	quantified	from	a	standard	curve	of	known	ATP	concentrations	and	
was	constructed	in	Prism	8	software	using	linear	regression	analysis	(Figure	2.8).	
	
Figure	2.8:	Representative	ATP	standard	curve,	measured	using	the	ATP	Determination	
Kit	and	luminescence	analysed	in	a	Modulus	Microplate	Reader,	r2	=	0.9999.	
	
	
STATISTICS	
All	graphical	analysis	and	statistical	analysis	were	performed	using	GraphPad	Prism	8	
(GraphPad	Software,	San	Diego,	USA).			Data	is	presented	as	mean	±	standard	error	of	the	
mean	 (SEM).	 	 All	 curve	 and	 time	 point	 analysis	 were	 undertaken	 using	 non-linear	
regression	analysis	to	construct	concentration-response	and	frequency-response	curves,	
and	curve	fit	analysis	was	used	to	compare	curves	between	groups	and	generate	EC50	or	
IC50	 values.	 	 The	 EC50	 value	 is	 the	 concentration	 of	 drug	 that	 gives	 half	 the	maximal	
response	while	the	IC50	value	is	the	concentration	of	drug	that	inhibits	the	responses	by	
50%.	 	Specific	 statistical	analysis	will	be	discussed	 in	 the	 following	chapters.	The	null	
hypothesis	was	rejected	when	p<0.05.	
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SOLUTIONS	
Krebs	bicarbonate	solution	was	made	up	as	follows	(mM).		NaCl	118,	NaHCO3	24.9,	CaCl2	
1.9,	MgSO4	1.15,	KCl	4.7,	KH2PO4	1.15,	and	D-glucose	11.7.	 	All	reagents	were	obtained	
from	Sigma	Aldrich	Co	in	St.	Louis,	USA.		The	carbogen	gas	(95%	O2	and	5%	CO2)	used	
throughout	the	whole	bladder	preparations	was	obtained	from	BOC	Gasses	Australia.	
	
DRUGS	
All	of	the	drugs	used	in	the	whole	bladder	preparation	studies	are	listed	below	in	Table	
2.1.	 	 The	 concentrations	 of	 the	 drugs	 used	 in	 experiments	 were	 derived	 from	
concentrations	used	previously	in	the	literature.	 	All	drugs	were	obtained	from	Sigma-
Aldrich	(SA)	and	Cayman	Chemical	Company	(CCC).	
	
Table	2.1:	Pharmacological	agents	used	in	experiments	
Compound	 Main	Action	 Solvent	 Cat	No.	
1-[3’,4’-Dihydroxyphenyl]-2-
isopropyl-aminoethanol	
(isoprenaline)	
t-adrenoceptor	agonist	 H2O	 I5627	
u, t-Methyleneadenosine	 5’-
triphosphate	 lithium	 salt	
(u, tmATP)	
P2X	receptor	agonist	 H2O	 M6517	
Adenosine	 5’-triphosphate	
disodium	salt	(ATP)	
P2	purinoceptor	agonist	 H2O	 A7699	
Atropine	Sulfate	Salt	 Non-selective	 muscarinic	
antagonist	
H2O	 A0257	
Carbamylcholine	 chloride	
(carbachol)	
Cholinergic	 receptor	 agonist	
(muscarinic	>nicotinic)	
H2O	 C240-9	
Nw-Nitro-L-Arginine	(L-NNA)	 Nitric	oxide	synthase	inhibitor	 H2O	 N-1522	
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The	results	presented	in	this	chapter	have	been	published:	West	EG,	Sellers	DJ,	Chess-
Williams	R	and	McDermott	C.	(2020).	“Voiding	behaviour	and	efferent	bladder	function	
altered	in	mice	following	social	defeat	but	not	witness	trauma”.	Front.	Physiol.	11:247.	
doi:	https://doi.org/10.3389/fphys.2020.00247.	
Under	CC	BY	4.0	licence.	
INTRODUCTION	
As	covered	in	the	previous	chapter,	psychological	stress	affects	a	large	portion	of	society	
and	 is	 known	 to	 promote	 behavioural	 and	 psychological	 disturbances,	 in	 addition	 to	
affecting	physical	health	(Schneiderman	et	al.,	2005).		In	fulfilment	of	the	overall	aims	of	
this	thesis,	 two	different	stress	models	were	used	to	determine	the	effects	of	different	
forms	 of	 psychological	 stress	 on	 bladder	 function.	 	 This	 chapter	 describes	 the	 social	
defeat	and	witness	trauma	mouse	model	which	is	clinically	relevant	as	experiencing	or	
witnessing	traumatic	events	has	been	shown	to	increase	the	risk	of	developing	anxiety,	
depression,	and	PTSD.				
	
Socially	Induced	Stress:	Social	Defeat	and	Witness	Trauma	Model	
The	 witness	 trauma	 and	 social	 defeat	 mouse	 model	 is	 a	 relatively	 new	 model	
representative	of	social	stress,	which	aims	to	distinguish	between	the	effects	of	physical	
(social	defeat)	and	emotional	(witness)	social	stress,	while	also	introducing	a	component	
of	 social	 support	 (Li,	 Xu,	&	Wang,	2018).	 	There	are	 three	main	 types	of	 social	 stress	
(DeLamater	&	Ward,	2013);		
• Abrupt	and	severe	changes	in	life	events	
• Chronic	strains	which	are	defined	as	persistent	events	and	
• Daily	hassles	which	are	minor	events	which	do	not	require	minimal	adaptation	
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As	the	witness	trauma	and	social	defeat	murine	model	experimental	protocol	occurs	over	
a	10-day	period,	it	is	a	protocol	representative	of	chronic	stress.		Repeated	exposure	to	
stress	leads	to	habituation	in	many	animal	models	(Herman,	2013).		Habituation	occurs	
when	 the	 stressor	 becomes	 regimental	 and	 predictable.	 	 The	 rate	 of	 habituation	 is	
dependent	on	the	type	and	severity	of	the	stressor	(Bhatnagar,	Huber,	Nowak,	&	Trotter,	
2002).	It	can	result	in	decreased	responses	to	stressors	upon	repeated	exposure	leading	
to	 cumulative	 glucocorticoid	 secretion	 (Grissom	 &	 Bhatnagar,	 2009).	 	 However,	
habituation	is	less	likely	to	occur	in	the	witness	trauma	and	social	defeat	model	as	social	
stress	has	uncertain	and	unpredictable	outcomes	(Herman,	2013).		These	factors	result	
in	chronic	stress	leading	to	anxiety	and	depression.		
There	are	several	regions	of	the	brain	‘recruited’	in	the	case	of	unpredictable	social	stress.		
This	stress	response	is	multifaceted	and	results	in	enhanced	activity	of	the	HPA	axis.		As	
discussed	 in	 the	previous	chapter,	 increased	activity	of	 the	HPA	axis	 leads	to	elevated	
glucocorticoid	 production	 and	 engagement	 of	 anxiety-like	 behaviours	 (Kinzig	 et	 al.,	
2003).	 	There	 is	also	an	 increase	 in	drive	 to	 the	pre-frontal	 cortex	of	 the	brain	which	
subsequently	causes	endocrine,	behavioural	and	metabolic	dysfunction	(Flak,	Solomon,	
Jankord,	 Krause,	 &	 Herman,	 2012).	 	 This	 stress	 response	 is	 critical,	 however,	 when	
prolonged	 studies	 have	 associated	 this	 response	 with	 affective	 disorders	 such	 as	
depression	and	chronic	anxiety	(Kinzig	et	al.,	2003).		
Chronic	 stress	 disorders,	 such	 as	 anxiety,	 depression	 and	 PTSD	 have	 been	 linked	 to	
several	 different	 health	 problems.	 	 Comorbidity	with	 other	mental	 disorders,	 such	 as	
chronic	anxiety	and	depression,	is	common	in	PTSD	sufferers.	 	One	study	in	particular	
has	 observed	 that	 90%	of	 people	with	 PTSD	will	 have	 at	 least	 one	 lifetime	 comorbid	
mental	 disorder	 (Kessler,	 Sonnega,	 Bromet,	 Hughes,	 &	 Nelson,	 1995).	 	 Several	 other	
studies	 have	 linked	 stress	 with	 bone	 and	 joint	 disorders,	 cardiovascular	 conditions,	
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neurological	 conditions,	 respiratory	 conditions	 and	 metabolic	 disease	 (Sareen	 et	 al.,	
2007).		
Several	clinical	studies	have	investigated	correlations	between	psychological	stress	and	
bladder	pathologies.		Stress	appears	to	greatly	influence	or	worsen	symptom	severity	of	
bladder	 pathologies	 (Lai,	 2015).	 	 Overactive	 bladder	 in	 particular	 has	 been	 linked	 to	
traumatic	events	in	both	childhood	and	adult	life	(Bradley,	2017).		While	this	information	
gives	an	indication	of	the	impact	of	psychological	stress	affecting	the	bladder,	very	little	
information	is	available	on	the	exact	mechanisms	underlying	this	dysfunction.		
Traditional	rodent	models	of	social	stress	use	the	subordination	of	one	male	by	a	larger,	
more	aggressive	male	to	simulate	a	socially-induced	psychological	stressor	which	leads	
to	 anxiety	 and	 depressive	 behaviour	 patterns	 (Golden,	 Covington,	 Berton,	 &	 Russo,	
2011).	 	 An	 early	 study	 by	 Blanchard	 and	 Blanchard	 (1977)	 observed	 aggressive	
behaviour	between	‘intruder’	rats	and	colonies	of	laboratory	rats.		The	study	found	that	
when	the	male	rat	is	placed	with	the	aggressive	rat,	the	subordinate	male	will	assume	
supine	posture	and	emit	frequent	calls	of	distress,	which	has	been	labelled	as	‘freezing	
behaviour’.		The	social	defeat	model	is	not	only	a	test	of	physical	stress	but	also	measures	
the	 effect	 of	 continued	 psychogenic	 exposure	 after	 the	 protective	 barrier	 is	 placed	
between	 the	 dominant	 and	 submissive	 (Hollis	&	Kabbaj,	 2014).	 	 Another	 early	 study	
investigated	the	acquisition	of	self-administered	cocaine	after	social	stress	using	in	vivo	
micro	dialysis.		The	study	examined	behavioural	and	dopaminergic	responses,	to	social	
defeat,	in	previously	exposed	social	defeat	rats	and	rats	that	had	never	experienced	social	
defeat.	 	 Rats	 that	 had	previously	 been	 exposed	 to	 social	 defeat	 acquired	 cocaine	 self-
administration	in	half	the	time	of	non-defeated	rats	(Tidey	&	Miczek,	1997).		This	study	
demonstrates	 persistent	 emotional	 stress	 that	 the	 social	 defeat	 paradigm	may	 inflict.	
After	exposure	to	the	aggressor,	submissive	rats	and	mice	exhibit	elevated	glucocorticoid	
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levels	 and	hyperthermia,	which	 is	noted	 to	 take	many	hours	 to	 recover	 (Tornatzky	&	
Miczek,	1993).						
The	social	defeat	studies	mentioned	above,	however,	do	not	consider	the	effect	of	indirect	
trauma	 on	 a	 witness.	 	 Many	 studies	 have	 found	 clear	 associations	 between	 direct	
exposure	 to	 a	 traumatic	 event	 and	 the	 development	 of	 PTSD,	 anxiety	 and	 depression	
(Patki,	 Salvi,	 Liu,	 &	 Salim,	 2015).	 	 There	 has	 been	 less	 examination	 however,	 of	 the	
development	 of	 psychological	 disorders	 in	 persons	with	 indirect	 exposure	 to	 trauma.			
Studies	have	found	that	among	the	specific	 types	of	 traumatic	exposure,	sexual	abuse,	
followed	 by	 exposure	 to	 crime	 and	witnessing	 violence	most	 frequently	 led	 to	 PTSD	
(Perrin	et	al.,	2014).		For	this	reason,	a	new	model	has	been	designed	and	implemented	
into	 recent	 studies	 (Sial,	 Warren,	 Alcantara,	 Parise,	 &	 Bolanos-Guzman,	 2016).	 	 This	
model	 replicates	both	 the	 social	 and	physical	 stress	 in	 socially	defeated	mice	 and	 the	
emotional	stress	in	witness	mice,	and	when	repeated	over	time	to	simulate	chronic	stress.	
There	 have	 been	 several	 studies	 using	 models	 of	 social	 defeat	 which	 have	 reported	
altered	voiding	behaviour	of	male	rodents.		Chang	et	al	(2009)	observed	the	voiding	of	
both	the	dominant	and	submissive	animals	of	a	social	defeat	model	and	found	that	while	
voiding	 in	 the	dominant	 animals	 remains	unchanged,	 the	 submissive	 rodents	develop	
characteristics	 of	 urinary	 retention	 (Chang	 et	 al.,	 2009).	 	 Similarly,	 Mann	 (2015)	
observed	this	trend	with	social	defeat	mice	having	a	single	large	void.		These	changes	in	
voiding	 behaviour	 were	 also	 accompanied	 by	 bladder	 wall	 hypertrophy,	 increased	
bladder	capacity	and	the	upregulation	of	CRF	 in	Barrington’s	nucleus	neurons	(Wood,	
Baez,	 Bhatnagar,	 &	 Valentino,	 2009).	 	 While	 these	 studies	 have	 been	 successful	 in	
assessing	the	voiding	dysfunction	of	socially	defeated	mice,	the	underlying	mechanisms	
associated	with	this	dysfunction	are	still	generally	unknown.		Also,	the	combined	social	
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defeat/witness	 trauma	 model	 has	 never	 been	 used	 to	 investigate	 effects	 on	 bladder	
function.	
	
Aims	
The	aim	of	the	present	study	was	to	investigate	the	effects	of	a	social	defeat	and	witness	
trauma	model	on	murine	bladder	function.		Specific	aims	were:	
• To	 investigate	 the	 effects	 of	 witness	 trauma	 and	 social	 defeat	 on	 voiding	
behaviour.	
• To	assess	the	effects	of	witness	trauma	and	social	defeat	on	serum	corticosterone	
levels.	
• To	 determine	 the	 effects	 of	witness	 trauma	 and	 social	 defeat	 on	 local	 bladder	
function	 including	 compliance,	 contractile	 responses,	 and	 urothelial	 mediator	
release.	
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METHODS		
	
Animals	
Adult	male	C57BL/6J	 (12-14	weeks	old)	mice	were	used	as	 social	defeat	and	witness	
animals,	while	ex-breeder	ARC(S)	mice	were	used	as	aggressors.		All	mice	were	obtained	
and	 housed	 as	 outlined	 in	 the	 general	 methodology	 chapter	 (Chapter	 2)	 randomly	
allocated	 into	 one	 of	 three	 groups:	 (1)	 Control/Unstressed,	 (2)	 Social	 defeat	 and	 (3)	
Witness,	with	n=6	animals	included	in	each	group.		
	
Screening	of	Aggressors	
Male	 ex-breeder	 ARC(S)	 mice	 were	 housed	 individually	 and	 screened	 for	 persistent	
aggressive	 behaviour	 using	 test	 C57BL/6J	 mice	 prior	 to	 experimental	 work.	 	 The	
screening	protocol	is	one	that	has	previously	been	described	using	two	different	types	of	
aggressor	 strains,	 ARC(S)	 and	 CD1	 (Keeney	 et	 al.,	 2006;	 Sial	 et	 al.,	 2016).	 	 Due	 to	
availability,	 ARC(S)	 ex-breeders	were	 used	 for	 the	 experimental	 protocol.	 	 Screening	
involved	placing	an	ARC(S)	and	test	C57BL/6J	mouse	in	the	plexiglass	chamber	shown	in	
Figure	3.1.		The	removable	panel	was	lifted,	and	initial	time	to	attack	was	recorded	within	
a	maximum	5-minute	period.	 	To	be	 labelled	aggressive,	aggressor	mice	had	 to	attack	
within	the	first	60	seconds	of	interaction	for	3	consecutive	days,	over	a	5-day	period	(Sial	
et	 al.,	 2016).	 Of	 10	 aggressive	 mice,	 4	 were	 labelled	 as	 aggressive	 and	 used	 for	 the	
following	stress	protocol.		
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Witness	Trauma/Social	Defeat	Stress	Protocol	
A	 joint	model	of	social	defeat	(physical	stress)	and	witness	trauma	(emotional	stress)	
was	employed	using	a	variation	of	the	methods	previously	described	(Golden,	Covington,	
Berton,	&	Russo,	2015;	Li	et	al.,	2018;	Sial	et	al.,	2016).	
Adult	male	C57BL/6J	mice	(12-14	weeks)	were	housed	together	in	pairs	for	3-days	prior	
to	and	during	the	10-day	stress	protocol,	to	allow	for	bonding.		The	mice	were	randomly	
allocated	 to	 either	 the	 social	defeat	or	witness	 trauma	experimental	 group.	 	 C57Bl/6J	
pairs	were	placed	into	the	custom-made	plexiglass	chamber	with	one	ARC(S)	aggressor	
mouse	for	1	hour	per	day	for	10-days.		The	witness	mouse	was	physically	separated	from	
the	other	mice	during	the	1-hour	stress	protocol	by	a	transparent	perforated	wall	but	
could	observe	interactions	between	its	cage	mate	and	the	aggressor	ARC(S)	mouse.		The	
social	defeat	mouse	was	in	physical	contact	with	the	aggressor	ARC(S)	for	a	maximum	of	
5	minutes.		After	5	minutes,	the	ARC-1	mouse	was	separated	from	the	social	defeat	animal	
by	a	transparent	perforated	barrier	for	55	minutes,	so	the	mice	could	still	smell	and	see	
each	other.	 	This	protocol	was	repeated	 for	10	consecutive	days	with	Voiding	Pattern	
Analysis	taking	place	on	days	0,	1,	3,	5,	7	and	10	as	described	in	Chapter	2.			
To	maintain	aggression,	aggressor	mice	were	used	in	rotation,	so	social	defeat	mice	did	
not	encounter	 the	same	aggressor	on	consecutive	days.	 	 Several	aspects	of	aggressive	
behaviour	were	recorded,	including	latency	to	attack	(seconds)	and	how	many	bouts	of	
aggression	occurred.		A	‘bout’	of	aggression	was	defined	as	grabbing	and	pulling,	biting	
and	following	or	chasing.		It	was	also	noted	if	the	aggressors	drew	blood	and	at	what	time.		
To	minimize	risk	of	wounding,	all	social	defeat	sessions	were	observed	continuously,	and	
the	animals	separated	if	the	social	defeat	mouse	exhibited	clear	submissive	behaviour,	
including	 submissive	 posture	 or	 freezing.	 	 If	mice	were	 defeated	 before	 the	 5-minute	
interaction	period	ended,	mice	were	separated	early	using	the	plexiglass	barrier	shown	
 
 
65 
in	Figure	3.2.		Wounding,	but	not	superficial	scratches,	is	associated	with	innate	immune	
response	(Foertsch	et	al.,	2017)	and	through	all	the	observed	defeat	sessions,	no	social	
defeat	 animals	 received	wounds	 requiring	 their	 exclusion	 from	 the	 experiment.	 	 Age	
matched	control	C57Bl/6J	pairs	were	housed	under	normal	conditions	for	the	duration	
of	the	study.	
	
Figure	3.1:	Photograph	of	witness	trauma	and	social	defeat	chamber	(Photograph	taken	
by	the	author).		
	
	
Figure	3.2:	Diagram	of	social	defeat	and	witness	trauma	chamber	(Image	created	by	the	
author).	
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Whole	bladder	preparations	
Whole	 bladder	 preparations	 were	 performed	 as	 described	 in	 Chapter	 2,	 with	 the	
following	differences	due	to	sex	of	mice.		When	the	abdominal	region	was	secured	to	the	
dissection	 bath	 under	 the	 dissection	 microscope,	 male	 reproductive	 organs	 were	
removed	 including	 the	 testes,	prostate	and	surrounding	connective	 tissue.	 	The	whole	
bladder	preparation	then	continued	as	described	in	Chapter	2.		
	
Statistical	Analysis	
Two-way	 ANOVA	 with	 Tukey’s	 post	 hoc	 test	 for	 multiple	 comparisons	 was	 used	 to	
compare	the	different	time	points	and	voiding	variables.		The	same	statistical	tests	were	
also	 used	 to	 analyse	 the	 concentration-response	 curves.	 One-way	 ANOVA	 with	
Bonferroni	 post-hoc	 test	 was	 used	 to	 compare	 differences	 between	 the	 three	 animal	
groups	 (urothelial	mediator	 release	 data,	 animal	 parameters,	 spontaneous	 contractile	
activity	data,	contractile	responses	to	ATP	and	KCl).	
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RESULTS	
Animal	Parameters	and	Voiding	Behaviour	
During	 the	 stress	 exposure	 period,	 animal	 body	 weight	 and	 water	 consumption	 was	
measured	on	day	0	to	obtain	baseline	data	shown	below	(Table	3.1).		The	body	weight	
and	water	 consumption	 of	mice	was	 also	measured	 on	 day	 1,	 3,	 5,	 7	 and	 10.	 	 These	
parameters	were	unchanged	throughout	the	stress	protocol	and	neither	the	social	defeat	
or	witness	trauma	stress	affected	the	body	weight	or	water	consumption	over	time.	
Bladder	weight	was	measured	at	the	end	of	the	whole	bladder	preparation	protocol	and	
there	was	no	difference	between	the	unstressed,	social	defeat	or	witness	groups	as	seen	
below	(Table	3.1).	
	
At	the	time	of	euthanasia,	a	blood	sample	was	taken	for	plasma	corticosterone	analysis.		
Figure	3.3	below	shows	a	plasma	corticosterone	level	of	24.90	±	1.93	ng/mL	in	control	
(unstressed)	mice,	54.70	±	4.87	ng/mL	in	social	defeat	mice	(p	=	0.0001)	and	44.86	±	
4.66	ng/mL	 in	witness	mice	(p	=	0.0037).	 	This	significant	difference	 indicated	that	a	
hormonal	stress	response	was	present	in	both	social	defeat	and	witness	groups.		
TABLE	3.1:	Baseline	body	weight,	water	consumption	and	bladder	weight	(at	day	10)	
following	stress	protocol	in	control	(unstressed),	social	defeat	and	witness	mice.	
	 Unstressed	 Social	Defeat	 Witness	
Body	weight	(g)	 26.30	±	0.67	 26.70	±	0.68	 26.30	±	1.04	
Bladder	weight	(mg)	 22.30	±	1.18	 21.50	±	0.49	 22.96	±	0.21	
Water	consumption	(g)	 0.64	±	0.19	 0.79	±	0.23	 0.98	±	0.66	
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Figure	3.3:	Plasma	corticosterone	levels	in	mice	from	unstressed,	social	defeat	stress	and	
witness	groups.	Datum	is	represented	as	mean	±	SEM	(n	=	7).		Analysis	was	performed	
by	a	one-way	ANOVA	(***p	<	0.001,	unstressed	vs.	social	defeat)	(+p	<	0.05,	unstressed	
vs.	witness).	
	
Voiding	pattern	analysis	was	undertaken,	as	detailed	 in	Chapter	2,	 in	all	 three	animal	
groups	to	examine	changes	in	voiding	behaviour.	
Overall,	there	was	no	significant	difference	in	total	void	area	between	the	three	animal	
groups	over	time,	which	indicates	that	urine	production	was	not	affected	by	social	defeat	
or	witness	trauma	stress	(Figure	3.4.C).	 	There	was,	however,	a	significant	decrease	in	
urinary	frequency	(Figure	3.4.A),	between	the	social	defeat	group	and	both	witness	and	
unstressed	control	groups.		This	change	was	significantly	evident	following	day	3	(p	=	
0.027)	and	day	7	(p	=	0.019)	of	stress	exposure.		Although	variable	across	the	10-days	of	
stress,	average	void	size	was	significantly	increased	at	both	day	3	(p	=	0.0296)	and	day	
7	(p	=	0.0019)	in	the	social	defeat	group	compared	to	the	unstressed	controls	at	day	7	(p	
=	0.0168)	in	the	social	defeat	group	compared	to	the	witness.		This	fits	with	Figure	3.4.A	
in	that	when	the	number	of	voids	decreases,	the	average	void	size	increases,	meaning	that	
the	social	defeat	mice	are	voiding	less	frequently,	and	each	void	is	larger	than	in	controls.		
The	number	of	small	voids	less	than	0.2	cm2	(Figure	3.4.D),	was	decreased	in	the	social	
defeat,	 although	 not	 significantly,	 compared	 to	 the	 control	 and	 witness	 groups.	 	 The	
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absence	 of	 changes	 in	 both	water	 consumption	 and	 voided	 volume	 indicates	 that	 the	
change	 observed	 is	 an	 actual	 change	 in	 urinary	 frequency	 and	 not	 reduced	 urine	
production.		Voiding	behaviour	was	not	significantly	altered	in	the	witness	group.	
	
	
Figure	3.4:	Voiding	pattern	 analysis	 conducted	 in	mice	 from	unstressed,	 social	 defeat	
stress	and	witness	groups.		(A)	Number	of	voiding	events,	(B)	Average	voided	area,	(C)	
Total	voided	area	and	(D)	Number	of	small	urine	voids	smaller	than	0.2cm2.	 	Datum	is	
presented	as	mean	±	SEM	(n	=	7).	 	Analysis	was	performed	using	 two-way	repeated	
measures	ANOVA	(*p	<	0.05,	**p	<	0.01,	***p	<	0.001,	unstressed	vs.	stressed)	(#p	<	
0.05,	stressed	vs.	witness).	
	
	
At	 the	 time	of	 filter	paper	 collection	 after	 the	4-hour	 voiding	pattern	 analysis	period,	
faecal	 pellets	 were	 collected	 from	 the	 voiding	 paper	 and	 left	 to	 dry	 overnight	 to	 be	
weighed	the	next	day.		There	was	no	significant	difference	in	either	the	number	(Figure	
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3.5.A)	 or	 weight	 (Figure	 3.5.B)	 of	 the	 pellets	 between	 the	 social	 defeat,	 witness	 and	
unstressed	control	group.		
	
Figure	3.5:	Faecal	pellet	analysis	conducted	in	mice	from	unstressed,	social	defeat	stress	
and	witness	groups.	 	(A)	Number	of	faecal	pellets,	(B)	relative	weight	of	faecal	pellets.		
Datum	 is	presented	as	mean	±	SEM	(n	=	7).	 	Analysis	was	performed	using	 two-way	
repeated	measures	ANOVA.	
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Mediator	Release	
The	intraluminal	fluid,	taken	from	distended	bladders	at	20mmHg,	and	the	serosal	fluid,	
taken	from	the	bath	were	analysed	for	ATP	and	ACh	content.		The	concentration	of	each	
mediator	in	the	individual	samples	was	calculated	and	normalised	using	intraluminal	and	
serosal	volume	to	determine	 the	 total	amount	present.	 	Both	 intraluminal	and	serosal	
release	 of	 ATP	were	 not	 altered	 in	 social	 defeat	 or	witness	 trauma	 animals,	 nor	was	
serosal	 release	 of	 ACh	 (Figure	 3.6.A,	 B	 &	 D).	 	 However,	 total	 release	 of	 ACh	 into	 the	
bladder	lumen	was	greater,	and	borderline	significant,	in	the	social	defeat	group	(1.13	±	
0.16	nmoles	n=7)	when	compared	to	controls	(0.73	±	0.17	nmoles	n=7),	although	this	
change	did	not	meet	statistical	significance	(p	=	0.05)	(Figure	3.6.C).	
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Figure	3.6:	Release	of	ATP	and	ACh	into	the	(A	&	C)	intraluminal	and	(B	&	D)	serosal	fluid	
collected	following	distensions	of	isolated	bladders	from	unstressed,	social	defeat	stress	
and	 witness	 groups.	 	 Datum	 is	 represented	 as	 mean	 ±	 SEM	 (n	 =	 7).	 	 Analysis	 was	
performed	as	a	one-way	ANOVA.	
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Bladder	Compliance	and	Stretch-relaxation		
As	 a	measure	 of	 compliance,	 the	 volume-pressure	 relationship	 of	whole	 bladder	was	
assessed	during	filling	with	Krebs-bicarbonate	solution	to	a	physiological	pressure	of	20	
mmHg.		Bladder	compliance	was	not	significantly	changed	in	the	social	defeat	or	witness	
groups	compared	to	the	unstressed	controls	(Figure	3.7).		
	
	
Figure	 3.7:	 Volume-pressure	 relationship	 for	 bladders	 from	 unstressed,	 social	 defeat	
stress	and	witness	groups.		Datum	is	represented	as	mean	±	SEM	(n	=	7),	analysed	by	
two-way	ANOVA.	
	
To	measure,	bladders	were	infused	with	Krebs-bicarbonate	solution	to	a	pressure	of	20	
mmHg	at	which	point	the	perfusion	pump	was	stopped	and	outflow	tap	remained	closed.		
The	bladders	were	left	for	30	minutes	to	equilibrate	and	allow	for	the	muscle	to	stabilise.		
Over	the	course	of	30	minutes,	all	the	bladders	relaxed	from	their	 initial	pressure	and	
plateaued.		The	pressure-time	relationship	was	then	assessed	to	observe	overall	stretch-
relaxation	across	the	3	animal	groups	(Figure	3.8).		The	sharpest	decreases	in	response	
to	stretch	occurred	between	0	and	5	minutes,	and	therefore,	the	‘X’	axis	on	the	graph	is	
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extended	to	highlight	this	period.		There	was	no	significant	difference	between	any	of	the	
groups.		
	
	
Figure	3.8:	Pressure-time	relationship	for	bladders	from	unstressed,	social	defeat	stress	
and	witness	groups	after	filling	to	an	initial	pressure	of	20	mmHg.		Datum	is	represented	
as	mean	±	SEM	(n	=	7),	analysed	by	two-way	ANOVA.	
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Bladder	Contractility	and	Response	to	Electrical	Field	Stimulation	
There	was	no	significant	change	in	the	contractile	response	to	KCl	(60	mM)	across	the	
Unstressed,	social	defeat	and	witness	groups	with	mean	pressure	changes	recorded	as	
31.90	±	5.48	mmHg,	30.28	±	5.22	mmHg	and	31.30	±	2.44	mmHg	(n=7),	respectively	
(Figure	3.9).		
	
Figure	3.9:	Pressure	responses	to	KCl	(60	mM)	in	bladders	from	unstressed,	social	defeat	
stress	and	witness	groups.		Datum	is	represented	as	mean	±	SEM	(n	=	7)	and	analysed	
using	an	Ordinary	one-way	ANOVA	with	Tukey	Analysis.	
	
Increasing	frequencies	of	electrical	stimulation	elicited	frequency-dependent	increases	
in	 pressure	 in	 all	 three	 groups.	 	 The	 contractile	 responses	 to	 EFS	 were	 significantly	
enhanced	at	5,	10	and	20	Hz	(p	=	0.004,	p	=	0.001,	p	=	0.0001	respectively)	in	bladders	
from	 the	 social	 defeat	 animals	 compared	with	 the	 control	 and	witness.	 	Responses	of	
bladders	 from	witness	 animals	 to	EFS	were	unchanged	 as	 can	be	 seen	 in	Figure	3.10	
below.		
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Figure	3.10:	EFS-evoked	contraction	of	isolated	bladders	from	unstressed,	social	defeat	
stress	and	witness	mice,	at	1,	5,	10	and	20	Hz.		Responses	were	recorded	as	a	change	in	
pressure	from	baseline.		Datum	was	analysed	using	two-way	repeated	measures	ANOVA	
with	Tukeys	multiple	comparison	(**p	<	0.01,	***p	<	0.001,	social	defeat	vs.	witness)	
(##p	<	0.01,	###p	<	0.001,	social	defeat	vs.	witness).	
	
Responses	 to	 EFS	 were	 repeated	 at	 20	 Hz	 in	 the	 absence	 and	 presence	 of	 several	
pharmacological	agents	to	determine	to	relative	contribution	of	NO,	ACh	and	ATP	to	the	
responses.		
Addition	 of	 the	 NOS	 inhibitor	 LNNA	 (100	 µM)	 did	 not	 significantly	 alter	 bladder	
contraction	to	EFS	in	any	of	the	groups,	indicating	that	the	inhibitory	neurotransmitter	
NO	was	not	influencing	neurotransmission	(Figure	3.11.A).		Addition	of	the	muscarinic	
antagonist	atropine	(1	µM)	reduced	 the	responses	 to	20	Hz	EFS	by	48.50	±	7.99%	 in	
unstressed	 bladders,	 this	 change	 was	 lower	 in	 the	 social	 defeat	 and	 witness	 group,	
although	 not	 significantly	 so	 (33.30	 ±	 9.39%	 and	 32.30	 ±	 8.67%	 respectively,	 n=7)	
(Figure	3.11.A	 and	B).	 	Desensitization	of	purinergic	 receptors	with	αβmATP	 (1	mM)	
reduced	the	response	to	EFS	to	a	similar	extent	in	bladders	from	each	group	(unstressed	
41.90	±	6.53%;	social	defeat	54.80	±	8.55%;	witness	43.20	±	13.60%,	n=7),	with	no	
significant	 difference	 between	 the	 groups	 detected	 (Figure	 3.11.A	 and	 C).	 	 This	
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demonstrates	that	while	nerve-evoked	contractions	were	enhanced	by	social	defeat,	the	
relative	contribution	of	ACh	and	ATP	was	unchanged.		
	
	
	Figure	3.11:	(A)	Intravesical	pressure	responses	to	electrical	field	stimulation	at	20	Hz	
(baseline),	and	after	addition	of	L-NNA	(100	µM),	atropine	(1	µM)	and	αβmATP	(1	mM)	
to	bladders	from	unstressed,	social	defeat	stress	and	witness	mice.		Percentage	decrease	
in	 EFS	 response	 on	 addition	 of	 (B)	 atropine	 and	 (C)	 αβmATP	 to	 bladders	 from	 each	
group.	 Datum	 is	 expressed	 as	 mean	 ±	 SEM	 and	 analysed	 using	 two-way	 repeated	
measures	ANOVA	with	Dunnett’s	multiple	comparisons	test	for	(A)	and	one-way	ANOVA	
with	Dunnett’s	multiple	comparisons	test	for	(B	and	C)	(*p		<	0.05,	**p		<	0.01,	***p	<	
0.001	vs.	Baseline	(20	Hz)).	
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Responses	to	Pharmacological	Agents	
Contractile	responses	of	isolated	bladders	were	observed	following	addition	of	several	
pharmacological	agents.		These	pharmacological	agents	were	added	to	the	serosal	fluid	
and	pressure	responses	were	recorded	as	changes	from	baseline.		Purinergic	stimulation	
was	 assessed	 using	 ATP	 (10	mM)	 and	 αβmATP	 (1	mM).	 	 Responses	 to	 ATP	 (Figure	
3.12.A)	were	not	significantly	different	across	the	unstressed,	social	defeat	and	witness	
groups	(13.61	±	6.28	mmHg,	10.42	±	2.36	mmHg	and	8.09	±	2.02	mmHg	respectively,	
n=7).		
	
Figure	3.12:	Pressure	responses	to	ATP	(10	mM),	in	isolated	bladders	from	unstressed,	
social	defeat	stress	and	witness	mice.		Datum	is	represented	as	mean	±	SEM	(n	=	7)	and	
analysed	using	an	ordinary	one-way	ANOVA	with	Tukeys	comparison.	
	
The	 contractile	 response	 to	 αβmATP	 (1	 mM)	 was	 also	 recorded	 (Figure	 3.13).	 	 The	
responses	 displayed	 in	 the	 unstressed	 group	 (13.80	±	 1.84	mmHg,	 n=7)	 showed	 no	
significant	differences	when	compared	to	the	social	defeat	group	(19.20	±	4.05	mmHg,	
n=7)	and	the	witness	group	(7.88	±	1.19	mmHg,	n=7).	However,	there	was	a	significant	
difference	in	responses	between	the	social	defeat	stress	and	witness	group	(p	=	0.0156).		
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Figure	3.13:	Pressure	responses	to	{|mATP	(1	mM)	in	bladders	from	unstressed,	social	
defeat	 stress	 and	witness	mice.	 	 Datum	 is	 represented	 as	mean	 ±	 SEM	 (n	 =	 7)	 and	
analysed	using	an	ordinary	one-way	ANOVA	with	Tukey	comparison	(#p	<	0.05,	stressed	
vs.	witness).	
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Following	washout	to	baseline,	a	cumulative	concentration-response	curve	to	carbachol	
was	obtained	on	each	isolated	bladder	to	study	the	contractile	response	to	muscarinic	
stimulation	 (Figure	3.14).	 	 	 A	 two-way	ANOVA	with	Tukey	multiple	 comparisons	 test	
revealed	no	significant	difference	in	the	responses	to	carbachol	between	groups	(Figure	
3.14).		There	was	no	significant	difference	in	either	pEC50	values	or	maximal	responses	
(Table	3.2).		The	concentration	response	data	was	also	expressed	as	a	percentage	of	the	
KCl	response,	with	no	significant	difference	observed	between	the	groups.	
	
	
	
	
	
TABLE	3.2:	Whole	bladder	responses	to	carbachol	in	unstressed	controls,	social	
defeat	and	witness	mice	(n=7).	
	 Unstressed	 Social	Defeat	 Witness	
pEC50	 6.19	±	0.08	 6.04	±	0.10	 6.01	±	0.09	
Maximal	response	
∆Pressure	(mmHg)	
	
42.79	±	3.92	
	
36.66	±	3.91	
	
43.92	±	5.01	
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Figure	 3.14:	 Carbachol	 concentration-response	 curves,	 for	 isolated	 bladders	 from	
unstressed,	 social	 defeat	 stress	 and	witness	mice,	 recorded	 as	 change	 in	 intravesical	
pressure	from	baseline.		Datum	is	represented	as	mean	±	SEM	(n	=	7),	analysed	using	
non-linear	regression	and	two-way	ANOVA	with	Bonferroni’s	multiple	comparisons	test.	
	
One	 µM	 carbachol	 was	 added	 to	 the	 bath	 to	 pre-contract	 the	 bladder	 prior	 to	
measurement	 of	 relaxation	 to	 cumulative	 concentrations	 of	 isoprenaline	 (β-
adrenoceptor	 agonist).	 	No	 change	was	 evident	 in	 the	maximal	 response	 or	 the	 pIC50	
values	(Table	3.3).		
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TABLE	3.3:	Whole	bladder	responses	to	isoprenaline	in	unstressed	control,	social	
defeat	and	witness	mice	(n=7).	
	 Unstressed		 Social	Defeat	 Witness	
pIC50	 6.65	±	0.18	 6.73	±	0.31	 6.65	±	0.17	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%	Decrease)	
	
-	6.31	±	0.78	
5.14	±	12.42	
	
-4.34	±	0.35	
-17.53	±	22.05	
	
-5.26	±	0.92	
-4.37	±	18.52	
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Relaxations	 to	 isoprenaline	 were	 similar	 in	 all	 three	 groups	 when	 responses	 were	
expressed	 as	 a	 percentage	 of	 the	 carbachol	 pre-contraction.	 	 There	 was,	 however,	 a	
significant	difference	 in	maximum	relaxation	 to	 isoprenaline	 in	 the	 social	defeat	mice	
compared	to	the	unstressed	controls	at	higher	doses	(*p	=	0.01569	and	**p	=	0.0049).		
	
	
Figure	3.15:	Effect	of	 isoprenaline	on	 isolated	bladders,	 from	unstressed,	social	defeat	
stress	and	witness	mice.		(A)	Raw	datum	as	fall	in	pressure	from	pre-contraction	level,	
(B)	 Relaxation	 as	 a	 percentage	 (%)	 of	 the	 carbachol	 precontraction.	 	 Datum	 is	
represented	as	mean	±	SEM	(n	=	7),	using	two-way	ANOVA	and	non-linear	regression	
(**p	<	0.01,	***p	<	0.001,	stressed	vs.	unstressed).	
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Spontaneous	Phasic	Contractions	
During	 experiments,	 phasic	 activity	 was	 assessed	 twice;	 during	 bladder	 stretch-
relaxation	 and	 during	 the	 pre-contraction	 before	 isoprenaline	 responses	 (i.e.,	 in	 the	
presence	of	carbachol	(1	µM)).	 	The	first	was	spontaneous	contractions	of	the	bladder	
during	the	stretch-relaxation	period	from	an	elevated	intraluminal	pressure.		The	average	
frequency	(Figure	3.16.A)	and	the	amplitude	(Figure	3.16.B)	of	the	spontaneous	activity	
compared	 to	 the	 unstressed	mice	was	 increased	 in	 bladders	 from	 social	 defeat	mice,	
however	 this	 was	 not	 a	 statistically	 significant	 change.	 	 Witness	 mice	 had	 similar	
spontaneous	activity	compared	to	the	unstressed	control	mice.	
	
Figure	3.16:	Spontaneous	phasic	contractions	during	stretch-relaxation	from	unstressed,	
social	 defeat	 stress	 and	witness	mice.	 (A)	 Frequency	 of	 contractions/minute	 and	 (B)	
Amplitude	of	spontaneous	contractions.	Datum	is	represented	as	mean	±	SEM	(n	=	7),	
analysed	using	one-way	ANOVA	with	Tukey’s	multiple	comparison.	
	
The	 second	 period	 of	 phasic	 activity	 was	 measured	 following	 stimulation	 of	 a	 tonic	
contraction	with	1	µM	carbachol.	 	The	phasic	 contractions	were	measured	during	 the	
carbachol	pre-contraction	plateau.		There	was	no	significant	difference	in	either	the	tonic	
contraction,	 the	 frequency	 (Figure	 3.17.A)	 or	 amplitude	 (Figure	 3.17.B)	 of	 the	 phasic	
contractions	at	the	plateau,	across	any	of	the	animal	groups.	
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Figure	 3.17:	 Phasic	 response	 to	 1	 µM	 carbachol	 measured	 in	 isolated	 bladder	 from	
unstressed,	social	defeat	stress	and	witness	mice.	(A)	Frequency	of	phasic	contractions	
and	(B)	Amplitude	of	phasic	contractions.	Datum	is	represented	as	mean	±	SEM	(n	=	7),	
analysed	using	a	one-way	ANOVA	with	Tukey’s	analysis.	
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DISCUSSION	
An	animal	model	of	physical	and	emotional	social	stress	was	employed	to	determine	what	
impact	social	defeat	and	witness	trauma	stress	have	on	the	bladder,	and	if	both	types	of	
stressor	affect	the	bladder	in	the	same	way.	
		
Effects	of	Stress	on	Voiding	Behaviour	
Despite	 hormonal	 changes	 being	 similar	 in	 both	 the	 witness	 and	 social	 defeat	 mice,	
voiding	frequency	was	only	reduced	in	the	social	defeat	mice,	compared	to	the	control.	
This	voiding	dysfunction	has	also	been	observed	in	a	number	of	other	studies	using	the	
same	model	(Chang	et	al.,	2009;	Mann,	2015).		
The	study	by	Mann	(2015),	compared	the	altered	bladder	function	induced	by	two	types	
of	stress,	social	defeat	stress	and	chronic	restraint	stress.	 	The	study	showed	a	similar	
increase	 in	plasma	corticosterone	 levels	 in	both	animal	groups,	 as	 seen	 in	our	model.		
When	 analysing	 voiding	 pattern,	 Mann	 (2015)	 found	 that	 the	 social	 defeat	 mice	
performed	a	large	single	void	compared	to	multiple	smaller	voids	exhibited	by	the	control	
mice.		The	chronic	restraint	stressed	mice	however	showed	the	same	voiding	pattern	as	
the	control	mice.		This	is	similar	to	the	witness	mice	in	the	present	study,	where	no	change	
in	voiding	behaviour	was	observed.	 	The	 reason	 for	 this	may	 come	back	 to	 the	 social	
support	theory	discussed	above	and	by	Li	et	al.	(2018).		The	study	found	that	emotionally	
stressed	(witness)	adolescent	mice	benefited	 from	the	social	 support	gained	by	being	
housed,	 as	 a	 pair,	 with	 the	 physically	 stressed	 mice	 (social	 defeat)	 after	 aggressor	
interaction.		The	physically	stressed	mice	exhibited	impairment	of	social	interest	which	
would	suggest	 that	 this	stressed	group	 is	 less	capable	of	effectively	seeking	and	using	
social	support.		This	may	explain	why,	despite	the	similarly	raised	plasma	corticosterone	
levels	seen	in	our	study,	voiding	changes	are	less	evident	in	witness	mice.		
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While	voiding	frequency	of	the	social	defeat	mice	was	decreased,	the	average	void	volume	
increased.		However,	as	the	total	voided	volume	did	not	change	between	groups,	water	
consumption	 can	 be	 ruled	 out	 as	 the	 cause	 of	 this	 dysfunction.	 	 Several	 studies	 have	
observed	 the	 same	 trend	 in	 their	 social	 defeat	mice	 (Chang	 et	 al.,	 2009;	Mann,	 2015;	
Wood	 et	 al.,	 2009),	 however,	 the	 underlying	 mechanism	 of	 this	 urinary	 retention	
phenotype	has	never	been	discussed	in	detail.		Several	studies	have	observed	the	effect	
of	 social	 defeat	 stress	 on	 the	HPA	 axis	 and	Barrington’s	 nucleus	 (pontine	micturition	
centre)	in	relation	to	hormone	production	and	the	effect	on	the	micturition	reflex.		
A	study	by	Keeney	et	al.	(2006),	collected	the	brains	of	mice	which	had	undergone	both	
acute	and	chronic	social	defeat	stress.		The	brains	were	then	sectioned,	and	hybridisation	
was	performed	in	order	to	detect	CRF	mRNA	and	AVP	(arginine	vasopressin)	mRNA.		The	
study	found	that	CRF	mRNA	was	upregulated	after	acute	stress	while	AVP	mRNA	was	
upregulated	 in	 chronic	 social	 defeat	 mice.	 	 The	 study	 by	 Keeney	 et	 al.	 (2006)	 also	
associated	 increased	 AVP	 mRNA	 with	 a	 selective	 increase	 in	 AVP	 peptide	 hormone	
production	 and	 release	 into	 the	 portal	 system.	 	 AVP	 is	 primarily	 responsible	 for	
maintaining	body	fluid	homeostasis	and	acts	on	three	different	receptors;	V1a,	V1b	and	V2	
(Pisipati	&	Hashim,	 2011).	 	AVP	 receptors	 are	most	 commonly	 associated	with	blood	
vessel	constriction	and	fluid	reabsorption	in	the	kidneys	and	is	known	to	be	a	powerful	
vasoconstrictor.	 	 There	 have	 been	 studies,	 however,	 which	 have	 identified	 and	
characterised	 AVP	 receptors	 in	 the	 rat	 urinary	 bladder.	 	 One	 study	 used	 saturation	
binding	 experiments	 with	 radioactive	 AVP	 to	 identify	 one	 class	 of	 high-affinity,	 low-
capacity	binding	sites	in	the	bladder	(Thibonnier,	Snajdar,	&	Rapp,	1986).		The	study	then	
used	receptor	specific	antagonists	to	differentiate	between	the	V1	and	V2	AVP	receptors	
and	concluded	that	V1	AVP	receptors	were	the	main	receptor	in	the	rat	urinary	bladder	
(Thibonnier	et	al.,	1986).		A	later	study	observed	the	effect	of	in	vivo	versus	in	vitro	AVP	
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on	normal	and	obstructed	rat	urinary	bladder.		The	study	found	that	contractility	of	the	
detrusor	muscle	was	greater	in	the	normal	bladder	treated	with	AVP	compared	to	the	
obstructed	bladder	(Berggren,	Andersson,	Lundin,	&	Uvelius,	1993).		While	these	studies	
have	been	primarily	performed	on	rats	due	to	the	ease	of	working	with	a	larger	brain,	
they	 indicate	 that	 AVP	 may	 act	 on	 V1	 receptors	 on	 the	 bladder,	 thereby	 increasing	
contractile	ability	to	empty	the	bladder	on	a	single	void,	producing	the	urinary	retention	
phenotype	observed	in	our	study.		
In	terms	of	CRF,	a	study	by	Wood	et	al.	(2009),	found	that	chronic	social	defeat	of	male	
rats	also	caused	a	urinary	retention	phenotype.		The	study	looked	at	the	brains	of	stressed	
rats,	 24	 hours	 after	 the	 final	 stress	 exposure,	 and	 found	 that	 social	 defeat	 increased	
expression	of	CRF	in	the	Barrington’s	nucleus.		CRF	has	been	shown	to	have	an	inhibitory	
influence	 on	 the	 spinal	 projections	 of	 the	 Barrington’s	 nucleus,	 which	 regulate	 the	
micturition	reflex	(Pavcovich	&	Valentino,	1995).		CRF	expression	was	also	observed	to	
increase	 in	 the	 bladder	 and	 serum	 after	 psychological	 stress,	 which	 suggests	 central	
changes	are	also	at	play	(Seki	et	al.,	2019).		
	
Effects	of	Stress	on	Corticosterone	Release	
Exposure	to	physical	(social	defeat)	and	emotional	(witness)	stress	produced	a	similar	
hormonal	stress	response	in	both	animal	groups.		This	confirmed	that	the	mice	used	in	
this	study	were	stressed	when	compared	to	controls.		Many	experimental	studies	looking	
at	both	the	social	defeat	(Mann,	2015)	and	social	defeat/witness	model	(Li	et	al.,	2018;	
Sial	et	al.,	2016)	have	also	reported	increased	corticosterone	levels	in	their	animals.		
As	 stated	 in	 the	methodology,	plasma	samples	were	 collected	24	hours	after	 the	 final	
stress	exposure.		Several	studies	of	social	defeat	and	witness	trauma	have	also	observed	
the	 long-term	 release	 of	 corticosterone.	 	 One	 study	 measured	 plasma	 corticosterone	
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levels	of	both	the	witness	and	defeated	mice	40-minutes	after	the	first	stress	exposure	
and	24-hours	after	the	10th	day	of	stress.		This	method	allowed	the	group	to	compare	the	
hormonal	response	to	acute	versus	chronic	stress.		Both	witness	and	social	defeat	stress	
exposure	significantly	raised	corticosterone	 levels	after	acute	stress.	 	After	10-days	of	
stress	 exposure	 corticosterone	 levels	 were	 further	 increased,	 although	 the	 levels	 in	
witness	mice	were	never	 as	high	 as	 in	 social	 defeat	mice	 (Warren	et	 al.,	 2013).	 	 This	
correlates	with	the	data	presented	in	this	chapter	where	corticosterone	levels	of	witness	
mice	were	still	significantly	increased	compared	to	the	control	but	still	not	as	high	as	in	
the	social	defeat	mice.		
Increased	 corticosterone	 has	 been	 linked	 to	 hyperactivity	 of	 the	 HPA	 axis.	 	 This	
hyperactivity	has	been	implicated	in	the	pathogenesis	of	both	anxiety	and	depression	in	
humans	(Holsboer,	2001).	 	 	A	previous	study	 looking	at	a	murine	social	defeat	model	
observed	 the	 same	 trend	 in	 corticosterone	 levels,	 over	 four,	 eight	 and	 twelve	 stress	
exposures.	 	 The	 study	 found	 enhanced	 corticosterone	 release	 after	 twelve	 stress	
exposures	as	opposed	to	eight	and	four.	 	The	study	concluded	that	the	HPA	axis	stress	
response	 appears	 to	 adapt	 to	 short-term	acute	 stress,	 however	 after	 chronic	 stress	 it	
becomes	maladaptive	(Keeney	et	al.,	2006).		The	study	also	found	that	the	corticosterone	
response	is	also	dependent	on	the	where	the	subordinate	and	dominate	mice	are	housed.		
Another	study	by	the	same	group	found	that	living	in	close	proximity	to	the	dominant	
mouse	may	lead	to	an	‘anticipatory’	stress	of	the	HPA	axis	which	may	be	as	stimulating	
as	 actual	 perceived	 stress	 (Keeney	 &	 Hogg,	 1999).	 	 This	 indicates	 the	 importance	 of	
housing	of	animals	when	considering	the	social	defeat	model.			Housing	of	witness	and	
social	defeat	mice	has	also	been	examined	in	other	studies.		A	study	looking	at	isolation	
housing	of	social	defeat	rats	found	that	anxiety-like	behaviour	was	increased	in	animals	
housed	individually	after	stress	exposure	(Nakayasu	&	Ishii,	2008).		The	study	indicates	
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the	 importance	of	social	support	on	anxiety	behaviour	of	socially	defeated	mice.	 	This	
study	has	been	replicated	in	a	social	defeat	and	witness	model,	in	adolescent	mice,	which	
found	that	the	witness	mice	benefit	from	the	support	provided	by	pair	housing,	whereas	
the	socially	defeated	mice	do	not	benefit	and	develop	social	impairment	as	a	result	of	the	
stress	(Li	et	al.,	2018).		This	may	be	the	reason	why	there	was	slightly	reduced	plasma	
corticosterone	release	in	the	witness	group	and	no	evident	voiding	changes	in	the	present	
study.		Social	impairment	was	observed	in	the	present	study	after	stress	exposure,	when	
defeated	mice,	placed	back	in	the	cage	with	their	‘buddy’	witness	mouse,	would	initiate	
fighting	for	a	short	time.		This	social	ineptitude	of	defeated	mice	may	be	worthy	of	further	
investigation.	
	
Effects	of	Stress	on	Bladder	Physiology	
Local	bladder	mechanisms	were	investigated	to	ascertain	the	changes	which	contributed	
to	the	altered	voiding	phenotype	observed	in	the	social	defeat	mice.		A	number	of	ex-vivo	
experiments	 were	 conducted	 on	 isolated	 whole	 bladders	 after	 euthanasia.	 	 Bladder	
compliance,	 contractile	 response	 and	 serosal	 and	 urothelial	 mediator	 release	 were	
assessed.		
Release	of	signalling	molecules	from	the	bladder	urothelium	plays	an	important	role	in	
bladder	 function.	 	 Any	 change	 in	 this	 release	 has	 been	 linked	 to	 changes	 in	 bladder	
function	(Merrill	et	al.,	2016).	 	Stretch	of	the	bladder	has	been	linked	to	the	release	of	
several	mediators	including	ATP,	involved	in	purinergic	sensory	stimulation	to	promote	
the	micturition	reflex	(Yoshida	et	al.,	2009).		While	the	role	of	urothelial	ATP	released	has	
been	 discussed	within	 the	 literature	 in	 detail,	 the	 role	 of	 urothelial	 ACh	 is	 still	 being	
identified.	 	 Several	 theories	 involve	 stimulation	 of	 urothelial	 pacemaker	 activity	 and	
induced	 release	 of	 UDIF	 from	 the	 urothelium	 to	 inhibit	 detrusor	 muscle	 contraction	
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(Hawthorn	et	al.,	2000;	Templeman,	2002).		Total	ACh	release	into	the	intraluminal	fluid	
was	increased	in	the	social	defeat	stressed	group	compared	to	witness	and	unstressed	
group.		As	stated	previously,	the	role	of	urothelial	ACh	is	not	fully	understood,	however,	
there	 is	 some	 evidence	 that	 stimulation	 of	 muscarinic	 receptors	 in	 sensory	 nerves	
depresses	sensory	transduction	(Daly,	Chess-Williams,	Chapple,	&	Grundy,	2010).		Due	
to	the	fact	that	bladder	compliance	was	unchanged	across	all	groups,	there	may	be	a	link	
between	the	increased	urothelial	ACh	release	and	decrease	urinary	frequency	seen	in	the	
social	defeat	but	not	witness	group,	as	a	 larger	urine	volume	is	accommodated	before	
afferent	nerves	are	activated.			
Contractile	 responses	 to	 receptor	 independent	 (KCl)	 detrusor	 stimulation	 and	
muscarinic	(carbachol)	stimulation	were	not	affected	by	stress.		There	was	some	change	
within	the	beta-adrenoceptor	mediated	bladder	relaxation,	however,	this	can	be	linked	
to	the	slight	increase	in	the	pre-contraction	to	carbachol.		The	main	change	observed	with	
stress	was	in	purinergic	stimulated	contractions.	Stimulation	of	receptors	with	αβmATP	
produced	a	significantly	greater	pressure	response	in	bladders	from	social	defeat	mice.		
Similarly,	 the	 nerve	 mediated	 contractions	 seen	 with	 EFS	 were	 increased	 at	 all	
frequencies	in	the	social	defeat	group.		This	indicates	that	social	defeat	stress	increases	
intravesical	pressure	generated	during	voiding	contractions	which	is	likely	to	contribute	
to	the	larger	void	size	observed	during	voiding	pattern	analysis.	
The	reason	for	this	enhancement	of	the	purinergic	component	is	not	entirely	clear.		The	
response	 to	 αβmATP	 indicates	 an	 enhancement	 of	 the	 purinergic	 component	 of	 the	
bladder.		Studies	have	shown	that	there	is	co-transmission	of	ATP	and	Ach	in	the	bladder,	
and	the	purinergic	(ATP)	and	muscarinic	(Ach)	component	play	an	integral	role	in	the	
contractility	of	the	mouse	detrusor	smooth	muscle.		A	study	using	normal	male	mice	and	
P2X1-deficient	mice	 found	 that	 in	 the	 absence	 of	 P2X1	 receptors,	 atropine	 abolished	
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nearly	all	nerve-evoked	contractions	in	mice.	This	demonstrates	that	contraction	of	the	
mouse	 urinary	 bladder	 is	 dependent	 on	 both	 purinergic	 and	 muscarinic	 signalling	
(Heppner	 et	 al.,	 2009).	 	 This	 finding	 is	 also	 supported	 by	 Burnstock	 (2013),	 which	
indicated	that	there	is	equal	excitatory	co-transmission	with	purinergic	and	cholinergic	
components	working	via	P2X1	and	muscarinic	receptors	respectively.		Our	study	shows	
that	there	was	no	change	to	the	cholinergic	responses	of	the	bladder	between	any	of	the	
groups.			The	addition	of	atropine	had	a	similar	effect	on	responses	to	EFS	in	all	groups	
indicating	 no	 change	 in	 the	 cholinergic	 component.	 	 Therefore,	 with	 changes	 in	 the	
response	to	αβmATP	and	EFS	nerve-evoked	responses,	it	appears	that	social	defeat	stress	
causes	an	upregulation	in	the	purinergic	component.		
Purinergic	signalling	within	the	bladder	has	been	well	documented	to	be	involved	in	a	
number	of	physiological	 and	pathophysiological	 conditions	of	 the	 lower	urinary	 tract.		
Studies	 have	 shown	 that	 purinergic	 stimulation	 of	 P2X7	 receptors	 is	 involved	 in	
inflammation	and	fibrosis	in	the	bladder	(Knight,	2002).		Within	the	human	bladder,	3%	
of	neurotransmission	is	reliant	on	the	purinergic	component	of	stimulation,	however,	in	
diseased	conditions,	the	purinergic	component	is	increased	to	40%	(Burnstock,	2013),	
particularly	in	the	case	of	interstitial	cystitis	and	bladder	pain	syndrome	(Birder	et	al.,	
2003).		
	
	
	
	
	
	
	
 
 
92 
CONCLUSION	
The	results	presented	in	this	chapter	indicate	that	psychological	stress,	induced	by	social	
defeat	affects	voiding	and	local	bladder	function	in	male	mice.		The	enhanced	urothelial	
ACh	release	observed	 following	social	defeat	may	desensitize	bladder	afferent	nerves,	
which	coupled	with	increased	nerve	evoked	voiding	contractions	may	contribute	to	the	
decrease	 in	 urinary	 frequency	 and	 increased	 void	 size,	 previously	 referred	 to	 as	
‘retention’,	of	social	defeat	mice	but	not	witness	mice.		This	change	is	concluded	to	be	due	
to	enhanced	purinergic	responses	not	evident	within	the	witness	group.		Stress	induced	
bladder	changes	are	dependent	on	the	type	of	stressor,	with	no	voiding	changes	observed	
in	the	witness	trauma	model.	
	
	
	
	
	
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
CHAPTER	4:	EFFECTS	OF	WATER	
AVOIDANCE	STRESS	ON	BLADDER	
FUNCTION	AND	HOW	STRESS-FREE	
RECOVERY	AFFECTS	
PHYSIOLOGICAL	CHANGES	
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The	results	presented	in	Part	1	of	this	chapter	have	been	published:	West,	Eliza	G.,	
Sellers,	Donna	J.,	Chess-Williams,	Russ.,	McDermott,	Catherine.	(2020).	“Bladder	
overactivity	induced	by	psychological	stress	in	female	mice	is	associated	with	enhanced	
bladder	contractility”,	Life	Sciences,	2020,	118735,	
https://doi.org/10.1016/j.lfs.2020.118735.	Under	CC	BY	NC-ND	licence.	
	
INTRODUCTION	
Bladder	Pathologies	
Healthy	human	bladder	urodynamics	are	defined	by	low	detrusor	pressure	and	phasic	
activity	during	filling	and	adequate	flow	and	complete	emptying	during	voiding.		Several	
bladder	pathologies	affect	these	processes	leading	to	dysfunction.		
Overactive	bladder	(OAB)	is	defined	by	the	International	Continence	Society	as	urinary	
urgency,	with	or	without	urge	incontinence	and	is	usually	accompanied	by	frequency	and	
nocturia	 in	 the	 absence	 of	 urinary	 tract	 infection	 or	 other	 pathologies	 (Haylen	 et	 al.,	
2010).	 	OAB	 is	known	 to	negatively	 impact	 a	patient’s	quality	of	 life	 and	whilst	more	
common	in	older	patients,	is	also	known	to	affect	children	and	young	adults.		The	most	
common	 symptoms	 of	 OAB	 occur	 during	 bladder	 filling	 where	 patients	 experience	
micturition	 urgency	 and	 some	 associated	 incontinence	 (Arrabal-Polo	 et	 al.,	 2012).		
Neurogenic	and	myogenic	origins	are	believed	to	contribute	to	OAB.		Neurogenic	bladder	
dysfunction	often	occurs	with	other	neurological	diseases	and	injuries	such	as	spinal	cord	
injury	or	pelvic	and	sacral	fractures,	while	myogenic	dysfunction	refers	to	changes	to	the	
properties	of		the	detrusor	muscle	(Yoshimura	&	Chancellor,	2004).		In	many	instances	
though,	the	cause	of	OAB	symptoms	remains	idiopathic	(Leron,	Weintraub,	Mastrolia,	&	
Schwarzman,	2018).		
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Interstitial	 cystitis/Painful	 bladder	 syndrome	 (IC/PBS)	 is	 a	 chronic	 debilitating	
condition,	 sharing	 common	 symptoms	 with	 OAB	 including	 urinary	 urgency	 and	
frequency,	 but,	 unlike	OAB,	 is	 also	 associated	with	 pelvic	 pain	 (Marinkovic,	Moldwin,	
Gillen,	 &	 Stanton,	 2009).	 	 The	 condition	 is	 associated	 with	 local	 inflammation	 of	 the	
bladder	wall,	with	an	absence	of	bacterial	urinary	tract	infection	(Sant,	2002).		Afferent	
mechanisms	 are	 likely	 to	 contribute	 to	 pain	 experienced	 by	 a	 patient,	 however,	 the	
aetiology	of	the	symptoms	remains	unclear.		
Psychological	 stress	 can	 impact	 a	 number	 of	 visceral	 functions	 with	 pathological	
consequences,	and	a	significant	amount	of	evidence	has	linked	disorders	such	as	OAB	and	
IC/PBS	with	psychological	stress	and	stress	disorders	such	as	anxiety,	depression	and	
post-traumatic	 stress	 disorder	 (Lai,	 Morgan,	 Vetter,	 &	 Andriole,	 2016).	 	 Lai	 (2015),	
performed	a	case	control	study	to	assess	the	psychological	stress	levels	and	perceived	
stress	of	OAB	and	IC/PBS	patients	and	found	that	stress	levels	were	equally	elevated	in	
both	patient	groups,	with	a	positive	correlation	between	perceived	stress	and	urinary	
incontinence	symptoms	in	the	patients	reporting	only	OAB	compared	to	the	controls.		The	
study	concluded	 that	 there	was	an	overall	 impact	on	quality	of	 life,	which	 in	 turn	can	
further	exacerbate	symptoms	(Lai,	2015).		It	has	also	been	reported	that	childhood	sexual	
trauma	was	more	prevalent	in	patients	with	OAB	(29.4%)	compared	to	controls	(6.7%),	
with	this	group	reporting	more	pain	symptoms	and	poorer	mood,	however,	this	did	not	
correlate	 with	 the	 severity	 of	 OAB	 symptoms	 	 (Lai	 et	 al.,	 2016).	 	 A	 cohort	 study	
investigated	the	incidence	and	remission	of	OAB	in	female	US	veterans	and	identified	the	
impact	 of	 the	 symptoms	 on	 overall	 mental	 health.	 	 The	 study	 found	 that	 anxiety,	
depression	 and	 prior	 sexual	 assault	 influence	 the	 natural	 progression	 of	 OAB	 and	
recommended	that	medical	providers	should	screen	for	mental	health	conditions	with	
diagnosed	OAB	(Bradley,	2017).	
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Environmental	Stress	and	the	Water	Avoidance	Model	
While	clinical	studies	show	the	correlation	between	psychological	stress	and	exacerbated	
bladder	dysfunction,	experimental	models	of	psychological	stress	have	shown	that	stress	
may	 play	 a	 causal	 role	 in	 the	 development	 of	 bladder	 dysfunction	 (Merrill,	Malley,	 &	
Vizzard,	2013).		
Environmental	 stress	 refers	 to	 a	 subjective	 psychological	 response	 to	 changes	 in	 the	
normal	physical	environment.		The	detrimental	effects	of	chronic	stress	depend	on	how	
well	 the	 individual	adapts	to	cumulative	environmental	stress	(Clark,	Bond,	&	Hecker,	
2007).	 	For	humans,	environmental	stressors	 include	noise,	poor	housing	quality,	and	
crowding	amongst	others,	while	in	rodents	this	includes	any	change	to	normal	housing.		
This	 is	 the	 basis	 of	 the	 water	 avoidance	 stress	 model,	 a	 well-established	 model	 of	
psychological	stress	that	imitates	the	experience	of	negative	environmental	life	changes	
in	humans	(Lee	et	al.,	2016).		If	stress	is	prolonged,	it	can	have	adverse	effects	on	several	
physiological	functions	(Herman,	2013).		As	stated	previously,	the	exposure	to	physical	
and	emotional	stress	produces	a	hormonal	stress	response,	which	has	been	measured	in	
a	number	of	rodent	models	of	psychological	stress.	 	The	water	avoidance	stress	model	
has	previously	been	used	to	assess	the	development	of	bladder	dysfunction,	with	6-week-
old	 male	 mice	 developing	 moderate	 bladder	 wall	 hypertrophy	 and	 increased	 voided	
volumes	(McGonagle	et	al.,	2012).		However,	water	avoidance	stress	in	female	Wistar	rats	
is	reported	to	increase	micturition	frequency	and	urinary	noradrenaline,	in	addition	to	
reducing	mechanical	pain	threshold	causing	hyperalgesia	(Matos,	2017).		Similarly,	Smith	
et	 al	 (2011)	 found	 that	 female	 rats	 developed	 increased	 micturition	 frequency	 and	
decreased	latency	to	void	following	acute	and	chronic	water	avoidance	stress	(Smith	et	
al.,	2011);	this	was	associated	with	increased	vascularity,	in	addition	to	increased	total	
and	activated	mast	cells	in	the	bladder.		Due	to	the	overlap	in	brain	circuits	involved	in	
 
 
97 
stress,	anxiety	and	micturition,	another	study	by	Wang	et	al.	(2017),	evaluated	the	effects	
of	chronic	stress	on	the	brain	during	bladder	filling.	 	The	study	found	that	there	was	a	
greater	 activation	 of	 the	 micturition	 centre	 in	 the	 stressed	 animals,	 which	 lead	 to	
increased	urgency	to	void	during	bladder	filling,	contributing	to	both	an	OAB	and	IC/PBS	
phenotype	 (Wang	et	 al.,	 2017).	 	Another	 study	has	 looked	more	 closely	at	 the	 role	of	
inflammation	and	its	impact	on	bladder	function,	in	the	water	avoidance	stress	response.		
The	study	found	that	chronic	stress,	induced	by	perpetual	water	avoidance	stress,	caused	
urinary	 frequency,	and	 linked	this	symptom	to	cyclooxygenase-2	gene	upregulation	 in	
the	bladder	smooth	muscle	cells	(Yamamoto	et	al.,	2012).		These	studies	have	shown	that	
psychological	 stress	 plays	 a	 causal	 role	 in	 the	 development	 of	 bladder	 dysfunction,	
however,	 the	 local	 bladder	 mechanisms	 causing	 these	 changes	 remains	 generally	
unknown.		
	
Recovery	from	Psychological	Stress	
Recovery	of	bladder	pathologies	after	stress	has	not	been	well	documented.		However,	
due	to	the	recurring	nature	of	psychological	stress	it	is	an	important	aspect	that	must	be	
considered	 when	 assessing	 physiological	 change.	 	 Very	 few	 animal	 models	 of	
psychological	 stress	 have	 assessed	 the	 effects	 of	 recovery	 on	 physiological	 functions	
altered	with	stress.	 	The	water	avoidance	stress	model	has	been	used	by	one	group	to	
assess	recovery	of	voiding	frequency.	 	The	study	reported	that	water	avoidance	stress	
increases	micturition	frequency	and	that	these	voiding	changes	persisted	for	1	month,	
however,	no	voiding	data	was	shown	in	the	published	paper	(Smith	et	al.,	2011).		Another	
study	 has	 observed	 the	 effects	 of	 water	 avoidance	 stress	 on	 visceral	 and	 somatic	
nociception,	colonic	motility,	and	anxiety-like	behaviour.		The	study	found	that	chronic	
water	avoidance	stress	of	rats	resulted	in	long	lasting,	persistent	visceral	hyperalgesia	
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(Bradesi	et	al.,	2005).		A	male	mouse	social	defeat	model	was	used	over	a	30-day	period	
to	 stimulate	 psychoemotional	 stress	 which	 led	 to	 anxious	 and	 depressive	 symptoms.		
After	 psychological	 stress	 ceased,	 mice	 were	 housed	 for	 2	 weeks	 in	 comfortable	
conditions	 with	 other	 male	 mice.	 The	 study	 found	 that	 even	 after	 cessation	 of	
psychological	 stress,	 the	 male	 mice	 continued	 to	 show	 symptoms	 of	 anxiety	 and	
depression	 in	 behavioural	 tests	 (Avgustinovich,	 Kovalenko,	 &	 Kudryavtseva,	 2005).		
Clinical	 examination	 of	 cortisol	 responses	 to	 psychological	 stress	 was	 assessed	 in	 a	
separate	 study	 which	 found	 that	 non-depressed	 and	 clinically	 depressed	 individuals	
exhibited	 similar	 baseline	 cortisol	 levels.	 	 In	 the	 recovery	 period	 however,	 clinically	
depressed	 patients	 had	 a	 significantly	 higher	 cortisol	 level	 compared	 to	 their	 non-
depressed	counterparts	(Burke,	Davis,	Otte,	&	Mohr,	2005).		Several	clinical	studies	have	
also	 observed	 that	 delayed	 recovery	 from	 psychological	 stress	 leads	 to	 poor	
cardiovascular	outcomes	and	may	predict	earlier	death	(Chatkoff,	Maier,	&	Klein,	2010).			
It	is	clear	from	the	few	studies	mentioned	above	that	chronic	psychological	stress	results	
in	persistence	of	pathological	symptoms.		Besides	the	single	study	mentioned,	the	long-
term	 effect	 of	 psychological	 stress	 on	 bladder	 function	 has	 not	 been	 investigated.		
However,	 with	 the	 water	 avoidance	 recovery	model,	 described	 in	 this	 chapter,	 these	
bladder	changes	are	able	to	be	assessed.	
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Aims	
The	aim	of	the	present	study	was	to	investigate	the	effects	of	water	avoidance	stress	on	
murine	bladder	function.		Specific	aims	were:	
• To	investigate	the	effects	of	water	avoidance	stress	on	voiding	behaviour.	
• To	 determine	 the	 effects	 of	 water	 avoidance	 stress	 on	 local	 bladder	 function.	
including	 bladder	 compliance,	 contractile	 responses	 and	 urothelial	 mediator	
release.	
• To	assess	how	a	stress-free	recovery	period	impacts	voiding	behaviour	and	local	
bladder	mechanisms	induced	by	water	avoidance	stress.	
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METHODS	
Animals	
Young	adult	female	C57BL/6J	mice	were	obtained	and	housed	as	outlined	in	the	general	
methodology	chapter	(Chapter	2).		Mice	were	randomly	allocated	to	the	following	groups:	
Study	1:	Control	(Unstressed)	or	Water	Avoidance	Stress	(Stressed)	and	Study	2:	Control	
(Unstressed),	 Water	 Avoidance	 Stress	 (Stressed)	 or	 Recovered	 (Stress	 +	 10-days).	
Animal	cohorts	in	Part	1	and	Part	2	were	completely	separate.		
	
Water	Avoidance	Stress	Protocol	
Adult	female	(12-14	weeks)	mice	were	used	for	Water	Avoidance	Stress	(WAS)	studies.		
The	WAS	protocol	was	adapted	 from	several	previous	stress	protocols	 (Bradesi	et	al.,	
2005;	McGonagle	et	al.,	2012;	Wang	et	al.,	2017).		The	WAS	chamber	was	custom	made,	
measuring	 30	 cm	 in	 diameter	 and	 40	 cm	 high.	Within	 this	 larger	 chamber,	 a	 smaller	
podium	was	fitted	(7.5	cm	in	diameter	and	20	cm	high).		The	height	of	the	larger	tube	was	
to	ensure	the	mice	could	not	jump	out	during	the	1-hour	stress	protocol.		A	diagram	of	
this	structure	is	shown	below	(Figure	4.1A).	
Distilled	 water	 was	 used	 to	 fill	 the	 chamber	 to	 2	 cm	 below	 the	 central	 podium.	 	 A	
photograph	is	shown	below	of	mice	surrounded	by	distilled	water	within	the	chamber	
(Figure	4.1.B).	This	protocol	was	consistent	with	other	water	avoidance	stress	protocols	
found	in	the	literature.		
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Figure	 4.1:	 (A)	 Diagram	 displaying	 the	 dimensions	 of	 the	 water	 avoidance	 chamber	
(Created	by	the	author)	and	(B)	C57BL/6J	mice	sitting	on	the	podium	during	the	water	
avoidance	stress	protocol	(Photograph	taken	by	the	author).		
	
Mice	were	removed	from	their	normal	housing	and	placed	onto	the	podium	surrounded	
by	water	for	1	hour.	 	During	this	time,	the	mice	were	observed	in	case	they	fell	off	the	
podium.		In	most	cases,	the	mice	were	able	to	climb	back	onto	the	podium	if	they	fell	off,	
and	if	not,	the	mice	were	placed	back	onto	the	podium.		After	1	hour,	mice	were	placed	
back	 into	 their	 cage,	 the	water	was	emptied,	 and	 the	chamber	was	cleaned	with	80%	
ethanol	solution.		Mice	in	the	stress	group	were	placed	in	the	chamber	for	1	hour	per	day	
for	10	consecutive	days.		Control	(unstressed)	mice	were	age-matched	and	housed	under	
normal	conditions	without	environmental	stress	or	movement	from	normal	housing.		
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Recovery	Protocol	
Study	 2	 of	 this	 chapter	 investigates	 the	 potential	 for	 recovery	 from	 the	 impacts	 of	
psychological	 stress	 by	 allowing	mice	who	 have	 experienced	 10-days	WAS,	 a	 10-day	
stress-free	period.		Animals	were	age	matched	and	underwent	the	same	stress	exposure	
as	mice	in	the	original	stress	group	in	study	1,	however	instead	of	being	sacrificed	on	day	
10,	 they	were	maintained	 in	normal	housing	 to	recover	without	 further	stress	 for	10-
days.		Voiding	pattern	analysis	for	unstressed	and	stressed	animals	occurred	as	described	
in	chapter	2,	undertaken	on	days	0,	1,	3,	5,	7	and	10.	 	For	animals	that	underwent	the	
stress-free	recovery,	VPA	continued	on	days	11,	13,	15,	17	and	20.		Age	matched	controls	
also	 underwent	 VPA	 on	 these	 days.	 	 These	 animals	 were	 then	 sacrificed	 on	 day	 20	
following	 a	 final	 VPA	 and	whole	 bladder	 preparations	were	 undertaken	 as	 described	
below.	
	
Whole	Bladder	Preparation	
Whole	 bladder	 preparations	 were	 performed	 as	 described	 in	 chapter	 2,	 with	 the	
following	differences	due	to	the	sex	of	mice.		When	the	abdominal	region	was	secured	to	
the	 dissection	bath	under	 the	microscope,	 female	 reproductive	 organs	were	 removed	
including,	uterus,	fallopian	tubes,	ovaries	and	surrounding	connective	tissue.		The	whole	
bladder	preparation	then	continued	as	described	in	chapter	2.	
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Statistical	Analysis	
Two-way	 ANOVA	 with	 Tukey’s	 post	 hoc	 test	 for	 multiple	 comparisons	 was	 used	 to	
compare	the	different	time	point	and	voiding	variables.	The	same	statistical	tests	were	
also	 used	 to	 analyse	 the	 concentration-response	 curves.	 Student’s	 t-test	 was	 used	 to	
compare	 the	 difference	 between	 the	 two	 animal	 groups	 (Urothelial	mediator	 release	
data,	animal	parameters,	spontaneous	activity	data,	response	to	ATP	and	KCl)	in	Part	1.	
One-way	 ANOVA	 with	 Bonferroni	 post-hoc	 test	 was	 used	 to	 compare	 the	 difference	
between	the	three	animal	groups	(Urothelial	mediator	release	data,	animal	parameters,	
spontaneous	activity	data,	response	to	ATP	and	KCl)	in	Part	2.	
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RESULTS	
PART	1:	Impact	of	WAS	on	bladder	function	
Animal	Parameters	and	Voiding	Behaviour	
Animal	body	weight	and	water	consumption	were	measured	on	day	0	to	obtain	baseline	
data.		The	body	weight	and	water	consumption	of	mice	was	also	then	measured	on	days	
1,	3,	5,	7	and	10.		This	data	was	not	altered	by	WAS	compared	to	the	unstressed	control	
(TABLE	4.1).		Bladder	weight	was	measured	at	the	end	of	the	whole	bladder	preparation	
and	was	also	unchanged	in	the	water	avoidance	stress	group	compared	to	the	unstressed	
control.	
	
	
At	the	time	of	euthanasia,	a	blood	sample	was	taken	for	plasma	corticosterone	analysis.		
Figure	 4.2	 shows	 a	 significant	 increase	 in	 plasma	 corticosterone	 level	 in	 the	 water	
avoidance	 stress	 group	 (stressed),	 154.20	 ±	 29.24	 Äg/mL	 (n=6),	 compared	 to	 the	
unstressed	controls,	54.14	±	9.14	Äg/mL	(n=6).			
	
	
	
TABLE	4.1:		Baseline	body	weight,	water	consumption	and	bladder	weight	(at	day	10)	
in	control	(unstressed)	and	water	avoidance	stress	mice	(stressed)	(n=6).	
	 Unstressed	 Stressed	
Body	weight	(g)	 18.20	±	0.48	 18.50	±	0.67	
Bladder	weight	(mg)	 21.70	±	1.08	 20.78	±	0.53	
Water	consumption	(g)	 0.67	±	0.21	 0.79	±	0.23	
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Figure	4.2:	Concentration	of	plasma	corticosterone	in	in	Stressed	and	Unstressed	mice.		
Datum	is	represented	as	mean	±	SEM	(n	=	6).		Analysis	was	performed	by	an	unpaired	
Student’s	t-test	(*p	<	0.05).	
	
Voiding	 pattern	 analysis	 was	 undertaken	 to	 examine	 voiding	 behaviour,	 including	
number	of	voiding	events,	average	voided	area,	total	voided	area	and	number	of	voids	
smaller	than	0.2	cm2.		There	was	no	significant	difference	in	the	total	voided	area	(Figure	
4.3.C)	in	the	stressed	animals	compared	to	the	unstressed	animals,	indicating	that	urine	
production	was	not	affected	by	water	avoidance	stress.		There	was,	however,	an	increase	
in	urinary	 frequency	 in	 the	stressed	group	compared	 to	 the	unstressed	group	(Figure	
3.4.A).		This	increase	was	significant	at	day	3	(p	=	0.013),	day	5	(p	=	0.005),	day	7	and	
day	10	(both	p	=	<	0.001).	 	Although	variable	across	 the	10-days	of	 stress	exposure,	
average	 void	 size	 (Figure	 4.3.B)	 decreased	 in	 the	 stressed	 group	 compared	 to	 the	
unstressed	controls,	with	a	statistically	significant	reductions	at	day	3	(p	=	0.029)	and	
day	6	(p	=	0.014).		This	fits	with	Figure	4.3.A,	with	the	number	of	voids	increasing	while	
the	 average	 void	 size	 decreases,	 meaning	 that	 the	 stressed	 animals	 were	 urinating	
smaller	amounts,	less	frequently.		This	change	is	also	reflected	in	Figure	4.3.D	where	the	
number	of	small	voids	below	0.2cm2	increases	over	time,	and	significantly	increased	at	
day	3	(p	=	0.005),	day	5	(p	=	0.001),	day	7	(p	<	0.001)	and	day	10	(p	<	0.001).	 	The	
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absence	 of	 change	 in	 both	 water	 consumption	 (Table	 4.1)	 and	 total	 voided	 volume	
indicate	that	the	change	observed	in	the	stressed	group	is	an	actual	change	in	urinary	
frequency	and	not	increased	urine	production.		
	
Figure	 4.3:	 Voiding	 pattern	 analysis	 conducted	 in	 Stressed	 and	Unstressed	mice.	 	 (A)	
Number	 of	 voiding	 events,	 (B)	 Average	 voided	 area,	 (C)	 Total	 voided	 area	 and	 (D)	
Number	of	small	urine	voids	smaller	than	0.2	cm2.		Datum	is	presented	as	mean	±	SEM	
(n	 =	 7).	 Analysis	 was	 performed	 using	 two-way	 repeated	 measures	 ANOVA	 with	
Bonferroni	multiple	comparisons	test	(*p	<	0.05,	**p	<	0.01,	***p	<	0.001,	Unstressed	vs.	
stressed)	
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As	stated	previously,	at	the	time	of	filter	paper	collection	after	voiding,	faecal	pellets	were	
collected	from	the	voiding	paper	and	left	to	dry	overnight.		The	pellets	were	then	counted	
and	 weighed	 the	 next	 day.	 	 Faecal	 pellet	 data	 was	 variable	 across	 all	 days,	 with	 no	
significant	difference	between	the	stressed	and	unstressed	control	animals	(Figure	4.4).		
	
	
Figure	 4.4:	 Faecal	 pellet	 analysis	 conducted	 in	 in	 Stressed	 and	Unstressed	mice.	 	 (A)	
Number	of	faecal	pellets,	(B)	relative	weight	of	faecal	pellets.	Datum	is	presented	as	mean	
±	SEM	(n	=	7).		Analysis	was	performed	using	two-way	repeated	measures	ANOVA	with	
Bonferroni	multiple	comparisons	test.	
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Mediator	Release	
The	intraluminal	fluid,	taken	from	distended	bladders	(20	mmHg	intraluminal	pressure),	
and	the	serosal	fluid,	taken	from	the	water	bath,	were	analysed	for	ATP	and	Ach	content.		
The	 concentration	 of	 each	 mediator	 in	 individual	 samples	 was	 quantified	 and	 total	
amount	released	calculated	to	account	for	intraluminal	and	serosal	fluid	volume.		Both	
luminal	ATP	and	ACh	concentrations	were	greater	compared	to	the	serosal	fluid.		Water	
avoidance	stress	did	not	affect	the	total	amount	of	ATP	or	Ach	release	from	the	lumen	or	
serosa	of	the	mouse	bladders	(Figure	4.5).		
	
Figure	4.5:	Total	release	of	ATP	and	ACh	into	the	(A	&	C)	intraluminal	and	(B	&	D)	serosal	
fluid	collected	following	distensions	of	isolated	bladders	from	Stressed	and	Unstressed	
mice.	 	 Datum	 is	 represented	 as	mean	±	 SEM	 (n	=	6).	 Analysis	was	 performed	 by	 an	
unpaired	Student’s	t-test.	
	
	
	
Unstressed Stressed
0
1
2
3
4
To
ta
l A
TP
 (p
m
ol
es
)
Unstressed Stressed
0.0
0.1
0.2
0.3
0.4
0.5
To
ta
l A
C
h 
(n
m
ol
es
)
Unstressed Stressed
0
20
40
60
80
To
ta
l A
TP
 (p
m
ol
es
)
Unstressed Stressed
0
10
20
30
To
ta
l A
C
h 
(n
m
ol
es
)
INTRALUMINAL SEROSAL
A B
C D
 
 
109 
Bladder	Compliance	and	Stretch-relaxation	
Bladders	were	filled	with	Krebs-bicarbonate	solution	to	a	physiological	pressure	of	20	
mmHg.		A	volume-pressure	relationship	was	used	to	measure	bladder	compliance	across	
the	Unstressed	and	Stressed	groups.		Bladder	compliance	was	not	significantly	different	
in	the	stressed	compared	to	the	unstressed	group	(Figure	4.6).			
	
	
Figure	4.6:	Volume	pressure	relationship	for	bladders	from	in	Stressed	and	Unstressed	
mice.		Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	by	two-way	ANOVA.	
	
After	 fluid	 collection	 was	 completed,	 bladders	 were	 infused	 with	 Krebs-bicarbonate	
solution	to	a	pressure	of	20	mmHg	from	baseline,	at	which	point	the	perfusion	pump	was	
switched	 off	 and	 the	 outflow	 tap	 remained	 closed.	 	 The	 bladders	 were	 left	 to	
accommodate	the	pressure	and	stabilise	for	30	minutes	to	equilibrate.	Over	the	course	of	
30	minutes,	the	bladders	relaxed	and	pressure	plateaued.		The	pressure-time	relationship	
was	then	plotted	to	observe	overall	stretch-relaxation	of	the	equilibration	period.		There	
was	a	sharp	decrease	in	the	initial	5	minutes	of	relaxation	after	stretch,	therefore,	the	‘X	
axis’	of	the	graph	is	split	and	extended	to	highlight	this	change.		There	was	no	significant	
difference	between	the	Unstressed	and	Stressed	groups	(Figure	4.7).		
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Figure	4.7:	Pressure	time	relationship	for	bladders	from	Stressed	and	Unstressed	mice.	
Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	by	two-way	ANOVA.	
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Bladder	Contractility	and	Response	to	Electrical	Field	Stimulation	
Bladder	 contractile	 response	 to	KCl	was	measured	with	data	 recorded	as	 a	 change	 in	
pressure	from	baseline,	to	assess	the	impact	of	WAS	on	receptor-independent,	general	
contractility	of	the	bladder	(Figure	4.8).	There	was	a	significant	increase	in	the	response	
to	KCl	in	bladders	from	stressed	mice	compared	to	unstressed	controls	with	pressures	
recorded	(25.90	±	2.77	mmHg	and	17.1	±	1.91	mmHg	respectively,	n=6)	(p	=	0.03).	
	
	
Figure	4.8:	Pressure	responses	to	KCl	(60	mM)	in	Stressed	and	Unstressed	mice.	Datum	
is	represented	as	mean	±	SEM	(n	=	6)	and	analysed	using	an	unpaired	t-test	(*p	<	0.05).	
	
To	investigate	the	impact	of	WAS	on	nerve	evoked	contractile	responses,	bladders	were	
electrically	 stimulated	 at	 1,	 5,	 10	 and	 20	Hz.	 Stress	 did	 not	 change	 responses	 to	 EFS	
(Figure	4.9.A),	and	when	this	response	was	normalised	to	 the	KCl	response	the	nerve	
mediated	contractions	was	not	significantly	different	between	groups	(Figure	4.9.B).	
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Figure	 4.9:	 Nerve	 evoked	 pressure	 response	 of	 isolated	 bladders	 from	 Stressed	 and	
Unstressed	mice	 at	 1,	 5,	 10	 and	20	Hz.	 	Responses	were	 recorded	 as	 (A)	 a	 change	 in	
pressure	from	baseline	and	(B)	a	percentage	of	the	KCl	contractile	response.		Datum	is	
presented	as	the	mean	±	SEM	(n	=	6)	and	analysed	using	a	two-way	repeated	measures	
ANOVA.	
	
Addition	of	the	NOS	inhibitor	LNNA	did	not	significantly	alter	bladder	contraction	to	EFS	
in	either	of	the	groups,	indicating	the	inhibitory	neurotransmitter,	NO,	was	not	involved	
in	neurotransmission	(Figure	4.10.A).			Addition	of	the	muscarinic	antagonist,	atropine	
(1	µM),	reduced	the	response	to	EFS	(42.50	±	4.87%,	n=6)	in	unstressed	bladders,	this	
change	was	 less	 in	 the	 stressed	 group	 (28.90	±	 4.12%,	 n=6)	 (Figure	 4.10.A	 and	 B).		
Desensitisation	of	purinergic	receptors	with	utmATP	(1	mM)	reduced	the	responses	to	
EFS	to	a	similar	extent	in	bladders	from	both	groups	(Unstressed	50.50	±	4.50%,	Stressed	
65.69	±	4.44%,	n=6)	with	 a	 significant	difference	detected	between	 the	 groups	 (p	=	
0.04)	(Figure	4.10.A	and	C).		This	demonstrates	that	while	nerve	contractions	were	not	
changed	by	water	avoidance	stress,	the	relative	contribution	of	ACh	was	decreased	while	
the	ATP	contribution	was	slightly	increased.	
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Figure	4.10:	(A)	Intravesical	pressure	responses	to	electrical	field	stimulation	at	20	Hz	
(baseline),	and	after	addition	of	L-NNA	(100	µM),	atropine	(1	µM)	and	αβmATP	(1	mM)	
to	bladders	 from	Stressed	and	Unstressed	mice	bladders.	 	Percentage	decrease	 in	EFS	
response	on	addition	of	(B)	atropine	and	(C)	αβmATP	to	bladder	from	each	group.	Datum	
is	expressed	as	mean	±	SEM	and	analysed	using	 two-way	repeated	measures	ANOVA	
with	Dunnett’s	multiple	comparisons	test	 for	(A)	and	one-way	ANOVA	with	Dunnett’s	
multiple	comparisons	test	for	(B	and	C)	(*p		<	0.05,	**p		<	0.01	vs.	Baseline	(20	Hz)).	
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Response	to	Pharmacological	Agents	
Pharmacological	agents	were	added	to	the	bath	and	pressure	responses	were	recorded	
as	a	change	from	baseline.		Purinergic	stimulation	was	assessed	using	ATP	(10	mM)	and	
utmATP	(1	mM).		The	response	to	ATP	(Figure	4.11.A)	was	significantly	increased	in	the	
Stressed	group	compared	to	the	Unstressed	group	with	change	in	pressure	from	baseline	
(2.43	 ±	 0.58	 mmHg	 and	 1.37	 ±	 0.01	 mmHg	 (p	 =	 0.0106),	 respectively,	 n=6).	 	 The	
contractile	responses	were	also	normalised	to	KCl	response	resulting	 in	no	significant	
difference	between	groups	(Figure	4.11.B).		
	
Figure	4.11:	Contractile	responses	to	the	purinergic	agonist	(A)	ATP	(10	mM)	and	(B)	
ATP	response	normalised	to	the	KCl	response	in	Stressed	and	Unstressed	mice	bladders.		
Datum	is	represented	as	mean	±	SEM	(n	=	6)	and	analysed	using	an	unpaired	Student’s	
t-test	(*p	<	0.05).	
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After	 P2X	 receptor	 desensitisation	with	 αβmATP	 the	 initial	 contraction	was	 recorded	
(Figure	4.12).		Compared	to	the	Unstressed	bladders	(0.65	±	0.09	mmHg,	n=6)	there	was	
a	significant	increase	in	contractile	response	in	bladders	from	the	stressed	group	(1.00	±	
0.31	mmHg,	n=6)	(p	=	0.043).		The	contractile	responses	were	also	normalised	to	the	
KCl	response	resulting	in	no	significant	difference	between	groups	(Figure	4.12.B).	
	
	
Figure	4.12:	Pressure	responses	to	{|mATP	(1	mM)	in	in	Stressed	and	Unstressed	mice	
bladders.		Datum	is	represented	as	mean	±	SEM	(n	=	6)	and	analysed	using	an	unpaired	
t-test	(*p	<	0.05).	
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A	cumulative	concentration-response	to	carbachol	(muscarinic	agonist)	was	performed	
on	each	bladder	to	study	changes	in	the	muscarinic-receptor-mediated	response	(Figure	
4.13).		Analysis	was	performed	by	a	two-way	ANOVA	with	Tukey	multiple	comparisons	
test	and	showed	a	significant	increase	in	the	maximum	contraction	in	bladders	from	the	
stressed	group	compared	 to	 the	unstressed	group	(Figure	4.13.A),	with	no	significant	
difference	in	pEC50	(Table	4.2).		The	concentration-response	curve	was	also	normalised	
as	a	percentage	of	the	KCl	response,	resulting	 in	no	significant	difference	between	the	
groups	(Figure	4.13.B).		
	
	
	
	
	
	
TABLE	4.2:	Whole	bladder	responses	to	carbachol	in	control	(unstressed)	and	
stressed	mice	(n=6).	
	 Unstressed	 Stressed	
pEC50	 5.42	±	0.11	 5.41	±	0.07	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%	of	KCl)	
	
23.38	±	3.39	
115.99	±	7.67	
	
30.87	±	2.48	(p	<	0.01)	
124.47	±	4.91	
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Figure	4.13:	Carbachol	concentration-response	curves,	in	Stressed	and	Unstressed	mice.		
Responses	 to	 carbachol	 are	 presented	 as	 (A)	 change	 in	 intravesical	 pressure	 from	
baseline	and	(B)	change	in	intravesical	pressure	normalised	to	the	KCl	response.	Datum	
is	represented	as	mean	±	SEM	(n	=	6),	analysed	using	non-linear	regression	and	two-
way	ANOVA	with	Tukeys	multiple	comparisons	test	(**p	<	0.01).	
	
Carbachol	 (1	 µM)	 was	 used	 to	 pre-contract	 bladders	 before	 relaxation	 responses	 to	
isoprenaline,	 as	 a	 concentration-responses	 were	 measured.	 	 Maximal	 relaxation	 to	
isoprenaline	was	significantly	greater	(p	=	0.008)	in	bladders	from	the	stressed	group	
with	no	change	in	potency	(pIC50)	(Table	4.3).	
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TABLE	4.3:	Whole	bladder	responses	to	isoprenaline	in	control	(unstressed)	and	
stressed	mice	(n=6).	
	 Unstressed	 Stressed	
pIC50	 6.87	±	0.12	 6.71	±	0.16	
Maximal	response		
∆	Pressure	(mmHg)	
Response	(%	Decrease)	
	
-3.27	±	0.50	
-18.03	±	15.04	
	
-4.58	±	0.25	(p	<	0.01)	
-30.26	±	19.96	
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While	 maximal	 relaxation	 responses	 were	 greater	 (p	 <	 0.01)	 in	 the	 stressed	 group	
compared	 to	 the	 Unstressed	 group,	 there	 was	 no	 significant	 difference	 between	 the	
groups	when	relaxation	was	normalised	to	the	magnitude	of	carbachol	precontraction	
(Figure	4.14.B).		
	
	
Figure	4.14:	Effect	of	 isoprenaline	on	 isolated	bladders	 from	Stressed	and	Unstressed	
mice	with	datum	given	as	(A)	raw	data	as	change	in	pressure	from	pre-contraction,	(B)	
as	a	percentage	(%)	of	the	carbachol	precontraction.	Datum	represented	as	mean	±	SEM	
(n	=	6)	and	analysed	using	two-way	ANOVA.		
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Spontaneous	Phasic	Contractions	
Spontaneous	activity	was	measured	during	bladder	stretch-relaxation	and	the	average	
frequency	(Figure	4.15.A)	and	the	amplitude	(Figure	4.15.B)	of	spontaneous	contractile	
activity	was	unchanged	in	bladders	from	the	stressed	group	compared	to	the	Unstressed.		
	
	
Figure	4.15:	Spontaneous	phasic	contractions	in	isolated	Stressed	and	Unstressed	mouse	
bladders	 during	 stretch-relaxation	 period.	 (A)	 Frequency	 of	 contractions	 and	 (B)	
amplitude	of	spontaneous	contractions.	Datum	is	represented	as	mean	±	SEM	(n	=	6),	
analysed	using	unpaired	Student’s	t-test.	
	
Phasic	activity	was	also	measured	after	the	addition	of	1	µM	carbachol	to	pre-contraction.			
During	this	period	the	phasic	contractions	following	plateau	of	the	tonic	contraction	were	
measured	showing	a	significant	increase	(p	=	<0.001)	in	the	frequency	in	the	stressed	
group	(6.57	±	0.20	mmHg,	n=6)	compared	to	the	unstressed	group	(2.57	±	0.37	mmHg,	
n=6)	(Figure	4.16.A).	Amplitude	of	phasic	activity	was	also	increased	significantly	(p	=	
0.02)	in	the	stressed	group	(0.29	±	0.02	mmHg,	n=6)	compared	to	the	unstressed	control	
group	(0.20	±	0.02	mmHg,	n=6)	(Figure	4.16.B).	
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Figure	 4.16:	 Phasic	 response	 to	 tonic	 contraction	 of	 1	 µM	 carbachol	 in	 Stressed	 and	
Unstressed	mice	 bladder.	 (A)	 Frequency	 of	 phasic	 contractions	 and	 (C)	Amplitude	 of	
phasic	contractions.		Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	using	un-
paired	Student’s	t-test	(*p	<	0.05,	***p	<	0.001).	
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PART	2:	 Impact	of	a	stress-free	period	following	stress	exposure	on	
bladder	function	
Part	2	of	the	results	will	include	a	stressed	group	which	underwent	10-days	of	recovery	
after	 the	 10-days	 of	 water	 avoidance	 stress.	 	 Groups	 will	 be	 as	 follows;	 Control	
(Unstressed),	Water	Avoidance	Stress	(Stressed)	or	Recovered	(Stress	+	10-days).	
	
Animal	Parameters	and	Voiding	Behaviour	
Body	weight	and	water	consumption	was	unchanged	in	the	recovered	(Stress	+	10-days)	
mice	compared	to	the	unstressed	controls	and	stressed	mice	(Table	4.4).		Bladder	weight	
was	 measured	 following	 whole	 bladder	 preparation	 with	 no	 significant	 difference	
observed	between	the	groups.	
	
	
Plasma	corticosterone	levels	were	significantly	increased	in	the	stressed	group	(154.20	
±	29.24	µg/mL	(p	=	0.0048))	compared	to	unstressed	group	(54.14	±	9.14	µg/mL),	with	
corticosterone	levels	significantly	decreased	and	returned	to	unstressed	levels	after	10-
days	of	stress-free	recovery	(32.06	±	0.10	µg/mL)	(p	=	0.0031)	(Figure	4.17).		
	
TABLE	4.4	Baseline	body	weight,	water	consumption	and	bladder	weight	(at	day	10	and	
20)	in	control	(unstressed),	water	avoidance	stress	(Stressed)	and	recovered	(stress	+	
10-days)	mice.	
	 Unstressed	 Stressed	 Stress	+	10-days	
Body	weight	(g)	 21.2	±	0.28	 18.5	±	0.67	 20.6	±	0.67	
Bladder	weight	(mg)	 23.1	±	1.13	 20.78	±	0.53	 22.3	±	1.43	
Water	consumption	(g)	 0.95	±	0.06	 0.79	±	0.23	 1.15	±	0.12	
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Figure	4.17:	Plasma	corticosterone	levels	in	Stressed,	Unstressed	and	Stress	+	10-days	
groups.		Datum	is	represented	as	mean	±	SEM	(n	=	6).	Analysis	was	performed	using	a	
one-way	 ANOVA	 with	 Tukey	 multiple	 comparisons	 test	 (**p	 <	 0.01,	 unstressed	 vs.	
stressed)	(++p	<	0.01,	stressed	vs.	stress	+	10-days).	
	
	
Voiding	pattern	analysis	was	performed	in	stressed	mice	on	days	0,	1,	3,	5,	7	and	10	of	
the	stress	exposure	protocol	and	continued	during	the	stress-free	period	on	days	11,	13,	
17	 and	 20	 to	 assess	 recovery	 of	 bladder	 function	 after	 stress.	 	 Unstressed	mice	 also	
underwent	 voiding	 pattern	 analysis	 at	 the	 same	 timepoints,	 for	 comparison.	 	 Overall,	
voiding	 frequency	 increased	 in	 stressed	 mice	 over	 the	 initial	 10-day	 stress	 period	
compared	to	the	unstressed	group.		Over	the	following	10-days	of	stress-free	recovery,	
the	 voiding	 frequency	 decreased	 although	 not	 completely	 to	 baseline,	 remaining	
significantly	elevated	(p	=	<0.001)	compared	to	the	unstressed	group	(Figure	4.18.A).		
Total	voided	area	was	unchanged	over	the	10-days	of	stress	and	was	similarly	unchanged	
during	the	stress-free	recovery	period	(Figure	4.18.B).		Average	void	size	was	reduced	in	
stressed	 mice	 over	 the	 stress	 and	 stress-free	 recovery	 period	 (Figure	 4.18.C).	 	 The	
number	 of	 small	 voids	 was	 also	 increased	 over	 the	 10-days	 of	 stress	 and	 was	 still	
increased	in	the	following	10-day	stress-free	period	(p	=	<0.001)	(Figure	4.18.D).		These	
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changes	support	the	voiding	behaviour	changes	reported	in	Part	1	for	the	WAS	model	and	
suggest	 that	voiding	dysfunction	does	not	 fully	recover	 in	stressed	mice	 following	10-
days	stress-free.	
	
Figure	4.18:	Voiding	pattern	analysis	conducted	in	Stress	+	10-days	and	Unstressed	mice.	
(A)	 Number	 of	 voiding	 events,	 (B)	 Total	 voided	 area,	 (C)	 Average	 void	 size	 and	 (D)	
Number	 of	 small	 voids	 below	0.2	 cm2.	 	 Datum	 is	 presented	 as	mean	±	 SEM	 (n	=	 8).		
Analysis	was	performed	using	two-way	repeated	measures	ANOVA	(##p	<	0.01,	###p	<	
0.001).	
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Faecal	pellet	data	was	also	collected	over	the	20	days	of	stress	and	stress-free	recovery.		
There	was	no	significant	difference	 in	both	 the	number	of	pellets	 (Figure	4.19.A)	and	
weight	of	pellets	(Figure	4.19.B)	for	the	Unstressed	versus	the	stress	+	10-days	groups.		
	
Figure	4.19:	Faecal	pellet	analysis	conducted	in	Stress	+	10-days	and	Unstressed	mice.		
(A)	Number	of	faecal	pellets,	(B)	relative	weight	of	faecal	pellets.		Datum	is	presented	as	
mean	±	SEM	(n	=	6).	Analysis	was	performed	using	two-way	repeated	measures	ANOVA.	
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Mediator	Release	
Serosal	ATP	levels	were	unchanged	across	all	animal	groups	(Figure	4.20.B).		Overall,	the	
stress-free	period	of	recovery	did	not	affect	the	release	of	mediators	into	the	serosal	fluid.		
Similarly,	intraluminal	levels	of	ATP	and	ACh	were	not	significantly	altered	by	10-days	
exposure	to	WAS,	nor	did	10-days	stress-free	recovery	affect	release	of	these	signalling	
mediators	(Figure	4.20.A	and	C).	Release	of	Ach	into	the	serosal	fluid	was	increased	in	
the	Stressed	group	and	increased	significantly	 in	the	Stress	+	10-days	group,	but	only	
significantly	so	when	compared	to	the	unstressed	groups	(p	=	0.007)	(Figure	4.20.D).			
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Figure	4.20:	Total	 release	of	ATP	and	ACh	 into	 the	 (A	&	C)	 intraluminal	 and	 (B	&	D)	
serosal	fluid	collected	following	distensions	of	isolated	bladders	in	Stressed,	Unstressed	
and	Stress	+	10-days	groups.	Datum	is	represented	as	mean	±	SEM	(n	=	6).	Analysis	was	
performed	as	a	one-way	ANOVA	(##p	=	0.007,	Stress	+	10	day	vs.	Unstressed).	
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Bladder	Compliance	and	Stretch-relaxation	
Bladder	compliance	was	unchanged	in	the	Stressed	group	compared	to	the	Unstressed	
group,	 just	 as	 in	 part	 1	 of	 this	 chapter.	 Compliance	 (Figure	 4.21)	 was	 however,	
significantly	increased	in	the	Stress+10-days	group	when	compared	to	the	unstressed	
group.	
	
	
Figure	 4.21:	 Volume-pressure	 relationship	 for	 bladders	 in	 Stressed,	 Unstressed	 and	
Stress	+	10-days	groups.	Datum	represented	as	mean	±	SEM	(n	=	6),	analysed	by	two-
way	ANOVA	(#p	<	0.05,	unstressed	vs.	stress	+	10-days)	(##p	<	0.01,	unstressed	vs.	stress	
+	10-days).	
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The	fall	in	intraluminal	pressure	from	20mmHg	over	time	was	also	assessed	as	a	measure	
of	compliance	and	this	pressure-time	relationship	was	observed	in	bladders	from	the	3	
groups	 to	 assess	 relaxation	 after	 stretch	 (Figure	 4.22).	 There	 was	 no	 significant	
difference	in	relaxation	after	stretch	between	the	3	groups.		
	
	
Figure	4.22:	Pressure	time	relationship	for	bladders	from	mice	in	Stressed,	Unstressed	
and	Stress	+	10-days	groups.		Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	by	
two-way	ANOVA.	
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Bladder	Contractility	and	Electrical	Field	Stimulation	
There	was	 a	 significant	 increase	 in	 contractility	 to	 KCl	 in	 bladders	 from	 the	 stressed	
group	 (51.34	±	 3.69	mmHg,	 n=6),	 compared	 to	 the	 unstressed	 group	 (28.56	±	 5.14	
mmHg,	n=6),	as	seen	previously	in	part	1	of	this	chapter	(p	=	0.008).		The	response	to	
KCl	was	significantly	reduced	back	to	unstressed	levels,	 in	the	Stress	+	10-days	group	
(27.45	±	4.01	mmHg,	n=6)	(p	=	0.006)	(Figure	4.23).		
	
	
Figure	 4.23:	 Pressure-responses	 to	 KCl	 (60	 mM)	 in	 bladders	 from	 mice	 in	 Stressed,	
Unstressed	and	Stress	+	10-days	groups.		Datum	is	represented	as	mean	±	SEM	(n	=	6)	
and	analysed	using	an	Ordinary	one-way	ANOVA	with	Tukey	Analysis	(++p	<	0.01,	Stress	
+	10-days	vs.	Stressed)	(**p	<	0.01,	Stressed	vs.	Unstressed	Controls).	
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Similar	to	as	reported	in	Part	1,	stress	did	not	alter	nerve-mediated	bladder	contractions	
and	the	responses	to	EFS	were	also	not	changed	in	stressed	mice	following	the	10-days	
stress-free	period	(Figure	4.24.A).		When	the	EFS	responses	were	normalised	to	the	KCl	
response,	nerve	mediated	contractions	in	both	stress	groups	did	appear	to	be	depressed	
compared	to	the	unstressed	group,	however	there	was	no	significant	difference	between	
groups	(Figure	4.24.B).		
	
	
Figure	4.24:	Nerve-mediated	(1-20	Hz)	pressure	response	of	isolated	bladders	from	mice	
in	Stressed,	Unstressed	and	Stress	+	10-days	groups.		Responses	were	recorded	as	(A)	a	
change	 in	pressure	 from	baseline	and	(B)	a	percentage	of	 the	KCl	 response.	Datum	 is	
presented	 as	 the	 mean	 ±	 SEM	 (n	 =	 6).	 Datum	 analysed	 using	 a	 two-way	 repeated	
measures	ANOVA	with	Tukeys	comparison.	
	
Electrical	field	stimulation	was	repeated	at	20	Hz	in	the	absence	and	presence	of	several	
pharmacological	 agents.	 The	 addition	 of	 LNNA	 (100	 µM)	 did	 not	 significantly	 alter	
bladder	 contraction	 to	 EFS,	 as	 seen	 in	 the	 Part	 1,	 indicating	 that	 the	 inhibitory	
neurotransmitter,	NO,	was	not	involved	in	neurotransmission	(Figure	4.25.A).		Addition	
of	the	muscarinic	agonist,	atropine	(1	µM),	reduced	the	response	to	EFS	by	23.96	±	3.39%	
(n=6)	 in	Unstressed	bladders.	 	A	 similar	 reduction	was	observed	 in	 responses	 in	 the	
Stressed	and	Stress	+	10-days	group,	26.92	±	4.88%	and	20.91	±	4.89%,	respectively	
(n=6)	(Figure	4.25.B).	 	 	Finally,	with	addition	of	αβmATP	(1	mM),	 to	desensitise	P2X1	
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purinoceptors,	responses	were	further	decreased	by	51.16	±	5.04%	(n=6)	in	unstressed	
controls,	65.69	±	4.44%	in	Stressed	and	49.75	±	6.20%	in	Stress	+	10-days	groups	(n=6)	
(Figure	4.25.C).		
	
Figure	4.25:	A)	 Intravesical	pressure	responses	to	electrical	 field	stimulation	at	20	Hz	
(baseline),	and	after	addition	of	L-NNA	(100	µM),	atropine	(1	µM)	and	αβmATP	(1	mM)	
to	 for	 bladders	 from	 mice	 in	 Stressed,	 Unstressed	 and	 Stress	 +	 10-days	 groups.	
Percentage	decrease	in	EFS	response	on	addition	of	(B)	atropine	(1	µM)	and	(C)	αβmATP	
(1	mM)	to	bladder	from	each	group.	Datum	is	expressed	as	mean	±	SEM	and	analysed	
using	two-way	repeated	measures	ANOVA	with	Dunnett’s	multiple	comparisons	test	for	
(A)	and	one-way	ANOVA	with	Dunnett’s	multiple	comparisons	test	for	(B	and	C)	(*p		<	
0.05	vs.	Baseline	(20	Hz)).	
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Response	to	Pharmacological	Agents	
Responses	 to	 ATP	 were	 similar	 in	 bladders	 from	 the	 stressed	 groups	 (12.94	 ±	 1.39	
mmHg,	n=6),	compared	to	the	unstressed	group	(11.27	±	1.41	mmHg,	n=6),	as	seen	in	
part	1	of	 this	 chapter,	 but	 in	 this	 case	 the	difference	 in	 response	was	not	 statistically	
significant.		Responses	to	ATP	were	also	similar	in	the	stress-free	recovered	group	(9.58	
±	1.441	mmHg,	n=6)	compared	to	the	unstressed	group	(Figure	4.26.A).		The	contractile	
response	was	also	normalised	to	KCl	response,	with	no	significant	difference	between	the	
groups	(Figure	4.26.B).		
	
Figure	4.26:	Pressure	 responses	 to	 (A)	ATP	 (10	mM)	and	 (B)	ATP	normalised	 to	KCl	
response	 in	bladders	 from	mice	 in	Stressed,	Unstressed	and	Stress	+	10-days	groups.	
Datum	is	represented	as	mean	±	SEM	(n	=	6)	and	analysed	using	an	ordinary	one-way	
ANOVA	with	Tukeys	comparison.		
	
Contractile	bladder	responses	to	αβmATP	were	also	assessed.		Compared	to	unstressed	
group	 (15.13	±	3.41	mmHg,	 n=6),	 there	was	 no	 significant	 difference	 in	 response	 of	
recovered	(stress	+	10-days)	(13.5	±	2.17	mmHg,	n=6)	and	stressed	groups	(14.7	±	1.98	
mmHg,	 n=6).	 The	 contractile	 response	was	 also	normalised	 to	KCl	 response,	with	no	
significant	difference	between	the	groups	(Figure	4.27.A	&	B).		
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Figure	4.27:	(A)	Pressure	responses	to	{|mATP	(1	mM)	and	(B)	pressure	responses	as	
a	percentage	of	KCl,	from	bladders	in	Stressed,	Unstressed	and	Stress	+	10-days	groups.		
Datum	is	represented	as	mean	±	SEM	(n	=	7)	and	analysed	using	an	ordinary	one-way	
ANOVA	with	Tukey	comparison.	
	 	
Carbachol	 produced	 a	 concentration	 dependent	 increase	 in	 intravesical	 pressure	 in	
bladders	 from	 all	 three	 groups,	 with	 a	 significantly	 greater	 in	 the	maximal	 response	
evident	in	the	Stress	group	compared	to	Unstressed	and	Stress+10-days	groups	(Table	
4.5	 and	 Figure	 4.28).	 	 There	 was,	 however,	 no	 significant	 difference	 in	 pEC50	 as	
highlighted	in	Table	4.5.	 	When	the	concentration-response	curve	was	normalised	as	a	
percentage	 of	 the	 KCl	 response,	 no	 significant	 difference	 was	 observed	 between	 the	
groups.		The	response	to	carbachol	returned	to	unstressed	control	levels	in	bladders	from	
stressed	mice	following	10-days	stress-free	recovery	(Figure	4.28).		These	results	reveal	
that	 the	 stress-free	 recovery	period	 after	water	 avoidance	 stress	 returned	 contractile	
responses	 to	 the	 muscarinic	 agonist,	 carbachol	 to	 levels	 comparable	 to	 unstressed	
control	mice.			
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Figure	4.28:	Carbachol	concentration-response	curve	for	isolated	whole	bladders	from	
mice	 in	Stressed,	Unstressed	and	Stress	+	10-days	groups,	 recorded	as	 (A)	 change	 in	
intravesical	 pressure	 from	 baseline	 and	 (B)	 change	 in	 intravesical	 pressure	 as	 a	
percentage	of	the	KCl	response.		Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	
using	 non-linear	 regression	 and	 two-way	 ANOVA	 with	 Bonferroni’s	 multiple	
comparisons	test	(*p	<	0.05	Unstressed	vs.	stressed)	(+p	<	0.05,	stressed	+	10-days	vs.	
stressed).	
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TABLE	4.5:	Whole	bladder	responses	to	carbachol	in	control	(unstressed)	and	
water	avoidance	stress	(stressed)	and	recovered	(stress	+	10-days)	mice	(n=6).	
	 Unstressed	 Stressed	 Stress	+	10-days	
pEC50	 5.66	±	0.09	 5.53	±	0.03	 5.46	±	0.09	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%	of	KCl)	
	
44.41	±	6.88	
141.11	±	10.20	
	
56.56	±	1.91	(p	<	0.05)	
112.97	±	10.96	
	
44.73	±	5.65	
143.28	±	23.01	
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Following	carbachol	precontraction,	bladder	relaxation	to	the	beta-adrenoceptor	agonist	
isoprenaline	 was	 assessed	 and	 responses	 were	 not	 significantly	 affected	 by	 WAS	 or	
stress-free	recovery	(Figure	4.29.A).		There	was	no	significant	differences	in	either	the	
IC50	values	or	maximal	responses	between	the	groups	(Table	4.6).		Relaxation	responses	
were	also	presented	as	percentage	of	the	carbachol	pre-contraction,	but	again	there	were	
no	significant	differences	between	the	three	groups	(Figure	4.29.B).	
	
	
	
	
	
	
	
TABLE	 4.6:	Whole	 bladder	 responses	 to	 isoprenaline	 in	 control	 (unstressed),	
water	avoidance	stress	(stressed)	and	recovered	(stress	+	10-days)	mice	(n=6).	
	 Unstressed	 Stressed	 Stress	+	10-days	
pIC50	 6.86	±	0.08	 6.81	±	0.11	 6.58	±	0.15	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%	Decrease)	
	
-5.21	±	0.47	
-104.48	±	51.14	
	
-4.37	±	0.41	
-51.11	±	63.92	
	
-4.76	±	0.48	
-77.42	±	69.88	
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Figure	4.29:	Effect	of	isoprenaline	on	isolated	bladders	from	mice	in	Stressed,	Unstressed	
and	Stress	+	10-days	groups	with	datum	given	as	(A)	raw	data	as	change	in	pressure	
from	pre-contraction,	(B)	as	a	percentage	(%)	of	the	carbachol	precontraction.	Datum	
represented	as	mean	±	SEM	(n	=	6),	 analysed	using	 two-way	ANOVA	and	non-linear	
regression.	
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Spontaneous	Phasic	Contractions	
Spontaneous	 activity	 followed	 much	 of	 the	 same	 trend	 as	 stated	 previously	 in	 this	
chapter.	 During	 the	 stretch-relaxation	 period,	 the	 frequency	 and	 amplitude	 of	
spontaneous	 activity	 was	 not	 significantly	 altered	 by	 stress	 when	 compared	 to	
unstressed	controls,	and	10-days	stress-free	did	not	alter	these	responses	(Figure	4.30.A	
and	B).	
	
Figure	4.30:	Spontaneous	activity	during	stretch-relaxation	period	in	mice	from	Stressed,	
Unstressed	 and	 Stress	 +	 10-days	 groups.	 (A)	 Frequency	 of	 contractions	 and	 (B)	
Amplitude	of	 spontaneous	 contractions,	 compared	 to	 controls	 (Unstressed).	Datum	 is	
represented	as	mean	±	SEM	(n	=	6),	analysed	using	one-way	ANOVA.	
	
Phasic	 contractions	 were	 also	 measured	 following	 addition	 of	 1µM	 carbachol.	 	 The	
frequency	of	phasic	activity	was	significantly	elevated,	as	seen	previously	in	part	1	of	this	
chapter	(p	=	0.0024),	 in	bladders	 from	the	stressed	group	(7.00	±	0.31	mmHg,	n=6)	
compared	to	the	unstressed	group	(3.66	±	0.33	mmHg,	n=6).		Stress-free	recovery,	Stress	
+	 10-days	 (4.83	 ±	 0.79	 mmHg,	 n=6),	 appeared	 to	 reduce	 the	 frequency	 of	 phasic	
contractions	 significantly	 compared	 to	 the	 stressed	 group	 (p	=	0.04)	 (Figure	4.31.A).		
Across	all	groups	however,	amplitude	remained	unchanged	(Figure	4.31.B).			
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Figure	 4.31:	 Phasic	 response	 to	 tonic	 contraction	 of	 1	 µM	 carbachol	 in	 Stressed,	
Unstressed	and	Stress	+	10-days	groups.	(A)	Frequency	of	phasic	contractions	and	(B)	
Amplitude	of	phasic	contractions.		Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	
using	a	one-way	ANOVA	(**p	<	0.01,	Unstressed	vs.	stressed)	(+p	<	0.05,	stressed	+	10-
days	vs.	stressed).	
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DISCUSSION	
There	is	abundant	clinical	evidence	that	psychological	stress	is	associated	with	bladder	
dysfunction	 and	 pathologies.	 	 Currently,	 there	 is	 a	 lack	 of	 understanding	 of	 the	 local	
bladder	 changes	 that	 occur	 due	 to	 psychological	 environmental	 stress.	 	 This	 study	
employed	 an	 animal	 model	 of	 water	 avoidance	 stress	 to	 determine	 the	 impact	 of	
environmental	stress	on	voiding	behaviour	and	bladder	function	and	establish	the	role	
that	recovery	plays	in	this	dysfunction.	
	
Effects	of	Stress	on	Voiding	Behaviour	
In	 this	 study	 we	 observed	 a	 time-dependent	 increase	 in	 voiding	 frequency	 in	 water	
avoidance	stressed	mice	compared	to	the	unstressed	mice,	with	a	significant	change	as	
early	as	day	3	of	the	stress	protocol.		Yoon,	Lee,	Chun,	Yoon,	and	Yoo	(2010)	also	observed	
a	 similar	 increase	 in	 voiding	 frequency,	 which	 increased	 over	 time	 ,	 however,	 they	
reported	that	stress	also	increased	the	volume	of	urine	output	compared	to	the	control	
animals.	 	Our	study	found	no	change	in	urine	output	or	water	consumption,	indicating	
that	the	increase	in	voiding	frequency	caused	by	stress	is	due	to	changes	in	local	and/or	
central	 micturition	 control	 mechanisms	 and	 not	 excess	 water	 consumption/urine	
production	over	the	time	points	tested.		The	number	of	small	voids	increased	significantly	
in	 the	 stressed	 group,	while	 the	 average	 void	 size	 decreased;	 suggesting	 that	 voiding	
interval	 decreased	 in	 the	 stressed	 group,	 similar	 to	 previously	 observed	 changes	 in	
frequency,	latency	to	void,	voiding	interval	and	volume	in	stressed	versus	control	mice	
(Smith	et	al.,	2011).	 	These	findings	suggest	that	stressed	mice	are	urinating	a	smaller	
amount,	more	frequently	than	the	unstressed	mice	which	indicates	that	the	bladder	may	
not	be	emptying	completely	on	each	void	or	that	micturition	is	being	initiated	at	a	lower	
bladder	volume.		
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Evidence	 from	 the	 literature	 suggests	 that	 there	 are	 sex	 differences	 in	 voiding	
dysfunction	following	water	avoidance	stress.		In	our	model	of	water	avoidance	stress,	an	
increase	 in	 voiding	 frequency	 was	 observed	 in	 female	 mice,	 similar	 to	 the	 changes	
reported	 by	 Smith	 et	 al.	 (2011)	 in	 female	 rats.	 	 However,	 McGonagle	 et	 al.	 (2012),	
reported	a	decrease	in	voiding	frequency	in	male	mice	following	water	avoidance	stress.	
Studies	looking	at	other	models	of	psychological	stress	have	found	the	same	trend	with	
gender	(Mann,	2015;	West,	Sellers,	Chess-Williams,	&	McDermott,	2020).	
	
Effects	of	Stress	on	Corticosterone	Release	
Exposure	to	water	avoidance	stress	produced	a	significant	hormonal	stress	response	in	
the	stressed	mice,	with	elevated	plasma	corticosterone	levels	evident	following	10-days	
stress	exposure.		This	confirmed	that	the	mice	used	in	this	study	were	stressed	when	the	
voiding	 pattern	 analysis	 and	 whole	 bladder	 preparations	 were	 performed.	 	 This	 is	
consistent	 with	 other	 animal	 studies	 which	 have	 observed	 increased	 corticosterone	
levels	in	water	avoidance	stressed	mice	(Hassan	et	al.,	2014;	Wang	et	al.,	2017).		While	it	
is	 well	 documented	 that	 chronic	 and	 acute	 stress	 stimulate	 the	 release	 of	 stress	
hormones,	such	as	cortisol	in	the	human	and	corticosterone	in	the	rodent,	the	exact	effect	
of	the	hormone	on	the	bladder	has	thus	far	been	undocumented.		
In	 a	 rat	model	 of	water	 avoidance	 stress,	 it	 has	 been	 observed	 that	 chronic	 stress	 is	
associated	 with	 degenerative	 changes	 to	 the	 urothelial	 layer	 of	 the	 bladder	 (Cetinel,	
Ercan,	Cikler,	Contuk,	&	Sener,	2005).		Research	has	linked	this	change	in	the	bladder	to	
an	 increase	 in	 cyclooxygenase	 2	 (COX2)	 expression	 and	 subsequent	 release	 of	 pro-
inflammatory	 cytokines	 (Yamamoto	 et	 al.,	 2012).	 	 There	 are	 two	 isoforms	 of	
cyclooxygenase,	COX1	and	COX2	with	arachidonic	acid	being	the	substrate	for	both	forms	
(Ricciotti	&	FitzGerald,	2011).	 	COX2	in	particular,	 is	responsible	for	the	production	of	
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prostaglandin	E2	(PGE2)	which	causes	inflammation	and	pain	(Figure	4.32)	(Ong,	Lirk,	
Tan,	 &	 Seymour,	 2007).	 	 Interestingly,	 the	 same	 study	 also	 observed	 an	 increase	 in	
voiding	frequency	in	stressed	mice,	just	like	the	results	from	this	chapter.		Previously,	our	
group	has	 reported	 on	 an	 association	 between	 an	 increase	 in	 urinary	 frequency	with	
increased	COX2	production,	due	to	inflammation	(West	et	al.,	2018).		A	study	looking	at	
the	 role	 of	 cyclooxygenase	 in	 the	 HPA	 axis,	 found	 that	 there	 was	 considerable	
participation	of	COX1	and	COX2	in	the	stimulating	of	β2-adrenergic	receptor-mediated	
function	 of	 the	 HPA	 axis	 (Bugajski,	 Glod,	 Gadek-Michalska,	 &	 Bugajski,	 2001).	 	 This	
increase	 has	 also	 been	 assessed	 in	 aged	 rats	 and	 it	 was	 found	 that	 increased	 pro-
inflammatory	 cytokines	 target	 hypothalamic	 receptors	 of	 the	 HPA	 axis	 to	 stimulate	
corticotropin	secretion	(Sapolsky,	Rivier,	Yamamoto,	Plotsky,	&	Vale,	1987).		Therefore,	
a	suspected	increase	in	COX2	and	subsequent	release	of	inflammatory	cytokines	onto	the	
HPA	 axis,	may	 play	 a	 role	 in	 stress	 response	 and	 altered	 voiding	 in	water	 avoidance	
stressed	mice.	
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Figure	4.32:	Production	of	Cyclooxygenase	(COX).	Flow	chart	representing	the	actions	of	
COX	1	and	COX	2	from	arachidonic	acid	which	leads	to	further	production	of	PGE2	(pro-
inflammatory	cytokine),	leading	to	pain	and	inflammation.	(Created	with	BioRender.com	
by	the	author)	
	
Effects	of	Stress	on	Bladder	Physiology	
To	investigate	the	local	bladder	mechanisms	that	may	contribute	to	the	altered	voiding	
phenotype	 observed	 in	 the	 stressed	 mice,	 bladder	 compliance,	 urothelial	 signalling	
mediators	and	contractile	responses	were	assessed	using	a	whole-bladder	preparation.	
Nerve	mediated	bladder	responses	to	EFS,	at	all	frequencies,	were	not	affected	by	stress.	
Similarly,	 there	was	no	 change	 observed	 in	 the	 contribution	 of	ACh	or	ATP	 to	 nerve-
mediated	 responses	 to	 EFS	 or	 in	 the	 beta-adrenoceptor	mediated	 bladder	 relaxation.		
However,	 contractile	 responses	 to	 muscarinic	 (carbachol)	 and	 receptor-independent	
(KCl)	detrusor	 stimulation,	 as	well	 as	 responses	 to	αβmATP	and	ATP	were	 increased	
significantly	in	bladders	from	the	stressed	group.		This	suggests	that	an	overall	increase	
in	detrusor	contractility	rather	than	changes	in	receptor	expression	and	may	instead,	be	
related	to	Rho-kinase	and	calcium	sensitisation	(Frazier,	Peters,	Braverman,	Ruggieri,	&	
Michel,	2008).		
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Figure	 4.33:	 Intracellular	 mechanisms	 involved	 in	 smooth	 muscle	 contraction.	
Calmodulin	 (CaM),	 Calcium	 (Ca2+),	 Guanosine	 diphosphate	 (GDP),	 Guanosine	
triphosphate	(GTP),	G	protein-coupled	receptor	alpha	subunits	12/13	(G12/13),	Myosin	
light	 chain	 kinase	 (MLCK),	 Myosin	 light	 chain	 phosphatase	 (MLCP),	 Roh-associated	
protein	kinase	(ROCK),	Sarcoplasmic	reticulum	(SR).	(Created	with	Biorender.com	by	the	
author).	
	
Changes	in	intracellular	calcium	have	been	implicated	in	various	smooth	muscle	related	
disorders.	 	 Smooth	muscle	 contraction	 in	 the	 detrusor	 is	 driven	 by	 free	 intracellular	
calcium	concentration	and	phosphorylation	of	a	number	of	enzymes,	with	smooth	muscle	
contraction	being	dependent	on	the	phosphorylation	state	of	myosin	light	chain	kinase	
(MLCK).	 	 Studies	 have	 also	 demonstrated	 that	 smooth	muscle	 contraction	 can	 occur	
independently	of	calcium	concentration	by	inhibition	of	myosin	phosphatase	(MLCP)	by	
Rho-associated	 protein	 kinase	 (ROCK)	 (Somlyo	 &	 Somlyo,	 2000;	 Yoshii	 et	 al.,	 1999).		
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There	are	three	isoforms	of	Rho-kinase	that	make	up	the	GTPase	family,	RhoA,	RhoB	and	
RhoC.	 	 RhoA	 however,	 is	 the	 best	 understood	 isoform	 of	 Rho-kinase	 due	 to	 its	
involvement	 in	 smooth	muscle	 contraction	 (de	 Godoy	&	Rattan,	 2011)	 (Figure	 4.33).		
RhoA	is	part	of	a	molecular	switch	which	changes	from	active	guanosine	triphosphate	
(GTP)-bound	to	inactive	guanosine	diphosphate	(GDP)-bound	(Yoshii	et	al.,	1999).		This	
switch	is	activated	by	Rho-specific	guanine	nucleotide	exchange	factor	(RhoGEF).		Once	
converted	to	RhoA	GTP-bound,	interactions	occur	between	multiple	effectors	including	
ROCK	 (Wettschureck	 &	 Offermanns,	 2002).	 	 ROCK,	 once	 activated	 by	 RhoA,	
phosphorylates	the	myosin	binding	subunit,	leading	to	inactivation	of	MLCP.		Inhibition	
of	MLCP	leads	to	increased	activity	of	myosin	phosphorylation	which	acts	to	induce	actin-
myosin	 cross-bridging	 causing	 smooth	muscle	 contraction	 (Somlyo	&	 Somlyo,	 2000).		
There	has	also	been	evidence	of	ROCK	directly	phosphorylating	MLC20,	which	activates	
myosin	 to	 form	 cross-bridges	 with	 actin	 filaments,	 causing	 contraction	 (Somlyo	 &	
Somlyo,	 2000).	 	 Therefore,	 ROCK	 causes	 calcium	 sensitisation	 and	 enhances	 smooth	
muscle	contraction	independently	of	calcium	concentration.		
The	 ROCK	 pathway	 has	 been	 shown	 to	 be	 upregulated	 under	 pathophysiological	
conditions	in	bladder	smooth	muscle	(Zhang	&	DiSanto,	2011).		One	study	examined	the	
changes	 in	 Rho-kinase	 after	 environmental	 stress	 of	 female	 rats	 (Yoon	 et	 al.,	 2010),	
performing	 immunohistochemical	 staining	 for	 ROKα,	 the	 activating	 enzyme	 of	 ROCK.		
The	 study	 found	 that	 there	 was	 an	 increase	 in	 ROKα	 expression	 in	 the	 bladders	 of	
stressed	rats	compared	 to	 the	controls	and	 this	was	accompanied	with	an	 increase	 in	
voiding	frequency	with	stress	(Yoon	et	al.,	2010).		Chronic	variable	stress	also	increased	
RhoA/ROCK	 expression	 in	 the	 rat	 bladder,	 with	 a	 decrease	 in	 micturition	 duration,	
interval	and	volume	also	reported	(Han,	Jeong,	&	Lee,	2015).		The	changes	in	the	ROCK	
pathway	previously	described,	may	explain	the	overall	enhanced	bladder	contractility	of	
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the	stressed	mice	in	our	study,	and	may	contribute	to	alterations	in	voiding	behaviour	
with	water	avoidance	stress.		
Interestingly,	nerve	mediated	bladder	responses	to	EFS	stimulation	were	not	affected	by	
stress,	 even	 though	general	 contractility	was	 increased.	 	As	 stated	previously,	 normal	
physiological	 contraction	occurs	by	 the	 co-release	of	neurotransmitters	ACh	and	ATP,	
acting	on	M3	muscarinic	receptors	and	P2X1	receptors,	respectively.		As	seen	above,	the	
relative	contribution	of	these	neurotransmitters	was	not	altered	by	stress	in	the	present	
study.	 	As	an	 increase	 in	general	contractility	was	observed	 in	 the	stressed	group,	 the	
absence	 of	 changes	 in	 nerve	 mediated	 contraction	 suggests	 that	 the	 process	 of	
neurotransmission	and/or	the	efferent	nerves	were	affected	by	stress.		Many	studies	have	
reported	 increased	 nerve	 density	 in	 overactive	 bladder	 (Arrabal-Polo	 et	 al.,	 2012),	
however,	our	findings	would	not	support	this.		Instead,	it	may	be	suggested	that	there	is	
an	increased	breakdown	of	neurotransmitters	after	repeated	psychological	stress.		While	
this	theory	has	not	been	well	documented	previously,	one	study	investigated	the	effect	of	
acute	and	chronic	restraint	stress	on	ATP	hydrolysis	 in	hippocampal	synaptosomes	of	
male	 rats.	 	 The	 study	 observed	 that	 ATP	 diphosphohydrolase	 activity	 increases	 with	
acute	stress,	contributing	to	the	elimination	of	ATP	and	an	increase	in	the	availability	of	
extracellular	 adenosine.	 	 Chronic	 stress,	 however,	 resulted	 in	 increased	 ecto-ATPase	
(Fontella	et	al.,	2004),	which	works	to	catalyse	the	hydrolysis	of	extracellular	ATP	to	ADP	
and	 inorganic	 phosphate	 	 (Dombrowski,	 Ke,	 Brewer,	 &	 Kapp,	 1998).	 	 A1	 adenosine	
receptors	 have	 been	 implicated	 in	 modulating	 neuromuscular	 transmission	 in	 the	
detrusor	muscle.		One	study	has	observed	selective	A1	adenosine	receptor	agonists	on	the	
contractile	responses	of	detrusor	muscle	preparations	to	EFS	and	found	that	A1	agonists	
inhibited	murine	bladder	 contraction	 in	 response	 to	EFS	 (Searl	 et	 al.,	 2016).	 	Greater	
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neurotransmitter	breakdown	may	explain	why	 the	nerve-mediated	 contractions	were	
unchanged	in	the	stress	group,	despite	an	increase	in	bladder	contractility.		
A	 sub-maximal	 carbachol	 concentration	 produced	 a	 large	 tonic	 bladder	 contraction,	
followed	by	spontaneous	phasic	responses.		Both	amplitude	and	frequency	of	the	phasic	
responses	were	significantly	enhanced	in	bladders	from	the	stressed	group.		A	number	of	
theories	exist	as	to	why	spontaneous	activity	occurs.	For	instance,	muscarinic	receptor	
subtypes,	M2	and	M3,	have	been	linked	to	the	phasic	component	of	carbachol	contractions	
in	 guinea	 pig	 bladder,	 however,	 some	 studies	 have	 observed	 that	 bladder	 volume	
influences	the	response	in	the	murine	bladder	(Lagou,	Gillespie,	Andersson,	Kirkwood,	&	
Drake,	 2006;	 Srinivasan,	 Kim,	 Burbach,	 Ford,	 &	 Bhattacharya,	 2006).	 	 It	 has	 been	
previously	 reported	 that	 spontaneous	 contractions	 may	 occur	 in	 a	 murine	 model	 of	
bladder	overactivity	(McCarthy	et	al.,	2009;	West	et	al.,	2018).		PGE2	has	been	reported	
to	be	 increased	 in	 some	overactive	bladder	 conditions	 and	has	 the	 ability	 to	 increase	
phasic	contractions	of	the	detrusor	muscle.		PGE2	has	been	shown	in	previous	studies	to	
increase	 calcium	 transients	 thereby	 increasing	 the	 frequency	 of	 spontaneous	
depolarisation	(Kobayter	et	al.,	2012).	 	Other	studies	of	detrusor	smooth	muscle	have	
observed	 that	 spontaneous	 contractions	 are	 insensitive	 to	 tetrodotoxin,	 thereby	
confirming	 the	non-neurogenic	origin	of	 the	contractions,	which	 fits	 the	profile	of	our	
study	(Drake	et	al.,	2018).		Several	studies	have	associated	ROCK	with	the	regulation	of	
detrusor	smooth	muscle	tone		and	therefore	if	there	is	an	increase	in	ROCK	(Wibberley,	
Chen,	 Hu,	 Hieble,	 &	 Westfall,	 2003),	 as	 suspected	 due	 to	 the	 general	 increase	 in	
contractility,	there	would	naturally	be	an	increase	in	bladder	tone	(Shiomi	et	al.,	2013).		
Spontaneous	phasic	activity	has	been	linked	with	the	regulation	of	bladder	tone	(Drake	
et	al.,	2017).		As	tone	may	be	increased	in	the	stressed	bladders,	due	to	increased	ROCK	
expression,	this	may	be	the	reason	that	increased	spontaneous	activity	was	observed	in	
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stressed	bladders.	 	Given	that	bladder	compliance	was	not	altered	by	stress,	but	there	
was	an	 increase	 in	urinary	 frequency,	 it	suggests	 that	sensory	changes,	particularly	 in	
spontaneous	activity,	may	be	involved	in	altered	voiding	patterns	observed	here.	
The	 results	 presented	 here	 indicate	 that	 psychological	 stress	 affects	 local	 bladder	
function.		The	general	increase	in	contractility,	potentially	due	to	upregulation	of	the	Rho-
kinase	 calcium	 sensitisation	 pathway,	 may	 contribute	 to	 the	 increase	 in	 urinary	
frequency	and	decreased	void	 size	observed	 in	 the	water	 avoidance	 stressed	mice.	 In	
conclusion,	functional	bladder	changes	were	observed	in	stressed	mice	and	may	be	linked	
to	overall	increased	contractility	of	the	bladder,	independent	of	neuronal	stimulation.	
	
Effects	 of	 Stress-free	Recovery	 on	 Stress	 Induced	Changes	 to	Voiding	Behaviours	 and	
Plasma	Corticosterone	
To	our,	knowledge	there	are	few	studies	which	investigate	the	long-term	effects	of	stress	
of	voiding	behaviour	and	persistence	of	these	changes	once	stress	exposure	ends.		In	this	
study,	voiding	analysis	took	place	over	a	period	of	10-days	stress-free	following	exposure	
to	water	avoidance	stress.		The	aim	was	to	determine	if	there	is	recovery	from	the	initial	
voiding	dysfunction	seen	in	the	water	avoidance	stress	model	or	if	further	changes	occur.	
Voiding	 increased	over	the	10-days	stress	exposure,	as	seen	 in	part	1	using	the	water	
avoidance	stress	model	in	this	chapter.		While	voiding	frequency	did	decrease,	over	the	
following	 10-days	 stress-free	 period,	 voiding	 frequency	 still	 remained	 significantly	
elevated	compared	to	unstressed	controls,	with	an	apparent	spike	at	day	20.		The	same	
trend	was	 also	 observed	 in	 the	 number	 of	 small	 voids	 (<0.2cm2),	where	 the	 amount	
increased	 over	 the	 first	 10-days	 and	 decreased	 over	 the	 stress-free	 period,	 with	 a	
significant	increase	at	day	20.		This	demonstrates	the	long-term	effect	of	psychological	
stress	 on	 bladder	 function.	 	 We	 are	 aware	 of	 only	 one	 experimental	 study	 that	
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investigated	the	recovery	of	voiding	function	following	chronic	stress	exposure,	which	
reported	that	changes	in	micturition	persisted	for	approximately	1	month	in	female	rats	
following	WAS,	with	a	mean	duration	of	24	days,	although	surprisingly	 this	particular	
data	 was	 not	 presented	 in	 the	 paper	 (Smith	 et	 al.,	 2011).	 Clinical	 studies	 have	 also	
observed	 a	 positive	 correlation	 between	 perceived	 stress	 levels	 and	 the	 incontinence	
symptoms	 observed	 in	 overactive	 bladder	 and	 interstitial	 cystitis/bladder	 pain	
syndrome	(Lai,	2015).		These	findings	demonstrate	that	psychological	stress	may	have	a	
long-term	impact	on	voiding	dysfunction,	which	may	fluctuate	depending	on	perceived	
stressors.		
Corticosterone	 levels	have	been	documented	 to	 increase	 in	a	number	of	 rodent	stress	
models	(Hassan	et	al.,	2014;	Wang	et	al.,	2017).		Here	we	demonstrate	that	corticosterone	
levels	decreased	in	the	stressed	mice	after	10-days	of	stress-free	recovery,	returning	to	
control	 levels.	 	 This	 indicates	 that	 the	 hormonal	 response	 to	 psychological	 stress	
recovers,	however	this	does	not	necessarily	correlate	with	recovery	of	bladder	function.		
Several	experimental	studies	 look	at	corticosterone	 levels	 in	both	a	chronic	and	acute	
stress	scenario.	 	One	study	using	a	model	of	social	defeat	stress	observed	that	chronic	
stress	may	cause	short-term	adaptation	in	the	HPA	axis	resulting	in	a	maladaptive	stress	
response.		The	study	reported	a	biphasic	corticosterone	response	where	after	2	weeks,	a	
‘switch’	 occurs	 to	 desensitise	 CRF	 expression	 and	 instead	 elevate	AVP	 (Keeney	 et	 al.,	
2006).	Another	study	observing	repeat	restraint	stress	observed	that	desensitisation	of	
CRH	 occurs	 after	 2	 weeks	 of	 stress	 and	 therefore	 the	 hypothalamus	 is	 flexible	 to	
homotypic	stress	(Ma,	Lightman,	&	Aguilera,	1999).		Clinically,	studies	on	humans	have	
also	observed	a	switch	from	CRF	to	AVP	drive	on	the	HPA	axis,	which	may	play	a	role	in	
the	pathophysiology	of	clinical	depression	(Scott	&	Dinan,	2002).		This	may	explain	why,	
after	the	water	avoidance	stress	period	and	10-days	of	recovery,	corticosterone	hormone	
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levels	 are	 significantly	 decreased	 in	 the	 ‘recovered’	 group,	 compared	 to	 the	 stressed	
group	which	had	no	recovery	time.		
	
Effects	of	Stress-Free	Recovery	on	Mediator	Release	
Interestingly,	serosal	ACh	was	increased	in	the	stressed	group	and	significantly	increased	
in	the	10-day	stress-free	group.		This	was	not	seen	in	the	original	WAS	study,	where	there	
was	no	change	in	serosal	ACh	release,	and	this	can	only	be	attributed	to	the	fact	that	both	
studies	were	undertaken	 a	 year	 apart	 from	one	 another.	 	Due	 to	 there	not	 being	 any	
change	in	the	contribution	of	ACh	to	nerve	mediated	activity	after	the	addition	of	atropine	
to	the	bath,	discussed	later,	it	can	be	assumed	that	this	increase	in	ACh	was	from	a	non-
neuronal	source.	 	Studies	of	non-neuronal	ACh	release	have	found	that	urothelial	cells	
express	 high-affinity	 CHT1	 as	well	 as	 ChAT	 and	 CarAT	 (Hanna-Mitchell	 et	 al.,	 2007).		
While	vesicular	release	of	ACh	occurs	in	nerve	terminals,	non-vesicular	release	has	been	
shown	to	occur	from	the	urothelium,	due	to	the	absence	of	the	vesicular	acetylcholine	
transporter	(VAChT).		The	same	study	also	identified	organic	cation	transporters	(OCT),	
OCT1	and	OCT3,	which	are	important	for	the	release	of	ACh	(Lips	et	al.,	2007).			
The	 role	 of	 ACh	 is	 still	 being	 identified,	 however,	 there	 is	 some	 evidence	 that	 the	
neurotransmitter	 influences	 sensory	 nerve	 activity	 to	 stimulate	 the	 release	 of	 UDIF	
(Hawthorn	et	al.,	2000).				There	is	limited	literature	on	the	effect	of	recovery	after	water	
avoidance	stress	and	therefore	it	could	be	theorised	that	UDIF	acts	to	inhibit	detrusor	
muscle	contraction	(Templeman,	2002),	Therefore,	enhanced	ACh	release,	observed	in	
the	stress-free	recovery	group,	may	act	to	decrease	contractility	that	occurred	within	the	
group.		During	the	storage	phase,	stretch	of	the	urothelium	initiates	release	of	mediators	
(Birder,	Kanai,	 Cruz,	Moore,	&	Fry,	 2010).	 	 As	 there	was	 increased	 compliance	 in	 the	
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stress-free	recovery	group,	it	is	also	possible	that	this	has	caused	an	increased	release	of	
ACh	from	the	urothelium.		
	
Effects	of	Stress-Free	Recovery	on	Stress	Induced	Changes	to	Bladder	Physiology	
Part	1	of	this	chapter	reported	an	increase	in	general	contractility	after	10-days	of	water	
avoidance	 stress.	This	 increase	 in	 contractility	 caused	by	 stress	appears	 to	 recover	 to	
unstressed	 control	 levels	 following	 10-days	 stress-free.	 	 Nerve	 mediated	 bladder	
responses	to	EFS,	at	all	frequencies,	were	not	affected	by	recovery.		Similarly,	there	was	
no	change	observed	in	the	contribution	of	ACh	or	ATP	to	EFS-induced	responses	or	in	the	
beta-adrenoceptor	mediated	 bladder	 relaxation.	 	 Contractile	 responses	 to	muscarinic	
receptors	(carbachol)	and	receptor-independent	(KCl)	detrusor	stimulation	as	well	as	
response	to	αβmATP	and	ATP	were	also	reduced	in	the	recovered	group	compared	to	the	
stressed	 group.	 	 Sub-maximal	 tonic	 contraction	 to	 carbachol	was	 also	 reduced	 in	 the	
recovered	 group	 and	 the	 frequency	 of	 the	 subsequent	 phasic	 activity	 was	 reduced,	
compared	to	the	stressed	group.		These	changes	indicate	that	there	is	some	recovery	of	
the	bladders	after	chronic	water	avoidance	stress.		The	most	significant	change	observed,	
however,	was	in	the	compliance	of	bladders	from	stressed	mice	following	10-days	stress-
free	period,	which	increased	significantly	compared	to	both	the	bladders	from	unstressed	
and	stressed	mice.	 	This	suggests	that	a	stress-free	recovery	period	initiated	a	form	of	
compensation,	 increasing	 bladder	 compliance,	 thereby	 reducing	 the	 impact	 of	
psychological	stress	on	voiding.		
The	impact	of	stress	on	bladder	compliance	has	not	been	well	documented,	however,	one	
study	observed	nociceptive	responses	in	chronic	psychological	stress.		The	study	found	
that	water	avoidance	stress	causes	bladder	hypersensitivity	meaning	that	voiding	occurs	
at	 lower	bladder	pressures.	 	 This	may	 explain	why,	with	 increased	 compliance	 in	 the	
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recovered	group,	voiding	frequency	decreased	(Gao,	Zhang,	Chang,	&	Rodriguez,	2018).	
Changes	in	compliance	may	also	manifest	with	long	term	changes	in	bladder	morphology.	
Bladder	fibrosis	is	known	to	cause	changes	to	both	the	detrusor	muscle	and	extracellular	
matrix	(Lluel	et	al.,	2000).		The	extracellular	matrix	of	the	bladder	is	made	up	of	Type	I	
and	 Type	 III	 collagen.	 Type	 I	 collagen	 helps	 to	maintain	 tension	 and	 smooth	muscle	
binding,	leading	to	decreased	contractility	and	compliance	(Inaba	et	al.,	2007).		Type	III	
collagen	 increases	 bladder	 elasticity	 and	 contractility	 of	 smooth	 muscle	 (Stevenson,	
Kucich,	Whitbeck,	Levin,	&	Howard,	2006).		One	study	has	found	that	after	chronic	stress	
of	 female	 mice,	 both	 types	 I	 and	 III	 collagen	 were	 increased	 in	 bladders,	 which	
demonstrates	that	stress	can	induce	pathological	changes	in	bladder	stability	(Yoon	et	al.,	
2010).		It	may	be	hypothesised	that	changes	in	collagen,	due	to	stress,	may	continue	to	
increase	or	may	not	recuperate	to	unstressed	control	levels,	in	the	10-days	after	stress,	
thereby	increasing	compliance	in	the	recovered	bladders.		This	could	be	investigated	in	
future	studies,	by	performing	histology	and	 looking	at	markers	of	Type	 I	and	Type	 III	
collagen.	
The	long-term	changes	in	bladder	collagen	may	also	explain	why	symptoms	of	overactive	
bladder	reoccur	with	fluctuations	of	psychological	stress.	 	Increased	collagen	has	been	
linked	 to	detrusor	overactivity	 in	 a	number	of	 clinical	 studies	 and	has	been	 linked	 to	
detrusor	 overactivity	 and	 urinary	 retention	 in	men	 (Bellucci	 et	 al.,	 2017),	 and	 stress	
urinary	incontinence	in	women	(Kushner,	Mathrubutham,	Burney,	Greenwald,	&	Badlani,	
2004).	
The	 persistent	 elevation	 in	 voiding	 frequency	 following	 a	 stress-free	 period,	 despite	
increased	bladder	compliance	and	recovery	of	detrusor	contractile	responses	suggests	
that	 there	may	 also	 be	 sensitization	 of	 bladder	 afferent	 nerves	 and/or	 alterations	 to	
micturition	control	centre	contributing	to	the	stress	induced	voiding	dysfunction.	
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CONCLUSION	
The	 results	presented	here	 indicate	 that	psychological	 stress	 affects	bladder	 function,	
evident	in	the	increased	voiding	frequency	and	increased	contractile	responses.		There	
was	a	non-specific	 increase	 in	detrusor	 contraction	which	appears	 to	be	offset	by	 the	
efferent	 innervation/neurotransmission.	 	 Furthermore,	 urothelial	 release	 was	 not	
significantly	changed	following	WAS	at	the	level	of	distension	tested.		A	period	of	recovery	
appeared	to	reduce	the	increased	contractility	induced	by	stress	and	was	associated	with	
enhanced	 compliance.	 	 Interestingly,	 while	 voiding	 frequency	 was	 reduced	 following	
stress-free	 recovery,	 it	 remained	 elevated	 compared	 to	 unstressed	 controls	 which	
indicates	another	underlying	mechanism	may	be	responsible,	possibly	involving	sensory	
nerves.	
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The	results	presented	in	this	chapter	have	been	published:	West,	Eliza	G.,	Sellers,	Donna	
J.,	Chess-Williams,	Russ.,	McDermott,	Catherine.	(2021).	“The	anxiolytic	sertraline	
reduces	the	impact	of	psychological	stress	on	bladder	function	in	mice”,	Life	Sciences,	
2021,	119598,	https://doi.org/10.1016/j.lfs.2021.119598.	Under	CC	BY	NC-ND	licence.	
	
INTRODUCTION	
Depression	 and	 anxiety	 are	major	 contributors	 to	 the	 global	 burden	 of	 disease.	 	 The	
management	 of	 anxiety	 and	 depression	 is	 through	 primary	 care	 and	 often	 the	
administration	of	SSRI	antidepressants	(Lewis	et	al.,	2019).		One	of	the	most	prescribed	
SSRI’s	on	the	market	is	sertraline,	clinically	known	as	Zoloft	(Hillhouse	&	Porter,	2015)	
and	is	the	SSRI	used	in	the	current	study.			
	
Serotonin	and	Selective	Serotonin	Reuptake	Inhibitors	(SSRI)	
Serotonin	is	a	neurotransmitter	that	impacts	several	processes,	including	motor	activity,	
hormone	 secretion,	 cognition,	 and	 autonomic	 function.	 	 The	 activation	 of	 serotonin	
neurons	is	controlled	by	several	efferent	pathways	including	glutamatergic	input	in	the	
prefrontal	 cortex,	 tonic	 noradrenergic	 input	 from	 pontine	 nuclei	 and	 inhibitory	
GABAergic	 input	 from	 interneurons.	 	 Within	 the	 terminal	 axon	 of	 the	 serotonergic	
neuron,	a	complex	cascade	begins	with	tryptophan	converting	to	serotonin	(5-HT),	when	
stimulated	by	the	aforementioned	processes	(Adell,	Celada,	Abellan,	&	Artigas,	2002).		
5-HT	is	accumulated	and	stored	within	presynaptic	vesicles.		Release	of	serotonin	occurs	
from	the	presynaptic	vesicles	into	the	synaptic	cleft	when	an	action	potential	stimulates	
the	neuron.		The	released	5-HT	can	interact	with	both	post	and	pre-synaptic	receptors,	
which	 results	 in	 attenuation	 or	 stimulation	 of	 further	 release	 (Umehara	 et	 al.,	 2016).		
Postsynaptic	 receptors	 (5-HTR1	 and	 5-HTR2)	 work	 together	 to	 activate	 second	
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messenger	cascades	(Struder	&	Weicker,	2001),	with	the	main	signalling	pathway,	of	5-
HTR1,	being	coupling	via	G	proteins	to	decrease	cyclic	AMP	and	inhibit	adenylate	cyclase.		
The	 signalling	 pathway	 of	 5-HTR2	 activates	 phospholipase	 C,	 again	 via	 G	 protein	
coupling,	thereby	catalysing	the	formation	of	IP3	and	DAG	(Raymond	et	al.,	2001).		These	
pathways	then	activate	neurotransmitter	release	from	serotonergic,	noradrenergic,	and	
dopaminergic	neurons.		Serotonin	that	does	not	attach	to	receptors	is	transported	back	
into	the	presynaptic	terminals	via	the	membrane	protein,	solute	carrier	family	6	member	
4	(SCL6A4).		SCL6A4	is	part	of	the	Na+/Cl-	dependent	transporter	family	(Quick,	2003).		
See	Figure	5.1	for	a	diagram	of	this	pathway.			
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Figure	5.1:	Serotonergic	neuron	displaying	cascade	from	serotonin	(5-HT)	production	in	
presynaptic	neuron	to	stimulation	of	postsynaptic	neuron	and	subsequent	activation	of	
neurotransmitter	releases	from	serotonergic,	noradrenergic,	and	dopaminergic	neurons.		
Tryptophan	 (TRP),	 Postsynaptic	 neuron	 receptors	 (5-HTR1	 and	 5-HTR2),	 Adenylyl	
cyclase	 (ADCY),	Adenosine	Triphosphate	 (ATP),	 Cyclic	AMP	 (cAMP),	 Phospholipase	C	
(PLCB),	 Inositol	 triphosphate	 (IP3)	 and	 Diacylglycerol	 (DAG).	 	 (Created	 with	
Biorender.com	by	the	author).	
	
SSRIs	were	developed	over	several	years	to	target	specific	serotonin	uptake	sites	with	
high	affinity.		SSRIs	also	have	a	low	affinity	to	noradrenaline	uptake	sites	and	very	low	
affinity	to	other	neurotransmitters	uptake	sites	(Hiemke	&	Hartter,	2000).	 	SSRIs	have	
been	used	to	treat	both	major	clinical	and	minor	depression	and	have	also	been	used	to	
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treat	 other	 psychiatric	 disorders	 associated	 with	 serotonin	 system	 dysfunction	
(Denboer,	Westenberg,	Deleeuw,	&	Vanvliet,	1995).		SSRIs	block	reuptake	of	serotonin	
back	into	the	presynaptic	neuron,	thereby	increasing	the	amount	of	serotonin	available	
in	the	synapse.		The	serotonin	therefore	has	more	opportunity	to	attach	to	5-HTR1	and	
5-HTR2	receptors,	as	seen	in	Figure	5.1	(Hiemke	&	Hartter,	2000).		Ascending	serotonin	
neuron	projections	terminate	in	several	regions	including	the	cortical,	limbic,	midbrain	
and	hindbrain	regions.	 	These	regions	that	are	modulated	by	serotonin	production	are	
responsible	for	mood,	appetite	and	memory,	amongst	others,	which	explains	why	drugs	
targeting	 specific	 serotonin	 receptors	 have	 effects	 on	multiple	 behavioural	 processes	
(Giorgetti	&	Tecott,	2004).		
	
5-HT	Receptors	Involved	in	Bladder	Function	
As	discussed	 in	Chapter	1,	normal	bladder	 function	relies	on	a	coordinated	pattern	of	
relaxation	 and	 contraction	 by	 excitatory	 and	 inhibitory	 nerve	 activity,	 controlled	
predominately	by	the	pons	micturition	centre	and	forebrain	(Khaled	&	Elhilali,	2003).		
Three	subtypes	of	5-HT	receptors,	5-HT1,	5-HT2	and	5-HT3,	are	found	to	be	present	 in	
various	areas	of	the	lumbosacral	spinal	cord	known	to	innervate	the	bladder	(Monroe	&	
Smith,	1983).	 	These	areas	 include	 the	dorsal	horn,	 the	 site	of	bladder	 afferent	nerve	
terminals	 (Monroe	 &	 Smith,	 1983),	 the	 sacral	 parasympathetic	 nucleus,	 the	 site	 of	
efferent	neurons	to	the	bladder	(Thor,	Nickolaus,	&	Helke,	1993)	and	the	Onuf	nucleus,	
the	 site	 of	 efferent	 neurons	 to	 the	 external	 urethral	 sphincter	 (Helton,	 Thor,	 &	 Baez,	
1994).	 	While	 the	 role	 of	 serotonin	 as	 a	 key	 neurotransmitter	 in	 the	 central	 nervous	
system	has	been	well	established,	5-HT	has	also	been	documented	to	play	an	important	
role	in	LUT	function	(Nishizawa,	2015).			
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In	 addition	 to	 5-HT	 actions	 within	 the	 lumbosacral	 spinal	 cord,	 5-HT	 also	 acts	 on	
autonomic	excitatory	efferent	nerve	terminals.	 	5-HT2A	and	5-HT2C	receptors	in	guinea	
pig	 and	 rat	 bladder,	 respectively,	 have	 been	 shown	 to	 enhance	 nerve	 mediated	
contraction.	 	 These	 subtypes	were	 also	 found	 to	 facilitate	 purinergic	 transmission	 in	
autonomic	 efferent	 nerves	 (Inoue,	 Kitazawa,	 Cao,	 &	 Taneike,	 2003).	 	 Another,	 more	
controversial	 study	 has	 suggested	 that	 5-HT4	 enhances	 ACh	 release	 from	 autonomic	
efferent	nerve	terminals	in	human	detrusor	(Candura	et	al.,	1996).		In	contrast	to	this,	the	
5-HT1A	 subtype	 has	 been	 reported	 to	 have	 an	 inhibitory	 action	 on	 nerve	 evoked	ACh	
release	in	human	detrusor	(D'Agostino,	Condino,	Gallinari,	Franceschetti,	&	Tonini,	2006)	
(Figure	5.2).			
Within	the	bladder	itself,	a	number	of	5-HT	receptors	have	been	identified,	however	the	
effects	 of	 5-HT	 on	 voiding	 are	 poorly	 understood	 due	 to	multiple	 sites	 of	 action	 and	
several	receptor	subtypes.		Within	the	detrusor	muscle,	5-HT	receptor	subtypes	5-HT1A,	
5-HT2,	 5-HT3	 and	 5-HT7,	 have	 been	 identified	 at	 post	 junctional	 detrusor	 sites	
(Matsumoto-Miyai,	 Yoshizumi,	 &	 Kawatani,	 2015).	 	 Across	 different	 species,	 5-HT2	
subtypes	have	been	shown	to	be	involved	with	postjunctional	detrusor	smooth	muscle	
contraction,	particularly	 in	dogs	(Cohen	&	Tromba,	1989),	human	(Klarskov	&	Horby-
Petersen,	 1986)	 and	 rats	 (Sakai,	 Kasahara,	 Tomita,	 Ikegaki,	 &	 Kuriyama,	 2013).		
Stimulation	of	the	5-HT1A	receptor	has	also	been	shown	to	produce	a	reduction	in	cyclic	
AMP	(cAMP)	levels,	 thereby	increasing	detrusor	muscle	contraction	(Mittra,	Malhotra,	
Naruganahalli,	&	Chugh,	2007).		However,	another	study	of	rat	bladder	strips	found	that	
stimulation	 of	 5-HT3	 receptors	 inhibited	 detrusor	 contraction	 by	 direct	 muscle	
stimulation,	but	enhanced	nerve	stimulated	contraction	(Chetty,	Coupar,	Chess-Williams,	
&	 Kerr,	 2007).	 	 In	 terms	 of	 EFS-evoked	 contractions,	 stimulation	 of	 5-HT7	 receptors	
facilitates	detrusor	contraction	and	interestingly	appear	to	facilitate	the	release	of	ACh	
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from	 parasympathetic	 nerve	 terminals	 in	 human	 bladder	 (D'Agostino	 et	 al.,	 2006)	
(Figure	5.2).			
As	discussed	in	previous	sections,	distension	of	the	bladder	wall	evokes	release	of	ATP	
from	the	urothelium	via	a	downstream	release	of	Ca2+	from	the	endoplasmic	reticulum	
(Matsumoto-Miyai,	Kagase,	Murakawa,	Momota,	&	Kawatani,	2009).	 	There	have	been	
studies	 which	 suggest	 that	 5-HT	 reduces	 urothelial	 ATP	 release	 during	 distension,	
mediated	 by	 the	 5-HT1D	 receptor	 subtype	 (Matsumoto-Miyai,	 Yamada,	 Yoshizumi,	 &	
Kawatani,	2012)	(Figure	5.2).			
	
	
Figure	 5.2:	 Functions	 of	 peripheral	 serotonin	 (5-HT)	 receptor	 subtypes	 in	 urinary	
bladder.	+	 Induction	or	 facilitation,	 -	 Inhibition.	 	 (Created	with	BioRender.com	by	 the	
author).	
	
While	the	location	and	general	action	of	5-HT	receptors	have	been	somewhat	described	
in	the	literature,	it	remains	unclear	as	to	where	5-HT	is	being	released.		Due	to	the	fact	
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that	peripheral	nerves	do	not	release	5-HT	when	activated,	it	was	suggested	that	platelets	
or	mast	cells	may	be	releasing	5-HT	(Yazaki	et	al.,	1987;	Yu	et	al.,	1999).			
In	 summary,	 5-HT	 receptor	 subtypes	 on	detrusor	 smooth	muscle	 have	been	 found	 to	
induce	 contraction	 or	 relaxation,	 while	 receptors	 on	 autonomic	 efferent	 terminals	
indirectly	 influence	 contraction	 by	 modifying	 purinergic	 or	 cholinergic	 transmission	
(Matsumoto-Miyai	et	al.,	2015).			
	
Sertraline	
Sertraline	(Zoloft)	is	a	commonly	prescribed	SSRI,	which	was	introduced	as	a	treatment	
of	depression	in	1992	(Lewis	et	al.,	2019).	 	Sertraline	is	an	orally	ingested	drug	which	
reaches	 its	 maximum	 plasma	 concentration	 within	 6-8	 hours	 	 and	 the	 half-life	 is	
approximately	1	day	(Vanharten,	1993).		
Chronic	stress	alters	neuronal	circuits	in	the	brain,	leading	to	disruption	of	intracellular	
signalling	and	loss	of	function	(Flak	et	al.,	2012;	Fontella	et	al.,	2004).		Sertraline	has	been	
widely	documented	to	inhibit	reuptake	of	serotonin	into	the	presynaptic	neuron,	thereby	
increasing	the	neurotransmitter	in	the	synaptic	cleft	(Hiemke	&	Hartter,	2000).	 	While	
the	 blockage	 of	 serotonin	 reuptake	 is	 rapid,	 therapeutic	 action	 requires	 long	 term	
treatment	due	to	the	adaptive	mechanisms	of	the	presynaptic	and	postsynaptic	neuron	
(Celada,	Puig,	Amargos-Bosch,	Adell,	&	Artigas,	2004).		A	study	of	rhesus	monkeys	found	
that	elevation	of	serotonin,	after	administration	of	sertraline,	remains	constant	during	
prolonged	administration,	however,	quickly	returns	to	baseline	after	discontinuation	of	
the	drug	(Anderson	et	al.,	2005).		While	this	study	suggests	rapid	serotonin	increase	upon	
initial	 sertraline	 treatment,	 other	 studies	 have	 observed	 autoreceptor-mediated	
decreases	in	5-HT	neuronal	firing	which	is	believed	to	contribute	to	latency	of	sertraline	
response	 (Gray	 et	 al.,	 2013).	 	 There	 are	 alternative	 explanations	 for	 gradual	 onset,	
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including	a	downregulation	of	5-HT	transporters	over	the	first	2-3	weeks	of	treatment.		
This	results	in	reduced	clearance	of	5-HT	from	the	synaptic	cleft,	leading	to	increased	5-
HT	 in	 the	extracellular	 fluid	and	 increased	receptor	stimulation	(Benmansour,	Owens,	
Cecchi,	Morilak,	&	 Frazer,	 2002).	 	 Clinical	 studies	 of	 sertraline	 reveal	 that	 depressive	
symptoms	 reduce	within	 the	 first	 six	weeks	 of	 treatment,	 however	patients	 observed	
improvements	in	anxiety,	quality	of	life	and	overall	mental	health	before	this	time	(Lewis	
et	al.,	2019).	
	
Anxiolytics/anti-depressants	and	the	Bladder	
Overactive	bladder	 (OAB)	and	other	bladder	pathologies	are	known	 to	greatly	hinder	
quality	of	life	of	sufferers.		Due	to	the	correlation	between	decreased	quality	of	life	and	
depression,	 clinical	 and	 experimental	 studies	 have	 been	 conducted	which	 look	 at	 the	
effect	of	antidepressants	on	OAB,	although	 the	results	are	often	conflicting.	 	A	clinical	
study	conducted	 in	 the	United	States	 found	 that	males	 taking	certain	antidepressants,	
including	sertraline,	experienced	an	increase	in	the	incidence	and	symptom	severity	of	
OAB	(Solmaz	et	al.,	2017).	 	Conflicting	with	 this,	 a	prospective	 trial	was	 conducted	 to	
measure	 OAB	 symptoms	 in	 women	 taking	 antidepressants	 and	 found	 that	 sertraline	
treated	patients	had	the	lowest	prevalence	of	symptoms	(Albayrak	et	al.,	2015).		Some	
studies	 have	 observed	 that	 tricyclic	 antidepressants	 (TCAs)	 are	 effective	 in	 treating	
interstitial	 cystitis	and	some	OAB	symptoms,	however,	 these	drugs	 lack	specificity	 for	
receptors	 of	 the	 bladder	 (Solmaz	 et	 al.,	 2017).	 	 Instead,	 a	 study	 by	 Hillelsohn,	 Rais-
Bahrami,	Bagadiya,	Kashan,	and	Weiss	(2013),	has	used	a	different	TCA,	desipramine,	
and	found	that	 it	 is	a	potential	useful	treatment	in	patients	with	OAB,	especially	those	
who	also	experience	bladder	pain.		
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Though	 the	 association	 between	 bladder	 symptoms	 and	 depression	 has	 been	
documented	clinically,	no	studies	have	investigated	if	current	clinical	therapies	such	as	
the	 SSRI	 sertraline	 are	 of	 therapeutic	 benefit	 in	 managing	 the	 bladder	 dysfunction	
associated	with	 psychological	 stress.	 	 However,	 one	 experimental	 study	 assessed	 the	
effects	of	two	SSRIs,	sertraline,	and	fluoxetine,	on	changes	in	bladder	contractility	caused	
by	forced	swim	test	(FST).		While	the	FST	induced	detrusor	hypercontractility,	this	effect	
was	abolished	by	 long-term	 treatment	with	both	anti-depressants	 (Bilge	et	al.,	2008).				
Another	study	used	female	rats	and	subjected	them	to	corticosterone	treatment	and	the	
forced	 swim	 test	 to	measure	 levels	 of	 depression.	 	 The	 study	 found	 that	 this	 caused	
detrusor	inflammation	and	overactivity	as	well	as	depression.		Treatment	with	the	SNRI,	
duloxetine	 improved	 detrusor	 overactivity	 and	 depression	 via	 central	 mechanisms	
(Wrobel	et	al.,	2020).	
The	aforementioned	clinical	studies	of	sertraline	in	overactive	bladder	patients	highlight	
the	efficacy	of	the	drug	and	the	lack	of	adverse	effects	experienced	by	these	patients.		It	
is	for	this	reason	that	sertraline	was	chosen	to	be	used	in	the	current	study.	
	
Aims	
The	 aim	 of	 the	 present	 study	 was	 to	 investigate	 the	 effects	 of	 sertraline	 on	 bladder	
dysfunction	caused	by	water	avoidance	stress.		
Specific	aims	were;	
• To	 investigate	 the	effects	of	 sertraline	on	voiding	dysfunction	 caused	by	water	
avoidance	stress	
• To	assess	the	changes	mediated	by	sertraline	on	bladder	physiology	after	water	
avoidance	stress	
• To	investigate	if	water	avoidance	stress	or	sertraline	alter	animal	behaviour	using	
the	open	field	test	
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METHODS	
Animals	
Young	adult	female	C57BL/6J	mice	were	obtained	and	housed	as	outlined	in	the	general	
methodology	 chapter	 (Chapter	 2).	 	 Mice	 were	 randomly	 allocated	 into	 one	 of	 three	
groups:	 (1)	 Control/Unstressed,	 (2)	 Stressed	 and	 (3)	 Stress	 +	 Sertraline,	 with	 n=6	
animals	included	in	each	group.	
	
Sertraline	Treatment	Protocol	
As	stated	in	the	background	section,	sertraline	is	a	widely	used	SSRI	to	treat	depression,	
with	the	least	evidence	of	associated	incontinence	clinically,	so	it	was	chosen	for	use	in	
the	current	study.			
Sertraline	(hydrochloride)	was	obtained	from	Cayman	Chemicals	and	formulated	as	an	
oral	 suspension	 by	National	 Custom	Compounding	 Pharmacy	 and	 later	 diluted	 in	 the	
drinking	water.		A	drug	free	suspension	was	added	to	the	drinking	water	of	mice	in	the	
other	groups	to	account	for	any	potential	differences	in	water	consumption	due	to	the	
presence	of	the	oral	suspension.	
Most	studies	looking	at	the	efficacy	of	sertraline	have	commenced	treatment	between	1	
and	2	weeks	before	the	beginning	of	the	stress	exposure	(Renoir	et	al.,	2012).		For	this	
reason,	mice	in	the	present	study	were	treated	with	the	oral	sertraline	suspension	10-
days	 prior	 to	 stress	 exposure	 and	 throughout	 the	 10-day	 water	 avoidance	 stress	
exposure	 period	 (Di	 Rosso,	 Sterle,	 Cremaschi,	 &	 Genaro,	 2018).	 	 The	 vehicle	 control	
suspension	was	also	administered	to	age-matched	unstressed	control,	and	stressed	mice	
throughout	this	period.	 	The	typical	adult	human	dose	for	sertraline	is	50	mg/day	and	
was	used	to	calculate	the	equivalent	dose	in	mice	(10	mg/kg/day),	based	on	a	published	
dose	 conversion	 guide	 for	 humans	 to	 animals	 (Nair	 &	 Jacob,	 2016).	 	 The	 final	
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concentration	of	sertraline	in	the	drinking	water	was	50	µg/ml	which	was	available	24	
hours	a	day,	7	days	a	week.		
	
Water	Avoidance	Stress	Protocol	
Water	 avoidance	 stress	 protocol	 was	 undertaken	 in	 the	 same	manner	 as	 outlined	 in	
chapter	3.		
	
Open	Field	Tests	
The	open	field	test	is	a	very	common	measure	of	general	locomotor	activity	in	mice.		The	
test	is	widely	used	due	to	its	effectiveness	in	describing	several	components	of	rodent	
behaviour.	 	The	procedure	is	one	that	allows	the	study	of	different	strains	of	mice	and	
comparison	 between	 the	 effects	 of	 different	 pharmacological	 agents	 (Seibenhener	 &	
Wooten,	2015).		The	open	field	test	box	was	constructed	as	described	in	previous	studies.		
The	 ‘outer	 zone’	 consists	of	16	 segments	while	 the	 inner	 zone	 consists	of	9	 segments	
(Seibenhener	&	Wooten,	2015).		An	example	of	the	layout	is	given	below	in	Figure	5.3.			
Many	 aspects	 of	 behaviour	 can	 be	 assessed	 from	 an	 open	 field	 test,	 and	 the	 three	
parameters	measured	in	this	study	were	line	crossing,	thigmotaxis	and	rearing	(Burne,	
McGrath,	 Eyles,	 &	 Mackay-Sim,	 2005).	 	 The	 amount	 of	 line	 crossing,	 or	 ambulatory	
distance,	is	one	of	the	most	important	parameters	of	the	open	field	test.		Thigmotaxis	is	
the	tendency	of	the	subject	to	remain	close	to	the	walls	and	tends	to	increase	with	anxiety,	
as	mice	have	a	natural	tendency	to	remain	close	to	walls	and	away	from	brighter	light,	
and	was	assessed	as	the	number	of	 times	the	animal	entered	the	“inner	zone”	(Gould,	
2009).		The	third	parameter	measured	was	rearing.	Rearing	behaviour	occurs	when	the	
animal	 stands	 on	 its	 hind	 paws	 in	 an	 upright	 position.	 	 According	 to	 several	 studies,	
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increased	 rearing	 occurs	 in	 accordance	 with	 increase	 anxiety	 (Borta	 &	 Schwarting,	
2005).		
Stress	and	stress	+	sertraline	treated	mice	were	placed	in	the	open	field	test	box	for	5	
minutes	 on	 the	 day	 before	 drug/placebo	 treatment	 began,	 the	 day	 before	 first	 stress	
exposure	and	on	day	10	after	the	final	stress	exposure.		A	go-pro	camera	was	attached	to	
the	box	and	recorded	the	mouse	behaviour	during	the	open	field	test.	This	was	analysed	
at	a	later	date	assessing	the	number	of	lines	crossed,	number	of	inner	zone	entries	and	
number	of	rearing’s.	
	
Figure	 5.3:	 Example	 of	 layout	 of	 open	 field	 test	 box.	 	 Different	 zones	 are	 displayed.	
(Created	with	BioRender.com	by	the	author).	
	
Whole	Bladder	Preparation	
	Whole	bladder	preparation	was	performed	as	described	in	chapter	2,	with	the	following	
differences	due	to	the	sex	of	the	mice.		When	the	abdominal	region	was	secured	to	the	
dissection	bath	under	 the	microscope,	 the	 female	 reproductive	 organs	were	 removed	
including	 the	uterus,	 fallopian	 tubes,	 ovaries	 and	 surrounding	 connective	 tissue.	 	 The	
whole	bladder	preparation	was	then	continued	as	described	in	chapter	2.	
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Statistical	Analysis	
Two-way	 ANOVA	 with	 Tukey’s	 post	 hoc	 test	 for	 multiple	 comparisons	 was	 used	 to	
compare	 the	different	 time	points,	voiding	variables	and	dose-response	curves.	 	Open	
field	 test	 data	 was	 analysed	 by	 a	 one-way	 ANOVA	 with	 multiple	 comparisons	 and	
Bonferroni	tests.		One-way	ANOVA	with	Bonferroni	post-hoc	test	was	used	to	compare	
the	difference	between	the	three	animal	groups	(Urothelial	mediator	release	data,	animal	
parameters,	spontaneous	activity	data,	response	to	ATP,	αβmATP	and	KCl).		
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RESULTS	
Animal	Parameters	and	Voiding	Behaviour	
During	 the	 experimental	 protocol,	 water	 consumption	 and	 animal	 body	weight	 were	
measured	on	day	0,	1,	3,	5,	7	and	10.		This	data	was	unchanged	across	treatment	groups	
compared	 to	 the	 unstressed	 control	 and	 can	 be	 viewed	 in	 TABLE	 5.1.	 	 After	 final	
experiments,	bladders	were	weighed	and	weights	were	also	unchanged	across	all	groups.		
	
	
A	blood	sample	was	 taken	at	 the	 time	of	 euthanasia	and	plasma	corticosterone	 levels	
were	analysed.	 	There	was	a	significant	increase	in	plasma	corticosterone	levels	in	the	
stressed	group,	100.4	±	24.09	µg/mL	(n=6)	compared	to	the	unstressed	group	33.00	±	
6.05	µg/mL	(n=6)	(p	=	0.03).		Sertraline	treatment	significantly	decreased	this,	reducing	
levels	of	corticosterone	to	23.0	±	11.4	µg/mL	(n=6)	(p	=	0.01),	(Figure	5.4).	
	
TABLE	5.1:		Baseline	body	weight,	water	consumption	and	bladder	weight	(at	day	10)	
in	control	(unstressed),	water	avoidance	stress	(stressed)	and	sertraline	treated	(stress	
+	sert)	mice	(n=6).	
	 Unstressed	 Stressed	 Stress	+	Sert	
Body	weight	(g)	 20.8	±	0.12	 21.8	±	0.34	 20.9	±	0.23	
Bladder	weight	(mg)	 15.4	±	1.05	 17.8	±	1.27	 16.3	±	0.12	
Water	consumption	(g)	 1.52	±	0.18	 1.66	±	0.13	 1.67	±	0.11	
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Figure	5.4:	Plasma	corticosterone	levels	in	unstressed,	stressed	and	sertraline	treatment	
(stress	 +	 sert)	 mice.	 	 Datum	 is	 represented	 as	 mean	 ±	 SEM	 (n	 =	 6).	 Analysis	 was	
performed	as	a	one-way	ANOVA	with	Tukey	multiple	comparisons	test	(#p	<	0.05).	
	
As	 reported	 in	 the	 previous	 chapter,	 water	 avoidance	 stress	 resulted	 in	 a	 significant	
increase	 in	 urinary	 frequency	 in	 the	 Stressed	 group	 when	 compared	 to	 unstressed	
control	animals,	as	seen	by	the	increase	in	voiding	events	(Figure	5.5.A).		This	change	was	
significant	 as	 early	 as	 day	 1.	 	 The	 number	 of	 voiding	 events	 (Figure	 5.5.A)	 was	
significantly	reduced	in	the	sertraline	treated	group	compared	to	the	stressed	mice	at	day	
3	onwards	(p	<	0.001),	however,	was	not	 reduced	back	 to	unstressed	 levels	and	was	
significantly	 increased	 at	 day	 3	 (p	 =	 0.043)	 and	 day	 10	 (p	 =	 0.014)	 compared	 to	
unstressed	mice.	 	The	average	void	 size	 (Figure	5.5.B)	was	 significantly	decreased	by	
stress	but	increased	significantly	in	sertraline	treated	mice	at	day	0	(p	=	0.008)	and	day	
7	(p	=	0.014)	compared	to	the	stressed	group,	with	levels	similar	to	unstressed	animals.		
Total	voided	area	(Figure	5.5.C)	remained	unchanged	across	all	groups.		The	number	of	
small	voids	(Figure	5.5.D)	were	significantly	increased	in	the	stressed	group	compared	
to	the	unstressed	control	at	day	3	(p	=	0.008)	and	day	5,	7	and	10	(p	<	0.001),	while	
sertraline	 treatment	 reduced	 the	 number	 of	 voids	<	0.2	 cm2	 significantly	 from	day	 5	
onwards	(p	<	0.001)	compared	to	the	stressed	group.		
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Figure	5.5:	Voiding	pattern	 analysis	 conducted	 in	unstressed,	 stressed,	 and	Sertraline	
treated	 (stress	+	 sert)	mice.	 	 (A)	Urinary	Frequency	 (number	of	 voiding	events),	 (B)	
Average	void	size,	(C)	Total	voided	area	and	(D)	Number	of	small	urine	voids	smaller	
than	0.2	cm2.		Datum	is	presented	as	mean	±	SEM	(n=6).		Analysis	was	performed	using	
two-way	repeated	measures	ANOVA	(**p	<	0.01,	***p	<	0.001,	Unstressed	vs.	stressed)	
(#p	<	0.05,	###p	<	0.001,	stressed	vs.	stress	+	sert).	
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Faecal	 pellets	 were	 counted	 (Figure	 5.6.A)	 and	 weighed	 (Figure	 5.6.B)	 after	 voiding	
pattern	analysis.		Results	were	variable	across	all	groups	and	all	days.		There	were	some	
significant	changes	in	the	stressed	group,	compared	to	the	unstressed	group	in	both	the	
number	 of	 faecal	 pellets	 and	 weight.	 	 Number	 of	 pellets	 at	 day	 7,	 was	 significantly	
increased	in	the	stressed	group	compared	to	the	unstressed	group	(p	=	0.014).	 	Pellet	
weight	was	also	significantly	increased	at	day	1	(p	=	0.008)	and	day	10	(p	=	0.033).		
	
Figure	5.6:	Faecal	pellet	analysis	conducted	in	stressed,	unstressed	and	Sertraline	treated	
(stress	+	sert)	mice.		(A)	Number	of	faecal	pellets,	(B)	relative	weight	of	faecal	pellets.	
Datum	 is	presented	as	mean	±	SEM	(n	=	6).	 	Analysis	was	performed	using	 two-way	
repeated	measures	ANOVA	(*p	<	0.05,	unstressed	vs.	stressed).	
	
Three	parameters	of	the	open	field	test	were	measured	in	the	sertraline	treated	group	
and	stressed	group.	 	Line	crossing,	 inner	zone	entries	and	number	of	rearing	episodes	
were	not	altered	in	the	stressed	group	(Figure	5.7.A,	C,	E).		Mice	treated	with	sertraline	
entered	the	inner	zone	more	frequently	than	the	stressed	group,	however,	this	increase	
in	activity	was	not	 significant	 (Figure	5.7.D),	with	no	alteration	 in	 the	number	of	 line	
crossings.	 	 Rearing	 behaviour	 in	 mice	 indicates	 stress	 and	 anxiety,	 and	 this	 was	
significantly	decreased	in	the	sertraline	treated	group	at	day	0	(p	<	0.036)	and	day	10	(p	
<	0.021)	(Figure	5.7.F).		
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Figure	 5.7:	 Open	 field	 test	 analysis	 conducted	 in	 stressed,	 unstressed	 and	 Sertraline	
treated	(stress	+	sert)	mice.		(A	&	B)	Number	of	lines	crossed,	(C	&	D)	number	of	times	
the	inner	zone	was	entered	and	(E	&	F)	number	of	rearing	events.		Datum	is	presented	as	
mean	±	SEM	(n	=	6).		Analysis	was	performed	as	one-way	ANOVA	with	Tukey	multiple	
comparisons	test	(*p	<	0.05).	
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Mediator	Release	
Intraluminal	and	serosal	 fluid	was	analysed	 for	alterations	 in	release	of	ATP	and	ACh.		
Volume	at	the	time	of	collection	was	used	to	normalise	mediator	release	in	each	sample	
and	results	are	expressed	as	total	ATP	and	ACh.		Serosal	and	luminal	ATP	release	(Figure	
5.8.A	and	B)	were	unchanged	across	all	groups.		Total	intraluminal	ACh	was	not	altered	
by	stress	or	sertraline	treatment	(Figure	5.8.C),	however,	total	serosal	ACh	release	was	
significantly	increased	in	the	stressed	group	compared	to	unstressed	group	(2.30	±	0.15	
nmols	vs.	1.32	±	0.18	nmol,	p	=	0.006,	n=6)	and	significantly	decreased	in	the	sertraline	
treated	group	 compared	with	 the	 stressed	group	 (1.55	±	0.25	nmols,	 p	=	0.03,	n=6)	
(Figure	5.8.D).	
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Figure	5.8:	Total	release	of	ATP	and	ACh	into	the	(A	&	C)	intraluminal	and	(B	&	D)	serosal	
fluid	collected	following	distensions	of	isolated	bladders	from	stressed,	unstressed	and	
Sertraline	treated	(stress	+	sert)	mice.	Datum	is	represented	as	mean	±	SEM	(n	=	6).	
Analysis	was	performed	as	a	one-way	ANOVA.		
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Bladder	Compliance	and	Stretch-relaxation	
A	 volume-pressure	 relationship	 was	 used	 to	measure	 bladder	 compliance	 across	 the	
three	groups.		Bladder	compliance	was	not	significantly	altered	by	stress	and	similarly	
sertraline	treatment	had	no	effect	on	compliance	(Figure	5.9).	
	
Figure	5.9:	Volume-pressure	relationship	in	isolated	whole	bladders	stressed,	unstressed	
and	Sertraline	treated	(stress	+	sert)	mice.		Datum	is	represented	as	mean	±	SEM	(n	=	
6),	analysed	by	two-way	ANOVA.	
	
After	fluid	collection,	bladders	were	left	to	stabilise	and	equilibrate.		Pressure	stabilised	
over	30	minutes	and	the	pressure-time	relationship	were	assessed.		There	was	a	sharp	
decrease	over	the	initial	8	minutes	with	a	significant	decrease	in	pressure	in	the	stressed	
(p	=	0.01)	and	sertraline	treated	(p	=	0.05)	groups	compared	to	the	unstressed	group	
(Figure	5.10).		However,	there	was	no	significant	difference	in	final	pressure	between	the	
groups	at	the	end	of	the	stretch-relaxation	period.	
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Figure	5.10:	Pressure-time	relationship	for	isolated	bladders	from	stressed,	unstressed	
and	Sertraline	treated	(stress	+	sert)	mice	following	distension	to	20	mmHg.		Datum	is	
represented	 as	 mean	 ±	 SEM	 (n	 =	 6),	 analysed	 by	 two-way	 ANOVA	 (**p	 <	 0.01,	
Unstressed	vs.	stressed)	(^p	<	0.05,	Unstressed	vs.	stress	+	sert).	
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Bladder	Contractility	and	Electrical	Field	Stimulation	
Response	 to	 KCl	 was	 measured	 at	 the	 end	 of	 each	 experiment	 to	 assess	 absolute	
contractile	 response	 from	 baseline	 in	 isolated	 bladders	 (Figure	 5.11).	 	 Although	 the	
response	 in	 the	 isolated	 bladders	 from	 stressed	 mice	 was	 increased,	 there	 was	 no	
significant	difference	between	all	groups	with	responses	of	bladders	 from	unstressed,	
stressed	and	sertraline	treated	mice	recorded	as	31.2	±	3.27	mmHg,	38.2	±	4.65	mmHg	
and	30.6	±	4.43	mmHg,	respectively,	n=6.		
	
Figure	 5.11:	 Pressure	 responses	 to	 KCl	 (60	 mM)	 in	 isolated	 bladders	 from	 stressed,	
unstressed	and	Sertraline	treated	(stress	+	sert)	mice.		Datum	is	represented	as	mean	±	
SEM	(n	=	6)	and	analysed	using	an	Ordinary	one-way	ANOVA	with	Tukey	Analysis.	
	
A	full	frequency-response	curve	to	electrical	field	stimulation	was	performed	at	1,	5,	10	
and	20	Hz.		An	example	of	the	frequency-response	trace	is	shown	in	Chapter	2,	General	
Methods,	Figure	2.5.		Stress	did	not	change	responses	to	electrical	field	stimulation,	nor	
did	treatment	with	the	SSRI	sertraline	(Figure	5.12.A).		When	the	response	to	EFS	was	
normalised	to	the	KCl	contraction	(Figure	5.12.B),	the	response	in	the	stressed	group	was	
significantly	depressed	compared	to	unstressed	controls	at	10	Hz	(p	=	0.008)	and	20	Hz	
(p	=	0.019).		The	response	in	the	stressed	group	at	10	Hz	was	also	significantly	decreased	
compared	to	the	Stress	+	Sertraline	group	(p	=	0.014).			
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Figure	 5.12:	 Response	 of	 isolated	 bladders	 to	 EFS,	 from	 stressed,	 unstressed	 and	
Sertraline	treated	(stress	+	sert)	mice	at	1,	5,	10	and	20	Hz.	Responses	were	recorded	as	
(A)	a	change	in	pressure	from	baseline	and	(B)	a	percentage	of	the	KCl	response.		Datum	
is	presented	as	the	mean	±	SEM	(n	=	6)	and	analysed	using	a	two-way	repeated	measures	
ANOVA	with	Tukeys	multiple	comparison	(*p	<	0.05,	**p	<	0.01,	Unstressed	vs.	stressed)	
(#p	<	0.01,	stress	+	sert	vs.	stressed).	
	
Electrical	field	stimulation	was	repeated	at	20	Hz	in	the	absence	and	presence	of	several	
pharmacological	 agents.	 	 The	 addition	 of	 LNNA	 (100	 µM)	 did	 not	 significantly	 alter	
bladder	contraction	to	EFS,	as	seen	in	previous	chapters,	 indicating	that	the	inhibitory	
neurotransmitter	NO	was	not	involved	in	neurotransmission	(Figure	5.13.A).		Addition	
of	 the	muscarinic	 antagonist	 atropine	 (1	µM)	 reduced	 the	 response	 to	EFS	by	16.7	±	
3.03%	 (n=6)	 in	 unstressed	 control	 bladders.	 	 The	 same	 change	was	 observed	 in	 the	
stressed	and	sertraline	treated	groups,	16.48	±	2.84%	and	13.62	±	5.04%,	respectively	
(n=6)	(Figure	5.13.B).		Finally,	with	the	addition	of	αβmATP	(1	mM),	to	desensitise	P2X1	
purinoceptors,	 responses	 further	 decreased	 by	 43.85	 ±	 5.36%	 (n=6)	 in	 unstressed	
controls,	51.15	±	3.68%	(n=6)	in	stressed	and	52.63	±	5.39%	(n=6)	in	sertraline	treated	
groups	(Figure	5.13.C).	 	With	the	addition	of	TTX,	responses	were	almost	abolished	in	
bladders	 from	all	 groups	 (Figure	5.13.A).	 	A	 two-way	ANOVA	with	Tukey	comparison	
revealed	 no	 significant	 difference	 in	 responses	 to	 pharmacological	 agents	 between	
groups.	
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Figure	 5.13:	 (A)	 Intravesical	 pressure	 responses	 to	 electrical	 field	 stimulation	 at	
20Hz(baseline),	and	after	addition	of	L-NNA	(100	µM),	atropine	(1	µM),	αβmATP	(1	mM)	
and	TTX	(1	µM)	to	bladders	from	stressed,	unstressed	and	Sertraline	treated	(stress	+	
sert)	mice.	 Percentage	 decrease	 in	 EFS	 response	 on	 addition	 of	 (B)	 atropine	 and	 (C)	
αβmATP	to	bladder	from	each	group.	Datum	is	expressed	as	mean	±	SEM	and	analysed	
using	two-way	repeated	measures	ANOVA	with	Dunnett’s	multiple	comparisons	test	for	
(A)	and	one-way	ANOVA	with	Dunnett’s	multiple	comparisons	test	for	(B	and	C)	(*p		<	
0.05,	**p		<	0.01	vs.	Baseline	(20	Hz)).	
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Response	to	Pharmacological	Agents	
Pharmacological	 agents	 were	 added	 to	 the	 bathing	 fluid	 and	 pressure	 responses	
measured.	 	 	 ATP	 (10	 mM)	 and	 αβmATP	 (1	 mM)	 were	 added	 to	 the	 bath	 to	 assess	
purinergic	stimulation.		In	the	stressed	group	the	purinergic	response	of	bladders	to	ATP	
was	 increased	 (11.3	±	1.28	mmHg,	n=6),	 although	not	 significantly,	 compared	 to	 the	
unstressed	group	(8.89	±	1.50	mmHg,	n=6).		Sertraline	treatment	did	not	significantly	
change	 this	 response	 (10.5	 ±	 1.26	mmHg,	 n=6)	 (Figure	 5.14.A).	 	 The	 response	 was	
normalised	to	KCl,	with	similar	responses	observed	across	the	groups	(Figure	5.14B).		
	
Figure	5.14:	Pressure	 responses	 to	 (A)	ATP	 (10	mM)	and	 (B)	ATP	normalised	 to	KCl	
response,	 in	 isolated	whole	bladders	 from	stressed,	unstressed	and	Sertraline	 treated	
(stress	+	sert)	mice.	Datum	is	represented	as	mean	±	SEM	(n	=	6)	and	analysed	using	an	
ordinary	one-way	ANOVA	with	Tukeys	comparison.	
	
Contractile	 responses	 to	 αβmATP	 were	 assessed.	 	 Compared	 to	 unstressed	 controls,	
17.43	±	1.9	mmHg	(n=6),	 there	was	no	significant	difference	 in	response	 in	bladders	
from	the	stressed,	15.23	±	1.43	mmHg	(n=6),	and	sertraline	treated	group,	16.92	±	2.67	
mmHg	 (n=6)	 (Figure	 5.15.A).	 	 As	 a	 percentage	 of	 the	 KCl	 response,	 there	 was	 no	
significant	difference	between	the	groups	(Figure	5.15.B).		
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Figure	5.15:	Pressure	responses	to	(A)	to	{|mATP	(1	mM)	and	(B)	as	a	percentage	of	
the	KCl	contraction	in	bladders	from	stressed,	unstressed	and	Sertraline	treated	(stress	
+	 sert)	mice.	 	 Datum	 is	 represented	 as	mean	±	 SEM	 (n	=	 6)	 and	 analysed	 using	 an	
ordinary	one-way	ANOVA	with	Tukey	comparison.	
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The	 muscarinic	 agonist	 carbachol	 produced	 a	 concentration	 dependent	 increase	 in	
intravesical	 pressure	 in	 isolated	 bladders	 from	 unstressed,	 stressed	 and	 sertraline	
treated	mice	(Figure	5.16.A).		The	maximum	response	was	significantly	enhanced	in	the	
stressed	group	compared	to	both	the	unstressed	controls	and	sertraline	treated	animals	
(Figure	 5.16.A	 and	 Table	 5.2).	 	 There	 was	 no	 significant	 difference	 in	 the	 pEC50	 as	
highlighted	 in	 Table	 5.2.	 	 The	 concentration-response	 curve	 was	 also	 assessed	 as	 a	
percentage	 of	 the	 KCl	 response,	 with	 no	 significant	 difference	 observed	 between	 the	
groups	 (Figure	 5.16.B).	 	 Sertraline	 treatment	 significantly	 reduced	 the	 increased	
contractile	 response	 in	 the	 stressed	 group,	 back	 to	 unstressed	 control	 levels	 (Figure	
5.16.A).		
	
	
	
	
TABLE	5.2:	Whole	bladder	responses	to	carbachol	in	control	(unstressed),	water	
avoidance	stress	(stressed)	and	sertraline	(stress	+	sert)	treated	mice	(n=6).	
	 Unstressed	 Stressed	 Stress	+	Sert	
pEC50	 5.58	±	0.03	 5.40	±	0.04	 5.51	±	0.07	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%KCl)	
	
43.47	±	1.21	
145.20	±	12.82	
	
57.45	±	3.36***	
158.89	±	12.92	
	
39.49	±	4.21###	
136.02	±	13.23	
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Figure	5.16:	Carbachol	concentration-response	curves,	from	isolated	whole	bladder	from	
stressed,	unstressed	and	Sertraline	treated	(stress	+	sert)	mice,	recorded	as	(A)	change	
in	 intravesical	 pressure	 from	 baseline	 and	 (B)	 change	 in	 intravesical	 pressure	 as	 a	
percentage	of	the	KCl	response.	Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	
using	non-linear	regression	and	two-way	ANOVA	with	Tukey’s	multiple	comparisons	test	
(*p	<	0.05,	***p	<	0.001	Unstressed	vs.	stressed)	(##p	<	0.01,	###p	<	0.001	stress	+	sert	
vs.	stressed).	
	
	
A	 concentration-response	 to	 isoprenaline	was	performed	 to	assess	bladder	 relaxation	
following	carbachol	pre-contraction.		There	was	no	significant	difference	in	the	potency	
of	 isoprenaline	 as	 determined	 by	 pIC50	 values,	 (Table	 5.3)	 however,	 there	 was	 a	
significant	 decrease	 in	 the	maximal	 relaxation	 response	 of	 bladders	 in	 the	 stress	 and	
sertraline	treated	groups	compared	to	unstressed	controls	(Figure	5.17.A	and	B).		
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Figure	5.17:	Effect	of	 isoprenaline	on	 isolated	bladders,	 from	stressed,	unstressed	and	
Sertraline	treated	(stress	+	sert)	mice,	with	datum	given	as	(A)	raw	data	as	change	in	
pressure	from	pre-contraction,	(B)	change	in	intravesical	pressure	as	a	percentage	of	the	
KCl	response.		Datum	represented	as	mean	±	SEM	(n	=	6),	using	two-way	ANOVA	and	
non-linear	 regression	 (*p	 <	 0.05,	 **p	 <	 0.01,	 Unstressed	 vs.	 stressed)	 (^p	 <	 0.05,	
unstressed	vs.	stress	+	sert).	
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TABLE	 5.3:	Whole	 bladder	 responses	 to	 isoprenaline	 in	 control	 (unstressed),	
water	 avoidance	 stress	 (stressed)	 and	 sertraline	 treated	 (stress	+	 sert)	mice	
(n=6).	
	 Unstressed	 Stressed	 Stress	+	Sert	
pIC50	 6.71	±	0.10	 6.83	±	0.09	 7.05	±	0.08	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%	Decrease)	
	
-	5.91	±	0.46	
14.37	±	10.61	
	
-	4.68	±	0.31**	
34.09	±	7.58	
	
-	4.83	±	0.31^	
26.58	±	7.06	
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Spontaneous	Phasic	Contractions	
During	 the	stretch-relaxation	phase,	 the	 frequency	of	 spontaneous	phasic	activity	was	
increased	in	bladders	from	the	stressed	group	compared	to	unstressed	group,	although	
not	significantly	(Figure	5.18.A).		However,	sertraline	treatment	significantly	decreased	
the	frequency	(p	=	0.032)	of	spontaneous	phasic	contractions	compared	to	the	stressed	
group.	 	 The	 same	 trend	 was	 also	 observed	 in	 the	 amplitude	 of	 spontaneous	 activity	
(Figure	5.18.B).	 	Sertraline	again	significantly	decreased	the	amplitude	of	spontaneous	
phasic	contractions	compared	to	the	stressed	group	(p	=	0.006).		
	
	
Figure	 5.18:	 Spontaneous	 phasic	 contractions	measured	 during	 the	 stretch-relaxation	
period	as	(A)	frequency	and	(B)	amplitude	in	isolated	bladders	from	stressed,	unstressed	
and	Sertraline	treated	(stress	+	sert)	mice.		Datum	is	represented	as	mean	±	SEM	(n	=	
6),	analysed	using	one-way	ANOVA	with	Tukey’s	multiple	comparison	(#p	<	0.05,	##p	<	
0.01,	stressed	vs.	stress	+	sert).	
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Phasic	 activity	 was	 also	 analysed	 after	 the	 tonic	 contraction	 to	 carbachol	 (1	 µM).		
Frequency	 of	 phasic	 activity	 was	 significantly	 increased	 in	 the	 stressed	 group	 and	
sertraline	treated	group	compared	to	the	unstressed	controls	(p	<	0.001	and	p	=	0.032,	
respectively)	(Figure	5.19.A).		However,	the	frequency	of	contractions	in	bladders	from	
sertraline	treated	mice	was	significantly	lower	compared	to	the	stress	only	group	(p	=	
0.019).		The	amplitude	of	phasic	activity	was	unchanged	across	all	groups	(Figure	5.19.B).		
	
	
Figure	 5.19:	 Tonic	 and	 phasic	 contractions	 after	 1	 µM	 carbachol	 in	 isolated	 whole	
bladders	from	stressed,	unstressed	and	Sertraline	treated	(stress	+	sert)	mice,	following	
addition	of	carbachol	(1	µM).		(A)	Frequency	of	phasic	contractions	and	(B)	Amplitude	of	
phasic	contractions.	Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	using	a	one-
way	ANOVA	(***p	<	0.001,	Unstressed	vs.	stressed)	(#p	<	0.05,	stressed	vs.	stress	+	sert)	
(^p	<	0.05,	Unstressed	vs.	stress	+	sert).		
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DISCUSSION	
In	previous	chapters,	water	avoidance	stress	was	shown	to	increase	voiding	frequency	
and	 cause	 changes	 in	 bladder	 physiology,	 including	 an	 increase	 in	 detrusor	 muscle	
contractility.		SSRIs	such	as	sertraline	are	commonly	used	in	the	clinical	management	of	
anxiety	 and	 depression,	 with	 a	 low	 side-effect	 profile	 compared	 to	 other	 anti-
depressants,	 however	 their	 benefit	 in	 the	 management	 of	 stress-induced	 voiding	
dysfunction	is	unknown.		Experimental	studies	have	linked	depletion	of	serotonin	in	the	
CNS	to	increases	in	urinary	frequency	and	detrusor	overactivity	(Chiba	et	al.,	2016),	with	
serotonin	depletion	being	postulated	to	play	a	role	in	the	pathophysiology	of	OAB.		This	
would	 suggest	 that	 an	 SSRI	 may	 be	 of	 therapeutic	 benefit	 in	 managing	 the	 voiding	
dysfunction	associated	with	stress.	 	This	section	will	discuss	the	alterations	in	bladder	
physiology	after	sertraline	treatment	and	examine	the	ability	of	sertraline	to	resolve	the	
voiding	changes	caused	by	repeated	water	avoidance	stress	exposure.		
	
Effects	of	Sertraline	on	Behavioural	Responses	in	Open	Field	Test	and	Voiding	Behaviour	
The	 open	 field	 test	 was	 used	 to	 measure	 the	 anxious	 and	 depressive	 state	 of	 mice	
following	water	avoidance	stress	and	sertraline	treatment.		Interestingly,	the	WAS	model	
was	 not	 associated	 with	 anxiety	 like	 behaviour,	 with	 similar	 behaviours	 observed	 at	
baseline	and	following	repeated	stress.	 	This	supports	a	study	by	Hassan	et	al	(2014),	
who	similarly	found	7-days	of	WAS	in	mice	had	little	influence	on	behaviour	(Hassan	et	
al.,	2014).		Conversely,	Bradesi	et	al.	(2005)	reported	increased	anxiety-like	behaviours	
in	male	rats	 following	10-days	of	WAS	exposure,	and	this	may	reflect	a	species	or	sex	
differences	 in	 response	 to	 WAS	 (Bradesi	 et	 al.,	 2005).	 	 Line	 crossing	 and	 therefore	
ambulatory	 distance	was	 unchanged	between	 the	 animal	 groups	 in	 the	 current	 study	
which	means	that	the	mice	are	not	affected	by	inactivity	or	pain	(Gould,	2009).	 	 Inner	
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zone	entering	was	 increased	 in	 the	 sertraline	 treated	mice,	 although	not	 significantly.		
This	 parameter	 measures	 the	 natural	 aversion	 rodents	 have	 to	 exposed	 areas,	 and	
because	of	the	increased	activity	in	the	‘inner	zone’	by	the	sertraline	treated	mice,	it	can	
be	concluded	 that	 these	mice	were	suffering	 less	 from	anxiety-like	behaviour	 (Carola,	
D'Olimpio,	Brunamonti,	Mangia,	&	Renzi,	2002).		Rearing	was	significantly	decreased	in	
the	sertraline	treated	group	compared	to	the	stressed	group,	over	the	course	of	the	stress	
period.	 	 There	 is	 still	 some	 debate	 as	 to	 what	 type	 of	 behaviour	 rearing	 indicates,	
however,	 the	 general	 consensus	 is	 that	 rearing	 is	 indicative	 of	 anxiety	 (Borta	 &	
Schwarting,	2005),	therefore,	sertraline	treatment	reduced	anxiety-like	behaviour	which		
has	been	reported	previously	in	rodents	(Bikomo,	Ebuehi,	&	Magbageola,	2017).	
The	primary	outcome	of	this	study	was	to	determine	whether	treatment	with	sertraline	
would	 limit	 the	 impact	 of	 water	 avoidance	 stress	 on	 urinary	 frequency.	 	 	 Sertraline	
treatment	significantly	decreased	voiding	frequency	over	the	course	of	the	10-days	stress	
exposure	compared	to	the	untreated	water	avoidance	stress	group.	 	While	this	change	
alludes	to	effective	management	of	stress-induced	voiding	dysfunction,	it	must	be	noted	
that	there	are	still	days	on	which	urinary	frequency	remained	significantly	elevated	in	
the	sertraline	treated	group	compared	to	the	unstressed	controls.		There	have	been	no	
experimental	 or	 clinical	 studies	 which	 have	 investigated	 the	 effects	 of	 sertraline	 on	
urinary	frequency	with	stress.		However,	from	what	we	know	of	the	actions	of	SSRIs	like	
sertraline	 and	 the	 role	 of	 serotonergic	mechanisms	 in	 regulating	 lower	 urinary	 tract	
function,	the	benefits	of	sertraline	observed	in	the	current	study	are	not	surprising.		
Sertraline	is	an	SSRI	which	increases	the	amount	of	available	serotonin	(Anderson	et	al.,	
2005),	 an	 important	 neurotransmitter	which	 plays	 a	 role	 in	 the	 control	 of	 the	 lower	
urinary	tract	(Andersson	&	Pehrson,	2003).		Serotonergic	neurons	are	present	in	several	
regions	of	the	CNS	which	are	involved	in	providing	descending	inhibition	to	the	bladder,	
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including	 the	 Onuf	 nuclei	 and	 the	 lumbosacral	 autonomic	 nuclei	which	 innervate	 the	
urethral	sphincters	(Andersson	&	Pehrson,	2003).		The	raphe	nuclei	of	the	medulla	has	
been	shown	to	contain	serotonergic	neurons	with	descending	projections	to		the	bladder,	
urethra	and	external	urethral	sphincter	(Espey,	Du,	&	Downie,	1998).		
Raymond	 et	 al.	 (2001)	 compiled	 a	 review	 discussing	 the	 7	 subtypes	 of	 serotonin	
receptors,	 and	 when	 serotonin	 is	 administered	 experimentally,	 it	 either	 results	 in	
inhibitory	 or	 facilitatory	 affects,	 depending	 on	 which	 receptor	 dominates.	 	 An	
experimental	 study	 on	 cats	 found	 that	 serotonin	 induces	 external	 urethral	 sphincter	
activity	to	prevent	leakage	of	urine	during	the	storage	phase	(Espey	et	al.,	1998).		This	is	
also	supported	by	other	animal	studies	which	have	observed	Onuf	nucleus	stimulation	
with	 serotonin	 to	 cause	 contraction	 of	 the	 external	 urethral	 sphincter	 (Thor,	 2003).		
Experimental	studies	in	cats	suggest	that	stimulation	of	5-HT	receptors	suppresses	the	
processing	of	afferent	input	from	the	bladder	and	results	in	excitation	of	sympathetic	and	
inhibition	 of	 parasympathetic	 preganglionic	 neurons	 (De	 Groat	 &	 Ryall,	 1967;	 Espey,	
Downie,	&	Fine,	1992;	Ryall	&	DeGroat,	1972).	
Clinical	studies	have	observed	urinary	hesitancy	and	retention	after	beginning	treatment	
with	sertraline	(Lowenstein,	Mueller,	Sharma,	&	FitzGerald,	2007).		As	stated	above,	this	
may	be	due	to	the	number	of	serotonergic	neurons	present	within	the	neural	centres	of	
micturition.	 	 Increased	 control	 of	 the	 external	 urethral	 sphincter	 by	 the	 serotonergic	
neurons,	may	explain	why	the	mice	 treated	with	sertraline	showed	decreased	voiding	
frequency	 compared	 to	 the	 stressed	 group	 in	 the	 present	 study.	 	 Both	 clinical	 and	
experimental	studies	have	shown	that	duloxetine,	a	noradrenaline-serotonin	reuptake	
inhibitor,	 is	of	benefit	 in	 treatment	of	OAB	(Steers	et	al.,	2007;	Wrobel,	Rechberger,	&	
Rechberger,	2018).	
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Effects	of	Sertraline	on	Corticosterone	Release	
The	stress	hormone	corticosterone	was	increased	by	water	avoidance	stress,	however,	
levels	were	significantly	decreased	 following	sertraline	 treatment.	 	Many	studies	have	
linked	 stress	 and	 increased	 corticosterone	 within	 the	 blood	 stream,	 due	 to	 the	
hyperactivity	of	the	HPA	axis	during	stress	(Keeney	et	al.,	2006).		One	study	has	observed	
that	 chronic	 stress	 caused	 by	 the	 FST	 promotes	 anxiety	 and	 depression.	 	 The	 study	
treated	the	stressed	mice	with	sertraline	and	found	that	the	SSRI	prevents	the	altered	
behaviour	associated	with	increased	corticosterone	levels	and	stress	(Ulloa	et	al.,	2010).		
There	is	some	evidence	to	indicate	that	synthesis	of	serotonin	within	the	neuronal	cells	
is	regulated	by	substrate	availability	which	is	affected	by	L-tryptophan	in	the	diet	and	
cytosolic	enzymes	in	the	liver.		When	there	is	hyperactivity	of	the	HPA	axis,	during	stress,	
increased	 cortisol	 induces	 the	 breakdown	 of	 L-tryptophan,	 meaning	 that	 there	 is	
decreased	 substrate	 availability	 for	 the	 neuronal	 cells	 (Bano,	 Gitay,	 Ara,	 &	 Badawy,	
2010).		Clinically,	there	have	been	studies	which	have	observed	this	decrease	in	serotonin	
with	increased	cortisol	 levels.	 	One	study	of	young	women,	observed	that	a	number	of	
SSRIs,	including	sertraline,	reduce	cortisol	levels	throughout	the	day	(Ronaldson	et	al.,	
2018).		
	
Effects	of	Sertraline	on	Mediator	Release	
As	observed	in	previous	chapters,	serosal	release	of	ACh	was	significantly	increased	in	
bladders	from	the	stressed	group.		In	addition	to	this,	sertraline	treatment	significantly	
decreased	serosal	ACh	release.		It	has	been	reported	previously	that	ACh	is	released	from	
the	urothelium	in	a	non-neuronal	capacity	(Yoshida	et	al.,	2006)	and	along	with	ATP,	has	
been	linked	to	several	bladder	pathologies	(Apodaca,	Balestreire,	&	Birder,	2007).		The	
urothelium	 is	 a	 structure	 that	 is	 believed	 to	 be	 an	 important	 component	 in	 sensory	
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function	 and	 neurotransmitter	 release	 and	 plays	 a	 role	 in	 the	 regulation	 of	 normal	
bladder	function	(Birder	et	al.,	2010).		Studies	have	shown	that	bladder	afferent	neurons	
express	muscarinic	receptor	subtypes,	M2,	M3	and	M4,	which	suggests	that	urothelial	ACh	
may	play	a	role	in	regulating	sensory	processing	(Nandigama	et	al.,	2010).	 	A	study	of	
bladder	afferent	activation	has	confirmed	the	involvement	of	the	M2	muscarinic	receptors	
in	 rats	with	 spinal	 cord	 injury	 (Matsumoto	 et	 al.,	 2012).	 	 Evidence	 also	 suggests	 that	
release	of	urothelial	ACh	may	be	involved	in	afferent	function	of	the	bladder	(Daly	et	al.,	
2010).		Greater	ACh	release	in	the	stressed	group	during	filling	could	therefore	stimulate	
bladder	sensory	nerves,	triggering	the	micturition	reflex	at	lower	volumes,	which	would	
explain	the	subsequent	overactive	bladder	phenotype	observed	in	the	stressed	animals.				
	
Effects	of	Sertraline	on	Bladder	Physiology	
As	seen	in	previous	chapters,	general	bladder	contractility	was	increased	in	mice	in	the	
stressed	group.	 	Although	not	 significant,	 sertraline	 treatment	 reduced	 the	contractile	
responses	to	KCl.		There	was	however	a	significant	decrease	in	maximal	contraction	to	
carbachol	in	bladders	from	the	sertraline	treated	group,	compared	to	the	stressed	group.		
There	was	also	a	significant	decrease	in	frequency	and	amplitude	of	spontaneous	phasic	
activity,	and	frequency	of	the	phasic	activity	following	tonic	contractions	to	carbachol.		
While	 the	use	of	sertraline	 to	 treat	psychological	ailments	has	been	well	documented,	
little	 is	 known	 of	 the	 underlying	 effects	 the	 drug	 has	 on	 the	 bladder.	 	 As	 discussed	
previously,	there	has	been	some	clinical	studies	which	have	investigated	the	urological	
side	effects	of	sertraline,	however,	experimental	studies	have	been	limited.	 	One	study	
has	used	sertraline	to	treat	detrusor	hyperactivity	induced	by	the	FST.		The	study	found	
that	sertraline	significantly	decreased	contractility	to	carbachol	and	potassium	chloride.		
Due	 to	 the	 inhibition	 of	 KCl-stimulated	 contractile	 response	 by	 sertraline,	 the	 study	
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suggested	 that	 the	 mode	 of	 action	 of	 the	 SSRI	 was	 not	 via	 the	 muscarinic	 receptors	
themselves,	but	by	 the	 inhibition	of	downstream	signalling	or	contractile	mechanisms	
beyond	the	receptor	(Bilge	et	al.,	2008).		The	inhibition	of	contractile	responses	following	
sertraline	treatment	has	been	studied	in	a	number	of	different	tissues.		A	study	looking	at	
rat	aortic	rings	found	that	calcium	channels	are	inhibited	by	sertraline	(Becker,	Morel,	
Vanbellinghen,	&	Lebrun,	2004).		Contractile	responses	to	noradrenaline,	KCl	and	EFS	in	
rat	isolated	vas	deferens	was	also	inhibited	by	sertraline	treatment	via	effects	on	calcium	
channels	 (Kalyoncu,	 Ozyavuz,	 &	 Karaoglu,	 1999).	 	 KCl	 causes	 contraction	 of	 smooth	
muscle	by	opening	calcium	channels	and	increasing	intracellular	calcium	levels,	thereby	
inducing	contractions	that	are	independent	of	muscarinic	or	purinergic	receptor	activity	
(Bilge	et	al.,	2008).	 	The	 inhibitory	action	of	 sertraline	on	calcium	channels	may	have	
contributed	 to	 the	 overall	 decrease	 in	 bladder	 contractility	 witnessed	 within	 the	
sertraline	treated	group	in	the	present	study.		Due	to	the	high	number	of	5-HT	receptors	
present	on	the	bladder,	it	is	also	possible	that	the	increase	of	sertraline	within	the	blood,	
following	 sertraline	 treatment,	 had	 a	direct	 effect	 via	 these	 receptors.	 	 A	 study	of	 pig	
urinary	bladder	neck	found	that	5-HT	relaxed	smooth	muscle	through	5-HT7	receptors	
(Recio	et	al.,	2009).		This	will	be	further	discussed	later	in	Chapter	7.				
It	is	well	established	that	detrusor	smooth	muscle	exhibits	spontaneous	phasic	activity	
(Levin	 et	 al.,	 1986)	which	 is	 shown	 to	 be	myogenic	 in	 origin	 (Buckner,	Milicic,	 Daza,	
Coghlan,	 &	 Gopalakrishnan,	 2002;	 Liu,	 Volfson,	 Horan,	 &	 Levin,	 1998).	 	 Spontaneous	
activity	in	isolated	detrusor	muscle	has	been	reported	to	be	dependent	on	both	calcium	
entry	mechanisms	 and	 potassium	 channels	 and	 is	 modulated	 by	 the	 presence	 of	 the	
urothelium	 (Buckner	 et	 al.,	 2002;	 Vahabi,	 Sellers,	 Bijos,	 &	 Drake,	 2013).	 	 Sertraline	
treatment	had	a	significant	effect	on	spontaneous	phasic	activity	and	phasic	responses	
following	the	tonic	contraction	to	the	muscarinic	agonist	carbachol.		After	treatment	with	
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sertraline,	 frequency	 of	 phasic	 activity	 was	 significantly	 decreased	 compared	 to	 the	
stressed	group.	While	the	anti-depressant	effects	of	sertraline	are	typically	attributed	to	
inhibition	of	 serotonin	reuptake	mechanisms,	 the	biological	actions	of	SSRIs	are	more	
complex	with	evidence	of	inhibition	of	sodium,	potassium	and	calcium	channels	(Deak	et	
al.,	2000;	Frizzo,	2017;	Lee,	Kim,	Hyun,	Park,	&	Kim,	2012;	Ohno,	Hibino,	Lossin,	Inanobe,	
&	Kurachi,	2007).	 	While	it	has	previously	been	reported	that	sertraline	has	effects	on	
general	contractility,	as	discussed	above,	no	studies	have	measured	spontaneous	activity	
after	treatment	with	this	drug.		It	may	be	postulated	that	due	to	the	reported	actions	of	
sertraline	on	calcium	and	potassium	channels,	and	the	role	of	these	channels	in	regulating	
the	 frequency	 and	 amplitude	 of	 phasic	 activity	 in	 the	 bladder;	 this	 may	 explain	 the	
decreased	spontaneous	activity	observed	in	bladders	from	the	sertraline	treated	group	
(Becker	et	al.,	2004;	Ohno	et	al.,	2007).		The	therapeutic	benefit	of	sertraline	in	improving	
voiding	behaviour	with	stress	exposure	may	in	part	be	due	to	this	reduction	in	phasic	
activity	in	the	bladder.	
	
CONCLUSION	
Repeated	exposure	to	water	avoidance	stress	induced	bladder	overactivity	and	treatment	
with	 the	 anxiolytic,	 sertraline	 reduced	 the	 effects	 of	 stress.	 	 Voiding	 behaviour	 was	
decreased	but	did	not	return	to	control	levels,	whilst	sertraline	treatment	abolished	the	
stress-induced	 changes	 in	 bladder	 contractile	 activity.	 	 This	 chapter	 indicates	 that	
management	of	bladder	dysfunction	caused	by	psychological	stress	may	be	aided	by	the	
addition	of	sertraline.		
	 	
 
 
	
	
	
	
	
	
	
	
	
	
	
	
CHAPTER	6:	EFFECTS	OF	
MIRABEGRON	AND	SOLIFENACIN	ON	
BLADDER	DYSFUNCTION	
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INTRODUCTION	
Antimuscarinic	agents	are	the	most	common	oral	pharmacotherapy	available	for	treating	
OAB	(Abrams	et	al.,	2015).		The	antimuscarinic	drugs	main	mode	of	action	was	originally	
thought	to	be	via	inhibition	of	detrusor	smooth	muscle	contraction,	however	they	also	
reduce	sensory	symptoms	during	the	filling	and	storage	phase	of	the	micturition	cycle	
(Batista	et	al.,	2015).	 	More	recently,	the	β3-adrenoceptor	(β3-AR)	agonist,	mirabegron	
was	introduced	and	has	shown	similar	efficacy	to	the	antimuscarinics,	but	with	a	lower	
incidence	of	side	effects	(Andersson,	2017a).		It	is	currently	unclear	whether	these	drugs	
are	useful	in	managing	voiding	dysfunction	caused	by	psychological	stress.	 	This	study	
investigates	the	potential	benefit	of	the	muscarinic	antagonist	solifenacin	and	the	β3-AR	
agonist	mirabegron	 in	 treating	 the	 increased	 urinary	 frequency	 observed	with	water	
avoidance	stress.	
	
Muscarinic	Antagonist	Solifenacin:	Mechanism	of	Action		
Micturition	normally	occurs	following	the	release	of	Ach	from	parasympathetic	nerves	
onto	the	muscarinic	M3	receptors	of	the	detrusor	muscle	(Chilman-Blair	&	Bosch,	2004).		
This	causes	contraction	of	the	smooth	muscle	to	void	stored	urine	(Andersson	&	Arner,	
2004).	 	 Several	 antimuscarinic	 drugs	 have	 been	 developed	 which	 directly	 target	
muscarinic	receptors	and	reduce	symptoms	of	OAB	and	for	many	years	these	were	the	
only	 available	 treatment.	 	While	 these	 treatments	 are	 effective	 in	 treating	 symptoms	
(Figure	6.1),	 they	 are	 associated	with	 a	number	of	 side	 effects	 resulting	 in	decreased	
persistence	in	patients	(Duckett,	Hall,	&	Woodward,	1998).		
In	the	1970s,	the	non-selective	muscarinic	antagonist	oxybutynin	became	available,	with	
clinical	 trials	 showing	 the	 drug	 was	 effective	 in	 managing	 the	 symptoms	 of	 OAB.			
However,	 oxybutynin	 is	 associated	 with	 numerous	 side-effects	 including	 dry	 mouth,	
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constipation	 and	 blurred	 vision	 (Riva	 &	 Casolati,	 1984)	 leading	 to	 many	 patients	
discontinuing	treatment	(Sexton	et	al.,	2011).		Since	the	1990’s	more	selective	muscarinic	
antagonists	have	been	developed	with	the	aim	of	improving	efficacy	and	reducing	side-
effects.	
	
	
Figure	6.1:	Diagram	showing	how	solifenacin	acts	as	a	competitive	muscarinic	receptor	
(M3)	antagonist	to	decrease	detrusor	muscle	contraction.	Acetylcholine	(ACh).	(Created	
with	BioRender.com	by	the	author).	
	
Solifenacin,	 a	 competitive	 M3	 selective	 receptor	 antagonist,	 was	 found	 to	 be	 more	
selective	for	bladder	over	salivary	glands	in	in	vivo	and	in	vitro	studies	(Ohtake	et	al.,	
2004).		Tolerability	studies	of	solifenacin	found	that	of	1637	patients,	81%	completed	40	
weeks	of	 open	 label	 treatment	where	 solifenacin	was	well	 tolerated	and	 rates	of	 side	
effects	were	low.		In	this	study,	only	4.7%	of	patients	ceased	treatment,	and	significant	
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improvements	in	OAB	symptoms	was	observed	after	52	weeks.	 	Overall,	tolerability	of	
solifenacin	was	85%	and	efficacy	of	solifenacin	was	74%	after	long	term	treatment	with	
solifenacin	(Haab,	Cardozo,	Chapple,	&	Ridder,	2005).	
There	 has	 been	 evidence	 that	 antimuscarinic	 agents	 targeting	 M1	 receptors	 cause	
cognitive	impairments	because	of	the	way	they	cross	the	blood	brain	barrier	(Kay	et	al.,	
2006).		Studies	of	other	M3	receptor	selective	drugs,	such	as	darifenacin	and	tolterodine	
have	found	that	they	do	not	cross	the	blood	brain	barrier	to	any	significant	extent	to	cause	
cognitive	 dysfunction	 (Kay	 et	 al.,	 2006).	 	 Solifenacin	 targets	 M3	 receptors,	 therefore	
cognitive	dysfunction	is	unlikely.			
There	 is	no	 literature	 surrounding	 the	use	of	OAB	 treatments	 in	psychological	 stress-
induced	bladder	dysfunction.		Most	studies	have	instead	focussed	on	the	quality-of-life	
related	outcomes	of	patients	with	OAB	symptoms	being	treated	with	solifenacin.	 	One	
study	performed	two	double-blind	trials	of	1033	and	857	patients	to	assess	quality	of	life	
(QoL)	outcomes	after	12	weeks	of	treatment	with	solifenacin.		The	study	found	significant	
improvement	 in	 patient	 QoL	 after	 treatment	 with	 solifenacin	 compared	 to	 placebo	
treatment	(Kelleher,	Cardozo,	Chapple,	Haab,	&	Ridder,	2005).		The	VESIcare	Efficacy	and	
Research	Study	US	has	used	a	cohort	of	OAB	patients	who	have	described	their	bladder	
condition	as	severe.	 	After	treatment	with	solifenacin,	the	patients	reported	decreased	
urinary	urgency	and	improvement	of	overall	OAB	symptoms	as	well	as	an	improvement	
in	health	related	QoL	(Swift,	Siami,	&	Forero-Schwanhaeuser,	2009).	
Many	studies	of	QoL	improvement	have	focused	on	sleep	disturbance	as	a	symptom	of	
OAB,	also	known	as	nocturia,	the	urge	to	urinate	at	night	(Wein	&	Rovner,	2002).		Sleep	
disturbance	because	of	OAB	symptoms	has	been	reported	by	patients	to	interfere	with	
cognitive	function,	impair	concentration,	increase	anxiety	and	low	self-esteem	(Abrams,	
Kelleher,	Kerr,	&	Rogers,	2000).		A	study	of	OAB	and	insomnia	enrolled	15	patients	into	a	
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study	looking	at	effects	of	solifenacin	on	both	conditions.		The	study	found	that	solifenacin	
significantly	improved	both	OAB	symptoms	and	insomnia	scale	results,	improving	both	
total	sleep	time	and	sleep	efficacy	(Takao	et	al.,	2011).		
	
β3-Adrenoceptor	Agonist	Mirabegron:	Mechanism	of	Action		
The	β3-adrenoceptor	(β3-AR)	is	the	most	widely	expressed	adrenoceptor	subtype	on	the	
detrusor	muscle	in	humans	(Michel,	Ochodnicky,	Homma,	&	Igawa,	2011).		Sympathetic	
nerve	activity	triggers	the	release	of	NA	onto	the	β3-ARs,	causing	relaxation	of	the	smooth	
muscle	cells	of	the	detrusor	muscle	and	contraction	of	the	urethra	via	α1-adrenoceptors,	
thereby	contributing	to	urine	storage	(Goulooze,	Cohen,	&	Rissmann,	2015).		Mirabegron	
is	the	first	selective	β3-AR	agonist	and	acts	like	noradrenaline	to	trigger	detrusor	muscle	
relaxation	(Figure	6.2),	which	is	useful	in	the	treatment	of	OAB	syndrome	(Andersson,	
2017a).		Mirabegron	is	one	of	the	most	selective	OAB	treatments	and	due	to	its	success	
in	clinical	practice,	there	is	increased	interest	in	the	mechanism	of	action	of	this	agonist	
(Andersson,	2017b).		
On	 a	molecular	 level,	mirabegron	 couples	 to	 G-proteins	which	 increases	 intracellular	
cAMP,	 thereby	 activating	 potassium	 (K+)	 channels	 and	 causing	 hyperpolarisation	 of	
detrusor	 smooth	 muscle	 (Igawa	 &	 Michel,	 2013).	 	 There	 is	 also	 some	 evidence	 that	
mirabegron	 acts	 to	 inhibit	 spontaneous	 activity	 in	 the	 bladder	 by	 inhibiting	 micro-
contractions	which	appear	to	be	myogenic	in	origin	(Aizawa,	Homma,	&	Igawa,	2012).		
Studies	have	also	shown	that	the	β3-AR	agonist	inhibits	C-	and	Aδ-afferent	nerves	in	the	
rat	bladder	(Aizawa,	Igawa,	Nishizawa,	&	Wyndaele,	2010).		Both	the	C-	and	Aδ-afferent	
nerves	convey	sensations	of	bladder	filling	and	a	study	looking	at	these	fibres	found	that	
mirabegron	inhibited	afferent	activities	of	both	fibres	(Aizawa	et	al.,	2012),	and	this	may	
contribute	to	its	therapeutic	benefit	in	patients	with	OAB.		
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Figure	6.2:	Diagram	showing	how	mirabegron	acts	of	β3-adrenoceptors	(β3)	to	increase	
relaxation	of	the	bladder	smooth	muscle	(Created	with	BioRender.com	by	the	author).		
	
From	the	previous	studies	 in	 this	 thesis,	 it	 is	 clear	 that	psychological	 stress	 results	 in	
enhanced	 voiding	 and	 increased	 detrusor	 contractility,	 both	 phenotypic	 of	 overactive	
bladder	syndrome.		There	have	been	no	studies	observing	the	effects	of	mirabegron	on	
bladder	dysfunction	induced	by	psychological	stress,	although	studies	have	focused	on	
psychological	stress	as	an	outcome	of	overactive	bladder.		
One	of	 the	 largest	 studies	 looking	 at	 the	quality	of	 life	 of	OAB	 sufferers	 found	 that	 of	
20,000	patients,	68%	of	the	women	and	60%	of	the	men	report	bothersome	symptoms	
which	worsen	 scores	 of	 anxiety	 and	 depression	 in	 the	 Health	 Related	 Quality	 of	 Life	
(HRQoL)	 survey	 (Milsom,	 Kaplan,	 Coyne,	 Sexton,	 &	 Kopp,	 2012).	 	 Another	 study	 has	
scored	OAB,	anxiety	and	depression	and	found	that	after	treatment	of	OAB	symptoms,	
there	is	also	an	improvement	of	anxiety	symptoms	(Kinjo,	Yamaguchi,	Tambo,	Okegawa,	
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&	Fukuhara,	2019).		This	correlates	with	other	studies	which	found	that	female	patients	
treated	with	mirabegron	reported	significantly	decreased	anxiety	and	depression	on	the	
Hospital	Anxiety	Depression	Scale	(HADS)	and	improved	in	QoL	surveys	(Athanasiou	et	
al.,	 2020;	 Castro-Diaz	 et	 al.,	 2015).	 	 Another	 study	 looking	 at	 mirabegron	 treatment	
specifically	 used	 the	 European	 Quality	 of	 Life	 Survey	 (EuroQoL)	 to	 measure	 5	
dimensions,	one	of	which	was	anxiety	and	depression.	 	The	study	 found	 that	patients	
treated	with	mirabegron	 showed	quicker	 and	 superior	 improvement	 in	quality	 of	 life	
compared	to	other	treatments	(Pavesi	et	al.,	2013).		Persistence	of	OAB	treatments	has	
also	been	measured	in	a	large	prospective,	non-interventional	study.		The	study	assessed	
QoL	and	found	that	patients	receiving	mirabegron	treatment	reported	improvement	in	
QoL	and	increased	persistence	rate	of	53.8%	for	12	months	(Freeman	et	al.,	2018).	
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Aims	
Mirabegron	and	solifenacin	are	common	clinical	treatments	for	symptoms	of	overactive	
bladder.		Due	to	the	patient	reported	improvement	in	quality	of	life	and	decreased	anxiety	
symptoms	after	treatment,	the	present	study	aims	to	observe	the	effects	of	mirabegron	
and	solifenacin	on	water	avoidance	stress	induced	bladder	dysfunction.		
Specific	aims	were:	
• To	investigate	the	effects	of	solifenacin	and	mirabegron	on	voiding	dysfunction	
caused	by	water	avoidance	stress.	
• To	 assess	 how	 treatment	 with	 solifenacin	 or	 mirabegron	 affects	 bladder	
physiology	in	water	avoidance	stress	mice	
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METHODS	
Animals		
Young	 adult	 female	 C57BL/6J	mice	were	 obtained	 and	 housed	 as	 outlined	 in	 general	
methodology	chapter	(Chapter	2).		Mice	were	randomly	allocated	into	one	of	four	groups:	
(1)	 Control	 (Unstressed),	 (2)	 Stressed,	 (3)	 Stress	 +	 Mirabegron	 and	 (4)	 Stress	 +	
Solifenacin,	with	n=6	animals	included	in	each	group.	
	
Drug	protocol	
Both	mirabegron	and	solifenacin	were	obtained	 from	Cayman	Chemicals	and	National	
Custom	Compounding	Pharmacy	(Merrimac,	QLD)	 formulated	both	drugs	 into	an	oral	
suspension	which	was	added	to	the	animals	drinking	water.		A	placebo	suspension	was	
added	to	the	drinking	water	of	animals	not	in	the	drug	treatment	groups	to	control	for	
variables	in	water	consumption	due	to	the	presence	of	the	oral	suspension.		
Several	 studies	 have	 observed	 and	 recorded	 the	 effects	 of	 oral	 mirabegron	 and	
solifenacin	treatment	on	mice.		Both	drugs	have	been	documented	to	take	effect	over	a	
number	of	days	and	for	this	reason,	mice	in	this	protocol	commenced	treatment	with	oral	
mirabegron	or	solifenacin	on	the	first	day	of	the	stress	exposure	period	and	continued	
for	the	remaining	10-days.			
The	typical	adult	human	dose	for	mirabegron	(10	mg/day)	and	solifenacin	(50	mg/day)	
was	used	to	calculate	the	equivalent	does	in	mice	(2	mg/kg/day	for	mirabegron	and	10	
mg/kg/day	for	solifenacin)	based	on	a	published	dose	conversion	guide	for	humans	to	
animals	(Nair	&	Jacob,	2016).		The	final	concentration	of	solifenacin	in	the	drinking	water	
was	50	µg/ml	and	 for	mirabegron	10	µg/ml	which	was	available	 for	 consumption	24	
hours	per	day,	7	days	per	week.		
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Water	Avoidance	Stress	Protocol	
Water	 avoidance	 stress	 protocol	 was	 performed	 in	 the	 same	 manner	 as	 outlined	 in	
chapter	3.		
	
Whole	Bladder	Preparation	
Whole	bladder	preparation	was	performed	as	described	in	chapter	2,	with	the	following	
differences	due	to	the	sex	of	the	mice.		When	the	abdominal	region	was	secured	to	the	
dissection	bath	under	 the	microscope,	 the	 female	 reproductive	 organs	were	 removed	
including	 the	uterus,	 fallopian	 tubes,	 ovaries	 and	 surrounding	 connective	 tissue.	 	 The	
whole	bladder	preparation	was	then	continued	as	described	in	chapter	2.	
	
Statistical	Analysis	
Two-way	 ANOVA	 with	 Tukey’s	 post	 hoc	 test	 for	 multiple	 comparisons	 was	 used	 to	
compare	the	different	time	point,	voiding	variables	and	dose-response	curves.		One-way	
ANOVA	with	Bonferroni	post-hoc	test	was	used	to	compare	the	difference	between	the	
four	animal	groups	(urothelial	mediator	release	data,	animal	parameters,	spontaneous	
activity	data,	response	to	ATP,	αβmATP	and	KCl).	
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RESULTS	
Animal	Parameters	and	Voiding	
Animal	body	weight	and	water	consumption	were	measured	during	the	stress	exposure	
period	on	days	0,	1,	3,	5,	7	and	10.	 	The	data	was	unchanged	across	all	animal	groups	
compared	to	the	unstressed	group,	and	data	from	day	10	is	shown	below	in	Table	6.1.		
Bladder	weight	was	measured	after	whole	bladder	preparations	and	these	parameters	
were	also	unchanged	across	all	animal	groups.		
	
	
Blood	samples	were	 taken	at	 the	 time	of	euthanasia	and	plasma	corticosterone	 levels	
were	measured.		There	was	a	significant	increase	in	plasma	corticosterone	levels	in	the	
stressed	group,	107±	21.90	µg/mL	(n=6),	compared	to	the	unstressed	group,	44.78	±	
8.89	 µg/mL	 (p	 =	 0.034)	 (n=6).	 	 Solifenacin	 significantly	 decreased	 plasma	
corticosterone	 levels,	 37.01	 ±	 10.45	 µg/mL	 (^p	 =	 0.026)	 (n=6),	 and	 although	 not	
significantly	 different	 to	 the	 stressed	 group,	 mirabegron	 treatment	 also	 decreased	
corticosterone	levels,	45.75	±	17.03	µg/mL	(p	=	0.059)	(n=6)	(Figure	6.3).		
	
TABLE	6.1:		Baseline	body	weight,	water	consumption	and	bladder	weight	(at	day	10)	in	
control	(unstressed),	water	avoidance	stress	(stressed),	mirabegron	(stress	+	mira)	and	
solifenacin	(stress	+	soli)	treated	mice	(n=6).		
		 Unstressed	 Stressed	 Stress	+	Mira	 Stress	+	Soli	
Body	weight	(g)		 20.43	±	0.28	 21.35	±	0.34	 20.33	±	0.48	 20.03	±	0.59	
Bladder	weight	(mg)		 17.21	±	1.30	 18.49	±	1.00	 16.88	±	1.28	 17.92	±	2.36	
Water	consumption	(g)		 1.33	±	0.16	 1.47	±	0.14	 1.86	±	0.09	 1.97	±	0.05	
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Figure	6.3:	Plasma	corticosterone	 levels	 in	unstressed,	stressed,	mirabegron	(Stress	+	
Mira)	or	solifenacin	(Stress	+	Soli)	treated	mice.		Datum	is	represented	as	mean	±	SEM	
(n	 =	 6).	 	 Analysis	 was	 performed	 as	 a	 one-way	 ANOVA	 (*p	 <	 0.05,	 Unstressed	 vs.	
stressed)	(#p	<	0.05,	stressed	vs.	stress	+	soli).	
	
As	observed	in	the	previous	chapters,	urinary	frequency	was	significantly	increased	by	
WAS,	 which	 was	 associated	 with	 a	 significant	 decrease	 in	 the	 average	 void	 size	 and	
increase	in	the	number	of	small	spots	(Figure	6.4).		Total	voided	area	was	unchanged	by	
WAS.		The	number	of	voiding	events	(Figure	6.4.A)	was	significantly	reduced	in	animals	
from	both	the	mirabegron	and	solifenacin	treated	groups	compared	to	the	stressed	mice	
from	day	3	onwards.		Average	void	size	(Figure	6.4.B)	was	significantly	decreased	in	the	
stressed	 group	 from	day	 1	 onwards	 compared	 to	 the	 unstressed	 group.	 	 From	day	 3	
onwards,	mirabegron	and	solifenacin	treatment	significantly	increased	average	void	size	
to	unstressed	control	levels.	 	Total	voided	area	remained	unchanged	across	all	groups,	
meaning	that	the	mice	urinated	the	same	amount	(Figure	6.4.C).		Number	of	small	urine	
spots	below	<	0.2	cm2	(Figure	6.4.D)	was	significantly	increased	in	the	stressed	group	
compared	to	the	unstressed	group	at	day	3	and	from	day	5	onwards.	 	Mirabegron	and	
solifenacin	significantly	reduced	the	number	of	small	voids	to	unstressed	control	levels.	
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Figure	 6.4:	 Voiding	 pattern	 analysis	 conducted	 in	 unstressed,	 stressed,	 mirabegron	
(Stress	+	Mira)	or	solifenacin	(Stress	+	Soli)	treated	mice.		(A)	Number	of	voiding	events,	
(B)	Average	 voided	 area,	 (C)	Total	 voided	 area	 and	 (D)	Number	of	 small	 urine	 voids	
smaller	 than	 0.2	 cm2.	 	 Datum	 is	 presented	 as	 mean	 ±	 SEM	 (n	 =	 9).	 Analysis	 was	
performed	 using	 two-way	 repeated	 measures	 ANOVA	 (**p	 <	 0.01,	 ***p	 <	 0.001,	
Unstressed	vs.	stressed)	(+p	<	0.05,	+++p	<	0.001,	stressed	vs.	stress	+	mira)	(#p	<	0.05,	
###p	<	0.001,	stressed	vs.	stress	+	soli).	
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Faecal	 pellets	 were	 counted	 (Figure	 6.5.A)	 and	 weighed	 (Figure	 6.5.B)	 after	 voiding	
pattern	analysis.	Number	of	faecal	pellets	was	variable	and	statistically	unchanged	across	
all	groups.	There	were	some	significant	changes	in	the	weight	of	pellets	at	day	1	where	in	
the	stressed	and	mirabegron	treated	animals	faecal	weight	was	significantly	decreased	
compared	to	the	unstressed	animals	(p	=	0.0218,	p	=	0.0201).	At	day	5,	faecal	weight	
was	significantly	decreased	in	the	solifenacin	treated	group	compared	to	the	unstressed	
controls	(p	=	0.0452).	
	
Figure	6.5:	Faecal	pellet	analysis	conducted	in	unstressed,	stressed,	mirabegron	(Stress	
+	Mira)	or	solifenacin	(Stress	+	Soli)	 treated	mice.	 	 (A)	Number	of	 faecal	pellets,	 (B)	
relative	weight	of	faecal	pellets.	Datum	is	presented	as	mean	±	SEM	(n	=	9).	Analysis	was	
performed	 using	 two-way	 repeated	 measures	 ANOVA	 (*p	 <	 0.05,	 unstressed	 vs.	
stressed)	(~p	<	0.05,	unstressed	vs.	stress	+	mira)	(^p	<	0.05,	unstressed	vs.	stress	+	
soli).	
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Mediator	Release	
Serosal	and	intraluminal	fluid	was	analysed	for	[ATP]	and	[ACh]	content.		The	volume	at	
time	of	fluid	collection	was	used	to	normalise	mediator	concentration	of	each	sample	and	
results	are	expressed	as	total	ATP	and	ACh.		Both	intraluminal	ATP	and	ACh	(Figure	6.6.A	
and	C)	concentrations	were	unchanged	across	all	animal	groups.		Total	serosal	ATP	was	
also	 unchanged	 across	 all	 groups	 (Figure	 6.6.B).	 	 There	 was	 however	 a	 significant	
increase	 in	 total	 serosal	 ACh	 release	 in	 the	 stressed	 group	 (2.30	±	0.15	 nmols,	 n=6)	
compared	 to	 the	 unstressed	 controls	 (1.32	±	 0.18	 nmols,	 n=6)	 (p	=	 0.0005).	 	 Total	
serosal	ACh	was	then	decreased	significantly	in	the	mirabegron	treated	group	(1.48	±	
0.12	nmols,	n=6)	and	solifenacin	treated	group	(1.52	±	0.11	nmols,	n=6),	compared	to	
the	stressed	group	(p	=	0.003,	p	=	0.007).			
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Figure	6.6:	Total	release	of	ATP	and	ACh	into	the	(A	&	C)	intraluminal	and	(B	&	D)	serosal	
fluid	 collected	 following	 distensions	 of	 isolated	 bladders	 from	 unstressed,	 stressed,	
mirabegron	 (Stress	 +	 Mira)	 or	 solifenacin	 (Stress	 +	 Soli)	 treated	 mice.	 Datum	 is	
represented	as	mean	±	SEM	(n	=	6).	Analysis	was	performed	as	a	one-way	ANOVA	(***p	
<	0.001,	unstressed	vs.	stressed)	(++p	<	0.01,	stressed	vs.	stress	+	mira)	(##p	<	0.01,	
stressed	vs.	stress	+	soli).	
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Bladder	Compliance	and	Stretch-relaxation	
A	volume-pressure	 relationship	was	used	 to	measured	bladder	compliance	across	 the	
four	 animal	 groups.	 Bladder	 compliance	 was	 not	 significantly	 altered	 by	 stress,	
mirabegron	or	solifenacin	treatment	(Figure	6.7).	
	
Figure	 6.7:	 Volume	 pressure	 relationship	 for	 bladders	 from	 unstressed,	 stressed,	
mirabegron	 (Stress	 +	 Mira)	 or	 solifenacin	 (Stress	 +	 Soli)	 treated	 mice.	 Datum	 is	
represented	as	mean	±	SEM	(n	=	9),	analysed	by	two-way	ANOVA.	
	
After	 intraluminal	and	serosal	 fluid	collection,	bladders	were	 left	 to	equilibrate	 for	30	
minutes.	Over	 this	period,	 the	pressure-time	 relationship	was	assessed.	 Initially	 there	
was	 a	 sharp	 decrease	 over	 the	 first	 8	 minutes.	 There	 was	 no	 significant	 difference	
between	 the	 groups	 during	 the	 stretch-relaxation	 period	 or	 at	 final	 basal	 pressure	
(Figure	6.8).	
	
	
0 5 10 15 20
0
50
100
150
200
Pressure (mmHg)
Vo
lu
m
e 
(u
L)
Unstressed
Stressed
Stress + Soli
Stress + Mira
 
 
210 
	
Figure	6.8:	Pressure	time	relationship	for	isolated	bladders	from	in	unstressed,	stressed,	
mirabegron	 (Stress	 +	 Mira)	 or	 solifenacin	 (Stress	 +	 Soli)	 treated	 mice	 following	
distension	to	20	mmHg.	Datum	is	represented	as	mean	±	SEM	(n	=	9),	analysed	by	two-
way	ANOVA.		
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Bladder	Contractility	and	Electrical	Field	Stimulation	
KCl	 responses	were	measured	 at	 the	 end	 of	 each	 experiment	 to	 assess	 non-receptor	
mediated	bladder	contractility	(Figure	6.9).	 	There	was	no	significant	difference	in	KCl	
contractility	 between	 all	 groups	 with	 bladder	 responses	 from	 unstressed,	 stressed,	
mirabegron	and	solifenacin	treated	animals	recorded	as	31.23	±	3.27	mmHg,	38.16	±	
4.65	mmHg,	36.92	±	8.785	mmHg	and	38.45	±	5.277	mmHg,	respectively	(n=9).		
	
Figure	6.9:	Pressure	responses	to	KCl	(60	mM)	in	isolated	whole	bladders	in	unstressed,	
stressed,	mirabegron	(Stress	+	Mira)	or	solifenacin	(Stress	+	Soli)	treated	mice.	Datum	
is	represented	as	mean	±	SEM	(n	=	9)	and	analysed	using	an	Ordinary	one-way	ANOVA	
with	Tukey	Analysis.	
	
Nerve	mediated	responses	were	assessed	using	electrical	field	stimulation	at	1,	5,	10	and	
20	Hz.		An	example	of	a	frequency-response	trace	is	shown	in	Chapter	2,	Figure	2.5.		Stress	
did	 not	 change	 the	 response	 to	 electrical	 field	 stimulation	 (Figure	 6.10.A)	 and	
mirabegron	 and	 solifenacin	 did	 not	 have	 any	 effect	 on	 nerve	 mediated	 contractions.		
When	the	electrical	field	stimulation	was	normalised	to	KCl	contraction	(Figure	6.10.B),	
the	 response	 in	 the	 stress	 groups	was	decreased	 compared	 to	unstressed	 controls,	 at	
higher	frequencies,	however,	this	was	not	statistically	significant.		
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Figure	6.10:	Responses	 of	 isolated	whole	 bladders	 to	 electrical	 field	 stimulation	 from	
unstressed,	stressed,	mirabegron	(Stress	+	Mira)	or	solifenacin	(Stress	+	Soli)	treated	
mice,	at	1,	5,	10	and	20	Hz.	Responses	were	recorded	as	(A)	a	change	in	pressure	from	
baseline	and	(B)	a	percentage	of	the	KCl	response.	Datum	is	presented	as	the	mean	±	
SEM	 (n	=	 9)	 and	 analysed	 using	 a	 two-way	 repeated	measures	 ANOVA	with	 Tukeys	
multiple	comparison.	
	
Relative	 contribution	of	NO,	ACh	and	ATP	 to	nerve	mediated	 responses	was	 assessed	
using	electrical	field	stimulation	at	20Hz,	with	addition	of	pharmacological	agents.		The	
addition	 of	 LNNA	 did	 not	 significantly	 alter	 bladder	 contractions	 to	 EFS,	 as	 seen	 in	
previous	 chapters	 which	 indicates	 that	 the	 inhibitory	 neurotransmitter	 NO	 was	 not	
involved	 in	neurotransmission	(Figure	6.11.A).	 	Addition	of	 the	muscarinic	antagonist	
atropine	 (1	µM)	 reduced	 the	 response	 to	EFS	by	16.85	±	2.57%	(n=9)	 in	unstressed	
controls.	There	was	no	significant	difference	between	the	groups	with	the	same	change	
observed	in	the	stressed	(15.38	±	2.69%,	n=9),	mirabegron	treated	(9.59	±	1.73%,	n=9)	
and	solifenacin	treated	(14.91	±	2.41%,	n=9)	groups	(Figure	6.11.B).		With	the	addition	
of	αβmATP	to	desensitise	the	P2X1	purinoceptors,	responses	further	decreased	by	43.83	
±	4.53%	(n=9)	in	unstressed	controls,	51.48	±	3.21%	(n=9)	in	stressed,	46.36	±	6.03%	
(n=9)	 in	mirabegron	 treated	and	50.68	±	8.18%	(n=9)	 in	 solifenacin	 treated	groups	
(Figure	 6.11.C).	 	 A	 two-way	 ANOVA	 with	 Tukey	 multiple	 comparisons	 revealed	 no	
significant	difference	in	responses	to	pharmacological	agents	between	groups.		
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Figure	6.11:	(A)	Intravesical	pressure	responses	to	electrical	field	stimulation	at	20	Hz	
(baseline),	and	after	addition	of	L-NNA	(100	µM),	atropine	(1	µM),	αβmATP	(1	mM)	and	
TTX	 (1	 µM)	 to	 bladders	 from	 unstressed,	 stressed,	 mirabegron	 (Stress	 +	 Mira)	 or	
solifenacin	(Stress	+	Soli)	treated	mice.		Percentage	decrease	in	EFS	response	on	addition	
of	(B)	atropine	and	(C)	αβmATP	to	bladder	from	each	group.	Datum	is	expressed	as	mean	
±	SEM	and	analysed	using	two-way	repeated	measures	ANOVA	with	Dunnett’s	multiple	
comparisons	test	for	(A)	and	one-way	ANOVA	with	Dunnett’s	multiple	comparisons	test	
for	(B	and	C)	(*vs	Baseline	(20	Hz)).	Data	analysed	using	two-way	repeated	measures	
ANOVA	(**p		<	0.01,	***p	<	0.001	vs.	Baseline	(20	Hz)).	
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Response	to	Pharmacological	Agents	
ATP	 (10	 mM)	 and	 abmATP	 (1	 mM)	 were	 added	 to	 the	 bath	 to	 assess	 purinergic	
stimulation.	 While	 not	 significant,	 ATP-induced	 pressure	 responses	 were	 increased	
slightly	in	bladders	from	the	stressed	group	(11.28	±	1.28	mmHg,	n=9)	compared	to	the	
unstressed	control	group	(8.89	±	1.51	mmHg,	n=9).	 	Mirabegron	did	not	decrease	the	
contractile	 response	 (11.2	 ±	 0.907	 mmHg,	 n=9),	 however,	 solifenacin	 treatment	 did	
decrease	 ATP	 contractile	 responses	 by	 8.96	 ±	 1.375	 mmHg	 (n=9),	 although	 not	
significantly	(Figure	6.12.A).	The	response	was	normalised	to	the	KCl	response	with	no	
significant	change	indicated	(Figure	6.12.B).		
	
Figure	6.12:	Pressure	 responses	 to	 (A)	ATP	 (10	mM)	and	 (B)	ATP	normalised	 to	KCl	
response,	in	isolated	bladders	from	unstressed,	stressed,	mirabegron	(Stress	+	Mira)	or	
solifenacin	(Stress	+	Soli)	treated	mice.	Datum	is	represented	as	mean	±	SEM	(n	=	9)	
and	analysed	using	an	ordinary	one-way	ANOVA	with	Tukeys	comparison.	
	
Contractile	responses	to	abmATP	(1	mM)	were	also	used	to	assess	purinergic	responses	
and	 no	 significant	 difference	 was	 observed	 between	 the	 groups	 (Figure	 6.13.A).		
Responses	were	also	compared	as	a	percentage	of	the	KCl	response,	and	there	was	no	
significant	difference	between	the	groups	(Figure	6.13.B).		
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Figure	6.13:	Pressure	responses	to	(A)	to	{|mATP	(1	mM)	and	(B)	as	a	percentage	of	
the	KCl	contraction,	in	unstressed,	stressed,	mirabegron	(Stress	+	Mira)	or	solifenacin	
(Stress	+	Soli)	treated	mice.		Datum	is	represented	as	mean	±	SEM	(n	=	6)	and	analysed	
using	an	ordinary	one-way	ANOVA	with	Tukey	comparison.	
	
	
A	two-way	ANOVA	with	Tukey	multiple	comparisons	test	revealed	a	significant	difference	
in	 maximum	 response	 to	 muscarinic	 agonist	 carbachol,	 between	 bladders	 from	 the	
stressed	 and	 unstressed	 groups.	 	 Mirabegron	 treatment	 significantly	 reduced	 the	
maximum	contractile	response	compared	to	the	stressed	group.		Solifenacin	treatment	
did	 not	 affect	 the	 stress-induced	 increase	 in	 response	 and	 the	 response	 was	 still	
significantly	increased	compared	to	the	unstressed	control	(p	=	0.0266).		There	was	no	
significant	 difference	 in	 the	 pEC50	 values	 for	 carbachol,	 as	 highlighted	 in	 TABLE	 6.2.		
When	 expressed	 as	 a	 percentage	 of	 the	KCl	 response,	 no	 significant	 differences	were	
observed	between	the	groups	(Figure	6.14.B).		Solifenacin	treatment	had	no	effect	on	the	
increased	contractile	response	observed	after	water	avoidance	stress,	while	mirabegron	
reduced	the	contractile	responses	to	carbachol	(Figure	6.14.A).	
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Figure	6.14:	Carbachol	concentration-response	curve,	for	isolated	whole	bladders	from	
unstressed,	stressed,	mirabegron	(Stress	+	Mira)	or	solifenacin	(Stress	+	Soli)	treated	
mice,	recorded	as	(A)	change	in	intravesical	pressure	from	baseline	and	(B)	change	in	
intravesical	pressure	as	a	percentage	of	the	KCl	response.		Datum	is	represented	as	mean	
±	 SEM	 (n	 =	 9),	 analysed	 using	 non-linear	 regression	 and	 two-way	 ANOVA	 with	
Bonferroni’s	multiple	comparisons	test	(**p	<	0.01,	unstressed	vs.	stressed)	(^p	<	0.05,	
unstressed	vs.	stress	+	soli)	(+p	<	0.05,	stressed	vs.	stress	+	mira).	
	
A	concentration-response	curve	to	 isoprenaline	was	performed	to	assess	relaxation	of	
the	bladder.		There	was	no	significant	difference	in	the	pIC50	values,	however	there	was	a	
significant	difference	in	maximal	pressure	response	(TABLE	6.3).	When	expressed	as	a	
percentage	of	the	carbachol	precontraction	the	maximum	response	of	bladders	from	the	
mirabegron	treated	group	was	significantly	decreased	compared	to	the	unstressed	group	
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TABLE	6.2:	Whole	bladder	responses	to	carbachol	in	control	(unstressed),	water	avoidance	
stress	(stressed),	mirabegron	(stress	+	mira)	and	solifenacin	(stress	+	soli)	treated	mice	
(n=9).	
	 Unstressed	 Stressed	 Stress	+	Mira	 Stress	+	Soli	
pEC50	 5.55	±	0.06	 5.42	±	0.06	 5.57	±	0.12	 5.41	±	0.06	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%KCl)	
	
43.46	±	1.21	
145.19	±	12.82	
	
57.45	±	3.35**	
158.89	±	12.92	
	
46.97	±	6.51+	
139.67	±	14.20	
	
53.23	±	4.14^	
146.67	±	14.96	
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(Figure	6.15.B),	as	displayed	in	TABLE	6.3.	 	Solifenacin	had	no	effect	on	the	relaxation	
responses	of	the	bladder	after	psychological	stress	(Figure	6.15.A).	
	
	
	
Figure	 6.15:	 Effect	 of	 isoprenaline	 on	 isolated	 bladders,	 from	 unstressed,	 stressed,	
mirabegron	(Stress	+	Mira)	or	solifenacin	(Stress	+	Soli)	treated	mice,	with	datum	given	
as	(A)	raw	data	as	change	in	pressure	from	pre-contraction,	(B)	change	in	intravesical	
pressure	as	a	percentage	of	the	KCl	response.		Datum	is	represented	as	mean	±	SEM	(n	
=	 9),	 using	 two-way	 ANOVA	 and	 non-linear	 regression	 (*p	 <	 0.05,	 unstressed	 vs.	
stressed)	(~p	<	0.05,	~~p	<	0.01,	unstressed	vs.	stress	+	mira).	
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TABLE	6.3:		Whole	bladder	responses	to	isoprenaline	in	control	(unstressed),	water	
avoidance	stress	(stressed),	mirabegron	(stress	+	mira)	and	solifenacin	(stress	+	soli)	
treated	mice	(n=9).	
	 Unstressed	 Stressed	 Stress	+	Mira	 Stress	+	Soli	
pIC50	 6.77	±	0.10	 6.83	±	0.07	 6.92	±	0.10	 7.03	±	0.10	
Maximal	response	
∆Pressure	(mmHg)	
Response	(%	Decrease)	
	
-6.07	±	0.57	
13.26	±	0.03	
	
-4.84	±	0.36*	
32.60	±	6.81	
	
-4.51	±	0.19~~	
45.27	±	8.90	
	
-5.04	±	0.51	
17.69	±	16.67	
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Spontaneous	Contractions	
During	the	stretch-relaxation	phase,	the	frequency	of	spontaneous	activity	was	increased	
in	 bladders	 from	 the	 stressed	 group,	 although	 not	 significantly	 (Figure	 6.16.A).	
Mirabegron	 and	 Solifenacin	 treatment	 decreased	 frequency	 of	 spontaneous	 activity	
compared	 to	 the	 stressed	 group,	 however	 this	was	 also	 not	 significant.	 Amplitude	 of	
spontaneous	activity	was	unchanged	across	all	groups	(Figure	6.16.B).		
	
Figure	6.16:	Spontaneous	contractions	during	the	stretch-relaxation	period,	in	isolated	
bladders	from	unstressed,	stressed,	mirabegron	(Stress	+	Mira)	or	solifenacin	(Stress	+	
Soli)	 treated	 mice.	 	 (A)	 Frequency	 of	 contractions/minute	 and	 (B)	 Amplitude	 of	
spontaneous	contractions.	Datum	is	represented	as	mean	±	SEM	(n	=	6),	analysed	using	
one-way	ANOVA	with	Tukey’s	multiple	comparison.	
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Phasic	 activity	 was	 analysed	 after	 a	 tonic	 contraction	 of	 bladders	 to	 the	 muscarinic	
agonist	carbachol	(1	µM).	Frequency	of	phasic	activity	was	significantly	increased	in	the	
stressed,	 7.42	±	 0.68	mmHg	 (p	<	0.001)	 (n=6),	 and	mirabegron	 treated,	 6.33	±	 0.42	
mmHg	(p	=	0.0027)	(n=6),	groups	compared	to	the	unstressed	group,	3.33	±	0.21	mmHg	
(n=6).	 	 Solifenacin	 treatment	 significantly	 decreased	 frequency	 of	 spontaneous	
contractions	to	3.66	±	0.49	mmHg	compared	to	the	stressed	group	(p	=	0.0001)	and	was	
also	significantly	lower	that	the	mirabegron	treated	group	(p	=	0.0076)	(Figure	6.17.A).			
The	amplitude	of	phasic	contractions	was	similar	across	all	groups	(Figure	6.17.B).	
	
Figure	6.17:	Phasic	 response	 to	 tonic	contraction	of	1	µM	carbachol	 in	 isolated	whole	
bladders	from	unstressed,	stressed,	mirabegron	(Stress	+	Mira)	or	solifenacin	(Stress	+	
Soli)	treated	mice,	following	stimulation	with	carbachol	(1	µM)	(A)	Frequency	of	phasic	
contractions	and	(B)	Amplitude	of	phasic	contractions.	Datum	is	represented	as	mean	±	
SEM	(n	=	9),	analysed	using	a	one-way	ANOVA	(***p	<	0.0001,	Unstressed	vs.	stressed)	
(++p	<0.01,	Unstressed	vs.	stress	+	mira)	(###p	<	0.001,	stressed	vs.	stress	+	soli)	(/	/	p	
<	0.01,	stress	+	mira	vs.	stress	+	soli).	
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DISCUSSION	
In	previous	chapters,	water	avoidance	stress	was	shown	to	increase	voiding	frequency	
and	cause	increased	detrusor	muscle	contractility.		This	chapter	assessed	the	ability	of	
mirabegron	and	solifenacin	to	resolve	the	voiding	dysfunction	and	physiological	bladder	
changes	caused	by	stress.		
	
Effects	of	Mirabegron	and	Solifenacin	on	Voiding	Behaviour	
Mirabegron	 and	 solifenacin	 treatment	 significantly	 decreased	 voiding	 frequency,	
compared	 to	 animals	 in	 the	 water	 avoidance	 stress	 group.	 	 The	 decreased	 voiding	
frequency	was	accompanied	by	 increased	average	void	 size	and	decreased	number	of	
small	voids.		There	was	no	difference	in	total	voided	area,	meaning	that	the	mice	were	
still	producing	 the	same	volume	of	urine	and	 therefore	 the	changes	observed	were	 in	
voiding	phenotype	rather	than	urine	production.		Both	drugs	returned	voiding	behaviour	
to	unstressed	control	levels,	despite	continued	stress	exposure.		As	discussed	previously,	
mirabegron	and	solifenacin	are	common	pharmaceutical	agents	used	clinically	to	treat	
the	symptoms	of	OAB	(Alcantara-Montero,	2016).		
Solifenacin	and	mirabegron	have	different	modes	of	action,	and	these	differences	have	
been	 highlighted	 in	 several	 studies.	 	 In	 one	 study,	 solifenacin	 and	 mirabegron	 were	
injected	intravenously	and	bladder	and	urethral	activity	were	recorded.		Solifenacin	was	
found	 to	 be	 more	 effective	 in	 increasing	 bladder	 capacity	 without	 affecting	 residual	
volume	(Sugaya	et	al.,	2020).	 	This	correlates	with	another	study	of	solifenacin	which	
used	cystometry	in	rats	and	also	reported	that	solifenacin	increased	bladder	capacity	by	
37%	at	a	dose	of	0.1	mg/kg	intravenously	(Suzuki	et	al.,	2005).		Studies	of	mirabegron	on	
rat	 bladder	 have	 shown	 increased	 bladder	 capacity	 without	 any	 effect	 on	 voiding	
pressure	or	residual	volume	(Kanai	&	Andersson,	2010;	Sugaya	et	al.,	2020).	 	Another	
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study	 using	 cystometry	 in	 conscious	 rats	 observed	 the	 effects	 of	 tolterodine	 and	
mirabegron	on	voiding	and	non-voiding	contractions.		The	study	found	that	tolterodine	
decreases	voiding	contraction	while	mirabegron	did	not	have	this	effect	and	is	therefore	
unlikely	to	produce	urinary	retention	(Gillespie	et	al.,	2012).			
Several	 studies	 have	 examined	 the	 effect	 of	 mirabegron	 and	 solifenacin	 in	 a	 clinical	
capacity.	 	A	review	of	the	safety,	efficacy	and	tolerability	of	mirabegron	has	concluded	
that	doses	of	50	and	100	mg	per	day	were	the	most	efficient	in	treating	the	symptoms	of	
OAB,	including	micturition	frequency	and	urgency	incontinence	(Chapple,	Cardozo,	Nitti,	
Siddiqui,	&	Michel,	2014).		This	is	much	the	same	for	solifenacin	treatment,	where	clinical	
studies	 have	 shown	 that	 patients	 report	 improved	 quality	 of	 life,	 with	 decreased	
symptom	severity	after	5	to	10	mg	per	day	over	a	12-week	period	(Kelleher	et	al.,	2005).			
Overall,	the	effects	of	mirabegron	and	solifenacin	on	the	urinary	bladder	would	explain	
why	both	drugs	are	able	to	decrease	voiding	frequency	without	affecting	total	volume.	
	
Effects	of	Mirabegron	and	Solifenacin	on	Corticosterone	Release	
Repeated	 psychological	 stress	 exposure	 significantly	 increased	 plasma	 corticosterone	
levels	compared	to	the	unstressed	controls,	as	seen	in	previous	chapters.		Interestingly,	
plasma	corticosterone	levels	were	decreased	by	mirabegron	treatment	and	significantly	
decreased	 by	 solifenacin	 treatment,	 compared	 to	 the	 stressed	 group.	 	 Due	 to	 these	
changes,	possible	sites	of	action	of	mirabegron	and	solifenacin	are	of	particular	interest.		
ACTH	 is	 a	 regulator	 of	 steroidogenesis	 in	 the	 adrenal	 cortex;	 however,	 it	 has	 been	
suggested	 that	 there	 are	 also	 other	 local	 and	 central	 mechanisms	 controlling	
adrenocortical	steroidogenesis,	 including	corticosterone	release.	 	Muscarinic	receptors	
are	known	to	regulate	numerous	central	and	peripheral	functions,	and	the	HPA	axis	in	
humans	 and	 rodents	 is	 reportedly	 affected	 by	 activation	 or	 blockade	 of	 this	 receptor	
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family	 (Rhodes,	 Billings,	 Czambel,	 &	 Rubin,	 2005).	 	 Central	 muscarinic	 receptors	
reportedly	 modulate	 corticosterone	 secretion,	 with	 some	 conflicting	 evidence	 of	 the	
specific	 receptor	 type	 involved	 (as	 reviewed	 by	 Thomsen,	 Sorensen,	 and	 Dencker	
(2018)).		A	recent	study	using	wild-type,	M2	and	M4	single-knockout	(KO)	mice	reported	
that	administration	of	a	muscarinic	agonist	stimulates	corticosterone	release	in	vivo	via	
M2	 muscarinic	 receptors	 (Hemrick-Luecke,	 Bymaster,	 Evans,	 Wess,	 &	 Felder,	 2002).		
Direct	actions	of	acetylcholine	on	adrenal	cortical	cells	to	simulate	steroidogenesis	was	
first	 reported	 in	 1977	 (Rosenfeld,	 1955)	 and	 later	 confirmed	 to	 rely	 on	 activation	 of	
muscarinic	 receptors	 in	several	 species	 (Hadjian,	Guidicelli,	&	Chambaz,	1982;	Porter,	
Whitehouse,	Taylor,	&	Nussey,	1988).		The	presence	of	cholinergic	fibres	in	the	adrenal	
cortex	has	also	been	observed	in	several	species	(Edwards	&	Jones,	1993).		This	would	
suggest	 that	 the	anti-muscarinic,	solifenacin	may	be	reducing	corticosterone	secretion	
via	actions	on	central	or	adrenocortical	muscarinic	receptors.	
Studies	of	micturition	function	have	found	the	cholinergic,	glutamatergic,	dopaminergic	
and	GABAergic	systems	in	the	central	nervous	system	are	all	involved	in	bladder	activity	
(Kanie	 et	 al.,	 2000),	 for	 this	 reason	 solifenacin	 may	 be	 acting	 at	 additional	 sites.		
Solifenacin	has	been	found	to	have	low	affinity	for	GABA	and	dopamine	receptors	at	high	
concentration	 and	 varied	 affinity	 for	 the	 different	 muscarinic	 receptors	 in	 humans.		
Solifenacin	has	selectivity	for	M1,	M2	and	M3	receptors	with	pKi	values	of	7.6,	6.9	and	8.0	
respectively	(Ikeda	et	al.,	2002),	where	solifenacin	has	higher	affinity	for	M3	receptors	
over	M2	 receptors.	 	M3	 receptors	 are	 the	minority	 of	muscarinic	 receptors	 in	 bladder	
smooth	 muscle,	 compared	 to	 M2,	 however	 studies	 have	 found	 that	 M3	 plays	 the	
predominant	role	in	detrusor	muscle	contractions	of	the	human	bladder	(Ehlert,	Ostrom,	
&	Sawyer,	1997).		M1	receptors	however,	are	located	on	pyramidal	cells	and	some	axons	
and	 nerve	 terminals	 (Abrams	 et	 al.,	 2006)	 in	 the	 neocortex,	 hippocampus	 and	
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neostriatum	(Volpicelli	&	Levey,	2004)	as	well	as	the	forebrain	which	is	known	to	play	a	
role	in	the	inhibitory	mechanisms	of	the	micturition	reflex	(Yokoyama	et	al.,	2001).		Due	
to	the	complex	neuronal	interactions,	there	may	be	a	link	between	the	effect	of	solifenacin	
on	M1	receptors	and	the	decreased	corticosterone	concentrations	that	were	observed	in	
the	present	study	(Sun,	Sun,	Zhai,	&	Dong,	2019).		
Research	 has	 shown	 that	 stress-induced	 increase	 in	 plasma	 corticosterone	 in	 rats	 is	
influenced	by	β-adrenoceptors	in	the	hypothalamic	paraventricular	nucleus	(Morton	et	
al.,	1990).		Additionally,	catecholaminergic	nerves	are	reported	to	be	distributed	in	the	
subcapsular	 regions	 of	 the	 adrenal	 gland	 including	 the	 zona	 fasciculata	 (Charlton,	
McGadey,	 Russell,	 &	 Neal,	 1992;	 Kleitman	&	Holzwarth,	 1985),	with	 pharmacological	
approaches	 indicating	 that	 noradrenaline	 may	 be	 an	 important	 regulator	 of	
glucocorticoid	secretion,	possibly	via	β1-adrenoceptors	(Walker,	Lightly,	Clyne,	Williams,	
&	 Bird,	 1991).	 	 These	 provide	 a	 plausible	mechanism	 by	which	mirabegron	 reduced	
plasma	corticosterone	in	WAS	mice	in	the	current	study.	
As	discussed	briefly	in	the	introduction,	mirabegron	acts	specifically	on	β3-adrenoceptors	
which	are	expressed	in	a	number	of	different	tissues,	including	the	brain	(Ursino,	Vasina,	
Raschi,	Crema,	&	De	Ponti,	2009).		Studies	have	used	the	process	of	reverse	transcription-
PCR	to	confirm	the	presence	of	β3-adrenoceptors	mRNA	in	several	regions	of	both	the	
human	 and	 rat	 brain,	 including	 hippocampus,	 amygdala,	 hypothalamus	 and	 cerebral	
cortex	(Rodriguez	et	al.,	1995;	Summers,	Papaioannou,	Harris,	&	Evans,	1995).		Due	to	
the	presence	of	the	adrenoceptors	in	the	brain,	there	has	been	some	interest	in	targeting	
these	receptor	subtypes	to	treat	disorders	such	as	anxiety	and	depression	(Ursino	et	al.,	
2009).		One	study	has	looked	at	chronic	and	acute	administration	of	the	β3-adrenoceptor	
agonist,	 CL	 316243,	 and	 found	 that	 acute	 administration	 of	 the	 agonist	 increased	
hypothalamic	5-HT	(serotonin)	synthesis	(Conley,	Li,	Ivarsson,	&	Hutson,	2007).		Another	
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β3-adrenoceptor	 agonist	 has	 also	 been	 of	 interest	 in	 treating	 anxiety	 and	 depression	
(Nisoli,	Tonello,	Benarese,	&	Carruba,	1995).	A	study	by	Stemmelin	et	al.	(2008)	used	a	
number	of	tests,	including	the	social	defeat	and	forced	swim	test	to	measure	anxiety	and	
depression	related	behaviour.		The	β3	agonist,	SR58611A	(amibegron)	was	given	orally	
to	the	rats	and	resulted	in	anxiolytic	and	antidepressant	behavioural	effects	(Stemmelin	
et	 al.,	 2008).	 	 The	 study	 also	 found	 that	 administration	 of	 the	 β3	 agonist	 resulted	 in	
increased	 synthesis	 of	 5-HT	 and	 tryptophan	 in	 the	 cortex,	 hippocampus,	 and	
hypothalamus	which	correlates	with	a	number	of	other	findings	(Claustre	et	al.,	2008).		
Several	links	have	been	made	between	5-HT	and	cortisol/corticosterone	release	which	
indicate	that	5-HT	may	influence	the	peripheral	adrenomedullary	response	to	increase	
cortisol	in	humans	and	corticosterone	levels	in	rodents	(Cerit,	Jans,	&	Van	der	Does,	2013;	
Huang	&	Herbert,	2005;	Murphy	&	Lesch,	2008).		
Overactive	 bladder	 symptoms	 correlate	 with	 increased	 anxiety	 and	 depression	 in	
patients.		While	there	is	some	evidence	that	both	mirabegron	and	solifenacin	can	reduce	
the	associated	symptoms	of	anxiety	and	depression	 in	 clinical	 studies	 (Kelleher	et	al.,	
2005;	 Kinjo	 et	 al.,	 2019),	 here	we	 observed	 that	 oral	 treatment	with	 solifenacin	 and	
mirabegron	can	reduce	the	hormonal	stress	response	associated	with	water	avoidance	
stress.	
	
Effects	of	Mirabegron	and	Solifenacin	on	Mediator	Release	
Stretch	of	the	urothelium	promotes	release	of	mediators,	including	ACh	and	ATP,	which	
play	 an	 important	 role	 in	normal	 bladder	 function	 (Yoshida	 et	 al.,	 2006).	 	While	ATP	
concentration	levels	were	unchanged	in	the	present	study,	ACh	release	in	the	serosal	fluid	
was	significantly	 increased	 in	bladders	 from	the	stressed	animals,	as	seen	 in	previous	
chapters,	and	significantly	decreased	after	mirabegron	and	solifenacin	treatment.		It	was	
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briefly	described	in	Chapter	3	that	non-neuronal	release	of	ACh	has	been	reported	in	the	
bladder	 urothelium	 and	 that	 this	 is	 mediated	 by	 CHT1,	 acetylcholine	 synthesising	
enzymes	(ChAT	and	CarAT)	as	well	as	an	OCT,	which	is	involved	in	non-vesicular	release	
of	 ACh	 from	 the	 urothelium	 (Hanna-Mitchell	 et	 al.,	 2007).	 	 While	 it	 is	 unlikely	 that	
solifenacin	 and	mirabegron	 act	 directly	 to	 inhibit	 non-neuronal	 ACh	 release	 from	 the	
urothelium,	 there	 is	some	evidence	 from	an	 in	vitro	study	that	shows	mirabegron	has	
weak	 inhibition	 of	 OCT1	 in	 mouse	 kidney-derived	 S2	 cells,	 with	 an	 IC50	 of	 47.2	 µM	
(unpublished	 data	 reported	 by	 Groen-Wijnberg	 et	 al.	 (2017)).	 	 Interestingly,	 this	
concentration	 is	 175-fold	 higher	 than	 the	 mean	 maximum	 plasma	 concentration	 in	
healthy	subjects	after	the	administration	of	mirabegron	at	50mg	once	a	day,	the	highest	
approved	dose	(Krauwinkel	et	al.,	2012).		There	is,	however,	no	evidence	that	solifenacin	
has	any	effect	on	these	transporters.			
Multiple	 studies	 have	 identified	 that	 the	 urothelium	 expresses	 a	 range	 of	muscarinic	
receptors,	 including	 in	 the	mouse	 (M1	 -	M5)	 and	human	 (M1,	M2,	M3	 and	M5)	bladder	
(Mansfield	et	al.,	2005;	Zarghooni	et	al.,	2007).		Along	with	muscarinic	receptors,	beta-
adrenoceptors	have	also	been	 identified	 in	human	(β1	 –	β3)	and	 rat	 (β1	 –	β3)	bladder	
urothelium	(Kullmann	et	al.,	2011;	Otsuka,	Shinbo,	Matsumoto,	Kurita,	&	Ozono,	2008).		
The	studies	have	shown	that	these	receptors	all	contribute	to	normal	physiology	of	the	
bladder,	however	it	is	still	unknown	whether	their	function	may	affect	non-neuronal	ACh	
release.		It	may	be	possible	that	the	effect	on	ACh	release	was	due	to	the	decreased	plasma	
corticosterone	 levels	 by	 mirabegron	 and	 solifenacin,	 rather	 than	 a	 direct	 effect	 at	
urothelial	receptors	as	ACh	release	from	the	urothelium	may	act	via	a	negative	feedback	
mechanism,	inhibiting	further	release	of	ACh	(Hanna-Mitchell	et	al.,	2007).	
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Effects	of	Mirabegron	and	Solifenacin	on	Bladder	Physiology		
While	 voiding	 frequency	 was	 reduced	 by	 mirabegron	 and	 solifenacin	 treatment,	 the	
increase	 in	 bladder	 contractility	 observed	 following	 WAS	 was	 not	 altered	 in	 the	
solifenacin	and	mirabegron	treated	animal	groups.		This	would	suggest	that	the	increase	
in	contractility	does	not	play	a	causal	role	in	the	voiding	dysfunction	observed	with	stress	
and	may	instead	be	a	local	compensatory	mechanism	in	response	to	stress.		M3	are	the	
predominant	 muscarinic	 receptors	 involved	 in	 mediating	 contraction	 in	 the	 mouse	
urinary	 bladder	 (Choppin	&	 Eglen,	 2001),	 and	 solifenacin	 is	 a	muscarinic	 antagonist,	
acting	 on	 M3	 receptors	 to	 decrease	 contraction.	 	 Studies	 of	 pathogenic	 bladder	
dysfunction	 in	 humans	 however	 have	 found	 that	 both	 M2	 and	 M3	 receptors	 may	 be	
mediating	bladder	contractile	responses	in	pathological	states,	i.e.,	M2	receptors	play	a	
greater	role	in	pathological	states.	Darifenacin,	a	M3	receptor	antagonist,	did	not	affect	
bladder	 contractions	 until	 both	 M2	 and	 M3	 receptors	 were	 inhibited	 (Ruggieri	 &	
Braverman,	 2006).	 	 In	 the	 present	 study	 solifenacin	 may	 be	 acting	 to	 block	 the	
predominant	M3	 receptor	subtypes,	but	M2	 receptors	may	have	 taken	over	contractile	
role,	 affecting	 bladder	 contractile	 responses,	 while	 not	 contributing	 to	 an	 increase	
voiding	phenotype.	
An	in	vitro	study	on	mouse	urinary	bladder	reported	that	solifenacin	does	not	alter	the	
maximal	 response	 to	 carbachol	 (Salcedo	 et	 al.,	 2009),	 unlike	 darifenacin.	 	 Similarly,	
solifenacin	increases	bladder	capacity	without	affecting	maximum	micturition	pressure	
(Liu	et	al.,	2017;	Suzuki	et	al.,	2005)	in	rodents	in	vivo.		In	Chapter	4,	we	postulated	that	
the	 enhanced	 contractile	 response	 caused	 by	 repeated	 WAS	 may	 involve	 calcium-
sensitization	 through	 the	 Rho-kinase	 pathway.	 	 It	 is	 therefore	 not	 surprising	 that	
solifenacin	did	not	affect	this	change	in	contractility,	as	it	is	most	likely	independent	of	
receptor	type.	
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β-adrenoceptor	 relaxation	 of	 human	 detrusor	 is	 mediated	 predominately	 by	 β3-
adrenoceptors	(Wuest	et	al.,	2009),	whilst	most	studies	have	reported	 involvement	of	
both	β2	and	β3-adrenoceptors	in	rodents	(Takeda	et	al.,	2003).		A	study	has	measured	β-
adrenoceptor	subtype	expression	by	exposing	KCl	pre-contracted	detrusor	muscle	strips	
of	wild	type	and	β2	receptor	KO	mice,	to	β-adrenoceptor	agonist,	isoprenaline	and	the	β3-
agonist,	 CL	 316,243.	 	 The	 study	 found	 that	 the	 predominant	 receptor	 responsible	 for	
relaxation	was	the	β2-adrenoceptor,	while	β3-adrenoceptors	can	also	mediate	relaxation	
(Propping,	Lorenz,	Michel,	Wirth,	&	Ravens,	2016).		
The	present	study	found	that	maximal	relaxation	of	bladders	to	isoprenaline	was	reduced	
in	the	mirabegron	treated	animals	compared	to	the	unstressed	control	animals.		In	the	
study	 mentioned	 above,	 in	 the	 absence	 of	 β2	 receptors,	 isoprenaline	 concentrations	
required	for	half	the	maximum	relaxation	were	approximately	90-fold	higher	(Propping	
et	al.,	2016).		Studies	of	mouse	urethra	have	also	demonstrated	similar	findings.		A	study	
by	 Alexandre	 et	 al.	 (2016)	 found	 that	 isoprenaline	 produced	 a	 biphasic	 pattern	 of	
relaxation	 in	 isolated	mouse	urethra	which	turned	monophasic	at	high	concentrations	
with	β3-adrenoceptor	antagonist	L-748,337	causing	a	contraction	at	the	end	of	the	curve.		
Mirabegron	on	the	other	hand	produced	full	relaxation	responses	in	mouse	urethra,	up	
to	1µM	(Alexandre	et	al.,	2016),	whereas	isoprenaline	at	high	concentrations	interacts	
with	α1-adrenoceptors,	behaving	as	a	weak	partial	agonist	(Trendelenburg,	1974).		This	
changed	when	urethra	strips	were	pre-contracted	with	phenylephrine.	 	The	relaxation	
curve	after	pre-contraction	was	shallow	in	the	mirabegron	treated	group	and	L-748,337	
was	 able	 to	 antagonise	 the	 effects	 of	 mirabegron.	 	 This	 indicated	 that	 different	
mechanisms	 might	 be	 responsible	 for	 the	 relaxations	 produced	 at	 low	 or	 high	
concentrations	of	mirabegron	(Alexandre	et	al.,	2016).	 	While	these	experiments	were	
performed	in	the	urethra,	the	results	may	be	translatable	to	the	bladder.		
 
 
228 
There	 is	 also	 a	 possibility	 of	 desensitisation	 in	 β-adrenoceptors.	 	 Rat	 bladder	 strips	
following	6-hour	pre-treatment	with	1	µM	isoprenaline	or	mirabegron,	amongst	other	β	
agonists	 had	 reduced	 maximum	 relaxation	 responses.	 	 This	 desensitization	 was	
prominent	for	β2-adrenoceptor	mediated	relaxation	but	much	weaker	for	β3,	however,	
the	acute	agonist	pre-treatment	may	account	for	this	(Michel,	2014).		In	the	current	study	
mice	were	treated	with	mirabegron	at	a	clinically	relevant	dose	for	10-days,	 following	
which	 the	 maximal	 relaxation	 response	 was	 reduced.	 	 While	 this	 may	 reflect	
desensitization	of	β2	and/or	β3	adrenoceptors	in	the	mouse	bladder,	it	did	not	affect	the	
efficacy	of	this	drug	in	terms	of	its	ability	to	manage	the	voiding	dysfunction	caused	by	
WAS.	
The	 frequency	 of	 the	 phasic	 response	 induced	 by	 muscarinic	 stimulation	 was	
significantly	enhanced	by	stress	and	reduced	by	solifenacin	treatment.	 	Afferent	nerve	
terminals	are	 located	adjacent	to	the	bladder	urothelium	and	stimulation	of	urothelial	
muscarinic	receptors	may	contribute	to	activation	of	afferent	nerves	via	non-neuronal	
release	 of	ATP,	 causing	 urinary	 urgency	 (Yoshida	 et	 al.,	 2009).	 	 Phasic	 activity	 in	 the	
bladder	 wall	 may	 also	 arise	 from	 spontaneous	 increases	 in	 Ca2+	 which	 are	 always	
preceded	by	action	potentials.		The	action	potentials	and	calcium	increase	occur	along	the	
boundary	of	 the	 smooth	muscle	and	 then	move	 through	 the	gap	 junctions	 (Hashitani,	
Fukuta,	 Takano,	 Klemm,	&	 Suzuki,	 2001).	 	 Non-voiding	 activity	 has	 been	 found	 to	 be	
sensitive	 to	 muscarinic	 antagonists	 and	 β3-adrenoceptor	 agonists.	 	 Cytometry	 was	
performed	 in	 conscious	 rats	with	 replicated	partial	 bladder	outflow	obstruction	were	
given	intravenous	mirabegron	and	tolterodine	(Gillespie	et	al.,	2012).		The	study	found	
that	 as	 the	 fill	 progressed,	 both	 drugs	 reduced	 large	 non-voiding	 contractions,	
mirabegron	 only	 affected	 frequency	 but	 tolterodine	 affected	 both	 frequency	 and	
amplitude	(Gillespie	et	al.,	2012).		There	is	also	evidence	that	mirabegron	may	attenuate	
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micro	contractions	by	acting	on	the	β3	adrenoceptors	of	afferent	nerves.		Data	has	shown	
that	mirabegron	 in	 rats	 inhibits	Aδ-fibre	mechano-sensitive	afferent	 activity,	meaning	
that	there	is	decreased	afferent	signalling	from	the	periphery	to	the	brain	(Aizawa	et	al.,	
2012).		Decreased	spontaneous	activity	may	be	another	therapeutic	effect	of	solifenacin	
treatment	 while	 decreased	 afferent	 signalling	 may	 be	 another	 therapeutic	 effect	 of	
mirabegron	 thereby	 leading	 to	 decreased	 urgency	 to	 void	 and	 decreased	 urinary	
frequency	in	the	treated	mice.	
There	 is	 a	 possibility	 that	 both	 mirabegron	 and	 solifenacin	 had	 an	 effect	 on	 other	
locations	 where	 autonomic	 receptors	 are	 localised.	 	 For	 example,	 within	 the	 urinary	
system,	β3	adrenoceptors	have	also	been	located	in	the	nephron	segments	of	the	kidney	
and	when	stimulated	with	the	selective	agonist	BRL37344,	urine	concentration	increased	
while	urine	excretion	decreased	(Procino	et	al.,	2016).		Evidence	also	suggests	that	some	
neurons	 within	 the	 pelvic	 ganglion	 in	 rats	 express	 β3	 adrenoceptors,	 and	 when	
stimulated,	 are	 involved	with	 regulation	 of	 efferent	 outflow	 and	 sensation	 (Eastham,	
Stephenson,	Korstanje,	&	Gillespie,	2015).		In	the	case	of	solifenacin,	M3	receptors	have	
been	identified	in	numerous	areas	other	than	the	detrusor	muscle.		Previously	M1,	M2	and	
M4	muscarinic	receptors	have	been	identified	on	sympathetic	nerve	endings,	regulating	
noradrenaline	 release	 and	 on	 parasympathetic	 nerve	 endings,	 regulating	 ACh	 release	
(Chess-Williams,	2002).		While	these	muscarinic	receptor	subtypes	are	less	affected	by	
solifenacin,	there	is	evidence	that	in	diseased	states,	there	is	upregulation	of	M3	receptors	
at	M1	receptor	sites	(Somogyi	et	al.,	2003).		As	seen	in	the	current	and	previous	chapters,	
psychological	stress	induces	physiological	changes	within	the	bladder	which	in	turn	leads	
to	voiding	dysfunction.		While	we	have	examined	the	bladder	changes	specifically	here,	
there	 may	 be	 other	 physiological	 changes	 occurring	 which	 could	 be	 remedied	 by	
solifenacin	and	mirabegron	treatment.			
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CONCLUSION	
Treatment	 with	 the	 muscarinic	 antagonist,	 solifenacin	 and	 β	 adrenoceptor	 agonist,	
mirabegron,	 decreased	 the	 effects	 of	water	 avoidance	 stress	 on	 voiding	 behaviour	 to	
unstressed	 control	 levels.	 	 Both	 therapeutics	 also	 reduced	 changes	 in	 ACh	 urothelial	
mediator	release	and	plasma	corticosterone	levels	that	were	observed	following	stress.		
These	results	indicate	that	management	of	bladder	dysfunction	caused	by	psychological	
stress	may	benefit	from	the	addition	of	an	antimuscarinic	such	as	solifenacin	or	the	β3-
adrenoceptor	agonist,	mirabegron.	
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The	purpose	of	 these	studies	was	 to	understand	 the	effects	of	psychological	 stress	on	
overall	physiological	bladder	function	and	which	currently	used	treatments	may	aid	in	
combating	this	dysfunction.		There	is	abundant	clinical	evidence	that	psychological	stress	
is	 associated	 with	 bladder	 dysfunction	 (Lai,	 2015),	 however	 the	 underlying	 local	
mechanisms	involved	in	this	dysfunction	are	still	generally	unknown.		There	is	also	recent	
evidence	 that	 suggests	 that	 diagnosis	 of	 bladder	 pathologies	 should	 include	
measurement	 of	 serum	 and	 urine	 concentrations	 of	 stress-related	 hormones	 such	 as	
cortisol	 and	 CRF,	 in	 order	 to	 tailor	 treatment	 of	 overactive	 bladder	 to	 the	 patient,	
highlighting	 the	 significance	 of	 psychological	 stress	 in	 the	 development	 	 of	 bladder	
disorders	(Peyronnet,	Chapple,	&	Cornu,	2019).			
Here,	a	body	of	work	was	described	which	initially	assessed	the	impacts	of	different	types	
of	 psychological	 stress	 on	 bladder	 function.	 	 Social	 defeat	 and	witness	 trauma	 stress	
(Chapter	3)	and	water	avoidance	stress	(Chapter	4,	Part	1),	surprisingly,	produced	vastly	
different	bladder	pathologies,	observed	mainly	as	changes	in	voiding	frequency.		Water	
avoidance	 stress	 produced	 an	 overactive	 bladder	 phenotype,	 whereas	 social	 defeat	
produced	a	urinary	retention	pattern.		Given	the	numerous	clinical	reports	of	increased	
urinary	frequency	due	to	stress,	we	used	the	water	avoidance	model	to	assess	the	effect	
of	a	recovery	period	(Chapter	4,	Part	2)	and	pharmacological	intervention	(Chapter	5	and	
6)	on	these	changes.		
While	the	general	findings	of	this	thesis	are	that	psychological	stress	increases	urinary	
frequency,	 as	 well	 as	 overall	 bladder	 contractility,	 and	 that	 these	 changes	 can	 be	
remedied,	at	least	in	part,	by	stress-free	recovery	time	and	pharmacological	treatments,	
there	is	some	dissemblance	in	the	chapters	which	will	be	discussed	here	in	the	General	
Discussion.			
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THE	DIFFERENT	MODELS	OF	PSYCHOLOGICAL	STRESS		
Between	the	social	defeat/witness	trauma	model	and	the	water	avoidance	model	there	
were	 various	 differences	 in	 voiding	 behaviour	 and	 overall	 physiological	 bladder	
mechanisms.		It	is	therefore	worth	discussing	the	differences	between	the	models.		
To	 begin,	 social	 defeat	 and	witness	 trauma	 stress	 are	models	 of	 social	 stress.	 	 Unlike	
previous	studies,	which	have	only	focused	on	the	social	defeat	aspect,	our	study	allowed	
for	the	observation	of	both	emotional	and	physical	stress,	as	well	as	the	aspect	of	a	social	
support	(Li	et	al.,	2018).		Water	avoidance	stress	however	replicates	an	environmental	
stress	 model	 (Yamamoto	 et	 al.,	 2012).	 	 As	 stated	 above,	 both	 studies	 produced	
phenotypes	 of	 voiding	 dysfunction,	 however,	 social	 defeat	 stress	 appeared	 to	 lead	 to	
urinary	retention	while	water	avoidance	stress	led	to	bladder	overactivity.		The	increased	
purinergic	 response	 in	 bladders	 from	 the	 social	 defeat	 animals	 appears	 to	 lead	 to	 a	
retention	phenotype	according	to	our	study	and	others	(Mann,	2015;	West	et	al.,	2020).		
There	could	be	some	argument	however	that	the	term	‘retention’	does	not	quite	fit	this	
model,	and	instead	the	effect	could	be	due	to	more	efficient	nerve	evoked	contractions	
and	therefore	more	efficient	voiding.		These	pathological	differences	observed	could	be	
due	to	several	factors	including	the	model	of	psychological	stress	itself	and	its	duration,	
the	changes	in	underlying	bladder	mechanisms	or	the	differences	in	sex	of	animals	used	
in	the	models.				
The	majority	of	studies	using	a	model	of	social	defeat	have	used	male	rodents,	due	to	the	
challenge	in	implementing	the	model	in	female	rodents	(Harris	et	al.,	2018).		Our	model	
of	social	defeat	produced	a	urinary	frequency	phenotype	similar	to	what	would	be	seen	
in	urinary	retention,	corresponding	with	other	studies	of	this	model	(Mann,	2015;	Wood	
et	al.,	2009).		There	was	one	study	however	which	found	that	social	stress	in	6-week-old	
male	mice,	lead	to	increased	urinary	frequency	evident	after	analysis	of	bladder	afferent	
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nerve	activity	(Mingin	et	al.,	2015).		Currently	there	are	no	studies	that	have	observed	
the	effect	of	social	defeat	on	the	voiding	behaviour	of	female	mice.		This	is	reported	to	be	
mainly	due	to	 the	complexity	of	 the	model,	as	male	and	female	mice	will	 typically	not	
attack	intruder	females	(Harris	et	al.,	2018).		Research	groups	have	attempted	to	mediate	
this	by	using	a	model	of	maternal	aggression	(Bourke	&	Neigh,	2012)	or	social	instability	
(Haller,	Fuchs,	Halasz,	&	Makara,	1999).	 	Neither	of	these	models,	however,	have	been	
used	to	assess	bladder	function.		
In	contrast	 to	 the	social	defeat	model,	water	avoidance	stress	has	been	undertaken	 in	
both	male	and	 female	rodents,	with	varying	results.	 	 Interestingly,	one	study	of	water	
avoidance	stress	found	that	male	mice	presented	with	a	decrease	in	voiding	frequency	
and	 increase	average	voided	volumes	(McGonagle	et	al.,	2012),	similar	 to	 that	seen	 in	
social	 defeat	 stress.	 	 Another	 study	 however	 contradicts	 this	 finding,	 with	 increased	
urinary	 frequency	 observed	 in	male	mice	 (Yamamoto	 et	 al.,	 2012).	 	Water	 avoidance	
stress,	has	however,	been	used	 to	 study	several	 aspects	of	bladder	 function	 in	 female	
mice,	with	most	studies	concluding	that	the	model	leads	to	increased	urinary	frequency	
(Lee	et	al.,	2015;	Matos,	2017).		Sex	differences	between	models	of	psychological	stress	
have	not	been	directly	studied	with	regard	to	bladder	function,	however	several	studies	
have	looked	at	this	difference	with	regard	to	other	pathologies	reporting	sex	differences	
in	neural	and	behavioural	responses	to	psychological	stress	(Gruene,	Flick,	Stefano,	Shea,	
&	Shansky,	2015;	Hodes	et	al.,	2015;	Lebron-Milad	&	Milad,	2012;	Shansky	et	al.,	2010).		
Sex	differences	in	relation	to	bladder	dysfunction	are	clinically	relevant	however	since	
both	 anxiety	 related	 disorders	 (Breslau	 et	 al.,	 1995)	 as	 well	 as	 the	 symptoms	 of	
overactive	bladder	syndrome	are	more	prevalent	in	woman	than	men	(Temml,	Heidler,	
Ponholzer,	&	Madersbacher,	2005).			
	
 
 
235 
PHYSIOLOGICAL	BLADDER	CHANGES	
It	should	be	noted	here	that	there	were	some	differences	in	bladder	responses	between	
the	original	water	avoidance	stress	study	(Chapter	4,	Part	1)	and	the	other	studies	in	this	
thesis	where	the	model	was	used	(Chapter	4,	Part	2	and	Chapter	5	and	6).		The	magnitude	
of	 all	 bladder	 responses	 in	 the	 whole	 bladder	 preparation	 studies	 was	 generally	
increased	from	Chapter	4,	Part	2	onwards,	and	the	only	aspect	of	the	project	which	may	
have	 contributed	 to	 this	was	 the	 time	 between	 experimental	 studies.	 	 However,	 each	
experimental	 study	 was	 performed	 with	 separate	 groups	 of	 age-matched	 unstressed	
controls	and	separate	WAS	animals,	and	so	we	are	confident	that	despite	some	changes	
in	 the	 magnitude	 of	 the	 responses,	 the	 difference	 observed	 between	 the	 groups	 are	
genuine.		
It	was	clear	throughout	the	various	studies	that	mice	were	experiencing	psychological	
stress,	due	to	the	increase	in	plasma	corticosterone	levels	seen	in	the	stressed	animals.		
In	 terms	 of	 physiological	 bladder	 changes,	 an	 increase	 in	 the	 purinergic	 system	was	
observed	in	the	social	defeat	paradigm,	while	water	avoidance	stress	caused	a	general	
increase	 in	bladder	contractility	 in	stressed	groups,	consistent	across	chapters.	 	These	
common	changes	seen	across	chapters	will	be	discussed	here.		
For	 many	 years	 the	 bladder	 urothelium	 was	 considered	 to	 act	 as	 a	 passive	 barrier,	
however,	 studies	 have	 shown	 that	 the	 urothelium	 has	 specialised	 sensory	 and	
transduction	 properties	 (Merrill	 et	 al.,	 2016).	 	 The	 release	 of	 urothelial	 mediators,	
including	ATP	and	ACh	has	been	shown	to	change	depending	on	urothelial	stretch	and	
chemical	 stimuli,	 and	 may	 affect	 sensory	 signalling	 and	 overall	 bladder	 function	
(Apodaca	et	al.,	2007).		Fry	and	Vahabi	(2016)	undertook	a	review	of	studies	using	the	
whole	bladder,	isolated	sections	of	the	bladder	wall,	detrusor-free	mucosa	and	isolated	
urothelial	 cells,	 and	 concluded	 that	 all	 studies	 reported	 release	 of	 ATP,	 ACh,	
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prostaglandins	and	NO,	when	physical	or	chemical	stress	was	applied.	 	As	all	of	 these	
preparations	released	these	mediators,	it	would	be	correct	to	assume	that	the	source	is	
the	urothelium	(Fry	&	Vahabi,	2016).	 	These	studies	highlight	the	complex	interaction	
between	the	detrusor	and	urothelium	and	support	the	belief	that	mediators	are	able	to	
move	throughout	the	layers	of	the	bladder	(Fry	&	Vahabi,	2016).	
Interestingly,	 across	 all	 chapters	 of	 this	 thesis	 there	 was	 a	 trend	 towards	 increased	
release	of	ACh	into	the	intraluminal	fluid	(social	defeat	and	witness	study)	and	serosal	
fluid	(WAS	studies).			
In	urothelial	cells,	choline	uptake	transporters,	as	well	as	the	enzymes	for	ACh	synthesis,	
have	 been	 identified	 (Hanna-Mitchell	 et	 al.,	 2007).	 	 Typically,	 changes	 in	 urothelial	
release	of	ACh	has	not	been	implicated	in	diseased	states,	only	with	age	(Yoshida	et	al.,	
2006),	while	stretch-evoked	release	of	ATP	has	been	linked	to	a	number	of	conditions	of	
bladder	dysfunction	(Birder	&	de	Groat,	2007).		Studies	of	aged	bladder	tissues	from	both	
animals	and	human	have	found	that	ATP	release	is	increased	with	age	(Daly	et	al.,	2014;	
Yoshida,	 Miyamae,	 Iwashita,	 Otani,	 &	 Inadome,	 2004),	 while	 there	 are	 conflicting	
opinions	 whether	 ACh	 cholinergic	 transmission	 decreases	 (Daly	 et	 al.,	 2014)	 or	 is	
enhanced	with	age	(McDermott	et	al.,	2013).	 	Bladder	biopsies	from	OAB	patients	also	
revealed	that	ATP	levels	were	elevated	(Munoz,	Smith,	Boone,	&	Somogyi,	2011).		
As	stated	in	relevant	chapters,	non-neuronal	release	of	ACh	is	not	completely	understood,	
but	could	have	a	number	of	consequences	in	bladder	physiology.		As	stated	above,	after	
release,	urothelial	mediators	typically	go	on	to	interact	with	cell	in	several	layers	of	the	
bladder	(Fry	&	Vahabi,	2016)	(Figure	7.1).	 	This	suggests	that	non-neuronal	release	of	
ACh	 may	 have	 both	 autocrine	 and	 paracrine	 signalling	 roles,	 potentially	 stimulating	
further	release	of	ATP,	NO	or	prostanoids	from	urothelial	cells,	or	acting	back	on	its	own	
receptors	(Wessler	&	Kirkpatrick,	2008).		There	is	also	possibility	that	non-neuronal	ACh	
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may	act	on	the	detrusor	muscle	directly.	 	There	has	been	convincing	evidence	that	the	
detrusor	muscle	 and	urothelium	have	a	 complex	 interaction.	 	 Studies	of	detrusor	and	
attached	 urothelial	 mucosa	 have	 found	 that	 when	 detrusor	 is	 denuded,	 spontaneous	
activity	is	reduced	(Kanai	et	al.,	2007;	Sui	et	al.,	2008).		As	we	saw	throughout	the	stress	
studies,	both	types	of	psychological	stress	increased	phasic	contractile	activity,	which	is	
known	to	play	a	role	in	several	bladder	pathologies	(Meng	et	al.,	2008).		It	is	therefore	
possible	 that	non-neuronal	release	of	ACh	contributes	 to	 this	 increase	 in	spontaneous	
activity	by	 stimulating	 the	 release	of	ATP,	 the	mediator	which	has	been	 implicated	 in	
increased	 spontaneous	 activity	 (Kushida	 &	 Fry,	 2016).	 	 There	 is	 evidence	 that	 non-
neuronal	released	ACh	may	also	be	acting	on	afferent	nerve	fibres	via	both	nicotinic	and	
muscarinic	ACh	receptors	(Apodaca	et	al.,	2007).		There	is	conflicting	evidence	however,	
as	 to	 the	 effect	 ACh	 has	 on	 these	 receptors.	 	 Evidence	 suggests	 that	 stimulation	 of	
muscarinic	receptors	can	depress	sensory	transduction	via	afferent	nerves		(Daly	et	al.,	
2010;	Kim,	Yoshimura,	Masuda,	de	Miguel,	&	Chancellor,	2005),	while	studies	of	nicotinic	
receptors	 indicate	 that	 stimulation	 may	 enhance	 bladder	 afferent	 nerve	 activity	
originating	at	afferent	receptors	near	the	urothelium	(Yu,	Daugherty,	&	de	Groat,	2016).		
If	 this	 were	 the	 case,	 stimulation	 of	 nicotinic	 receptors	 would	 lead	 to	 alterations	 in	
bladder	sensation,	which	may	be	involved	in	the	increased	urinary	frequency	that	was	
observed	in	water	avoidance	stress	animals.		
A	summary	of	urothelial	ACh	release	and	subsequent	actions	of	the	mediators	is	given	
below	in	Figure	7.1.	
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Figure	7.1:	Interactions	of	mediators	from	urothelium	after	urothelial	cell	stretch	during	
bladder	filling.		Interactions	occur	between	urothelial	cells	as	well	as	afferent	and	efferent	
nerves,	 smooth	 muscle	 cells	 and	 interstitial	 cells.	 Acetylcholine	 (ACh),	 Adenosine	
triphosphate	(ATP),	Muscarinic	receptors	(mAChR),	Nicotinic	receptors	(nAChR),	Nitric	
oxide	(NO).	(Created	with	BioRender.com	by	the	author).		
	
As	 discussed	 above,	 ATP	 release	 was	 unchanged	 in	 bladders	 across	 all	 groups	 in	 all	
chapters,	 which	was	 unexpected	 due	 to	 the	 link	 between	 urothelial	 ATP	 release	 and	
bladder	disorders	(Birder	&	de	Groat,	2007).		Studies	of	ATP	release	during	bladder	filling	
have	indicated	that	urothelial	ATP	release	occurs	via	exocytosis	during	the	early	stages	
of	bladder	filling	(Nakagomi	et	al.,	2016).		Another	study	of	whole	rat	bladder	measured	
mediator	release	at	low	and	high	distensions	and	found	that	at	both	pressures,	ATP	was	
released	in	a	similar	amount	(Bravo	et	al.,	2017).		This	finding	was	supported	by	another	
study	which	 looked	at	 luminal	ATP	release	 in	women	with	detrusor	overactivity.	 	The	
study	found	that	ATP	concentrations	were	only	increased	in	the	early	filling	stage	(200	
mL)	of	bladder	distension	as	opposed	to	the	later	stage	of	filling	(400	mL)	(Cheng	et	al.,	
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2014).		This	may	explain	why	we	did	not	see	a	change	in	ATP	release,	since	we	collected	
intraluminal	 and	 serosal	 fluid	 at	 the	 later	 stage	 of	 filling	 (20mmHg)	 from	 the	mouse	
bladders.	
Overall,	 enhanced	 contractility	 following	water	 avoidance	 stress	 does	 not	 completely	
explain	 why	 stressed	 mice	 experience	 increased	 urinary	 frequency,	 since	 stronger	
contractility	 could	 be	 thought	 to	 induce	 more	 efficient	 voiding.	 	 This	 is	 particularly	
relevant	 in	 the	recovery	group,	which	showed	decreased	overall	bladder	contractility,	
possibly	 due	 to	 increased	 compliance	 (as	 discussed	 in	 Chapter	 4,	 Part	 2),	 but	 still	
exhibited	increased	urinary	frequency.	This	data	suggests	that	there	is	a	possible	change	
occurring	in	afferent	nerves,	to	trigger	voiding	at	lower	volumes.		Work	by	others	in	our	
group,	currently	unpublished,	shows	that	at	low	physiological	pressures,	afferent	nerve	
activity	is	enhanced	by	water	avoidance	stress	(Figure	7.2).	This	indicates	that	stressed	
mice	 are	 experiencing	 enhanced	 sensory	 activity	 and	 subsequent	 voiding	 at	 lower	
physiological	pressure	and	volumes.		The	changes	in	bladder	contractility	may	therefore	
by	a	compensatory	mechanism	rather	than	a	causal	factor.	
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Figure	 7.2:	Afferent	 nerve	 recording	 during	 filling	 of	 bladder,	 from	mice	 after	 10-day	
water	avoidance	stress	(Stressed)	and	Unstressed	(Control)	groups.		Physiological	range	
is	indicated	above	graph	and	bladders	are	filled	to	a	pressure	of	40	mmHg.	(Unpublished	
data,	reproduced	with	permission	from	Kylie	Mills,	2020).		
	
	
TREATMENT	OF	PSYCHOLOGICAL	STRESS	AND	BLADDER	DYSFUNCTION	
The	 final	question	of	 this	 thesis	 lies	 in	what	 the	most	 suitable	 treatment	would	be	 to	
combat	bladder	dysfunction	caused	by	psychological	stress.	In	Chapter	5	and	Chapter	6,	
we	found	that	sertraline,	an	anxiolytic	drug,	as	well	as	mirabegron	and	solifenacin	were	
successful	in	reducing	the	overall	increase	in	bladder	contractility	seen	in	the	stressed	
groups.		To	distinguish,	between	the	most	appropriate	treatment,	the	interactions	of	each	
drug	and	subsequent	adverse	effects	should	be	considered.	
Sertraline	is	an	SSRI	used	in	the	management	of	anxiety	and	depression	but	unlike	other	
SSRI’s,	 it	 has	 very	 few	 adverse	 effects.	 	 The	 potential	 use	 of	 sertraline	 in	 treating	
overactive	 bladder	 stems	 from	 studies	 which	 have	 found	 that	 depletion	 of	 serotonin	
within	the	CNS	leads	to	increased	urinary	frequency	and	detrusor	overactivity	(Chiba	et	
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al.,	 2016).	 	 The	 role	 of	 sertraline	 is	 predominantly	 to	 increase	 serotonin	 availability	
within	 the	brain	which	may	 then	act	on	 serotonergic	neurons	 involved	 in	descending	
inhibition	of	the	bladder,	including	the	Onuf	nuclei	and	the	lumbosacral	autonomic	nuclei,	
which	 innervate	 urethral	 sphincters	 (Andersson	 &	 Pehrson,	 2003).	 	 As	 discussed,	
sertraline	acts	predominately	in	the	CNS,	but	there	may	be	potential	local	bladder	‘flow	
on’	 effects	 of	 sertraline	 (Konthapakdee	 et	 al.,	 2019).	 	 5-HT	 receptors	 are	 located	
throughout	 the	bladder	and	depending	on	 the	 location,	play	different	 roles	 in	bladder	
physiology.		Interestingly,	stimulation	of	5-HT	with	serotonin	has	been	shown	to	increase	
bladder	afferent	nerve	activity	and	significantly	 increase	detrusor	muscle	contractility	
(Konthapakdee	 et	 al.,	 2019).	 	 This	 is	 supported	 by	 other	 findings	 that	 selective	 5-HT	
receptor	 agonists	 cause	 contraction	of	 bladder	 strips	 (Hattori,	 Lluel,	 Rouget,	Rekik,	&	
Yoshiyama,	2017).	 	These	 findings	would	 seem	 to	 contradict	our	 studies	of	 sertraline	
here,	as	afferent	nerve	 firing	would	most	 likely	be	 leading	to	early	voiding.	 	However,	
early	studies	also	observed	that	stimulation	of	5-HT	receptors	suppresses	the	processing	
of	afferent	input	from	the	bladder,	resulting	in	inhibition	of	preganglionic	neurons	and	
excitation	of	sympathetic	neurons,	leading	to	decreased	contractility	and	increased	urine	
storage	(De	Groat	&	Ryall,	1967;	Espey	et	al.,	1992).	 	There	is	evidence,	however,	that	
sertraline	can	desensitise	5-HT	receptors	after	chronic	administration	in	the	rat	cortex	
(Sanders-Bush,	Breeding,	Knoth,	&	Tsutsumi,	1989).		This	is	supported	by	a	more	recent	
study	 which	 found	 that	 mild	 administration	 of	 sertraline	 was	 effective	 in	 reducing	
depression-like	behaviour,	however	towards	the	end	of	the	treatment	phase,	there	was	a	
rapid	onset	of	depressive	behaviour,	indicating	desensitisation	of	5-HT	receptors	within	
the	brain	(Mukherjee,	Sen,	Biswas,	Barman,	&	Tripathi,	2015).		Clinically,	patients	have	
reported	moderate-to-severe	depression	while	on	a	long-term	antidepressant	treatment	
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regime,	which	may	indicate	desensitisation	in	clinical	cases	(Cartwright,	Gibson,	Read,	
Cowan,	&	Dehar,	2016).				
Mirabegron	 and	 solifenacin	 are	 drugs	 that	 act	 directly	 on	 the	 bladder,	 increasing	
relaxation	 as	 a	 β-adrenoceptor	 agonist	 and	 decreasing	 contraction,	 amongst	 other	
actions,	 as	 an	 M3	 muscarinic	 antagonist	 respectively	 (Abrams	 et	 al.,	 2015).	 	 Unlike	
sertraline,	 mirabegron	 and	 solifenacin	 are	 not	 thought	 to	 directly	 target	 the	 CNS	 to	
reduce	anxiety	and	depression	but	rather	target	the	bladder	directly	to	combat	overactive	
bladder	 symptoms.	 	 Studies	 have	 found	 a	 link	 however,	 between	 targeting	 bladder	
symptoms	and	improving	quality	of	life	with	solifenacin	treatment	(Kelleher	et	al.,	2005),	
and	decreasing	anxiety	symptoms	after	mirabegron	treatment	(Kinjo	et	al.,	2019).		There	
is	evidence	that	these	therapeutics	may	be	targeting	other	areas	of	the	body	as	well	as	
the	bladder.		
Mirabegron,	for	instance,	specifically	targets	β3	receptors	which	are	present	within	the	
brain,	heart	and	throughout	the	gastrointestinal	tract	as	well	as	in	the	bladder	(Dehvari,	
da	 Silva	 Junior,	 Bengtsson,	 &	 Hutchinson,	 2018).	 	 One	 study	 has	 observed	 that	
mirabegron	increases	the	uptake	of	glucose	into	brown	adipose	tissue,	however,	at	the	
dose	of	200mg	per	day,	there	was	adverse	cardiac	effects	within	the	cohort	(Cypess	et	al.,	
2015).	 	The	role	of	β3	adrenoceptors	within	 the	heart	has	 long	been	debated,	but	 it	 is	
known	that	heart	failure	is	induced	by	sustained	activation	of	β1/2	adrenoceptors,	due	to	
increased	 catecholamine	 release	 from	 the	 sympathetic	 nerves	 (Bernstein,	 Fajardo,	 &	
Zhao,	2011).		This	causes	desensitisation	and	internalisation	of	the	receptors	and	loss	of	
contractile	 function	 and	 cardiac	 remodelling	 (Dehvari	 et	 al.,	 2018).	 	 Interestingly,	 the	
expression	of	β3	adrenoceptors	increases	in	rodent	heart	after	prolonged	stimulation	by	
catecholamines	 (Germack	 &	 Dickenson,	 2006)	 and	 during	 cardiac	 disease	 in	 human	
myocardium	(Moniotte	et	al.,	2001).		This	may	be	a	protective	mechanism	for	the	heart	
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under	myocardial	stress	and	stimulation	of	these	receptors	in	mice	has	shown	no	change	
in	 overall	 cardiac	 function	 (Belge	 et	 al.,	 2014).	 	 This	 indicates	 that	 targeting	 of	 β3	
adrenoceptors	may	 be	 beneficial	 in	 treating	 heart	 failure,	 as	 these	 receptors	 are	 not	
desensitised	 after	 prolonged	 agonist	 exposure	 (Dehvari	 et	 al.,	 2018).	 	 A	 clinical	 trial	
observing	left	ventricular	ejection	fractions	(LVEF)	found	that	mirabegron	significantly	
improved	LVEF	 compared	with	patients	 given	a	placebo	 (Bundgaard	et	 al.,	 2017).	 	 In	
terms	 of	 the	 bladder,	 β3	 adrenoceptors	 have	 been	 found	 to	 not	 be	 internalised	 or	
degraded	like	cardiac	β1/2	adrenoceptors	(Dehvari	et	al.,	2018),	but	responses	may	be	
affected	 by	 downregulation	 of	 other	 components	 of	 the	 signalling	 pathway,	 at	 the	
adenylyl	 cyclase	 level	 (Michel-Reher	 &	Michel,	 2013).	 	 Clinically,	 this	means	 that	 the	
features	 of	 β3	 adrenoceptors	 allow	 for	 long	 term	 pharmacological	 stimulation	 with	
limited	adverse	effects	or	risk	of	desensitisation	(Schena	&	Caplan,	2019).	
Solifenacin	may	have	several	tissue	targets	due	to	the	wide	range	of	locations	where	M3	
receptors	are	present.		Studies	have	shown	that	M1	and	M3	receptors	are	present	in	the	
salivary	 gland	 (Culp,	 Luo,	 Richardson,	 Watson,	 &	 Latchney,	 1996),	 while	 only	 M3	 is	
present	in	the	parotid	glands	(Watson	et	al.,	1996).		Salivation	is	therefore	predominately	
mediated	 by	 M3	 receptors	 which	 is	 illustrated	 in	 preclinical	 trials	 which	 have	
demonstrated	 that	 selective	 antagonism	of	M3	 receptors	 inhibits	 salivary	 response	 to	
carbachol	(Ikeda	et	al.,	2002).		Clinical	studies	have	found	that	M3-selective	drugs,	such	
as	solifenacin	appear	to	reduce	salivation,	leading	to	dry	mouth	and	discontinuation	of	
treatment	(Chapple	et	al.,	2005).		Within	the	gut,	M2	receptors	outnumber	M3	receptors,	
but	M3	still	plays	a	prominent	role	in	cholinergic	stimulation	of	gastrointestinal	activity	
(Matsui	et	al.,	2002),	in	a	similar	way	that	M3	receptors	play	a	prominent	role	in	detrusor	
contraction	 within	 the	 bladder	 (Abrams	 et	 al.,	 2006).	 	 Interestingly,	 serotonergic	
receptors	 have	 also	 been	 identified	 within	 the	 gastrointestinal	 tract,	 where	 5-HT4	
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mediates	excitatory	effects	(Gershon,	2003),	which	explains	why	M3	KO	mice,	in	another	
study,	 had	 no	 explicit	 gastrointestinal	 problems	 (Matsui	 et	 al.,	 2000).	 	 There	 is	 also	
evidence	for	expression	of	all	five	muscarinic	subtypes	in	the	brain,	however,	M3	receptor	
expression	is	low	in	the	brain	(Volpicelli	&	Levey,	2004).	 	Similarly,	all	five	muscarinic	
receptor	subtypes	are	present	within	the	eye,	however,	in	contrast	to	the	brain,	M3	is	the	
predominant	 receptor.	 	 Although	 ocular	 events	 have	 been	 reported	 to	 occur	 during	
muscarinic	 receptor	 antagonism,	 the	 selective	 M3	 antagonist,	 darifenacin,	 has	 been	
reported	 to	 cause	 no	 greater	 blurred	 vision	 compared	 to	 the	 less	 selective	 agent,	
oxybutynin	(Zinner,	Tuttle,	&	Marks,	2005).	
When	choosing	a	treatment	for	psychological	stress	and	increased	urinary	frequency,	the	
primary	site	of	action	of	the	drug	would	have	to	be	taken	into	consideration.		As	stated	
above,	 sertraline	 primarily	 acts	 centrally	 before	 having	 downstream	 effects	 on	 the	
bladder,	 which	 is	 evident	 in	 the	 urinary	 frequency	 data,	 where	 frequency	 was	 not	
reduced	 back	 to	 unstressed	 control	 levels,	 as	 was	 observed	 after	 mirabegron	 and	
solifenacin	treatment.		It	is	also	evident	that	all	three	treatments	reduced	the	hormonal	
stress	 response,	 although	 not	 significantly	 so	 for	 mirabegron.	 	 It	 can	 therefore	 be	
concluded	that	environmental	psychological	stress	induces	urinary	frequency	and	that	
the	 best	 available	 treatment	 for	 both	 conditions	 is	 the	 anti-muscarinic	 solifenacin.	 In	
terms	of	managing	voiding	dysfunction	alone,	mirabegron	and	solifenacin	were	equally	
effective	and	superior	to	sertraline.	
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STRENGTHS	AND	LIMITATIONS	
The	experiments	carried	out	in	the	Social	Defeat	model	as	well	as	the	Water	Avoidance	
Model	 demonstrated	 that	 both	 social	 and	 environmental	 stress	 impact	 psychological	
wellbeing	as	well	as	overall	bladder	function.	 	The	Social	Defeat	model,	carried	out	on	
male	 mice,	 caused	 urinary	 retention	 patterns	 and	 while	 this	 is	 a	 disorder	 that	 is	
understood	 to	 be	 prevalent	 within	 the	 community,	 as	 a	 research	 group	 we	 were	
interested	in	the	pathophysiology	of	incontinence	specifically	which	is	why,	after	analysis	
of	both	models,	the	water	avoidance	model	was	chosen.		It	would	be	interesting,	however,	
to	 understand	 more	 thoroughly	 the	 pathophysiology	 of	 psychological	 stress	 induced	
urinary	retention	and	this	model	would	be	beneficial	in	that	area	of	future	study.				
The	limitation	of	only	being	able	to	complete	this	Social	Defeat	model	on	male	mice	also	
impacted	the	overall	thesis	design	as	it	would	have	been	valuable	to	have	the	same	sex	
mice	use	 throughout	 the	experimental	 studies,	 for	continuity.	As	discussed	previously	
however,	there	is	still	discussion	to	be	had	around	the	viability	of	a	female	mouse	social	
defeat	study,	as	typically,	male	mice	are	used	for	their	territorial	nature.		
The	overall	 finding	of	 the	water	 avoidance	drug	model	was	 that	 both	 Solifenacin	 and	
Mirabegron	were	able	to	reduce	both	psychological	stress	indicators	(corticosterone)	as	
well	as	the	incontinent	voiding	pattern	back	to	baseline	urinary	data.		Sertraline	was	also	
efficient	 in	 reducing	 psychological	 stress	 levels,	 however,	 urinary	 symptoms	 of	
incontinence	were	 not	 completely	 recovered	with	 treatment.	 	 Now	 that	 experimental	
work	 is	 complete	 and	 knowing	what	 we	 know	 now,	 it	 may	 be	 useful	 to	 think	 about	
prolonging	 the	Sertraline	 treatment.	 	Typically,	 the	severity	of	anxiety	and	depression	
symptoms	occur	in	‘waves’	and	patients	will	be	on	treatment	for	an	extended	period	of	
time	to	manage	these	symptoms.		If	the	water	avoidance	model	was	to	mimic	typically	
what	occurs	 in	a	human	population,	 I	would	suggest	a	model	 that	extends	 for	 several	
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more	weeks	where	the	mice	undergo	intermittent	periods	of	variant	stress	rather	than	
the	10	continuous	days	that	we	 focused	on.	 	This	may	better	reflect	a	real	 time	stress	
scenario	where	the	bladder	may	be	allowed	to	recover	which	may	provide	interesting	
and	helpful	information	regarding	dosage	and	medication	regimes	required	for	patients	
suffering	from	both	psychological	stress	and	bladder	dysfunction.		
Whole	 bladder	 experiments	 conducted	were	 able	 to	 give	 interesting	 insight	 as	 to	 the	
pathophysiology	behind	that	bladder	dysfunction	we	witnessed	in	the	stressed	mice.	Due	
to	changes	seen	in	mediator	release	and	electrical	field	stimulation,	it	may	be	useful	to	
study	this	change	in	an	afferent	nerve	activity.		In	future	studies	it	may	also	be	interesting	
to	look	into	bladder	histology	which	would	allow	us	to	understand	if	the	psychological	
stress	 or	 drugs	 used	 during	 this	 period,	 produced	 any	 long-term	 change	 within	 the	
bladder	wall	leading	to	dysfunction.	
 
 
CONCLUDING	REMARKS	
As	with	most	scientific	research,	work	in	this	thesis	has	generated	a	number	of	questions	
and	 interesting	 topics	 for	 future	 investigations.	 	 Firstly,	 the	 results	 presented	 here	
support	a	role	for	increased	afferent	nerve	signalling	and	overall	bladder	contractility	as	
a	result	of	psychological	stress.			
Investigations	into	mediator	release	at	lower	levels	of	bladder	distension	would	help	us	
understand	 the	 role	 that	 urothelial	 ATP	 and	 ACh	 are	 playing	 in	 this	 type	 of	 bladder	
dysfunction.	 	 Furthermore,	 investigation	 into	 the	 role	 that	 ACh	 plays	 in	 bladder	
dysfunction	would	provide	a	link	between	the	increased	release	of	this	mediator	and	its	
effect	in	psychological	stress-induced	bladder	dysfunction.			
Very	 little	 information	 is	 available	 on	 the	 long-term	effects	 of	 psychological	 stress	 on	
bladder	dysfunction.		Clinically	this	would	be	relevant	as	psychological	stress	presents	as	
anxiety	and	depression	in	a	human	population	and	these	are	ongoing	disorders	known	to	
repeat	over	a	 long	period	of	 time.	 	 It	would	therefore	be	beneficial	 to	analyse	bladder	
function	 over	 a	 longer	 period	 of	 time,	 where	 psychological	 stress	 is	 introduced	
periodically	 and	 is	more	 representative	of	 the	 life-long	periodic	 stress	 experienced	 in	
humans.		
In	 conclusion,	 this	 thesis	 has	 found	 that	 different	 forms	 of	 psychological	 stress	 cause	
variations	of	bladder	dysfunction.		Water	avoidance	stress	was	associated	with	detrusor	
hypercontractility,	 resulting	 in	 bladder	 overactivity.	 	 The	 impact	 of	 water	 avoidance	
stress	 on	 voiding	 behaviour	 was	 reduced	 equally	 by	 mirabegron	 and	 solifenacin	
treatment	and	both	drugs	were	superior	 to	 the	selective	serotonin	reuptake	 inhibitor,	
sertraline.	
	
	
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
REFERENCES		 	
 
 
249 
Abrams, P., Andersson, K. E., Buccafusco, J. J., Chapple, C., de Groat, W. C., Fryer, A. D., . . . 
Wein, A. J. (2006). Muscarinic receptors: their distribution and function in body 
systems, and the implications for treating overactive bladder. Br J Pharmacol, 148(5), 
565-578. doi:10.1038/sj.bjp.0706780 
Abrams, P., Kelleher, C., Staskin, D., Rechberger, T., Kay, R., Martina, R., . . . Ridder, A. (2015). 
Combination treatment with mirabegron and solifenacin in patients with overactive 
bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, 
phase 2 study (Symphony). Eur Urol, 67(3), 577-588. 
doi:10.1016/j.eururo.2014.02.012 
Abrams, P., Kelleher, C. J., Kerr, L. A., & Rogers, R. G. (2000). Overactive bladder significantly 
affects quality of life. Am J Manag Care, 6(11), S580-S590.  
Adell, A., Celada, P., Abellan, M. T., & Artigas, F. (2002). Origin and functional role of the 
extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev, 39(2-3), 
154-180. doi:10.1016/s0165-0173(02)00182-0 
Aizawa, N., Homma, Y., & Igawa, Y. (2012). Effects of mirabegron, a novel beta3-adrenoceptor 
agonist, on primary bladder afferent activity and bladder microcontractions in rats 
compared with the effects of oxybutynin. Eur Urol, 62(6), 1165-1173. 
doi:10.1016/j.eururo.2012.08.056 
Aizawa, N., Igawa, Y., Nishizawa, O., & Wyndaele, J. J. (2010). Effects of CL316,243, a beta 3-
adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder 
afferent activity of the rat. Neurourol Urodyn, 29(5), 771-776. doi:10.1002/nau.20826 
Albayrak, S., Solmaz, V., Gencden, Y., Firat, F., Oran Demir, M., Aksoy, D., . . . Erdemir, F. 
(2015). Assessment of overactive bladder in women antidepressant users. Int Urol 
Nephrol, 47(9), 1479-1484. doi:10.1007/s11255-015-1054-5 
Alcantara-Montero, A. (2016). Combined treatment of solifenacin and mirabegron, an 
alternative in patients with overactive bladder (BESIDE study). Actas Urol Esp, 40(9), 
593-594. doi:10.1016/j.acuro.2016.03.005 
Alexandre, E. C., Kiguti, L. R., Calmasini, F. B., Silva, F. H., da Silva, K. P., Ferreira, R., . . . 
Antunes, E. (2016). Mirabegron relaxes urethral smooth muscle by a dual mechanism 
involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade. Br J 
Pharmacol, 173(3), 415-428. doi:10.1111/bph.13367 
Anderson, G. M., Barr, C. S., Lindell, S., Durham, A. C., Shifrovich, I., & Higley, J. D. (2005). Time 
course of the effects of the serotonin-selective reuptake inhibitor sertraline on central 
and peripheral serotonin neurochemistry in the rhesus monkey. Psychopharmacology 
(Berl), 178(2-3), 339-346. doi:10.1007/s00213-004-2011-7 
Andersson, K. E. (2017a). Drugs for the overactive bladder: are there differences in 
persistence and compliance? Transl Androl Urol, 6(3), 597-601. 
doi:10.21037/tau.2017.03.90 
Andersson, K. E. (2017b). On the Site and Mechanism of Action of beta3-Adrenoceptor 
Agonists in the Bladder. Int Neurourol J, 21(1), 6-11. doi:10.5213/inj.1734850.425 
Andersson, K. E., & Arner, A. (2004). Urinary bladder contraction and relaxation: physiology 
and pathophysiology. Physiol Rev, 84(3), 935-986. doi:10.1152/physrev.00038.2003 
Andersson, K. E., & McCloskey, K. D. (2014). Lamina propria: the functional center of the 
bladder? Neurourol Urodyn, 33(1), 9-16. doi:10.1002/nau.22465 
Andersson, K. E., & Pehrson, R. (2003). CNS involvement in overactive bladder: 
pathophysiology and opportunities for pharmacological intervention. Drugs, 63(23), 
2595-2611. doi:10.2165/00003495-200363230-00003 
 
 
250 
Apodaca, G., Balestreire, E., & Birder, L. A. (2007). The uroepithelial-associated sensory web. 
Kidney Int, 72(9), 1057-1064. doi:10.1038/sj.ki.5002439 
Arrabal-Polo, M. A., Palao-Yago, F., Campon-Pacheco, I., Martinez-Sanchez, M., Zuluaga-
Gomez, A., & Arrabal-Martin, M. (2012). Clinical efficacy in the treatment of overactive 
bladder refractory to anticholinergics by posterior tibial nerve stimulation. Korean J 
Urol, 53(7), 483-486. doi:10.4111/kju.2012.53.7.483 
Asagloo, S. J., G.; Meftahi, G.; Sahraei, H. (2015). Posttraumatic stress disorder (PTSD): 
mechanisms and possible treatments. Neurophysiology, 47, 7.  
Athanasiou, S., Pitsouni, E., Grigoriadis, T., Zacharakis, D., Salvatore, S., & Serati, M. (2020). 
Mirabegron in female patients with overactive bladder syndrome: What's new? A 
systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol, 251, 73-82. 
doi:10.1016/j.ejogrb.2020.05.018 
Avgustinovich, D. F., Kovalenko, I. L., & Kudryavtseva, N. N. (2005). A model of anxious 
depression: persistence of behavioral pathology. Neurosci Behav Physiol, 35(9), 917-
924. doi:10.1007/s11055-005-0146-6 
Balu, D. T., & Lucki, I. (2009). Adult hippocampal neurogenesis: regulation, functional 
implications, and contribution to disease pathology. Neurosci Biobehav Rev, 33(3), 
232-252. doi:10.1016/j.neubiorev.2008.08.007 
Banerjee, R., Hazra, S., Ghosh, A. K., & Mondal, A. C. (2014). Chronic administration of bacopa 
monniera increases BDNF protein and mRNA expressions: a study in chronic 
unpredictable stress induced animal model of depression. Psychiatry Investig, 11(3), 
297-306. doi:10.4306/pi.2014.11.3.297 
Bano, S., Gitay, M., Ara, I., & Badawy, A. (2010). Acute effects of serotonergic antidepressants 
on tryptophan metabolism and corticosterone levels in rats. Pak J Pharm Sci, 23(3), 
266-272.  
Batista, J. E., Kolbl, H., Herschorn, S., Rechberger, T., Cambronero, J., Halaska, M., . . . Grp, B. 
S. (2015). The efficacy and safety of mirabegron compared with solifenacin in 
overactive bladder patients dissatisfied with previous antimuscarinic treatment due 
to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv 
Urol, 7(4), 167-179. doi:10.1177/1756287215589250 
Beckel, Daugherty, S. L., Tyagi, P., Wolf-Johnston, A. S., Birder, L. A., Mitchell, C. H., & deGroat, 
W. C. (2015). Pannexin 1 channels mediate the release of ATP into the lumen of the 
rat urinary bladder (vol 593, pg 1857, 2015). J Physiol-London, 593(15), 3393-3393. 
doi:10.1113/Jp270812 
Beckel, J., Silberfeld, A., Chavez, B., Gianakas, C., Tandoc, B., & De Groat, W. C. (2018). The 
Urothelium Has Two Distinct Atp Release Mechanisms That Contribute Differently to 
Bladder Function. Neurourol Urodynam, 37, S304-S306.  
Becker, B., Morel, N., Vanbellinghen, A. M., & Lebrun, P. (2004). Blockade of calcium entry in 
smooth muscle cells by the antidepressant imipramine. Biochem Pharmacol, 68(5), 
833-842. doi:10.1016/j.bcp.2004.05.017 
Belge, C., Hammond, J., Dubois-Deruy, E., Manoury, B., Hamelet, J., Beauloye, C., . . . Balligand, 
J. L. (2014). Enhanced Expression of beta 3-Adrenoceptors in Cardiac Myocytes 
Attenuates Neurohormone-Induced Hypertrophic Remodeling Through Nitric Oxide 
Synthase. Circulation, 129(4), 451-462. doi:Doi 10.1161/Circulationaha.113.004940 
Bellucci, C. H. S., Ribeiro, W. D., Hemerly, T. S., de Bessa, J., Antunes, A. A., Leite, K. R. M., . . . 
Gomes, C. M. (2017). Increased detrusor collagen is associated with detrusor 
 
 
251 
overactivity and decreased bladder compliance in men with benign prostatic 
obstruction. Prostate Int, 5(2), 70-74. doi:10.1016/j.prnil.2017.01.008 
Benmansour, S., Owens, W. A., Cecchi, M., Morilak, D. A., & Frazer, A. (2002). Serotonin 
clearance in vivo is altered to a greater extent by antidepressant-induced 
downregulation of the serotonin transporter than by acute blockade of this 
transporter. J Neurosci, 22(15), 6766-6772.  
Berggren, T., Andersson, K. E., Lundin, S., & Uvelius, B. (1993). Effect and content of arginine 
vasopressin in normal and obstructed rat urinary bladder: an in vivo and in vitro 
investigation. J Urol, 150(5 Pt 1), 1540-1543. doi:10.1016/s0022-5347(17)35837-8 
Bernstein, D., Fajardo, G., & Zhao, M. (2011). THE ROLE OF beta-ADRENERGIC RECEPTORS IN 
HEART FAILURE: DIFFERENTIAL REGULATION OF CARDIOTOXICITY AND 
CARDIOPROTECTION. Prog Pediatr Cardiol, 31(1), 35-38. 
doi:10.1016/j.ppedcard.2010.11.007 
Bhatnagar, S., Huber, R., Nowak, N., & Trotter, P. (2002). Lesions of the posterior 
paraventricular thalamus block habituation of hypothalamic-pituitary-adrenal 
responses to repeated restraint. J Neuroendocrinol, 14(5), 403-410. 
doi:10.1046/j.0007-1331.2002.00792.x 
Bikomo, E. O., Ebuehi, O. A. T., & Magbageola, O. A. (2017). Antidepressant activity of ethanol 
leaf extract of annona muricata L., in Sprague-Dawley rats. Am J Biochem, 7(1), 5. 
doi:doi:10.5923/j.ajb.20170701.01 
Bilge, S., Bozkurt, A., Bas, D. B., Aksoz, E., Savli, E., Ilkaya, F., & Kesim, Y. (2008). Chronic 
treatment with fluoxetine and sertraline prevents forced swimming test-induced 
hypercontractility of rat detrusor muscle. Pharmacol Rep, 60(6), 872-879.  
Birder, L., & Andersson, K. E. (2013). Urothelial signaling. Physiol Rev, 93(2), 653-680. 
doi:10.1152/physrev.00030.2012 
Birder, L. A., Barrick, S. R., Roppolo, J. R., Kanai, A. J., de Groat, W. C., Kiss, S., & Buffington, C. 
A. (2003). Feline interstitial cystitis results in mechanical hypersensitivity and altered 
ATP release from bladder urothelium. Am J Physiol Renal Physiol, 285(3), F423-429. 
doi:10.1152/ajprenal.00056.2003 
Birder, L. A., & de Groat, W. C. (2007). Mechanisms of disease: involvement of the urothelium 
in bladder dysfunction. Nat Clin Pract Urol, 4(1), 46-54. doi:10.1038/ncpuro0672 
Birder, L. A., Kanai, A. J., Cruz, F., Moore, K., & Fry, C. H. (2010). Is the Urothelium Intelligent? 
Neurourol Urodynam, 29(4), 598-602. doi:10.1002/nau.20914 
Blanchard, R. J., & Blanchard, D. C. (1977). Aggressive behavior in the rat. Behav Biol, 21(2), 
197-224. doi:10.1016/s0091-6773(77)90308-x 
Borta, A., & Schwarting, R. K. (2005). Inhibitory avoidance, pain reactivity, and plus-maze 
behavior in Wistar rats with high versus low rearing activity. Physiol Behav, 84(3), 387-
396. doi:10.1016/j.physbeh.2005.01.009 
Bourke, C. H., & Neigh, G. N. (2012). Exposure to repeated maternal aggression induces 
depressive-like behavior and increases startle in adult female rats. Behav Brain Res, 
227(1), 270-275. doi:10.1016/j.bbr.2011.11.001 
Bradesi, S., Schwetz, I., Ennes, H. S., Lamy, C. M., Ohning, G., Fanselow, M., . . . Mayer, E. A. 
(2005). Repeated exposure to water avoidance stress in rats: a new model for 
sustained visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol, 289(1), G42-
53. doi:10.1152/ajpgi.00500.2004 
Bradley, C. S. N., I.E.; Hillis, S.L.; Torner, J.C.; Sadler, A.G. (2017). Longitudinal associations 
between mental health conditions and overactive bladder in women veterans. 
 
 
252 
American Journal of Obstetrics and Gynecology, 217(430), 8. 
doi:10.1016/j.ajog.2017.06.016 
Bravo, G., Massa, H., Rose'Meyer, R., Chess-Williams, R., McDermott, C., & Sellers, D. J. (2017). 
Effect of short-term androgen deficiency on bladder contractility and urothelial 
mediator release. N-S Arch Pharmacol, 390(5), 547-556. doi:10.1007/s00210-017-
1355-6 
Breslau, N., Schultz, L., & Peterson, E. (1995). Sex differences in depression: a role for 
preexisting anxiety. Psychiatry Res, 58(1), 1-12. doi:10.1016/0165-1781(95)02765-o 
Buckner, S. A., Milicic, I., Daza, A. V., Coghlan, M. J., & Gopalakrishnan, M. (2002). 
Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics 
and sensitivity to potassium channel modulators. Br J Pharmacol, 135(3), 639-648. 
doi:10.1038/sj.bjp.0704499 
Bugajski, J., Glod, R., Gadek-Michalska, A., & Bugajski, A. J. (2001). Involvement of constitutive 
(COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and 
corticosterone secretion. J Physiol Pharmacol, 52(4 Pt 2), 795-809.  
Bundgaard, H., Axelsson, A., Hartvig Thomsen, J., Sorgaard, M., Kofoed, K. F., Hasselbalch, R., 
. . . Rasmussen, H. H. (2017). The first-in-man randomized trial of a beta3 adrenoceptor 
agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail, 19(4), 566-575. 
doi:10.1002/ejhf.714 
Burke, H. M., Davis, M. C., Otte, C., & Mohr, D. C. (2005). Depression and cortisol responses 
to psychological stress: a meta-analysis. Psychoneuroendocrinology, 30(9), 846-856. 
doi:10.1016/j.psyneuen.2005.02.010 
Burne, T. H., McGrath, J. J., Eyles, D. W., & Mackay-Sim, A. (2005). Behavioural 
characterization of vitamin D receptor knockout mice. Behav Brain Res, 157(2), 299-
308. doi:10.1016/j.bbr.2004.07.008 
Burnstock, G. (2001). Purinergic and Pyrimidinergic Signalling II. Cardiovascular, Respiratory, 
Immune, Metabolic and Gastrointestinal Tract Function. In M. P. W. Abbracchio, M. 
(Ed.), Handbook of Experimental Pharmacology (pp. 423-515). Berlin: Springer. 
Burnstock, G. (2007). Physiology and pathophysiology of purinergic neurotransmission. 
Physiol Rev, 87(2), 659-797. doi:10.1152/physrev.00043.2006 
Burnstock, G. (2013). Purinergic signalling in the urinary tract in health and disease. Purinergic 
Signalling, 10(1). doi:10.1007/s11302-013-9395-y 
Butler, S., Luz, S., McFadden, K., Fesi, J., Long, C., Spruce, L., . . . Zderic, S. (2018). Murine social 
stress results in long lasting voiding dysfunction. Physiol Behav, 183, 10-17. 
doi:10.1016/j.physbeh.2017.09.020 
Candura, S. M., Messori, E., Franceschetti, G. P., D'Agostino, G., Vicini, D., Tagliani, M., & 
Tonini, M. (1996). Neural 5-HT4 receptors in the human isolated detrusor muscle: 
effects of indole, benzimidazolone and substituted benzamide agonists and 
antagonists. Br J Pharmacol, 118(8), 1965-1970. doi:10.1111/j.1476-
5381.1996.tb15631.x 
Caremel, R., Oger-Roussel, S., Behr-Roussel, D., Grise, P., & Giuliano, F. A. (2010). Nitric 
oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on 
sensory pathways of the micturition reflex in the rat. Eur Urol, 58(4), 616-625. 
doi:10.1016/j.eururo.2010.07.026 
Carola, V., D'Olimpio, F., Brunamonti, E., Mangia, F., & Renzi, P. (2002). Evaluation of the 
elevated plus-maze and open-field tests for the assessment of anxiety-related 
 
 
253 
behaviour in inbred mice. Behav Brain Res, 134(1-2), 49-57. doi:10.1016/s0166-
4328(01)00452-1 
Cartwright, C., Gibson, K., Read, J., Cowan, O., & Dehar, T. (2016). Long-term antidepressant 
use: patient perspectives of benefits and adverse effects. Patient Prefer Adher, 10, 
1401-1407. doi:10.2147/Ppa.S110632 
Castro-Diaz, D., Chapple, C. R., Hakimi, Z., Blauwet, M. B., Delgado-Herrera, L., Lau, W., & 
Mujais, S. (2015). The effect of mirabegron on patient-related outcomes in patients 
with overactive bladder: the results of post hoc correlation and responder analyses 
using pooled data from three randomized Phase III trials. Qual Life Res, 24(7), 1719-
1727. doi:10.1007/s11136-014-0904-4 
Celada, P., Puig, M., Amargos-Bosch, M., Adell, A., & Artigas, F. (2004). The therapeutic role 
of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci, 29(4), 252-265.  
Cerit, H., Jans, L. A. W., & Van der Does, W. (2013). The effect of tryptophan on the cortisol 
response to social stress is modulated by the 5-HTTLPR genotype. 
Psychoneuroendocrinology, 38(2), 201-208. doi:10.1016/j.psyneuen.2012.05.016 
Cetinel, S., Ercan, F., Cikler, E., Contuk, G., & Sener, G. (2005). Protective effect of melatonin 
on water avoidance stress induced degeneration of the bladder. J Urol, 173(1), 267-
270. doi:10.1097/01.ju.0000145891.35810.56 
Chaiyaprasithi, B., Mang, C. F., Kilbinger, H., & Hohenfellner, M. (2003). Inhibition of human 
detrusor contraction by a urothelium derived factor. J Urol, 170(5), 1897-1900. 
doi:10.1097/01.ju.0000091870.51841.ae 
Chang, A., Butler, S., Sliwoski, J., Valentino, R., Canning, D., & Zderic, S. (2009). Social stress in 
mice induces voiding dysfunction and bladder wall remodeling. Am J Physiol Renal 
Physiol, 297(4), F1101-1108. doi:10.1152/ajprenal.90749.2008 
Chapple, C., Steers, W., Norton, P., Millard, R., Kralidis, G., Glavind, K., & Abrams, P. (2005). A 
pooled analysis of three phase III studies to investigate the efficacy, tolerability and 
safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment 
of overactive bladder. BJU Int, 95(7), 993-1001. doi:10.1111/j.1464-
410X.2005.05454.x 
Chapple, C. R., Cardozo, L., Nitti, V. W., Siddiqui, E., & Michel, M. C. (2014). Mirabegron in 
overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn, 
33(1), 17-30. doi:10.1002/nau.22505 
Charlton, B. G., McGadey, J., Russell, D., & Neal, D. E. (1992). Noradrenergic innervation of 
the human adrenal cortex as revealed by dopamine-beta-hydroxylase 
immunohistochemistry. J Anat, 180 ( Pt 3), 501-506.  
Chatkoff, D. K., Maier, K. J., & Klein, C. (2010). Nonlinear associations between chronic stress 
and cardiovascular reactivity and recovery. Int J Psychophysiol, 77(2), 150-156. 
doi:10.1016/j.ijpsycho.2010.05.008 
Chaudhury, D., Walsh, J. J., Friedman, A. K., Juarez, B., Ku, S. M., Koo, J. W., . . . Han, M. H. 
(2013). Rapid regulation of depression-related behaviours by control of midbrain 
dopamine neurons. Nature, 493(7433), 532-536. doi:10.1038/nature11713 
Chemical, C. (2018). Corticosterone ELISA Kit (Kit Booklet). from Cayman Chemical 
Cheng, Y., Mansfield, K. J., Allen, W., Chess-Williams, R., Burcher, E., & Moore, K. H. (2014). 
ATP during Early Bladder Stretch Is Important for Urgency in Detrusor Overactivity 
Patients. Biomed Research International, 2014. doi:Artn 
20460410.1155/2014/204604 
 
 
254 
Cheng, Y., Mansfield, K. J., Sandow, S. L., Sadananda, P., Burcher, E., & Moore, K. H. (2011). 
Porcine bladder urothelial, myofibroblast, and detrusor muscle cells: characterization 
and ATP release. Front Pharmacol, 2, 27. doi:10.3389/fphar.2011.00027 
Chess-Williams, R. (2002). Muscarinic receptors of the urinary bladder: detrusor, urothelial 
and prejunctional. Auton Autacoid Pharmacol, 22(3), 133-145.  
Chetty, N., Coupar, I. M., Chess-Williams, R., & Kerr, K. P. (2007). Demonstration of 5-HT3 
receptor function and expression in the mouse bladder. N-S Arch Pharmacol, 375(6), 
359-368. doi:10.1007/s00210-007-0173-7 
Chiba, H., Mitsui, T., Kitta, T., Ohmura, Y., Moriya, K., Kanno, Y., . . . Shinohara, N. (2016). The 
role of serotonergic mechanism in the rat prefrontal cortex for controlling the 
micturition reflex: An in vivo microdialysis study. Neurourol Urodyn, 35(8), 902-907. 
doi:10.1002/nau.22843 
Chilman-Blair, K., & Bosch, J. L. (2004). Solifenacin: treatment of overactive bladder. Drugs 
Today (Barc), 40(4), 343-353. doi:10.1358/dot.2004.40.4.820080 
Choppin, A., & Eglen, R. M. (2001). Pharmacological characterization of muscarinic receptors 
in mouse isolated urinary bladder smooth muscle. Br J Pharmacol, 133(7), 1035-1040. 
doi:10.1038/sj.bjp.0704165 
Clark, M. S., Bond, M. J., & Hecker, J. R. (2007). Environmental stress, psychological stress and 
allostatic load. Psychol Health Med, 12(1), 18-30. doi:10.1080/13548500500429338 
Claustre, Y., Leonetti, M., Santucci, V., Bougault, I., Desvignes, C., Rouquier, L., . . . Steinberg, 
R. (2008). Effects of the beta(3)-adrenoceptor (Adrb3) agonist SR58611A (amibegron) 
on serotonergic and noradrenergic transmission in the rodent: Relevance to its anti 
depressant/anxiolytic-like profile. Neuroscience, 156(2), 353-364. 
doi:10.1016/j.neuroscience.2008.07.011 
Cohen, I., & Tromba, C. (1989). Inactivation of Ik1 in Isolated Canine Purkinje Myocytes Is 
Induced by Isoprenaline but Not Blocked by Propranolol. J Physiol-London, 418, P40-
P40.  
Cohen, S., Gianaros, P. J., & Manuck, S. B. (2016). A Stage Model of Stress and Disease. 
Perspect Psychol Sci, 11(4), 456-463. doi:10.1177/1745691616646305 
Conley, R. K., Li, J., Ivarsson, M., & Hutson, P. H. (2007). Effect of the beta 3 adrenoceptor 
agonist CL 316243 on hypothalamic 5-HT synthesis and suppression of REM steep in 
the rat. J Psychopharmacol, 21(6), 597-602. doi:10.1177/0269881106070424 
Coyne, K. S., Sexton, C. C., Vats, V., Thompson, C., Kopp, Z. S., & Milsom, I. (2011). National 
community prevalence of overactive bladder in the United States stratified by sex and 
age. Urology, 77(5), 1081-1087. doi:10.1016/j.urology.2010.08.039 
Culp, D. J., Luo, W., Richardson, L. A., Watson, G. E., & Latchney, L. R. (1996). Both M1 and M3 
receptors regulate exocrine secretion by mucous acini. Am J Physiol, 271(6 Pt 1), 
C1963-1972. doi:10.1152/ajpcell.1996.271.6.C1963 
Cypess, A. M., Weiner, L. S., Roberts-Toler, C., Franquet Elia, E., Kessler, S. H., Kahn, P. A., . . . 
Kolodny, G. M. (2015). Activation of human brown adipose tissue by a beta3-
adrenergic receptor agonist. Cell Metab, 21(1), 33-38. 
doi:10.1016/j.cmet.2014.12.009 
D'Agostino, G., Condino, A. M., Gallinari, P., Franceschetti, G. P., & Tonini, M. (2006). 
Characterization of prejunctional serotonin receptors modulating [3H]acetylcholine 
release in the human detrusor. J Pharmacol Exp Ther, 316(1), 129-135. 
doi:10.1124/jpet.105.092551 
 
 
255 
Daly, D. M., Chess-Williams, R., Chapple, C., & Grundy, D. (2010). The inhibitory role of 
acetylcholine and muscarinic receptors in bladder afferent activity. Eur Urol, 58(1), 22-
28; discussion 31-22. doi:10.1016/j.eururo.2009.12.030 
Daly, D. M., Nocchi, L., Liaskos, M., McKay, N. G., Chapple, C., & Grundy, D. (2014). Age-related 
changes in afferent pathways and urothelial function in the male mouse bladder. J 
Physiol, 592(3), 537-549. doi:10.1113/jphysiol.2013.262634 
Davila, G. W., Bernier, F., Franco, J., & Kopka, S. L. (2003). Bladder dysfunction in sexual abuse 
survivors. J Urol, 170(2 Pt 1), 476-479. doi:10.1097/01.ju.0000070439.49457.d9 
de Godoy, M. A., & Rattan, S. (2011). Role of rho kinase in the functional and dysfunctional 
tonic smooth muscles. Trends Pharmacol Sci, 32(7), 384-393. 
doi:10.1016/j.tips.2011.03.005 
De Groat, W. C., & Ryall, R. W. (1967). An excitatory action 0f 5-hydroxytryptamine on 
sympathetic preganglionic neurones. Exp Brain Res, 3(4), 299-305. 
doi:10.1007/BF00237556 
de Kloet, E. R. (2000). Stress in the brain. Eur J Pharmacol, 405(1-3), 187-198.  
de Kloet, E. R., Oitzl, M. S., & Joels, M. (1999). Stress and cognition: are corticosteroids good 
or bad guys? Trends Neurosci, 22(10), 422-426.  
Deak, F., Lasztoczi, B., Pacher, P., Petheo, G. L., Valeria, K., & Spat, A. (2000). Inhibition of 
voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. 
Neuropharmacology, 39(6), 1029-1036. doi:10.1016/s0028-3908(99)00206-3 
Dehvari, N., da Silva Junior, E. D., Bengtsson, T., & Hutchinson, D. S. (2018). Mirabegron: 
potential off target effects and uses beyond the bladder. Br J Pharmacol, 175(21), 
4072-4082. doi:10.1111/bph.14121 
DeLamater, J. D., & Ward, A. (2013). Handbook of social psychology (Second edition. ed.). 
Dordrecht ; New York: Springer. 
Deloitte Access Economics. (2011). The Economic Impact of Incontinence in Australia. 
Retrieved from ACT, Australia: www.deloitte.com/au/economics 
Denboer, J. A., Westenberg, H. G. M., Deleeuw, A. S., & Vanvliet, I. M. (1995). Biological 
Dissection of Anxiety Disorders - the Clinical Role of Selective Serotonin Reuptake 
Inhibitors with Particular Reference to Fluvoxamine. Int Clin Psychopharm, 9, 47-52. 
doi:Doi 10.1097/00004850-199501004-00007 
Di Rosso, M. E., Sterle, H. A., Cremaschi, G. A., & Genaro, A. M. (2018). Beneficial Effect of 
Fluoxetine and Sertraline on Chronic Stress-Induced Tumor Growth and Cell 
Dissemination in a Mouse Model of Lymphoma: Crucial Role of Antitumor Immunity. 
Front Immunol, 9, 1341. doi:10.3389/fimmu.2018.01341 
Dombrowski, K. E., Ke, Y., Brewer, K. A., & Kapp, J. A. (1998). Ecto-ATPase: an activation 
marker necessary for effector cell function. Immunol Rev, 161, 111-118. 
doi:10.1111/j.1600-065x.1998.tb01575.x 
Domin, H., Szewczyk, B., Wozniak, M., Wawrzak-Wlecial, A., & Smialowska, M. (2014). 
Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial 
degeneration model of depression. Behav Brain Res, 273, 23-33. 
doi:10.1016/j.bbr.2014.07.019 
Dou, X., Tian, X., Zheng, Y., Huang, J., Shen, Z., Li, H., . . . Shen, H. (2014). Psychological stress 
induced hippocampus zinc dyshomeostasis and depression-like behavior in rats. 
Behav Brain Res, 273, 133-138. doi:10.1016/j.bbr.2014.07.040 
 
 
256 
Drake, M. J., Fry, C. H., Hashitani, H., Kirschner-Hermanns, R., Rahnama'i, M. S., Speich, J. E., . 
. . McCloskey, K. D. (2018). What are the origins and relevance of spontaneous bladder 
contractions? ICI-RS 2017. Neurourol Urodynam, 37, S13-S19. doi:10.1002/nau.23485 
Drake, M. J., Kanai, A., Bijos, D. A., Ikeda, Y., Zabbarova, I., Vahabi, B., & Fry, C. H. (2017). The 
potential role of unregulated autonomous bladder micromotions in urinary storage 
and voiding dysfunction; overactive bladder and detrusor underactivity. BJU Int, 
119(1), 22-29. doi:10.1111/bju.13598 
Drew, J. S., & Murphy, R. A. (1997). Actin isoform expression, cellular heterogeneity, and 
contractile function in smooth muscle. Can J Physiol Pharmacol, 75(7), 869-877.  
Duckett, J. R., Hall, S., & Woodward, A. (1998). A medium term analysis of the subjective 
efficacy of treatment for women with detrusor instability and low bladder compliance. 
Br J Obstet Gynaecol, 105(12), 1337. doi:10.1111/j.1471-0528.1998.tb10024.x 
Duman, R. S., & Voleti, B. (2012). Signaling pathways underlying the pathophysiology and 
treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci, 
35(1), 47-56. doi:10.1016/j.tins.2011.11.004 
Eastham, J., Stephenson, C., Korstanje, K., & Gillespie, J. I. (2015). The expression of beta3-
adrenoceptor and muscarinic type 3 receptor immuno-reactivity in the major pelvic 
ganglion of the rat. Naunyn Schmiedebergs Arch Pharmacol, 388(7), 695-708. 
doi:10.1007/s00210-015-1122-5 
Edwards, A. V., & Jones, C. T. (1993). Autonomic control of adrenal function. J Anat, 183 ( Pt 
2), 291-307.  
Ehlert, F. J., Ostrom, R. S., & Sawyer, G. W. (1997). Subtypes of the muscarinic receptor in 
smooth muscle. Life Sci, 61(18), 1729-1740. doi:10.1016/s0024-3205(97)00433-5 
Espey, M. J., Downie, J. W., & Fine, A. (1992). Effect of 5-HT receptor and adrenoceptor 
antagonists on micturition in conscious cats. Eur J Pharmacol, 221(1), 167-170. 
doi:10.1016/0014-2999(92)90788-6 
Espey, M. J., Du, H. J., & Downie, J. W. (1998). Serotonergic modulation of spinal ascending 
activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res, 
798(1-2), 101-108. doi:10.1016/s0006-8993(98)00401-6 
Faria, R., Santana, M. M., Aveleira, C. A., Simoes, C., Maciel, E., Melo, T., . . . Domingues, M. 
R. (2014). Alterations in phospholipidomic profile in the brain of mouse model of 
depression induced by chronic unpredictable stress. Neuroscience, 273, 1-11. 
doi:10.1016/j.neuroscience.2014.04.042 
Farr, S. E. (2015). Intravesical gemcitabine treatment: repercussions on normal bladder 
function. (Doctor of Philosphy by Research). Bond University, Robina, QLD.  
Flak, J. N., Solomon, M. B., Jankord, R., Krause, E. G., & Herman, J. P. (2012). Identification of 
chronic stress-activated regions reveals a potential recruited circuit in rat brain. Eur J 
Neurosci, 36(4), 2547-2555. doi:10.1111/j.1460-9568.2012.08161.x 
Foertsch, S., Fuchsl, A. M., Faller, S. D., Holzer, H., Langgartner, D., Messmann, J., . . . Reber, 
S. O. (2017). Splenic glucocorticoid resistance following psychosocial stress requires 
physical injury. Sci Rep, 7(1), 15730. doi:10.1038/s41598-017-15897-2 
Folasire, O. S., Chess-Williams, R., & Sellers, D. J. (2017). Inhibitory effect of the 
urothelium/lamina propria on female porcine urethral contractility & effect of age. 
Clin Exp Pharmacol Physiol, 44(9), 954-960. doi:10.1111/1440-1681.12779 
Fontella, F. U., Bruno, A. N., Crema, L. M., Battastini, A. M., Sarkis, J. J., Netto, C. A., & Dalmaz, 
C. (2004). Acute and chronic stress alter ecto-nucleotidase activities in synaptosomes 
 
 
257 
from the rat hippocampus. Pharmacol Biochem Behav, 78(2), 341-347. 
doi:10.1016/j.pbb.2004.04.005 
Fowler, C. J., Griffiths, D., & de Groat, W. C. (2008). The neural control of micturition. Nat Rev 
Neurosci, 9(6), 453-466. doi:10.1038/nrn2401 
Frazier, E. P., Peters, S. L., Braverman, A. S., Ruggieri, M. R., Sr., & Michel, M. C. (2008). Signal 
transduction underlying the control of urinary bladder smooth muscle tone by 
muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch 
Pharmacol, 377(4-6), 449-462. doi:10.1007/s00210-007-0208-0 
Freeman, R., Foley, S., Rosa Arias, J., Vicente, E., Grill, R., Kachlirova, Z., . . . Choudhury, N. 
(2018). Mirabegron improves quality-of-life, treatment satisfaction, and persistence 
in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-
month study. Curr Med Res Opin, 34(5), 785-793. 
doi:10.1080/03007995.2017.1419170 
Frizzo, M. E. (2017). Can a Selective Serotonin Reuptake Inhibitor Act as a Glutamatergic 
Modulator? Curr Ther Res Clin E, 87, 9-12. doi:10.1016/j.curtheres.2017.07.001 
Fry, C. H., Meng, E., & Young, J. S. (2010). The physiological function of lower urinary tract 
smooth muscle. Auton Neurosci, 154(1-2), 3-13. doi:10.1016/j.autneu.2009.10.006 
Fry, C. H., & Vahabi, B. (2016). The Role of the Mucosa in Normal and Abnormal Bladder 
Function. Basic Clin Pharmacol Toxicol, 119 Suppl 3, 57-62. doi:10.1111/bcpt.12626 
Gandhi, D., Molotkov, A., Batourina, E., Schneider, K., Dan, H., Reiley, M., . . . Mendelsohn, C. 
(2013). Retinoid signaling in progenitors controls specification and regeneration of the 
urothelium. Dev Cell, 26(5), 469-482. doi:10.1016/j.devcel.2013.07.017 
Gao, Y., Zhang, R., Chang, H. H., & Rodriguez, L. V. (2018). The role of C-fibers in the 
development of chronic psychological stress induced enhanced bladder sensations 
and nociceptive responses: A multidisciplinary approach to the study of urologic 
chronic pelvic pain syndrome (MAPP) research network study. Neurourol Urodyn, 
37(2), 673-680. doi:10.1002/nau.23374 
Germack, R., & Dickenson, J. M. (2006). Induction of beta3-adrenergic receptor functional 
expression following chronic stimulation with noradrenaline in neonatal rat 
cardiomyocytes. J Pharmacol Exp Ther, 316(1), 392-402. doi:10.1124/jpet.105.090597 
Gershon, M. D. (2003). Serotonin and its implication for the management of irritable bowel 
syndrome. Rev Gastroenterol Disord, 3 Suppl 2, S25-34.  
Gillespie, J. I., Palea, S., Guilloteau, V., Guerard, M., Lluel, P., & Korstanje, C. (2012). 
Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and 
the beta(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow 
obstruction. Bju International, 110(2b), E132-E142. doi:10.1111/j.1464-
410X.2012.11240.x 
Giorgetti, M., & Tecott, L. H. (2004). Contributions of 5-HT(2C) receptors to multiple actions 
of central serotonin systems. Eur J Pharmacol, 488(1-3), 1-9. 
doi:10.1016/j.ejphar.2004.01.036 
Golden, S. A., Covington, H. E., 3rd, Berton, O., & Russo, S. J. (2011). A standardized protocol 
for repeated social defeat stress in mice. Nat Protoc, 6(8), 1183-1191. 
doi:10.1038/nprot.2011.361 
Golden, S. A., Covington, H. E., 3rd, Berton, O., & Russo, S. J. (2015). Corrigendum: a 
standardized protocol for repeated social defeat stress in mice. Nat Protoc, 10(4), 643. 
doi:10.1038/nprot0415-644a 
 
 
258 
Goldstein, D. S. (2010). Adrenal responses to stress. Cell Mol Neurobiol, 30(8), 1433-1440. 
doi:10.1007/s10571-010-9606-9 
Gordan, R., Gwathmey, J. K., & Xie, L. H. (2015). Autonomic and endocrine control of 
cardiovascular function. World J Cardiol, 7(4), 204-214. doi:10.4330/wjc.v7.i4.204 
Gould, T. D. D., D.T.; Kovacsics, C.E. (2009). The Open Field Test. In Mood and Anxiety Related 
Phenotypes in Mice (Vol. 42, pp. 1-20). Totowa, New Jersey: Humana Press. 
Goulooze, S. C., Cohen, A. F., & Rissmann, R. (2015). Mirabegron. Br J Clin Pharmacol, 80(4), 
762-764. doi:10.1111/bcp.12647 
Goya, R. G., Castro, M. G., Hannah, M. J., Sosa, Y. E., & Lowry, P. J. (1993). Thymosin peptides 
stimulate corticotropin release by a calcium-dependent mechanism. 
Neuroendocrinology, 57(2), 230-235. doi:10.1159/000126364 
Gray, N. A., Milak, M. S., DeLorenzo, C., Ogden, R. T., Huang, Y. Y., Mann, J. J., & Parsey, R. V. 
(2013). Antidepressant treatment reduces serotonin-1A autoreceptor binding in 
major depressive disorder. Biol Psychiatry, 74(1), 26-31. 
doi:10.1016/j.biopsych.2012.11.012 
Grissom, N., & Bhatnagar, S. (2009). Habituation to repeated stress: Get used to it. Neurobiol 
Learn Mem, 92(2), 215-224. doi:10.1016/j.nlm.2008.07.001 
Groen-Wijnberg, M., van Dijk, J., Krauwinkel, W., Kerbusch, V., Meijer, J., Tretter, R., . . . van 
Gelderen, M. (2017). Pharmacokinetic Interactions Between Mirabegron and 
Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Eur J Drug Metab Ph, 
42(3), 417-429. doi:10.1007/s13318-016-0350-5 
Gruene, T. M., Flick, K., Stefano, A., Shea, S. D., & Shansky, R. M. (2015). Sexually divergent 
expression of active and passive conditioned fear responses in rats. Elife, 4. 
doi:10.7554/eLife.11352 
Haab, F., Cardozo, L., Chapple, C., & Ridder, A. M. (2005). Long-term open-label solifenacin 
treatment associated with persistence with therapy in patients with overactive 
bladder syndrome. Eur Urol, 47(3), 376-384. doi:10.1016/j.eururo.2004.11.004 
Hadjian, A. J., Guidicelli, C., & Chambaz, E. M. (1982). Cholinergic muscarinic stimulation of 
steroidogenesis in bovine adrenal cortex fasciculata cell suspensions. Biochim Biophys 
Acta, 714(1), 157-163. doi:10.1016/0304-4165(82)90138-6 
Haferkamp, A., Dorsam, J., Resnick, N. M., Yalla, S. V., & Elbadawi, A. (2003). Structural basis 
of neurogenic bladder dysfunction. II. Myogenic basis of detrusor hyperreflexia. J Urol, 
169(2), 547-554. doi:10.1097/01.ju.0000042667.26782.c7 
Haller, J., Fuchs, E., Halasz, J., & Makara, G. B. (1999). Defeat is a major stressor in males while 
social instability is stressful mainly in females: Towards the development of a social 
stress model in female rats. Brain Res Bull, 50(1), 33-39. doi:Doi 10.1016/S0361-
9230(99)00087-8 
Han, D. Y., Jeong, H. J., & Lee, M. Y. (2015). Bladder Hyperactivity Induced by Chronic Variable 
Stress in Rats. Luts, 7(1), 56-61. doi:10.1111/luts.12048 
Hanna-Mitchell, A. T., Beckel, J. M., Barbadora, S., Kanai, A. J., de Groat, W. C., & Birder, L. A. 
(2007). Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci, 80(24-
25), 2298-2302. doi:10.1016/j.lfs.2007.02.010 
Harris, A. Z., Atsak, P., Bretton, Z. H., Holt, E. S., Alam, R., Morton, M. P., . . . Gordon, J. A. 
(2018). A Novel Method for Chronic Social Defeat Stress in Female Mice. 
Neuropsychopharmacology, 43(6), 1276-1283. doi:10.1038/npp.2017.259 
 
 
259 
Hashitani, H., Fukuta, H., Takano, H., Klemm, M. F., & Suzuki, H. (2001). Origin and 
propagation of spontaneous excitation in smooth muscle of the guinea-pig urinary 
bladder. J Physiol, 530(Pt 2), 273-286. doi:10.1111/j.1469-7793.2001.0273l.x 
Hassan, A. M., Jain, P., Reichmann, F., Mayerhofer, R., Farzi, A., Schuligoi, R., & Holzer, P. 
(2014). Repeated predictable stress causes resilience against colitis-induced 
behavioral changes in mice. Front Behav Neurosci, 8, 386. 
doi:10.3389/fnbeh.2014.00386 
Hattori, T., Lluel, P., Rouget, C., Rekik, M., & Yoshiyama, M. (2017). Ketanserin and Naftopidil 
Enhance the Potentiating Effect of Alpha-Methyl-Serotonin on the Neurally-Induced 
Contraction of Human Isolated Urinary Bladder Muscle Strips. Int Neurourol J, 21(1), 
20-28. doi:10.5213/inj.1732758.379 
Hawthorn, M. H., Chapple, C. R., Cock, M., & Chess-Williams, R. (2000). Urothelium-derived 
inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol, 
129(3), 416-419. doi:10.1038/sj.bjp.0703068 
Hayase, M., Hashitani, H., Kohri, K., & Suzuki, H. (2009). Role of K+ channels in regulating 
spontaneous activity in detrusor smooth muscle in situ in the mouse bladder. J Urol, 
181(5), 2355-2365. doi:10.1016/j.juro.2009.01.013 
Haylen, B. T., de Ridder, D., Freeman, R. M., Swift, S. E., Berghmans, B., Lee, J., . . . Schaer, G. 
N. (2010). An International Urogynecological Association (IUGA)/International 
Continence Society (ICS) joint report on the terminology for female pelvic floor 
dysfunction. Int Urogynecol J, 21(1), 5-26. doi:10.1007/s00192-009-0976-9 
Hegde, S. S., Mandel, D. A., Wilford, M. R., Briaud, S., Ford, A. P., & Eglen, R. M. (1998). 
Evidence for purinergic neurotransmission in the urinary bladder of pithed rats. Eur J 
Pharmacol, 349(1), 75-82.  
Helton, L. A., Thor, K. B., & Baez, M. (1994). 5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 
and 5-hydroxytryptamine2C receptor mRNA expression in the spinal cord of rat, cat, 
monkey and human. Neuroreport, 5(18), 2617-2620. doi:10.1097/00001756-
199412000-00053 
Hemrick-Luecke, S. K., Bymaster, F. P., Evans, D. C., Wess, J., & Felder, C. C. (2002). Muscarinic 
agonist-mediated increases in serum corticosterone levels are abolished in m(2) 
muscarinic acetylcholine receptor knockout mice. J Pharmacol Exp Ther, 303(1), 99-
103. doi:10.1124/jpet.102.036020 
Heppner, T. J., Werner, M. E., Nausch, B., Vial, C., Evans, R. J., & Nelson, M. T. (2009). Nerve-
evoked purinergic signalling suppresses action potentials, Ca2+ flashes and 
contractility evoked by muscarinic receptor activation in mouse urinary bladder 
smooth muscle. J Physiol, 587(Pt 21), 5275-5288. doi:10.1113/jphysiol.2009.178806 
Herman, J. P. (2013). Neural control of chronic stress adaptation. Front Behav Neurosci, 7, 61. 
doi:10.3389/fnbeh.2013.00061 
Hickling, D. R., Sun, T. T., & Wu, X. R. (2015). Anatomy and Physiology of the Urinary Tract: 
Relation to Host Defense and Microbial Infection. Microbiol Spectr, 3(4). 
doi:10.1128/microbiolspec.UTI-0016-2012 
Hiemke, C., & Hartter, S. (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. 
Pharmacol Ther, 85(1), 11-28. doi:10.1016/s0163-7258(99)00048-0 
Hill, W. G. (2015). Control of urinary drainage and voiding. Clin J Am Soc Nephrol, 10(3), 480-
492. doi:10.2215/CJN.04520413 
 
 
260 
Hillelsohn, J. H., Rais-Bahrami, S., Bagadiya, N., Kashan, M., & Weiss, G. H. (2013). Use of 
Desipramine for the Treatment of Overactive Bladder Refractory to Antimuscarinic 
Therapy. Urol J, 10(4), 1114-1118.  
Hillhouse, T. M., & Porter, J. H. (2015). A brief history of the development of antidepressant 
drugs: from monoamines to glutamate. Exp Clin Psychopharmacol, 23(1), 1-21. 
doi:10.1037/a0038550 
Hodes, G. E., Pfau, M. L., Purushothaman, I., Ahn, H. F., Golden, S. A., Christoffel, D. J., . . . 
Russo, S. J. (2015). Sex Differences in Nucleus Accumbens Transcriptome Profiles 
Associated with Susceptibility versus Resilience to Subchronic Variable Stress. J 
Neurosci, 35(50), 16362-16376. doi:10.1523/JNEUROSCI.1392-15.2015 
Hollis, F., & Kabbaj, M. (2014). Social Defeat as an Animal Model for Depression. Ilar Journal, 
55(2), 221-232. doi:10.1093/ilar/ilu002 
Holsboer, F. (2001). Stress, hypercortisolism and corticosteroid receptors in depression: 
implications for therapy. J Affect Disord, 62(1-2), 77-91. doi:10.1016/s0165-
0327(00)00352-9 
Huang, G. J., & Herbert, J. (2005). Serotonin modulates the suppressive effects of 
corticosterone on proliferating progenitor cells in the dentate gyrus of the 
hippocampus in the adult rat. Neuropsychopharmacology, 30(2), 231-241. 
doi:10.1038/sj.npp.1300609 
Igawa, Y., & Michel, M. C. (2013). Pharmacological profile of beta(3)-adrenoceptor agonists in 
clinical development for the treatment of overactive bladder syndrome. N-S Arch 
Pharmacol, 386(3), 177-183. doi:10.1007/s00210-012-0824-1 
Ikeda, K., Kobayashi, S., Suzuki, M., Miyata, K., Takeuchi, M., Yamada, T., & Honda, K. (2002). 
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary 
bladder and salivary gland. N-S Arch Pharmacol, 366(2), 97-103. doi:10.1007/s00210-
002-0554-x 
Inaba, M., Ukimura, O., Yaoi, T., Kawauchi, A., Fushiki, S., & Miki, T. (2007). Upregulation of 
heme oxygenase and collagen type III in the rat bladder after partial bladder outlet 
obstruction. Urol Int, 78(3), 270-277. doi:10.1159/000099351 
Inoue, M., Kitazawa, T., Cao, J., & Taneike, T. (2003). 5-HT7 receptor-mediated relaxation of 
the oviduct in nonpregnant proestrus pigs. Eur J Pharmacol, 461(2-3), 207-218. 
doi:10.1016/s0014-2999(03)01312-8 
Joels, M., Fernandez, G., & Roozendaal, B. (2011). Stress and emotional memory: a matter of 
timing. Trends Cogn Sci, 15(6), 280-288. doi:10.1016/j.tics.2011.04.004 
Kalyoncu, N. I., Ozyavuz, R., & Karaoglu, S. (1999). Sertraline inhibits the contractile responses 
to noradrenaline, KCl and electrical field stimulation of rat isolated vas deferens. J 
Auton Pharmacol, 19(6), 365-369. doi:DOI 10.1111/j.1365-2680.1999.tb00010.x 
Kanai, A., & Andersson, K. E. (2010). Bladder afferent signaling: recent findings. J Urol, 183(4), 
1288-1295. doi:10.1016/j.juro.2009.12.060 
Kanai, A., Roppolo, J., Ikeda, Y., Zabbarova, I., Tai, C., Birder, L., . . . Fry, C. (2007). Origin of 
spontaneous activity in neonatal and adult rat bladders and its enhancement by 
stretch and muscarinic agonists. Am J Physiol Renal Physiol, 292(3), F1065-1072. 
doi:10.1152/ajprenal.00229.2006 
Kanie, S., Yokoyama, O., Komatsu, K., Kodama, K., Yotsuyanagi, S., Niikura, S., . . . Namiki, M. 
(2000). GABAergic contribution to rat bladder hyperactivity after middle cerebral 
artery occlusion. Am J Physiol Regul Integr Comp Physiol, 279(4), R1230-1238. 
doi:10.1152/ajpregu.2000.279.4.R1230 
 
 
261 
Kay, G., Crook, T., Rekeda, L., Lima, R., Ebinger, U., Arguinzoniz, M., & Steel, M. (2006). 
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on 
memory in older subjects. Eur Urol, 50(2), 317-326. doi:10.1016/j.eururo.2006.03.057 
Keane, D. P., & O'Sullivan, S. (2000). Urinary incontinence: anatomy, physiology and 
pathophysiology. Baillieres Best Pract Res Clin Obstet Gynaecol, 14(2), 207-226.  
Keeney, A., Jessop, D. S., Harbuz, M. S., Marsden, C. A., Hogg, S., & Blackburn-Munro, R. E. 
(2006). Differential effects of acute and chronic social defeat stress on hypothalamic-
pituitary-adrenal axis function and hippocampal serotonin release in mice. J 
Neuroendocrinol, 18(5), 330-338. doi:10.1111/j.1365-2826.2006.01422.x 
Keeney, A. J., & Hogg, S. (1999). Behavioural consequences of repeated social defeat in the 
mouse: preliminary evaluation of a potential animal model of depression. Behav 
Pharmacol, 10(8), 753-764. doi:10.1097/00008877-199912000-00007 
Kelleher, C. J., Cardozo, L., Chapple, C. R., Haab, F., & Ridder, A. M. (2005). Improved quality 
of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int, 
95(1), 81-85. doi:10.1111/j.1464-410X.2004.05255.x 
Kessler, R. C., Sonnega, A., Bromet, E., Hughes, M., & Nelson, C. B. (1995). Posttraumatic stress 
disorder in the National Comorbidity Survey. Arch Gen Psychiatry, 52(12), 1048-1060. 
doi:10.1001/archpsyc.1995.03950240066012 
Khaled, S. M., & Elhilali, M. (2003). Role of 5-HT receptors in treatment of overactive bladder. 
Drugs Today (Barc), 39(8), 599-607. doi:10.1358/dot.2003.39.8.799407 
Khansari, D. N., Murgo, A. J., & Faith, R. E. (1990). Effects of stress on the immune system. 
Immunol Today, 11(5), 170-175.  
Kim, Y., Yoshimura, N., Masuda, H., de Miguel, F., & Chancellor, M. B. (2005). Antimuscarinic 
agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent 
pathways. Urology, 65(2), 238-242. doi:10.1016/j.urology.2004.11.021 
Kinjo, M., Yamaguchi, T., Tambo, M., Okegawa, T., & Fukuhara, H. (2019). Effects of 
Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder. 
Urol Int, 102(3), 331-335. doi:10.1159/000497282 
Kinzig, K. P., D'Alessio, D. A., Herman, J. P., Sakai, R. R., Vahl, T. P., Figueiredo, H. F., . . . Seeley, 
R. J. (2003). CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety 
responses to interoceptive and psychogenic stressors. J Neurosci, 23(15), 6163-6170.  
Klarskov, P., & Horby-Petersen, J. (1986). Influence of serotonin on lower urinary tract smooth 
muscle in vitro. Br J Urol, 58(5), 507-513. doi:10.1111/j.1464-410x.1986.tb05456.x 
Kleitman, N., & Holzwarth, M. A. (1985). Catecholaminergic innervation of the rat adrenal 
cortex. Cell Tissue Res, 241(1), 139-147. doi:10.1007/BF00214635 
Knight, G. E., Bodin, P., De Groat, W.C., & Burnstock, G. (2002). ATP is released from guinea 
pig ureter epithelium on distension. American Journal of Physiology 282(2). 
doi:10.1152/ajprenal.00293.2000 
Kobayter, S., Young, J. S., & Brain, K. L. (2012). Prostaglandin E2 induces spontaneous rhythmic 
activity in mouse urinary bladder independently of efferent nerves. Br J Pharmacol, 
165(2), 401-413. doi:10.1111/j.1476-5381.2011.01543.x 
Konthapakdee, N., Grundy, L., O'Donnell, T., Garcia-Caraballo, S., Brierley, S. M., Grundy, D., 
& Daly, D. M. (2019). Serotonin exerts a direct modulatory role on bladder afferent 
firing in mice. J Physiol, 597(21), 5247-5264. doi:10.1113/JP278751 
Konturek, P. C., Brzozowski, T., & Konturek, S. J. (2011). Stress and the gut: pathophysiology, 
clinical consequences, diagnostic approach and treatment options. J Physiol 
Pharmacol, 62(6), 591-599.  
 
 
262 
Krauwinkel, W., van Dijk, J., Schaddelee, M., Eltink, C., Meijer, J., Strabach, G., . . . van 
Gelderen, M. (2012). Pharmacokinetic properties of mirabegron, a beta3-
adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in 
healthy young and elderly men and women. Clin Ther, 34(10), 2144-2160. 
doi:10.1016/j.clinthera.2012.09.010 
Krishnan, V., Han, M. H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., . . . Nestler, E. J. 
(2007). Molecular adaptations underlying susceptibility and resistance to social defeat 
in brain reward regions. Cell, 131(2), 391-404. doi:10.1016/j.cell.2007.09.018 
Kullmann, F. A., Downs, T. R., Artim, D. E., Limberg, B. J., Shah, M., Contract, D., . . . 
Rosenbaum, J. S. (2011). Urothelial Beta-3 Adrenergic Receptors in the Rat Bladder. 
Neurourol Urodynam, 30(1), 144-150. doi:10.1002/nau.20965 
Kushida, N., & Fry, C. H. (2016). On the origin of spontaneous activity in the bladder. BJU Int, 
117(6), 982-992. doi:10.1111/bju.13240 
Kushner, L., Mathrubutham, M., Burney, T., Greenwald, R., & Badlani, G. (2004). Excretion of 
collagen derived peptides is increased in women with stress urinary incontinence. 
Neurourol Urodynam, 23(3), 198-203. doi:10.1002/nau.10174 
Lagou, M., Gillespie, J. I., Andersson, K. E., Kirkwood, T., & Drake, M. J. (2006). Bladder volume 
alters cholinergic responses of the isolated whole mouse bladder. J Urol, 175(2), 771-
776. doi:10.1016/S0022-5347(05)00140-0 
Lai, H., ; Gardner, V.; Vetter, J. & Andriole, G.L. (2015). Correlation between psychological 
stress levels and the severity of overactive bladder symptoms. BMC Urology, 15(14). 
doi:10.1186/s12894-015-0009-6 
Lai, H. H., Morgan, C. D., Vetter, J., & Andriole, G. L. (2016). Impact of childhood and recent 
traumatic events on the clinical presentation of overactive bladder. Neurourol Urodyn, 
35(8), 1017-1023. doi:10.1002/nau.22872 
Lai., R., Shen., 2016. (2016). The relationship between anxiety and overactive bladder or 
urinary incontinence symptoms in the clinical population. Elsevier Inc. 
doi:10.1016/j.urology.2016.07/013 
Lebron-Milad, K., & Milad, M. R. (2012). Sex differences, gonadal hormones and the fear 
extinction network: implications for anxiety disorders. Biol Mood Anxiety Disord, 2, 3. 
doi:10.1186/2045-5380-2-3 
Lee, H. A., Kim, K. S., Hyun, S. A., Park, S. G., & Kim, S. J. (2012). Wide spectrum of inhibitory 
effects of sertraline on cardiac ion channels. Korean J Physiol Pharmacol, 16(5), 327-
332. doi:10.4196/kjpp.2012.16.5.327 
Lee, J. Y., Kim, N., Kim, Y. S., Nam, R. H., Ham, M. H., Lee, H. S., . . . Lee, D. H. (2016). Repeated 
Water Avoidance Stress Alters Mucosal Mast Cell Counts, Interleukin-1beta Levels 
with Sex Differences in the Distal Colon of Wistar Rats. J Neurogastroenterol Motil, 
22(4), 694-704. doi:10.5056/jnm16007 
Lee, U. J., Ackerman, A. L., Wu, A., Zhang, R., Leung, J., Bradesi, S., . . . Rodriguez, L. V. (2015). 
Chronic psychological stress in high-anxiety rats induces sustained bladder 
hyperalgesia. Physiol Behav, 139, 541-548. doi:10.1016/j.physbeh.2014.11.045 
Lee, W. C., Chiang, P. H., Tain, Y. L., Wu, C. C., & Chuang, Y. C. (2012). Sensory dysfunction of 
bladder mucosa and bladder oversensitivity in a rat model of metabolic syndrome. 
PLoS One, 7(9), e45578. doi:10.1371/journal.pone.0045578 
Leron, E., Weintraub, A. Y., Mastrolia, S. A., & Schwarzman, P. (2018). Overactive Bladder 
Syndrome: Evaluation and Management. Curr Urol, 11(3), 117-125. 
doi:10.1159/000447205 
 
 
263 
Levin, R. M., Ruggieri, M. R., Velagapudi, S., Gordon, D., Altman, B., & Wein, A. J. (1986). 
Relevance of spontaneous activity to urinary bladder function: an in vitro and in vivo 
study. J Urol, 136(2), 517-521. doi:10.1016/s0022-5347(17)44934-2 
Lewis, G., Duffy, L., Ades, A., Amos, R., Araya, R., Brabyn, S., . . . Lewis, G. (2019). The clinical 
effectiveness of sertraline in primary care and the role of depression severity and 
duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. 
Lancet Psychiatry, 6(11), 903-914. doi:10.1016/S2215-0366(19)30366-9 
Lewis, S. A. (2000). Everything you wanted to know about the bladder epithelium but were 
afraid to ask. Am J Physiol Renal Physiol, 278(6), F867-F874. 
doi:10.1152/ajprenal.2000.278.6.F867 
Li, F., De Godoy, M., & Rattan, S. (2004). Role of adenylate and guanylate cyclases in beta1-, 
beta2-, and beta3-adrenoceptor-mediated relaxation of internal anal sphincter 
smooth muscle. J Pharmacol Exp Ther, 308(3), 1111-1120. 
doi:10.1124/jpet.103.060145 
Li, M., Xu, H., & Wang, W. (2018). An Improved Model of Physical and Emotional Social Defeat: 
Different Effects on Social Behavior and Body Weight of Adolescent Mice by 
Interaction With Social Support. Front Psychiatry, 9, 688. 
doi:10.3389/fpsyt.2018.00688 
Lips, K. S., Volk, C., Schmitt, B. M., Pfeil, U., Arndt, P., Miska, D., . . . Koepsell, H. (2005). 
Polyspecific cation transporters mediate luminal release of acetylcholine from 
bronchial epithelium. Am J Respir Cell Mol Biol, 33(1), 79-88. doi:10.1165/rcmb.2004-
0363OC 
Lips, K. S., Wunsch, J., Zarghooni, S., Bschleipfer, T., Schukowski, K., Weidner, W., . . . Kummer, 
W. (2007). Acetylcholine and molecular components of its synthesis and release 
machinery in the urothelium. Eur Urol, 51(4), 1042-1053. 
doi:10.1016/j.eururo.2006.10.028 
Liu, Q., Luo, D., Yang, T., Liao, B., Li, H., & Wang, K. J. (2017). Protective Effects of 
Antimuscarinics on the Bladder Remodeling After Bladder Outlet Obstruction. Cell 
Physiol Biochem, 44(3), 907-919. doi:10.1159/000485358 
Liu, S. P., Volfson, I., Horan, P., & Levin, R. M. (1998). Effects of hypoxia, calcium, carbachol, 
atropine and tetrodotoxin on the filling of the in-vitro rabbit whole bladder. J Urol, 
160(3 Pt 1), 913-919. doi:10.1097/00005392-199809010-00088 
Lluel, P., Palea, S., Barras, M., Grandadam, F., Heudes, D., Bruneval, P., . . . Martin, D. J. (2000). 
Functional and morphological modifications of the urinary bladder in aging female 
rats. Am J Physiol Regul Integr Comp Physiol, 278(4), R964-972. 
doi:10.1152/ajpregu.2000.278.4.R964 
Lowenstein, L., Mueller, E. R., Sharma, S., & FitzGerald, M. P. (2007). Urinary hesitancy and 
retention during treatment with sertraline. Int Urogynecol J Pelvic Floor Dysfunct, 
18(7), 827-829. doi:10.1007/s00192-006-0241-4 
Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. (2009). Effects of stress throughout the 
lifespan on the brain, behaviour and cognition. Nat Rev Neurosci, 10(6), 434-445. 
doi:10.1038/nrn2639 
Ma, X. M., Lightman, S. L., & Aguilera, G. (1999). Vasopressin and corticotropin-releasing 
hormone gene responses to novel stress in rats adapted to repeated restraint. 
Endocrinology, 140(8), 3623-3632. doi:10.1210/endo.140.8.6943 
 
 
264 
MacQueen, G., & Frodl, T. (2011). The hippocampus in major depression: evidence for the 
convergence of the bench and bedside in psychiatric research? Mol Psychiatry, 16(3), 
252-264. doi:10.1038/mp.2010.80 
Maier, S. F., & Watkins, L. R. (2005). Stressor controllability and learned helplessness: the roles 
of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci 
Biobehav Rev, 29(4-5), 829-841. doi:10.1016/j.neubiorev.2005.03.021 
Mann, E. A. A., Z.; Hufgard, J.R.; Mogle, M.; Williams, M.T.; Vorhees, C.V.; Reddy, P. (2015). 
Chronic Social Defeat, But Not Restraint Stress, Alters Bladder Function in Mice. 
Physiol Behav, 150, 83-92. doi:10.1016/j.physbeh.2015.02.021 
Mansfield, K. J., Liu, L., Mitchelson, F. J., Moore, K. H., Millard, R. J., & Burcher, E. (2005). 
Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by 
radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J 
Pharmacol, 144(8), 1089-1099. doi:10.1038/sj.bjp.0706147 
Marinkovic, S. P., Moldwin, R., Gillen, L. M., & Stanton, S. L. (2009). The management of 
interstitial cystitis or painful bladder syndrome in women. BMJ, 339, b2707. 
doi:10.1136/bmj.b2707 
Martin, S. A., Haren, M. T., Marshall, V. R., Lange, K., Wittert, G. A., & Members of the Florey 
Adelaide Male Ageing, S. (2011). Prevalence and factors associated with 
uncomplicated storage and voiding lower urinary tract symptoms in community-
dwelling Australian men. World J Urol, 29(2), 179-184. doi:10.1007/s00345-010-0605-
8 
Matos, R. S., P.; Rodriguez, L.; Birder, L.A.; Cruz, F.; Charrua, A. (2017). The water avoidance 
stress induces bladder pain due to a prolonged alpha1A adrenoceptor stimulation. 
Naunyn Schmiedebergs Archives of pharmacology, 390(8), 5. doi:10.1007/s00210-
017-1384-1 
Matsui, M., Motomura, D., Fujikawa, T., Jiang, J., Takahashi, S., Manabe, T., & Taketo, M. M. 
(2002). Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of 
cholinergic smooth muscle contractions but still viable. J Neurosci, 22(24), 10627-
10632.  
Matsui, M., Motomura, D., Karasawa, H., Fujikawa, T., Jiang, J., Komiya, Y., . . . Taketo, M. M. 
(2000). Multiple functional defects in peripheral autonomic organs in mice lacking 
muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A, 
97(17), 9579-9584. doi:10.1073/pnas.97.17.9579 
Matsumoto, Y., Miyazato, M., Yokoyama, H., Kita, M., Hirao, Y., Chancellor, M. B., & 
Yoshimura, N. (2012). Role of M2 and M3 muscarinic acetylcholine receptor subtypes 
in activation of bladder afferent pathways in spinal cord injured rats. Urology, 79(5), 
1184 e1115-1120. doi:10.1016/j.urology.2012.01.022 
Matsumoto-Miyai, K., Kagase, A., Murakawa, Y., Momota, Y., & Kawatani, M. (2009). 
Extracellular Ca2+ regulates the stimulus-elicited ATP release from urothelium. Auton 
Neurosci, 150(1-2), 94-99. doi:10.1016/j.autneu.2009.05.253 
Matsumoto-Miyai, K., Yamada, E., Yoshizumi, M., & Kawatani, M. (2012). The regulation of 
distention-induced ATP release from urothelium by the adenylyl cyclase-cyclic AMP 
pathway. Biomed Res, 33(3), 153-157. doi:10.2220/biomedres.33.153 
Matsumoto-Miyai, K., Yoshizumi, M., & Kawatani, M. (2015). Regulatory Effects of 5-
Hydroxytryptamine Receptors on Voiding Function. Adv Ther, 32 Suppl 1, 3-15. 
doi:10.1007/s12325-015-0240-2 
 
 
265 
McCarthy, C. J., Zabbarova, I. V., Brumovsky, P. R., Roppolo, J. R., Gebhart, G. F., & Kanai, A. J. 
(2009). Spontaneous contractions evoke afferent nerve firing in mouse bladders with 
detrusor overactivity. J Urol, 181(3), 1459-1466. doi:10.1016/j.juro.2008.10.139 
McDermott, C., Chess-Williams, R., Mills, K. A., Kang, S. H., Farr, S. E., Grant, G. D., . . . 
Anoopkumar-Dukie, S. (2013). Alterations in acetylcholine, PGE2 and IL6 release from 
urothelial cells following treatment with pyocyanin and lipopolysaccharide. Toxicol In 
Vitro, 27(6), 1693-1698. doi:10.1016/j.tiv.2013.04.015 
McEwen, B. S., & Morrison, J. H. (2013). The Brain on Stress: Vulnerability and Plasticity of the 
Prefrontal Cortex over the Life Course. Neuron, 79(1), 16-29. 
doi:10.1016/j.neuron.2013.06.028 
McEwen, B. S., Weiss, J. M., & Schwartz, L. S. (1968). Selective retention of corticosterone by 
limbic structures in rat brain. Nature, 220(5170), 911-912.  
McGonagle, E., Smith, A., Butler, S., Sliwoski, J., Valentino, R., Canning, D., & Zderic, S. A. 
(2012). Water avoidance stress results in an altered voiding phenotype in male mice. 
Neurourol Urodyn, 31(7), 1185-1189. doi:10.1002/nau.22207 
McLafferty, E., Johnstone, C., Hendry, C., & Farley, A. (2014). The urinary system. Nurs Stand, 
28(27), 43-50. doi:10.7748/ns2014.03.28.27.43.e7283 
Meng, E., Young, J. S., & Brading, A. F. (2008). Spontaneous activity of mouse detrusor smooth 
muscle and the effects of the urothelium. Neurourol Urodyn, 27(1), 79-87. 
doi:10.1002/nau.20456 
Merrill, L., Gonzalez, E. J., Girard, B. M., & Vizzard, M. A. (2016). Receptors, channels, and 
signalling in the urothelial sensory system in the bladder. Nat Rev Urol, 13(4), 193-204. 
doi:10.1038/nrurol.2016.13 
Merrill, L., Malley, S., & Vizzard, M. A. (2013). Repeated variate stress in male rats induces 
increased voiding frequency, somatic sensitivity, and urinary bladder nerve growth 
factor expression. Am J Physiol Regul Integr Comp Physiol, 305(2), R147-156. 
doi:10.1152/ajpregu.00089.2013 
Michel, M. C. (2014). Do beta-adrenoceptor agonists induce homologous or heterologous 
desensitization in rat urinary bladder? N-S Arch Pharmacol, 387(3), 215-224. 
doi:10.1007/s00210-013-0936-2 
Michel, M. C., Ochodnicky, P., Homma, Y., & Igawa, Y. (2011). beta-adrenoceptor agonist 
effects in experimental models of bladder dysfunction. Pharmacol Ther, 131(1), 40-
49. doi:10.1016/j.pharmthera.2011.03.014 
Michel-Reher, M. B., & Michel, M. C. (2013). Agonist-induced desensitization of human beta3-
adrenoceptors expressed in human embryonic kidney cells. N-S Arch Pharmacol, 
386(10), 843-851. doi:10.1007/s00210-013-0891-y 
Milsom, I., Kaplan, S. A., Coyne, K. S., Sexton, C. C., & Kopp, Z. S. (2012). Effect of bothersome 
overactive bladder symptoms on health-related quality of life, anxiety, depression, 
and treatment seeking in the United States: results from EpiLUTS. Urology, 80(1), 90-
96. doi:10.1016/j.urology.2012.04.004 
Minassian, V. A., Devore, E., Hagan, K., & Grodstein, F. (2013). Severity of urinary incontinence 
and effect on quality of life in women by incontinence type. Obstet Gynecol, 121(5), 
1083-1090. doi:10.1097/AOG.0b013e31828ca761 
Mingin, G. C., Heppner, T. J., Tykocki, N. R., Erickson, C. S., Vizzard, M. A., & Nelson, M. T. 
(2015). Social stress in mice induces urinary bladder overactivity and increases TRPV1 
channel-dependent afferent nerve activity. Am J Physiol Regul Integr Comp Physiol, 
309(6), R629-638. doi:10.1152/ajpregu.00013.2015 
 
 
266 
Mittra, S., Malhotra, S., Naruganahalli, K. S., & Chugh, A. (2007). Role of peripheral 5-HT1A 
receptors in detrusor over activity associated with partial bladder outlet obstruction 
in female rats. Eur J Pharmacol, 561(1-3), 189-193. doi:10.1016/j.ejphar.2007.01.031 
Moniotte, S., Kobzik, L., Feron, O., Trochu, J. N., Gauthier, C., & Balligand, J. L. (2001). 
Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic 
amines in human failing myocardium. Circulation, 103(12), 1649-1655. 
doi:10.1161/01.cir.103.12.1649 
Monroe, P. J., & Smith, D. J. (1983). Characterization of multiple [3H]5-hydroxytryptamine 
binding sites in rat spinal cord tissue. J Neurochem, 41(2), 349-355. 
doi:10.1111/j.1471-4159.1983.tb04749.x 
Moro, C., Uchiyama, J., & Chess-Williams, R. (2011). Urothelial/lamina propria spontaneous 
activity and the role of M3 muscarinic receptors in mediating rate responses to stretch 
and carbachol. Urology, 78(6), 1442 e1449-1415. doi:10.1016/j.urology.2011.08.039 
Morton, K. D. R., Vandekar, L. D., Brownfield, M. S., Lorens, S. A., Napier, T. C., & Urban, J. H. 
(1990). Stress-Induced Renin and Corticosterone Secretion Is Mediated by 
Catecholaminergic Nerve-Terminals in the Hypothalamic Paraventricular Nucleus. 
Neuroendocrinology, 51(3), 320-327.  
Mukherjee, S., Sen, S., Biswas, A., Barman, T. K., & Tripathi, S. K. (2015). Impact on behavioral 
changes due to chronic use of sertraline in Wistar albino rats. Indian J Pharmacol, 
47(6), 657-662. doi:10.4103/0253-7613.169590 
Munoz, A., Smith, C. P., Boone, T. B., & Somogyi, G. T. (2011). Overactive and underactive 
bladder dysfunction is reflected by alterations in urothelial ATP and NO release. 
Neurochem Int, 58(3), 295-300. doi:10.1016/j.neuint.2010.12.002 
Munoz, A. G., D.A.; Smith, C.P.; Boone, T.B.; Somogyi, G.T. (2010). Removal of urothelium 
affects bladder contractility and release of ATP but not release of NO in rat urinary 
bladder. BMC Urology, 10(10).  
Murphy, D. L., & Lesch, K. P. (2008). Targeting the murine serotonin transporter: insights into 
human neurobiology. Nat Rev Neurosci, 9(2), 85-96. doi:10.1038/nrn2284 
Nair, A. B., & Jacob, S. (2016). A simple practice guide for dose conversion between animals 
and human. J Basic Clin Pharm, 7(2), 27-31. doi:10.4103/0976-0105.177703 
Nakagomi, H., Yoshiyama, M., Mochizuki, T., Miyamoto, T., Komatsu, R., Imura, Y., . . . Koizumi, 
S. (2016). Urothelial ATP exocytosis: regulation of bladder compliance in the urine 
storage phase. Sci Rep, 6, 29761. doi:10.1038/srep29761 
Nakayasu, T., & Ishii, K. (2008). Effects of pair-housing after social defeat experience on 
elevated plus-maze behavior in rats. Behav Processes, 78(3), 477-480. 
doi:10.1016/j.beproc.2008.02.007 
Nandigama, R., Bonitz, M., Papadakis, T., Schwantes, U., Bschleipfer, T., & Kummer, W. (2010). 
Muscarinic acetylcholine receptor subtypes expressed by mouse bladder afferent 
neurons. Neuroscience, 168(3), 842-850. doi:10.1016/j.neuroscience.2010.04.012 
Nasihatkon, Z. S., Khosravi, M., Bourbour, Z., Sahraei, H., Ranjbaran, M., Hassantash, S. M., . . 
. Baghlani, K. (2014). Inhibitory effect of NMDA receptors in the ventral tegmental area 
on hormonal and eating behavior responses to stress in rats. Behav Neurol, 2014, 
294149. doi:10.1155/2014/294149 
Nausch, B., Heppner, T. J., & Nelson, M. T. (2010). Nerve-released acetylcholine contracts 
urinary bladder smooth muscle by inducing action potentials independently of IP3-
mediated calcium release. Am J Physiol Regul Integr Comp Physiol, 299(3), R878-888. 
doi:10.1152/ajpregu.00180.2010 
 
 
267 
Ng, Y. K., de Groat, W. C., & Wu, H. Y. (2006). Muscarinic regulation of neonatal rat bladder 
spontaneous contractions. Am J Physiol Regul Integr Comp Physiol, 291(4), R1049-
1059. doi:10.1152/ajpregu.00236.2006 
Nickel, J. C., Tripp, D. A., Pontari, M., Moldwin, R., Mayer, R., Carr, L. K., . . . Nordling, J. (2011). 
Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome: a 
case control study. Can Urol Assoc J, 5(6), 410-415. doi:10.5489/cuaj.11110 
Nile, C. J. G., J.I. (2012). Interactions between cholinergic and prostaglandin signaling 
elements in the urothelium: role for muscarinic type 2 receptors. Journal of Urology, 
79(1), 6. doi:10.1016/j.urology.2011.08.029 
Nishizawa, O. (2015). How Serotonin is Related with Lower Urinary Dysfunction. Adv Ther, 32, 
S1-S2. doi:10.1007/s12325-015-0241-1 
Nisoli, E., Tonello, C., Benarese, M., & Carruba, M. O. (1995). Rat Frontal-Cortex Beta(1)-
Adrenoceptors Are Activated by the Beta(3)-Adrenoceptor Agonists Sr-58611a and Sr-
58878a but Not by Brl-37344 or Ici-215,001. J Neurochem, 65(4), 1580-1587.  
O'Mahony, S. M., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A. M., Quigley, E. M., . . . Dinan, 
T. G. (2009). Early life stress alters behavior, immunity, and microbiota in rats: 
implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry, 
65(3), 263-267. doi:10.1016/j.biopsych.2008.06.026 
Ohno, Y., Hibino, H., Lossin, C., Inanobe, A., & Kurachi, Y. (2007). Inhibition of astroglial Kir4.1 
channels by selective serotonin reuptake inhibitors. Brain Res, 1178, 44-51. 
doi:10.1016/j.brainres.2007.08.018 
Ohtake, A., Ukai, M., Hatanaka, T., Kobayashi, S., Ikeda, K., Sato, S., . . . Sasamata, M. (2004). 
In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary 
bladder over salivary gland in rats. Eur J Pharmacol, 492(2-3), 243-250. 
doi:10.1016/j.ejphar.2004.03.044 
Ong, C. K., Lirk, P., Tan, C. H., & Seymour, R. A. (2007). An evidence-based update on 
nonsteroidal anti-inflammatory drugs. Clin Med Res, 5(1), 19-34. 
doi:10.3121/cmr.2007.698 
Orabi, H., Bouhout, S., Morissette, A., Rousseau, A., Chabaud, S., & Bolduc, S. (2013). Tissue 
engineering of urinary bladder and urethra: advances from bench to patients. 
ScientificWorldJournal, 2013, 154564. doi:10.1155/2013/154564 
Otsuka, A., Shinbo, H., Matsumoto, R., Kurita, Y., & Ozono, S. (2008). Expression and 
functional role of beta-adrenoceptors in the human urinary bladder urothelium. N-S 
Arch Pharmacol, 377(4-6), 473-481. doi:10.1007/s00210-008-0274-y 
Paner, G. P., Ro, J. Y., Wojcik, E. M., Venkataraman, G., Datta, M. W., & Amin, M. B. (2007). 
Further characterization of the muscle layers and lamina propria of the urinary 
bladder by systematic histologic mapping: implications for pathologic staging of 
invasive urothelial carcinoma. Am J Surg Pathol, 31(9), 1420-1429. 
doi:10.1097/PAS.0b013e3180588283 
Patki, G., Salvi, A., Liu, H., & Salim, S. (2015). Witnessing traumatic events and post-traumatic 
stress disorder: Insights from an animal model. Neurosci Lett, 600, 28-32. 
doi:10.1016/j.neulet.2015.05.060 
Pavcovich, L. A., & Valentino, R. J. (1995). Central regulation of micturition in the rat the 
corticotropin-releasing hormone from Barrington's nucleus. Neurosci Lett, 196(3), 
185-188. doi:10.1016/0304-3940(95)11873-u 
Pavesi, M., Devlin, N., Hakimi, Z., Nazir, J., Herdman, M., Hoyle, C., & Odeyemi, I. A. (2013). 
Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed 
 
 
268 
analysis of EQ-5D clinical trial data for mirabegron. J Med Econ, 16(7), 866-876. 
doi:10.3111/13696998.2013.802240 
Perrin, M., Vandeleur, C. L., Castelao, E., Rothen, S., Glaus, J., Vollenweider, P., & Preisig, M. 
(2014). Determinants of the development of post-traumatic stress disorder, in the 
general population. Soc Psychiatry Psychiatr Epidemiol, 49(3), 447-457. 
doi:10.1007/s00127-013-0762-3 
Peyronnet, B., Chapple, C., & Cornu, J. N. (2019). Reply to Bernhard Liedl, Klaus Goeschen, 
and Florian Wagenlehner's Letter to the Editor re: Benoit Peyronnet, Emma Mironska, 
Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder 
Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019, 75:988-1000. Eur 
Urol, 76(4), e107-e108. doi:10.1016/j.eururo.2019.07.004 
Pierce, A. N., Di Silvestro, E. R., Eller, O. C., Wang, R., Ryals, J. M., & Christianson, J. A. (2016). 
Urinary bladder hypersensitivity and dysfunction in female mice following early life 
and adult stress. Brain Res, 1639, 58-73. doi:10.1016/j.brainres.2016.02.039 
Pisipati, S., & Hashim, H. (2011). Vasopressin receptors in voiding dysfunction. Handb Exp 
Pharmacol(202), 453-483. doi:10.1007/978-3-642-16499-6_21 
Porter, I. D., Whitehouse, B. J., Taylor, A. H., & Nussey, S. S. (1988). Effect of arginine 
vasopressin and oxytocin on acetylcholine-stimulation of corticosteroid and 
catecholamine secretion from the rat adrenal gland perfused in situ. Neuropeptides, 
12(4), 265-271. doi:10.1016/0143-4179(88)90065-0 
Procino, G., Carmosino, M., Milano, S., Dal Monte, M., Schena, G., Mastrodonato, M., . . . 
Svelto, M. (2016). beta(3) adrenergic receptor in the kidney may be a new player in 
sympathetic regulation of renal function. Kidney Int, 90(3), 555-567. 
doi:10.1016/j.kint.2016.03.020 
Propping, S., Lorenz, K., Michel, M. C., Wirth, M. P., & Ravens, U. (2016). beta-Adrenoceptor-
mediated Relaxation of Urinary Bladder Muscle in beta2-Adrenoceptor Knockout 
Mice. Front Pharmacol, 7, 118. doi:10.3389/fphar.2016.00118 
Qin, H. Y., Cheng, C. W., Tang, X. D., & Bian, Z. X. (2014). Impact of psychological stress on 
irritable bowel syndrome. World J Gastroenterol, 20(39), 14126-14131. 
doi:10.3748/wjg.v20.i39.14126 
Quick, M. W. (2003). Regulating the conducting states of a mammalian serotonin transporter. 
Neuron, 40(3), 537-549. doi:Doi 10.1016/S0896-6273(03)00605-6 
Ranabir, S., & Reetu, K. (2011). Stress and hormones. Indian J Endocrinol Metab, 15(1), 18-22. 
doi:10.4103/2230-8210.77573 
Raymond, J. R., Mukhin, Y. V., Gelasco, A., Turner, J., Collinsworth, G., Gettys, T. W., . . . 
Garnovskaya, M. N. (2001). Multiplicity of mechanisms of serotonin receptor signal 
transduction. Pharmacol Ther, 92(2-3), 179-212. doi:10.1016/s0163-7258(01)00169-3 
Recio, P., Barahona, M. V., Orensanz, L. M., Bustamante, S., Martinez, A. C., Benedito, S., . . . 
Hernandez, M. (2009). 5-hydroxytryptamine induced relaxation in the pig urinary 
bladder neck. Br J Pharmacol, 157(2), 271-280. doi:10.1111/j.1476-
5381.2009.00144.x 
Reiche, E. M., Nunes, S. O., & Morimoto, H. K. (2004). Stress, depression, the immune system, 
and cancer. Lancet Oncol, 5(10), 617-625. doi:10.1016/S1470-2045(04)01597-9 
Renoir, T., Pang, T. Y., Zajac, M. S., Chan, G., Du, X., Leang, L., . . . Hannan, A. J. (2012). 
Treatment of depressive-like behaviour in Huntington's disease mice by chronic 
sertraline and exercise. Br J Pharmacol, 165(5), 1375-1389. doi:10.1111/j.1476-
5381.2011.01567.x 
 
 
269 
Retana-Marquez, S., Bonilla-Jaime, H., Vazquez-Palacios, G., Dominguez-Salazar, E., Martinez-
Garcia, R., & Velazquez-Moctezuma, J. (2003). Body weight gain and diurnal 
differences of corticosterone changes in response to acute and chronic stress in rats. 
Psychoneuroendocrinology, 28(2), 207-227. doi:10.1016/s0306-4530(02)00017-3 
Reznikov, L. R., Grillo, C. A., Piroli, G. G., Pasumarthi, R. K., Reagan, L. P., & Fadel, J. (2007). 
Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: 
differential effects of antidepressant treatment. Eur J Neurosci, 25(10), 3109-3114. 
doi:10.1111/j.1460-9568.2007.05560.x 
Rhodes, M. E., Billings, T. E., Czambel, R. K., & Rubin, R. T. (2005). Pituitary-adrenal responses 
to cholinergic stimulation and acute mild stress are differentially elevated in male and 
female M-2 muscarinic receptor knockout mice. J Neuroendocrinol, 17(12), 817-826. 
doi:10.1111/j.1365-2826.2005.01376.x 
Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arterioscler Thromb 
Vasc Biol, 31(5), 986-1000. doi:10.1161/ATVBAHA.110.207449 
Riva, D., & Casolati, E. (1984). Oxybutynin chloride in the treatment of female idiopathic 
bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol, 
11(1-2), 37-42.  
Robbins, M., DeBerry, J., & Ness, T. (2007). Chronic psychological stress enhances nociceptive 
processing in the urinary bladder in high-anxiety rats. Physiol Behav, 91(5), 544-550. 
doi:10.1016/j.physbeh.2007.04.009 
Rodriguez, M., Carillon, C., Coquerel, A., Le Fur, G., Ferrara, P., Caput, D., & Shire, D. (1995). 
Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. 
Brain Res Mol Brain Res, 29(2), 369-375. doi:10.1016/0169-328x(94)00274-i 
Ronaldson, A., Carvalho, L. A., Kostich, K., Lazzarino, A. I., Urbanova, L., & Steptoe, A. (2018). 
The effects of six-day SSRI administration on diurnal cortisol secretion in healthy 
volunteers. Psychopharmacology (Berl), 235(12), 3415-3422. doi:10.1007/s00213-
018-5050-1 
Rosenfeld, G. (1955). Stimulative effect of acetylcholine on the adrenocortical function of 
isolated perfused calf adrenals. Am J Physiol, 183(2), 272-278. 
doi:10.1152/ajplegacy.1955.183.2.272 
Rosol, T. J. Y., J.T.; Latendresse, J.; Capen, C.C. (2001). Adrenal Gland: Structure, Function, and 
Mechanisms of Toxicity. Toxicologic Pathology, 29(1), 7.  
Rothrock, N. E., Lutgendorf, S. K., Hoffman, A., & Kreder, K. J. (2002). Depressive symptoms 
and quality of life in patients with interstitial cystitis. J Urol, 167(4), 1763-1767.  
Ruggieri, M. R., Sr., & Braverman, A. S. (2006). Regulation of bladder muscarinic receptor 
subtypes by experimental pathologies. Auton Autacoid Pharmacol, 26(3), 311-325. 
doi:10.1111/j.1474-8673.2006.00377.x 
Ryall, R. W., & DeGroat, W. C. (1972). The microelectrophoretic administration of 
noradrenaline, 5-hydroxytryptamine, acetylcholine and glycine to sacral 
parasympathetic preganglionic neurones. Brain Res, 37(2), 345-347. 
doi:10.1016/0006-8993(72)90683-x 
Sakai, T., Kasahara, K., Tomita, K., Ikegaki, I., & Kuriyama, H. (2013). Naftopidil inhibits 5-
hydroxytryptamine-induced bladder contraction in rats. Eur J Pharmacol, 700(1-3), 
194-200. doi:10.1016/j.ejphar.2012.12.022 
Salcedo, C., Davalillo, S., Cabellos, J., Lagunas, C., Balsa, D., Perez-Del-Pulgar, S., . . . Fernandez, 
A. (2009). In vivo and in vitro pharmacological characterization of SVT-40776, a novel 
 
 
270 
M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J 
Pharmacol, 156(5), 807-817. doi:10.1111/j.1476-5381.2008.00082.x 
Sanders-Bush, E., Breeding, M., Knoth, K., & Tsutsumi, M. (1989). Sertraline-induced 
desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. 
Psychopharmacology (Berl), 99(1), 64-69. doi:10.1007/BF00634454 
Sant, G. R. (2002). Etiology, pathogenesis, and diagnosis of interstitial cystitis. Rev Urol, 4 
Suppl 1, S9-S15.  
Sapolsky, R., Rivier, C., Yamamoto, G., Plotsky, P., & Vale, W. (1987). Interleukin-1 stimulates 
the secretion of hypothalamic corticotropin-releasing factor. Science, 238(4826), 522-
524. doi:10.1126/science.2821621 
Sapolsky, R. M., Uno, H., Rebert, C. S., & Finch, C. E. (1990). Hippocampal damage associated 
with prolonged glucocorticoid exposure in primates. J Neurosci, 10(9), 2897-2902.  
Sareen, J., Cox, B. J., Stein, M. B., Afifi, T. O., Fleet, C., & Asmundson, G. J. (2007). Physical and 
mental comorbidity, disability, and suicidal behavior associated with posttraumatic 
stress disorder in a large community sample. Psychosom Med, 69(3), 242-248. 
doi:10.1097/PSY.0b013e31803146d8 
Schena, G., & Caplan, M. J. (2019). Everything You Always Wanted to Know about (3)-AR * (* 
But Were Afraid to Ask). Cells, 8(4). doi:ARTN 357 
10.3390/cells8040357 
Schneiderman, N., Ironson, G., & Siegel, S. D. (2005). Stress and health: psychological, 
behavioral, and biological determinants. Annu Rev Clin Psychol, 1, 607-628. 
doi:10.1146/annurev.clinpsy.1.102803.144141 
Scott, L. V., & Dinan, T. G. (2002). Vasopressin as a target for antidepressant development: an 
assessment of the available evidence. J Affect Disorders, 72(2), 113-124. doi:Doi 
10.1016/S0165-0327(02)00026-5 
Searl, T. J., Dynda, D. I., Alanee, S. R., El-Zawahry, A. M., McVary, K. T., & Silinsky, E. M. (2016). 
A1 Adenosine Receptor-Mediated Inhibition of Parasympathetic Neuromuscular 
Transmission in Human and Murine Urinary Bladder. J Pharmacol Exp Ther, 356(1), 
116-122. doi:10.1124/jpet.115.228882 
Seibenhener, M. L., & Wooten, M. C. (2015). Use of the Open Field Maze to Measure 
Locomotor and Anxiety-like Behavior in Mice. Jove-J Vis Exp(96). doi:ARTN e52434 
10.3791/52434 
Seki, M., Zha, X. M., Inamura, S., Taga, M., Matsuta, Y., Aoki, Y., . . . Yokoyama, O. (2019). Role 
of corticotropin-releasing factor on bladder function in rats with psychological stress. 
Sci Rep, 9. doi:ARTN 982810.1038/s41598-019-46267-9 
Sellers, D. J., & Chess-Williams, R. (2012). Muscarinic agonists and antagonists: effects on the 
urinary bladder. Handb Exp Pharmacol(208), 375-400. doi:10.1007/978-3-642-23274-
9_16 
Sexton, C. C., Notte, S. M., Maroulis, C., Dmochowski, R. R., Cardozo, L., Subramanian, D., & 
Coyne, K. S. (2011). Persistence and adherence in the treatment of overactive bladder 
syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin 
Pract, 65(5), 567-585. doi:10.1111/j.1742-1241.2010.02626.x 
Shansky, R. M., Hamo, C., Hof, P. R., Lou, W., McEwen, B. S., & Morrison, J. H. (2010). Estrogen 
promotes stress sensitivity in a prefrontal cortex-amygdala pathway. Cereb Cortex, 
20(11), 2560-2567. doi:10.1093/cercor/bhq003 
 
 
271 
Shiomi, H., Takahashi, N., Kawashima, Y., Ogawa, S., Haga, N., Kushida, N., . . . Yamaguchi, O. 
(2013). Involvement of stretch-induced Rho-kinase activation in the generation of 
bladder tone. Neurourol Urodyn, 32(7), 1019-1025. doi:10.1002/nau.22360 
Sial, O. K., Warren, B. L., Alcantara, L. F., Parise, E. M., & Bolanos-Guzman, C. A. (2016). 
Vicarious social defeat stress: Bridging the gap between physical and emotional stress. 
J Neurosci Methods, 258, 94-103. doi:10.1016/j.jneumeth.2015.10.012 
Siddiqui, H., Lagesen, K., Nederbragt, A. J., Jeansson, S. L., & Jakobsen, K. S. (2012). Alterations 
of microbiota in urine from women with interstitial cystitis. BMC Microbiol, 12, 205. 
doi:10.1186/1471-2180-12-205 
Sinclair, A. J. R., I.N. (2011). The psychosocial impact of urinary incontinence in women. The 
obstetrician and gynaecologist, 13, 5. doi:10.1576/toag.13.3.143.27665 
Smith, A. L., Leung, J., Kun, S., Zhang, R., Karagiannides, I., Raz, S., . . . Rodriguez, L. V. (2011). 
The effects of acute and chronic psychological stress on bladder function in a rodent 
model. Urology, 78(4), 967 e961-967. doi:10.1016/j.urology.2011.06.041 
Snellings, A. E., Yoo, P. B., & Grill, W. M. (2012). Urethral flow-responsive afferents in the cat 
sacral dorsal root ganglia. Neurosci Lett, 516(1), 34-38. 
doi:10.1016/j.neulet.2012.03.045 
Solmaz, V., Albayrak, S., Tekatas, A., Aksoy, D., Gencten, Y., Inanir, S., & Erdemir, F. (2017). 
Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study. 
Int Neurourol J, 21(1), 62-67. doi:10.5213/inj.1732652.326 
Somlyo, A. P., & Somlyo, A. V. (2000). Signal transduction by G-proteins, Rho-kinase and 
protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol-London, 
522(2), 177-185. doi:DOI 10.1111/j.1469-7793.2000.t01-2-00177.x 
Somogyi, G. T., Zernova, G. V., Yoshiyama, M., Rocha, J. N., Smith, C. P., & de Groat, W. C. 
(2003). Change in muscarinic modulation of transmitter release in the rat urinary 
bladder after spinal cord injury. Neurochem Int, 43(1), 73-77. doi:10.1016/s0197-
0186(02)00193-6 
Song, C., & Leonard, B. E. (2005). The olfactory bulbectomised rat as a model of depression. 
Neurosci Biobehav R, 29(4-5), 627-647. doi:10.1016/j.neubiorev.2005.03.010 
Spalding, K. L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H. B., . . . Frisen, 
J. (2013). Dynamics of hippocampal neurogenesis in adult humans. Cell, 153(6), 1219-
1227. doi:10.1016/j.cell.2013.05.002 
Srinivasan, D., Kim, J. M., Burbach, L. R., Ford, A. P. D. W., & Bhattacharya, A. (2006). 
Pharmacology of carbachol induced phasic contractions in isolated guinea pig bladder: 
M-2 or M-3. Faseb Journal, 20(4), A660-A660.  
Statistics, A. B. o. (2008). National Survey of Mental Health and Wellbeing: Summary of 
Results. Retrieved from Canberra: www.abs.gov.au 
Steers, W. D., Herschorn, S., Kreder, K. J., Moore, K., Strohbehn, K., Yalcin, I., . . . Duloxetine, 
O. A. B. S. G. (2007). Duloxetine compared with placebo for treating women with 
symptoms of overactive bladder. BJU Int, 100(2), 337-345. doi:10.1111/j.1464-
410X.2007.06980.x 
Stemmelin, J., Cohen, C., Terranova, J. P., Lopez-Grancha, M., Pichat, P., Bergis, O., . . . Griebel, 
G. (2008). Stimulation of the beta(3)-adrenoceptor as a novel treatment strategy for 
anxiety and depressive disorders. Neuropsychopharmacol, 33(3), 574-587. doi:DOI 
10.1038/sj.npp.1301424 
Stephens, M. A. C., & Wand, G. (2012). Stress and the HPA Axis. Alcohol Res, 34(4), 15.  
 
 
272 
Stevenson, K., Kucich, U., Whitbeck, C., Levin, R. M., & Howard, P. S. (2006). Functional 
changes in bladder tissue from type III collagen-deficient mice. Mol Cell Biochem, 
283(1-2), 107-114. doi:10.1007/s11010-006-2388-1 
Struder, H. K., & Weicker, H. (2001). Physiology and pathophysiology of the serotonergic 
system and its implications on mental and physical performance. Part I. Int J Sports 
Med, 22(7), 467-481. doi:10.1055/s-2001-17605 
Sugaya, K., Nishijima, S., Kadekawa, K., Noguchi, K., Ueda, T., & Yamamoto, H. (2020). 
Mirabegron causes vesical and urethral relaxation in rats with spinal cord injury. Low 
Urin Tract Symptoms, 12(1), 92-98. doi:10.1111/luts.12279 
Sugaya, K., Nishijima, S., Miyazato, M., & Ogawa, Y. (2005). Central nervous control of 
micturition and urine storage. J Smooth Muscle Res, 41(3), 117-132. 
doi:10.1540/jsmr.41.117 
Sui, G., Fry, C. H., Montgomery, B., Roberts, M., Wu, R., & Wu, C. (2014). Purinergic and 
muscarinic modulation of ATP release from the urothelium and its paracrine actions. 
Am J Physiol Renal Physiol, 306(3), F286-298. doi:10.1152/ajprenal.00291.2013 
Sui, G. P., Wu, C., Roosen, A., Ikeda, Y., Kanai, A. J., & Fry, C. H. (2008). Modulation of bladder 
myofibroblast activity: implications for bladder function. Am J Physiol Renal Physiol, 
295(3), F688-697. doi:10.1152/ajprenal.00133.2008 
Summers, R. J., Papaioannou, M., Harris, S., & Evans, B. A. (1995). Expression of beta 3-
adrenoceptor mRNA in rat brain. Br J Pharmacol, 116(6), 2547-2548. 
doi:10.1111/j.1476-5381.1995.tb17205.x 
Sun, X., Sun, C., Zhai, L., & Dong, W. (2019). A Selective M1 and M3 Receptor Antagonist, 
Penehyclidine Hydrochloride, Exerts Antidepressant-Like Effect in Mice. Neurochem 
Res, 44(12), 2723-2732. doi:10.1007/s11064-019-02891-5 
Sung, Y. H., Shin, M. S., Cho, S., Baik, H. H., Jin, B. K., Chang, H. K., . . . Kim, C. J. (2010). 
Depression-like state in maternal rats induced by repeated separation of pups is 
accompanied by a decrease of cell proliferation and an increase of apoptosis in the 
hippocampus. Neurosci Lett, 470(1), 86-90. doi:10.1016/j.neulet.2009.12.063 
Suzuki, M., Ohtake, A., Yoshino, T., Yuyama, H., Hayashi, A., Ukai, M., . . . Sasamata, M. (2005). 
Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral 
infarcted rats. Eur J Pharmacol, 512(1), 61-66. doi:10.1016/j.ejphar.2005.02.023 
Swift, S. E., Siami, P., & Forero-Schwanhaeuser, S. (2009). Diary and Patient-Reported 
Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine 
Extended Release 4 mg/day to Solifenacin Treatment An Open-Label, Flexible-Dosing, 
Multicentre Study. Clin Drug Invest, 29(5), 305-316. doi:Doi 10.2165/00044011-
200929050-00003 
Szigeti, G. P., Somogyi, G. T., Csernoch, L., & Szell, E. A. (2005). Age-dependence of the 
spontaneous activity of the rat urinary bladder. J Muscle Res Cell Motil, 26(1), 23-29. 
doi:10.1007/s10974-005-9003-z 
Takao, T., Tsujimura, A., Yamamoto, K., Fukuhara, S., Nakayama, J., Matsuoka, Y., . . . 
Nonomura, N. (2011). Solifenacin May Improve Sleep Quality in Patients With 
Overactive Bladder and Sleep Disturbance. Urology, 78(3), 648-652. 
doi:10.1016/j.urology.2011.04.020 
Takeda, H., Matsuzawa, A., Igawa, Y., Yamazaki, Y., Kaidoh, K., Akahane, S., . . . Nishizawa, O. 
(2003). Functional characterization of beta-adrenoceptor subtypes in the canine and 
rat lower urinary tract. J Urol, 170(2 Pt 1), 654-658. 
doi:10.1097/01.ju.0000074622.50255.a8 
 
 
273 
Teleman, P. M., Lidfeldt, J., Nerbrand, C., Samsioe, G., Mattiasson, A., & group, W. s. (2004). 
Overactive bladder: prevalence, risk factors and relation to stress incontinence in 
middle-aged women. BJOG, 111(6), 600-604. doi:10.1111/j.1471-0528.2004.00137.x 
Temml, C., Heidler, S., Ponholzer, A., & Madersbacher, S. (2005). Prevalence of the overactive 
bladder syndrome by applying the International Continence Society definition. Eur 
Urol, 48(4), 622-627. doi:10.1016/j.eururo.2005.04.026 
Templeman, L. C., C.R.; Chess-Williams, R. (2002). Urothelium derived inhibitory factor and 
cross-talk among receptors in the trigone of the bladder of the pig. The journal of 
urology, 167(2), 3.  
Thibonnier, M., Snajdar, R. M., & Rapp, J. P. (1986). Characterization of vasopressin receptors 
of rat urinary bladder and spleen. Am J Physiol, 251(1 Pt 2), H115-120. 
doi:10.1152/ajpheart.1986.251.1.H115 
Thomsen, M., Sorensen, G., & Dencker, D. (2018). Physiological roles of CNS muscarinic 
receptors gained from knockout mice. Neuropharmacology, 136(Pt C), 411-420. 
doi:10.1016/j.neuropharm.2017.09.011 
Thor, K. B. (2003). Serotonin and norepinephrine involvement in efferent pathways to the 
urethral rhabdosphincter: implications for treating stress urinary incontinence. 
Urology, 62(4 Suppl 1), 3-9. doi:10.1016/s0090-4295(03)00754-4 
Thor, K. B., Nickolaus, S., & Helke, C. J. (1993). Autoradiographic localization of 5-
hydroxytryptamine1A, 5-hydroxytryptamine1B and 5-hydroxytryptamine1C/2 binding 
sites in the rat spinal cord. Neuroscience, 55(1), 235-252. doi:10.1016/0306-
4522(93)90469-v 
Tidey, J. W., & Miczek, K. A. (1997). Acquisition of cocaine self-administration after social 
stress: role of accumbens dopamine. Psychopharmacology (Berl), 130(3), 203-212. 
doi:10.1007/s002130050230 
Tornatzky, W., & Miczek, K. A. (1993). Long-term impairment of autonomic circadian rhythms 
after brief intermittent social stress. Physiol Behav, 53(5), 983-993. doi:10.1016/0031-
9384(93)90278-n 
Torpy, J. M. K., S.; Golub, R.M. (2012). Interstitial Cystitis. JAMA, 307(20). 
doi:10.1001/jama.2012.3943 
Trendelenburg, U. (1974). An analysis of the alpha- and beta-effects of isoprenaline on the 
isolated nictitating membraen. N-S Arch Pharmacol, 285(4), 375-393. 
doi:10.1007/BF00501466 
Ulloa, J. L., Castaneda, P., Berrios, C., Diaz-Veliz, G., Mora, S., Bravo, J. A., . . . Fiedler, J. L. 
(2010). Comparison of the antidepressant sertraline on differential depression-like 
behaviors elicited by restraint stress and repeated corticosterone administration. 
Pharmacol Biochem Behav, 97(2), 213-221. doi:10.1016/j.pbb.2010.08.001 
Ulrich-Lai, Y. M., & Herman, J. P. (2009). Neural regulation of endocrine and autonomic stress 
responses. Nat Rev Neurosci, 10(6), 397-409. doi:10.1038/nrn2647 
Umehara, H., Numata, S., Tajima, A., Nishi, A., Nakataki, M., Imoto, I., . . . Ohmori, T. (2016). 
Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to 
Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients 
with Obsessive-Compulsive Disorder. PLoS One, 11(6), e0157232. 
doi:10.1371/journal.pone.0157232 
Ursino, M. G., Vasina, V., Raschi, E., Crema, F., & De Ponti, F. (2009). The beta(3)-adrenoceptor 
as a therapeutic target: Current perspectives. Pharmacol Res, 59(4), 221-234. 
doi:10.1016/j.phrs.2009.01.002 
 
 
274 
Vahabi, B., Sellers, D. J., Bijos, D. A., & Drake, M. J. (2013). Phasic contractions in urinary 
bladder from juvenile versus adult pigs. PLoS One, 8(3), e58611. 
doi:10.1371/journal.pone.0058611 
Vanharten, J. (1993). Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. 
Clin Pharmacokinet, 24(3), 203-220. doi:Doi 10.2165/00003088-199324030-00003 
Vial, C. E., R.J. (2000). P2X receptor expression in mouse urinary bladder and the requirement 
of P2X1 receptors for functional P2X receptor responses in the mouse urinary bladder 
smooth muscle. British Journal of Pharmacology, 131(7), 6. 
doi:10.1038/sj.bjp.0703720 
Vialou, V., Bagot, R. C., Cahill, M. E., Ferguson, D., Robison, A. J., Dietz, D. M., . . . Nestler, E. J. 
(2014). Prefrontal cortical circuit for depression- and anxiety-related behaviors 
mediated by cholecystokinin: role of DeltaFosB. J Neurosci, 34(11), 3878-3887. 
doi:10.1523/JNEUROSCI.1787-13.2014 
Volpicelli, L. A., & Levey, A. I. (2004). Muscarinic acetylcholine receptor subtypes in cerebral 
cortex and hippocampus. Prog Brain Res, 145, 59-66. doi:10.1016/S0079-
6123(03)45003-6 
von Gontard, A., Baeyens, D., Van Hoecke, E., Warzak, W. J., & Bachmann, C. (2011). 
Psychological and psychiatric issues in urinary and fecal incontinence. J Urol, 185(4), 
1432-1436. doi:10.1016/j.juro.2010.11.051 
von Poser Toigo, E., Diehl, L. A., Ferreira, A. G., Mackedanz, V., Krolow, R., Benitz, A. N., . . . 
Dalmaz, C. (2012). Maternal depression model: long-lasting effects on the mother 
following separation from pups. Neurochem Res, 37(1), 126-133. doi:10.1007/s11064-
011-0590-3 
Vrijkotte, T. G., van Doornen, L. J., & de Geus, E. J. (2000). Effects of work stress on ambulatory 
blood pressure, heart rate, and heart rate variability. Hypertension, 35(4), 880-886.  
Walker, S. W., Lightly, E. R., Clyne, C., Williams, B. C., & Bird, I. M. (1991). Adrenergic and 
cholinergic regulation of cortisol secretion from the zona fasciculata/reticularis of 
bovine adrenal cortex. Endocr Res, 17(1-2), 237-265. 
doi:10.1080/07435809109027200 
Wallace, K. M., & Drake, M. J. (2015). Overactive bladder. F1000Res, 4. 
doi:10.12688/f1000research.7131.1 
Wang, Lee, J. M., Ruiz, W. G., Balestreire, E. M., von Bodungen, M., Barrick, S., . . . Apodaca, 
G. (2005). ATP and purinergic receptor-dependent membrane traffic in bladder 
umbrella cells. J Clin Invest, 115(9), 2412-2422. doi:10.1172/JCI24086 
Wang, J., Fanous, S., Terwilliger, E. F., Bass, C. E., Hammer, R. P., Jr., & Nikulina, E. M. (2013). 
BDNF overexpression in the ventral tegmental area prolongs social defeat stress-
induced cross-sensitization to amphetamine and increases DeltaFosB expression in 
mesocorticolimbic regions of rats. Neuropsychopharmacology, 38(11), 2286-2296. 
doi:10.1038/npp.2013.130 
Wang, Z., Chang, H. H., Gao, Y., Zhang, R., Guo, Y., Holschneider, D. P., & Rodriguez, L. V. 
(2017). Effects of water avoidance stress on peripheral and central responses during 
bladder filling in the rat: A multidisciplinary approach to the study of urologic chronic 
pelvic pain syndrome (MAPP) research network study. PLoS One, 12(9), e0182976. 
doi:10.1371/journal.pone.0182976 
Wang, Z., Gu, J., Wang, X., Xie, K., Luan, Q., Wan, N., . . . Liu, D. (2013). Antidepressant-like 
activity of resveratrol treatment in the forced swim test and tail suspension test in 
 
 
275 
mice: the HPA axis, BDNF expression and phosphorylation of ERK. Pharmacol Biochem 
Behav, 112, 104-110. doi:10.1016/j.pbb.2013.10.007 
Warren, B. L., Vialou, V. F., Iniguez, S. D., Alcantara, L. F., Wright, K. N., Feng, J., . . . Bolanos-
Guzman, C. A. (2013). Neurobiological sequelae of witnessing stressful events in adult 
mice. Biol Psychiatry, 73(1), 7-14. doi:10.1016/j.biopsych.2012.06.006 
Watson, E. L., Abel, P. W., DiJulio, D., Zeng, W., Makoid, M., Jacobson, K. L., . . . Dowd, F. J. 
(1996). Identification of muscarinic receptor subtypes in mouse parotid gland. Am J 
Physiol, 271(3 Pt 1), C905-913. doi:10.1152/ajpcell.1996.271.3.C905 
Wein, A. J., & Rovner, E. S. (2002). Definition and epidemiology of overactive bladder. Urology, 
60(5 Suppl 1), 7-12; discussion 12.  
Wessler, I., & Kirkpatrick, C. J. (2008). Acetylcholine beyond neurons: the non-neuronal 
cholinergic system in humans. Br J Pharmacol, 154(8), 1558-1571. 
doi:10.1038/bjp.2008.185 
Wessler, I., Roth, E., Deutsch, C., Brockerhoff, P., Bittinger, F., Kirkpatrick, C. J., & Kilbinger, H. 
(2001). Release of non-neuronal acetylcholine from the isolated human placenta is 
mediated by organic cation transporters. Brit J Pharmacol, 134(5), 951-956. doi:DOI 
10.1038/sj.bjp.0704335 
West, E. G., Lang, R., Sellers, D., Chess-Williams, R., & McDermott, C. (2018). Ibuprofen 
Decreases Spontaneous Activity and Enhances Nerve-Evoked Contractions to 
Minimize Mitomycin C-Induced Bladder Dysfunction. J Pharmacol Exp Ther, 366(2), 
282-290. doi:10.1124/jpet.118.248989 
West, E. G., Sellers, D. J., Chess-Williams, R., & McDermott, C. (2020). Voiding Behavior and 
Efferent Bladder Function Altered in Mice Following Social Defeat but Not Witness 
Trauma. Front Physiol, 11. doi:ARTN 247 
10.3389/fphys.2020.00247 
Wettschureck, N., & Offermanns, S. (2002). Rho/Rho-kinase mediated signaling in physiology 
and pathophysiology. J Mol Med (Berl), 80(10), 629-638. doi:10.1007/s00109-002-
0370-2 
Wibberley, A., Chen, Z., Hu, E., Hieble, J. P., & Westfall, T. D. (2003). Expression and functional 
role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol, 138(5), 757-
766. doi:10.1038/sj.bjp.0705109 
Winder, M., Tobin, G., Zupancic, D., & Romih, R. (2014). Signalling molecules in the 
urothelium. Biomed Research International, 2014, 297295. doi:10.1155/2014/297295 
Woo, H. H., Gillman, M. P., Gardiner, R., Marshall, V., & Lynch, W. J. (2011). A practical 
approach to the management of lower urinary tract symptoms among men. Med J 
Aust, 195(1), 34-39. doi:10.5694/j.1326-5377.2011.tb03185.x 
Wood, E. R., Dudchenko, P. A., Robitsek, R. J., & Eichenbaum, H. (2000). Hippocampal neurons 
encode information about different types of memory episodes occurring in the same 
location. Neuron, 27(3), 10.  
Wood, S. K., Baez, M. A., Bhatnagar, S., & Valentino, R. J. (2009). Social stress-induced bladder 
dysfunction: potential role of corticotropin-releasing factor. Am J Physiol Regul Integr 
Comp Physiol, 296(5), R1671-1678. doi:10.1152/ajpregu.91013.2008 
Wrobel, A., Rechberger, E., & Rechberger, T. (2018). The influence of duloxetine on detrusor 
overactivity in rats with depression induced by 13-cis-retinoic acid. Int Urogynecol J, 
29(7), 987-995. doi:10.1007/s00192-017-3424-2 
Wrobel, A., Serefko, A., Wozniak, A., Kociszewski, J., Szopa, A., Wisniewski, R., & Poleszak, E. 
(2020). Duloxetine reverses the symptoms of overactive bladder co-existing with 
 
 
276 
depression via the central pathways. Pharmacol Biochem Behav, 189, 172842. 
doi:10.1016/j.pbb.2019.172842 
Wuest, M., Eichhorn, B., Grimm, M. O., Wirth, M. P., Ravens, U., & Kaumann, A. J. (2009). 
Catecholamines Relax Detrusor through beta(2)-Adrenoceptors in Mouse and beta(3)-
Adrenoceptors in Man. J Pharmacol Exp Ther, 328(1), 213-222. 
doi:10.1124/jpet.108.142562 
Yamamoto, K., Takao, T., Nakayama, J., Kiuchi, H., Okuda, H., Fukuhara, S., . . . Nonomura, N. 
(2012). Water avoidance stress induces frequency through cyclooxygenase-2 
expression: A bladder rat model. Int J Urol, 19(2), 155-162. doi:10.1111/j.1442-
2042.2011.02905.x 
Yamanishi, T. C. C.-W., R. (2001). Which muscarinic receptor is important in the bladder? The 
American Physiological Society, 01(08).  
Yang, S. J., Yu, H. Y., Kang, D. Y., Ma, Z. Q., Qu, R., Fu, Q., & Ma, S. P. (2014). Antidepressant-
like effects of salidroside on olfactory bulbectomy-induced pro-inflammatory cytokine 
production and hyperactivity of HPA axis in rats. Pharmacol Biochem Behav, 124, 451-
457. doi:10.1016/j.pbb.2014.07.015 
Yazaki, T., Inage, H., Iizumi, T., Koyama, A., Kanoh, S., Koiso, K., . . . Tojo, S. (1987). Studies on 
platelet function in patients with prostatic cancer. Preliminary report. Urology, 30(1), 
60-63. doi:10.1016/0090-4295(87)90574-7 
Yokoyama, O., Ootsuka, N., Komatsu, K., Kodama, K., Yotsuyanagi, S., Niikura, S., . . . Namiki, 
M. (2001). Forebrain muscarinic control of micturition reflex in rats. 
Neuropharmacology, 41(5), 629-638. doi:10.1016/s0028-3908(01)00102-2 
Yoon, H., Lee, D., Chun, K., Yoon, H., & Yoo, J. (2010). Effect of stress on the expression of rho-
kinase and collagen in rat bladder tissue. Korean J Urol, 51(2), 132-138. 
doi:10.4111/kju.2010.51.2.132 
Yoshida, M., Inadome, A., Maeda, Y., Satoji, Y., Masunaga, K., Sugiyama, Y., & Murakami, S. 
(2006). Non-neuronal cholinergic system in human bladder urothelium. Urology, 
67(2), 425-430. doi:10.1016/j.urology.2005.08.014 
Yoshida, M., Masunaga, K., Nagata, T., Maeda, Y., Miyamoto, Y., Kudoh, J., & Homma, Y. 
(2009). Attenuation of Non-neuronal Adenosin Triphosphate Release from Human 
Bladder Mucosa by Antimuscarinic Agents. Luts, 1(2), 88-92. doi:10.1111/j.1757-
5672.2009.00049.x 
Yoshida, M., Miyamae, K., Iwashita, H., Otani, M., & Inadome, A. (2004). Management of 
detrusor dysfunction in the elderly: changes in acetylcholine and adenosine 
triphosphate release during aging. Urology, 63(3 Suppl 1), 17-23. 
doi:10.1016/j.urology.2003.11.003 
Yoshii, A., Iizuka, K., Dobashi, K., Horie, T., Harada, T., Nakazawa, T., & Mori, M. (1999). 
Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-
27632 through inhibition of Ca2+ sensitization. Am J Resp Cell Mol, 20(6), 1190-1200. 
doi:DOI 10.1165/ajrcmb.20.6.3441 
Yoshimura, N., & Chancellor, M. B. (2003). Neurophysiology of lower urinary tract function 
and dysfunction. Rev Urol, 5 Suppl 8, S3-S10.  
Yoshimura, N., & Chancellor, M. B. (2004). Differential diagnosis and treatment of impaired 
bladder emptying. Rev Urol, 6 Suppl 1, S24-31.  
Yoshimura, N., Seki, S., & de Groat, W. C. (2001). Nitric oxide modulates Ca(2+) channels in 
dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol, 86(1), 
304-311. doi:10.1152/jn.2001.86.1.304 
 
 
277 
Yu, P. L., Fujimura, M., Okumiya, K., Kinoshita, M., Hasegawa, H., & Fujimiya, M. (1999). 
Immunohistochemical localization of tryptophan hydroxylase in the human and rat 
gastrointestinal tracts. J Comp Neurol, 411(4), 654-665. doi:10.1002/(sici)1096-
9861(19990906)411:4<654::aid-cne9>3.0.co;2-h 
Yu, Y., Daugherty, S. L., & de Groat, W. C. (2016). Effects of nicotinic receptor agonists on 
bladder afferent nerve activity in an in vitro bladder-pelvic nerve preparation. Brain 
Res, 1637, 91-101. doi:10.1016/j.brainres.2016.02.009 
Zarghooni, S., Wunsch, J., Bodenbenner, M., Bruggmann, D., Grando, S. A., Schwantes, U., . . 
. Lips, K. S. (2007). Expression of muscarinic and nicotinic acetylcholine receptors in 
the mouse urothelium. Life Sci, 80(24-25), 2308-2313. doi:10.1016/j.lfs.2007.01.046 
Zhang, X., & DiSanto, M. E. (2011). Rho-kinase, a common finial path of various contractile 
bladder and ureter stimuli. Handb Exp Pharmacol, 202, 543-568. doi:10.1007/978-3-
642-16499-6_24 
Zinner, N., Tuttle, J., & Marks, L. (2005). Efficacy and tolerability of darifenacin, a muscarinic 
M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the 
treatment of patients with overactive bladder. World J Urol, 23(4), 248-252. 
doi:10.1007/s00345-005-0507-3 
	
